Iridium-catalyzed asymmetric hydrogenation : development of New N,P ligands and hydrogenation of alkenyl boronic esters by Ganic, Adnan
  
Iridium-Catalyzed Asymmetric Hydrogenation: 
Development of New N,P Ligands and 
Hydrogenation of Alkenyl Boronic Esters 
 
 
Inauguraldissertation  
 
zur  
Erlangung der Würde eines Doktors der Philosophie 
vorgelegt der 
Philosophisch-Naturwissenschaftlichen Fakultät  
der Universität Basel 
 
 
 
 
von  
 
 
Adnan Ganić 
aus 
Hergiswil NW und Tranvik (Bosnien und Herzegowina) 
 
 
Basel 2013 
 
 
Bibliografische Information der Deutschen Nationalbibliothek
Die Deutsche Nationalbibliothek verzeichnet diese Publikation in der Deutschen Nationalbibliografie; 
detaillierte bibliografische Daten sind im Internet über
http://dnb.d-nb.de abrufbar.
ISBN 978-3-8439-0952-5
Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät
auf Antrag von
Prof. Dr. Andreas Pfaltz
Prof. Dr. Antonio Togni
Basel, den 20. September 2012
Prof. Dr. Jörg Schibler
Dekan
© Verlag Dr. Hut, München 2013
Sternstr. 18, 80538 München
Tel.: 089/66060798
www.dr.hut-verlag.de
Die Informationen in diesem Buch wurden mit großer Sorgfalt erarbeitet. Dennoch können Fehler nicht vollständig ausgeschlossen 
werden. Verlag, Autoren und ggf. Übersetzer übernehmen keine juristische Verantwortung oder irgendeine Haftung für eventuell 
verbliebene fehlerhafte Angaben und deren Folgen.
Alle Rechte, auch die des auszugsweisen Nachdrucks, der Vervielfältigung und Verbreitung in besonderen Verfahren wie 
fotomechanischer Nachdruck, Fotokopie, Mikrokopie, elektronische Datenaufzeichnung einschließlich Speicherung und 
Übertragung auf weitere Datenträger sowie Übersetzung in andere Sprachen, behält sich der Autor vor.
1. Auflage 2013
  
 
 
 
For my family 
  
  
This thesis was supervised by Prof. Dr. Andreas Pfaltz from March 2008 to August 2012 at 
the University of Basel, Department of Chemistry.  
 
 
Parts of this work have been previously published:  
“Iridium-Catalyzed Enantioselective Hydrogenation of Alkenylboronic Esters”  
A. Ganić, A. Pfaltz, Chem. Eur. J. 2012, 18, 6724. 
 
“Recent Advances in Iridium-Catalyzed Asymmetric Hydrogenation: New Catalysts, 
Substrates and Applications in Total Synthesis” 
A. Ganić, D. Rageot, L. Tröndlin, A. Pfaltz, Chimia 2012, 66, 187. 
  
  
Acknowledgements 
 
First of all I have to say, writing these lines makes me sad, because I realize that a great time 
is going to an end. I am thankful to many people, which I had a chance to interact during this 
time: 
My “Doktorvater” Prof. Dr. Andreas Pfaltz is gratefully acknowledged for the opportunity he 
gave me to work in his research group, for his support and for the freedom in developing my 
projects. He provides an excellent environment to carry out the research at highest possible 
level.  
I would like to thank Professor Dr. Antonio Togni for the co-examination of this thesis and 
Prof. Dr. Dennis Gillingham for chairing the defense. 
I thank Dr. Michael Parmentier for a fruitful collaboration we had working on cyclometallated 
iridium complexes, and I would like to thank Prof. Dr. Hans-Ulrich Reissig and Christian 
Eidamshaus from the FU Berlin for providing me some enantiopure pyridyl alcohols. In this 
line I am also thankfull to E. Hörmann, D. Rageot, A. Schumacher, Dr. M. Maywald and Dr. 
S. Gunzenhauser for sharing some of chemicals, which are not commerically available.  
I thank Nicola Polimene, Johanna Auth, Marc-André Müller, Michael Lüscher, Sarah Wehle 
and Adriana Edenharter for synthetic contributions to this piece of research during their 
practical courses like “Wahlpraktikum” or “Schlussversuch”. 
I would like to thank York Schramm, Johanna Auth, Jaroslav Padevet, Dr. Ivana Fleischer 
and Dr. Björn Gschwend for recording several 2D-NMR spectra. I am grateful to Dr. Markus 
Neuburger and Dr. Silvia Schaffner for collecting X-ray data and for structure refinement. Dr. 
Heinz Nadig recorded EI and FAB mass spectra, whereas Werner Kirsch and Dr. Sylvie 
Mittelheisser measured the elemental analyses. High resolution mass spectra were measured 
by the research group of Dr. Xiangyang Zhang (ETH Zürich). 
I want to thank all current and former members of the workshop for their technical support, 
and especially for the reparation of the autoclaves.  
I am extremely thankful to Dr. Paolo Tosatti and Marc-André Müller and York Schramm for 
spending their time proof-reading this manuscript. 
I thank Dr. Paolo Tosatti, Dr. René Tannert, and Dr. Eileen Jackson for proof-reading some of 
my english manuscripts. 
I thank Prof. T. Ward and all the members of the “Swiss Science Concentrates – A column in 
Chimia” team for a nice working atmosphere and intersesting discussion.  
I thank Marina Mambelli Johnson for all organization work beyond chemistry and for the 
contributions she is doing for the group. Furthermore, thank you Marina, Joe and Amanda for 
the delicious meals, which you served occasionally at “Causa Mambelli”. 
I thank all the past and present members of the Pfaltz group, and especially those of lab 204, 
for fruitful working atmosphere, nice musical entertainment and interesting discussion. 
I would like thank to the company F. Hoffmann-La Roche for a great time I have spent there 
and for their unconditional financial support during my studies in chemistry. Specially 
acknowledged are Alain Blumenthal, Robert Petrović, Christophe Pfleger, Pascal Dott, Dr. 
Uwe Klinkhammer and Dr. Georg Trickes for their support during my education as 
“Chemielaborant”. In this line, I also thank Dr. Henri Hoffmann and Franz Frei for the chance 
to start the apprenticeship in this company and finally Alois Kunz and Paul Viullard for their 
help related to scholarship during my studies. 
Ich bedanke mich beim Kanton Nidwalden für grosszügige finanzielle Unterstützung während 
meinem Studium. Weiterhing danke ich ganz herzlich meinem geschätzten 
Orientierungsstufen Lehrer Xaver Marty für seine Unterstützung. Ohne seine Hilfe und 
Anleitung wäre ich diesen Weg niemals eingegangen.  
Želim da se zahvalim cjeloj mojoj familiji Ganić, Beganović i Suljović, a pogotovo mojim 
roditeljima Mehmedu i Safiji i mojim sekama Aidi i Zineti za njihovu podrušku tokom mog 
života. 
Konaćno se zahvaljujem mojoj dragoj suprugi Belmi, za njenju ljubav i strpljenje u zadnja tri 
mjeseca i našem malom Edinu, koji nam je obogatio život.  
  
Table of Contents 
CHAPTER 1 
INTRODUCTION  13 
1.1 The Development of Asymmetric Synthesis 15 
1.2 Asymmetric Hydrogenation Using Rh- and Ru-Complexes 17 
1.3 Ir-Catalyzed Asymmetric Hydrogenation 19 
1.3.1 N,P Ligands Early Development 19 
1.3.2 The Counterion Effect 20 
1.3.3 NMR Study on Catalyst Activation 22 
1.3.4 Catalytic Cycle 24 
1.3.5 Selected N,P Ligands and Their Substrate Scope 25 
1.3.6 Important Parameters in the Ir-Catalyzed Asymmetric Hydrogenation 30 
1.4 Thesis Outline 32 
 
CHAPTER 2 
DEVELOPMENT OF A NEW SYNTHETIC ROUTE TO BICYCLIC PYRIDINE-PHOSPHINITE  
LIGANDS AND THEIR CORRESPONDING IR-COMPLEXES 33 
2.1 Introduction 35 
2.1.1 Bicyclic Pyridine-Phosphinite Ligands for Ir-Catalyzed Asymmetric 
Hydrogenation 35 
2.1.2 First Generation Synthesis of Pyridyl Alcohols 35 
2.1.3 Second Generation Synthesis of Pyridyl Alcohols 36 
2.1.4 Formation of N,P Ligands and Their Ir-complexes 37 
2.1.5 Objective of This Work 38 
2.2 Development of the New Synthesis 39 
2.2.1 New Synthetic Route to Racemic Pyridyl Alcohols 39 
2.2.2 Formation of N,P Ligands and Ir-Complexes 41 
2.3 Crystal Structure Analysis 44 
2.4 Summary 48 
 
CHAPTER 3 
NEW N,P LIGANDS WITH A QUATERNARY STEREOGENIC CENTER AND THEIR IR-COMPLEXES 49 
3.1 Introduction 51 
3.1.1 Model of Stereoinduction 51 
3.1.2 Cyclometallation and Formation of Inactive Ir(III)-complexes 53 
3.1.3 Objective of This Work 54 
3.2 Synthesis 56 
3.2.1 Ligand Core 56 
3.2.2 Phosphinite Ligands and Their Ir-Complexes 57 
3.2.3 Phosphine Ligands and Their Ir-Complexes 59 
3.3 Hydrogenation Results 61 
3.3.1 Studies Using Racemic Catalysts 61 
3.3.2 Asymmetric Hydrogenation of Terminal Olefins 64 
3.4 Crystal Structure Analysis 66 
3.5 Summary 68 
 
CHAPTER 4 
NEW PYRIDINE–PHOSPHINITE BASED LIGANDS FOR  
IRIDIUM-CATALYZED ASYMMETRIC HYDROGENATION 69 
4.1 Introduction 71 
4.1.1 N,P Ligands without Fused Bicycles Motif 71 
4.1.2 Objective of This Work 72 
4.2 Synthesis 73 
4.2.1 Synthesis of Chiral Pyridyl Alcohols by Enzymatic Kinetic Resolution 73 
4.2.2 Synthesis of Chiral Pyridyl Alcohols from the Chiral Pool 74 
4.2.3 Formation of N,P Ligands 76 
4.2.4 Formation of the Iridium Complexes 77 
4.3 Hydrogenation Results 78 
4.4 Summary 87 
 
CHAPTER 5 
NEW BICYCLIC PYRIDINE AMINO-PHOSPHINE DERIVED LIGANDS FOR  
IRIDIUM-CATALYZED ASYMMETRIC HYDROGENATIONS 89 
5.1 Introduction 91 
5.1.1 Electronic Properties of N,P Ligands 91 
5.1.2 Phosphine vs. Phosphinite Derived N,P Ligands 93 
5.1.3 Objective of This Work 94 
5.2 Synthesis 95 
5.2.1 Methods Described in the Literature 95 
5.2.2 Synthesis of Racemic Pyridyl Amines 97 
5.2.3 Preparation of Enantiopure Pyridyl Amines 98 
5.2.4 Formation of N,P Ligands and Their Ir-Complexes 100 
5.3 Crystal Structure Analysis 102 
5.4 Hydrogenation Results 104 
5.4.1 Potential Cyclometallation 104 
5.4.2 Hydrogenation of Model Substrates 105 
5.5 Summary and Outlook 113 
 
CHAPTER 6 
IRIDIUM-CATALYZED ENANTIOSELECTIVE HYDROGENATION OF ALKENYLBORONIC ESTERS 115 
6.1 Introduction 117 
6.1.1 Chiral Boronic Acids and Esters 117 
6.1.2 Hydrogenation of Boronic Esters Described in the Literature 118 
6.1.3 Objective of This Study 121 
6.2 Synthesis of Substrates 122 
6.2.1 Synthesis of Terminal Boronic Esters 122 
6.2.2 Synthesis of Trisubstituted Boronic Esters 123 
6.3 Hydrogenation Results 125 
6.3.1 Hydrogenation of Terminal Boronic Esters 125 
6.3.2 Hydrogenation of Trisubstituted Boronic Esters 132 
6.4 Summary and Outlook 136 
 
  
CHAPTER 7 
P-ALKYL SIMPLEPHIM DERIVED IR-COMPLEXES AND MODIFICATION OF  
SIMPLEPHOX DERIVED IR-COMPLEXES FOR ASYMMETRIC HYDROGENATION  139 
7.1 Introduction 141 
7.1.1 Objective of This Work 141 
7.1.2 Ir-SimplePHIM Complexes Prior to This Work 141 
7.1.3 Ir-SimplePHOX Complexes Prior to This Work 143 
7.2 Synthesis 144 
7.2.1 P-Alkyl Ir-SimplePHIM Complexes 144 
7.2.2 Cyclometalled P-Alkyl Ir-SimplePHIM Complexes 145 
7.2.3 SimplePHOX Derived Complexes 147 
7.3 Crystal Structure Analysis 148 
7.4 Hydrogenation Results 150 
7.5 Summary 157 
 
CHAPTER 8 
EXPERIMENTAL PART 159 
8.1 Working Techniques 161 
8.2 Analytical Methods 161 
8.3 Development of a New Synthetic Route to Bicyclic Pyridine-Phosphinite  
Ligands and Their Corresponding Ir-Complexes 163 
8.3.1 Formation of N-oxides 163 
8.3.2 Arylations of N-oxides 164 
8.3.3 Boeckelheide Rearrangement and Hydrolysis 167 
8.3.4 Formation of N,P Ligands From Pyridyl Alcohols and  
Subsequent Complexation with Iridium 170 
8.4 New N,P Ligands with a Quaternary Stereogenic Center  
and Their Ir-Complexes 175 
8.4.1 Preparation of Ligand Precursors 175 
8.4.2 Preparation Pyridyl Ketones 177 
8.4.3 Preparation Methyl-Phosphines-BH3-Adducts 181 
8.4.4 Addition of Phosphines 184 
8.4.5 Silylation of the Alcohol and Deprotection of Phosphine 189 
8.4.6 Preparation of the Ir-complexes 194 
8.5 New Pyridine–Phosphinite Based Ligands for Iridium-Catalyzed  
Asymmetric Hydrogenation 201 
8.5.1 Preparation of the Ligand Precursers 201 
8.5.2 Preparation of Ir-complexes 204 
8.6 New Bicyclic Pyridine Amino-Phosphine Derived Ligands  
for Iridium-Catalyzed Asymmetric Hydrogenations 213 
8.6.1 Formation of N-Oximies 213 
8.6.2 Reduction of N-Oximies 216 
8.6.3 Enzymatic Kinetic Resolution of Primary Amines 219 
8.6.4 Hydrolysis of Amides 225 
8.6.5 Preparation of Ligands and Complexes 226 
  
8.7 Iridium-Catalyzed Enantioselective Hydrogenation of Alkenylboronic Esters 235 
8.7.1 Substrate Synthesis 235 
8.7.2 Terminal Vinylboronates 235 
8.7.3 Terminal Vinylboronates 240 
8.7.4 Preparation of 1,2-Bis-Boronates  243 
8.7.5 Suzuki-Miyaura Coupling 245 
8.7.6 Hydrogenation at Low Pressure and Low Temperature 254 
8.7.7 Analytical Data for the Hydrogenation Products  
Derived from Terminal Alkenylboronic Esters 255 
8.7.8 Hydrogenation at Elevated Pressure 260 
8.7.9 Analytical Data for the Hydrogenation Products  
Derived from Trisubstituted Boronic Esters 260 
8.8 P-Alkyl SimplePHIM Derived Ir-Complexes and Modification of  
Simple PHOX Derived Ir- Complexes for Asymmetric Hydrogenation 269 
8.8.1 Formation of Ligand Precursorsors 269 
8.8.2 Formation of the P-Aryl Ligands and Their Complexes 273 
8.8.3 Formation of the P-Alkyl Ligands and Their Complexes 278 
8.9 Asymmetric Hydrogenation 283 
8.9.1 Hydrogenation at Elevated Pressure 283 
8.9.2 Hydrogenation at Ambient Pressure 283 
 8.9.3 Analytical Data for the Model Olefins 284 
 
CHAPTER 9 
APPENDIX 287 
9.1 Crystallographic Data 289 
9.2 List of Abbraviations 293 
 
CHAPTER 10 
REFERENCES 297 
CHAPTER 11 
SUMMARY 307 
 
  
 
Chapter 1  
 
Introduction 
1.1 The Development of Asymmetric Synthesis 15 
1.2 Asymmetric Hydrogenation Using Rh- and Ru-Complexes 17 
1.3 Ir-Catalyzed Asymmetric Hydrogenation 19 
1.3.1 N,P Ligands Early Development 19 
1.3.2 The Counterion Effect 20 
1.3.3 NMR Study on Catalyst Activation 22 
1.3.4 Catalytic Cycle 24 
1.3.5 Selected N,P Ligands and Their Substrate Scope 25 
1.3.6 Important Parameters in the Ir-Catalyzed Asymmetric Hydrogenation 30 
1.4 Thesis Outline 32 
 
 

Introduction 
13 
1.1 The Development of Asymmetric Synthesis 
Since the work of L. Pasteur in 1848,[1] scientist were aware of significance of stereoisomers 
in relation to biological activity.[2] Nevertheless, until 1992 most of the chiral drugs launched 
on the market were racemates, while only few new products were developed as enantiomeric 
pure compounds.[3] With the improvement of separation techniques, the progress of synthetic 
organic chemistry, insights of different pharmacokinetic behavior of enantiomers and 
tightened government regulations the situation changed.[2] Nowadays most of the newly 
launched chiral synthetic drugs are pure enantiomers.[3] As the result of growing demand for 
enantiopure compounds the development of stereoselective synthesis got more attention. 
Basically four different approaches are used to access enantiopure synthetic molecules:[3]  
  Chiral pool strategy  Resolution of racemic mixtures  Diasteoreoselective synthesis  Enantioselective synthesis 
 
One possibility is to use naturally occurring molecules, which are transformed to target 
compounds.[4] This so called “chiral pool” strategy seems to be very attractive at first glance, 
as Nature produces many different molecules with a variety of functionalities. However, there 
are two major limitations. The abundance of many natural products is limited, which makes 
their isolation difficult and expensive. Furthermore, most of the natural products appear only 
in one configuration, for example 20 out of the 21 proteinogenic amino acids. Very often 
several synthetic steps are required to invert the stereogenic center, which prolongs the 
reaction sequence. Nevertheless, this approach is still frequently applied in pharmaceutical 
industry.[3, 5] 
On the other hand, the preparation of racemates and separation of the enantiomers by 
resolution is also still popular in pharmaceutical industry.[3, 5] In this case three different 
categories are distinguished.[6] One is using chiral external resolving reagents, which form 
diasteroemeric salts with racemic targets. In contrast to enantiomers, diastereomeres can be 
separated by traditional techniques, for example by fractional crystallization. Alternatively, 
the separation of enantiomers is also possible in the absence of an external chiral reagent, for 
example by “simulated moving bed chromatography” on chiral stationary phase[7] or by 
“preferential crystallization” using enantiopure seed crystals.[8] These methods are very 
laborious as usually numerous recycling cycles are required in order to obtain pure 
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enantiomers. Furthermore, a maximum yield of 50% is possible, unless the “undesired” 
enantiomer can undergo racemization and further resolution. However, it should be mentioned 
that modern methods are available, where fast racemization of the starting material is induced, 
in order to obtain yields over 50%. This process is named as dynamic kinetic resolution 
(DKR) or also as dynamic kinetic asymmetric transformation (DYKAT).[9]  
Alternatively, chiral auxiliaries can be used in order to control stereoinduction.[10] Over the 
years several auxiliaries were introduced, which are based on naturally occurring molecules. 
Some of the privileged systems are depicted in scheme 1.1, like Evans’ oxazolidinones,[11] 
Enders’ SAMP[12] or Myers’ pseudoeffedrine[13] auxiliaries. Such chiral auxiliaries are 
covalently bound to a substrate (the positions are showed by arrows) and they are able to 
influence the stereochemical outcome of a reaction. Moreover as the stereoisomers formed 
during the reaction are diasteromers, their separation is also easily achieved by traditional 
separation techniques. After the reaction the auxiliaries are removed from the molecules and 
can be recycled. Therefore, there are always at least two additional steps in the synthetic 
sequence required, which prolong the synthesis.[10] Nevertheless, this methodology is still 
frequently applied in the pharmaceutical industry, especially in the early stages of process 
development as relatively short development times are usually required.[5]  
 
 
Figure 1.1: Selected chiral auxiliaries for diastereoselective synthesis.[10]  
 
In addition, to the diastereomeric synthesis, the stoichiometric use of chiral reagents for an 
asymmetric transformation is also possible. However, this approach is only interesting for 
chiral reagents which are based on cheap and readily available starting materials (for example 
α–pinene, ephedrine, cinchona alkaloids or tartaric acid). In contrast to the auxiliary approach 
this does not prolong the reaction sequence. Nevertheless, additional work is required for 
separation and recycling of the chiral reagent, in order to reduce the amount of waste and 
disposal.[5] 
Among all possible approaches to enantiomerically pure compounds, asymmetric synthesis 
using catalytic procedures is in the majority of the cases superior. Asymmetric synthesis 
allows the fast and direct generation of enantiopure compounds from simple and readily 
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available starting materials by using a substoichiometric amount of a chiral catalyst. 
Moreover, taking the limitation of raw materials and environmental issues in account, the 
catalytic synthesis of complex organic molecules will gain more importance in the near 
future. Over the past years several catalytic asymmetric transformations were investigated, 
which found numerous applications.[14] Metal-catalyzed asymmetric hydrogenation is one 
example, which allows the atom economic[15] incorporation of dihydrogen into unsaturated 
olefins and carbonyl compounds.[16] The importance of asymmetric hydrogenation was 
recognized by awarding W. Knowles[17] and R. Noyori[18] with the Nobel Prize in 2001 
together with B. Sharpless for his work on catalytic asymmetric oxidation reactions.[19]  
 
 
1.2 Asymmetric Hydrogenation Using Rh- and Ru-Complexes 
Asymmetric hydrogenation is a powerful tool to convert prochiral substrates into chiral 
products with high enantiomeric purity. The reaction fulfills all the requirements of modern 
asymmetric synthesis, such as perfect atom economy, mild conditions, low catalyst loading 
and high conversion.[20] Since the pioneering work of W. Knowles and R. Noyori these 
reactions enjoyed an unrivaled success in organic chemistry. W. Knowles implemented 
rhodium complexes in combination with P-chiral diphosphine ligands 3 for the hydrogenation 
of α,ß-dehydroamino acids such as 1, which was the key step in the Monsanto process for 
large-scale production of L-Dopa, a rare natural amino acid for the treatment of Parkinson’s 
disease.[17, 21]  
 
 
Scheme 1.1: Rh-catalyzed asymmetric hydrogenation as the key step in the Monsanto process for 
L-Dopa production. 
 
On the other hand R. Noyori introduced BINAP ligands 6 as versatile systems for the Rh- and 
Ru-catalyzed reduction of functionalized C=C and C=O bonds.[18] For instance, these 
catalysts showed high activity in the hydrogenation of substrates 4a[22] and 4b,[23] providing 
access to the antiinflammatory agents[24] naproxen (S)-5a and ibuprofen (S)-5b. 
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Scheme 1.2: Ru-BINAP-catalyzed asymmetric hydrogenation of C=C bonds, providing access to 
drugs naproxen 5a and ibuprofen 5b.[22-23]  
 
Despite the vast variety of chiral Rh and Ru catalyst developed so far (many of them are 
commercially available), the scope of substrates that can be hydrogenated with high 
enantioselectivity remains limited. In general, both rhodium und ruthenium complexes require 
substrates bearing a coordinating functional group adjacent to the C=C bond in order to 
achieve high levels of ee.[25] In 1993, R. Broene and S. Buchwald reported a chiral titanocene 
complex,[26] as an efficient catalyst for the hydrogenation of unfunctionalized trisubstituted 
olefins.[27] For example, in the hydrogenation of α-methylstilbene 7 an excellent ee was 
obtained (scheme 1.3). Furthermore, also a zircocene derived catalyst was developed for the 
asymmetric hydrogenation of tetrasubstituted olefins.[28] Due to the tedious preparation, 
moisture- and air-sensitivity and relatively high catalyst loadings such metallocenes have not 
found any general applicability.  
 
 
Scheme 1.3: First successful asymmetric hydrogenation of unfunctionalized olefins, like 7 using a 
chiral titanocene catalyst 9.[27]  
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1.3 Ir-Catalyzed Asymmetric Hydrogenation 
For a long period, iridium complexes were considered to be only interesting to provide 
isolable analogs of species thought to be important in rhodium catalysis.[29] However, the 
pioneer work of R. Crabtree, demonstrated clearly that Ir-complexes derived from mixed 
donor ligands are more active in the hydrogenation of tri- and tetrasubstituted olefins lacking 
coordinating groups.[30] 
Thanks to the high activity iridium catalysts are attractive for industrial applications. One 
such very successful example is the Ir-catalyzed asymmetric hydrogenation of imine 10 
mediated by a chiral ferrocenyl based diphosphine ligand called Xyliphos 12, a member of the 
extremely successful Josiphos[31] ligand family (scheme 1.4). The chiral amine obtained 11 is 
used for the production of an important grass herbicide named (S)-metolachlor. This process 
is running since 1996 at Syngenta and delivers the target compound on a large scale 
(>10000 t/y). 
 
 
Scheme 1.4: Ir-catalyzed asymmetric hydrogenation of imine 10 as a key step for the industrial 
production of herbicide (S)-metolachlor.[32] 
 
 
1.3.1 N,P Ligands Early Development 
All previously described ligands contained two phosphorus atoms, which coordinate to the 
metal center. In contrast to the ligands mentioned above chiral phosphinooxazoline (PHOX) 
were developed in order to coordinate to the metal via a hard σ-donor (N) and a soft σ-donor 
(P).[33] These N,P ligands were initially employed in the allylic substitution, but found also 
use in other asymmetric reactions.[34] Because of the obvious coordination similarity to the 
achiral Crabtree’s catalyst, A. Pfaltz and co-workers considered to use PHOX ligands in the 
asymmetric hydrogenation. Indeed, the results obtained in the reduction of imines were 
promising. Under optimized conditions the model substrate 13 could be fully reduced to 
afford the chiral amine (R)-14 with 89% ee (scheme 1.5).[35] 
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Scheme 1.5: Asymmetric hydrogenation of imine 13 mediated by Ir-PHOX catalyst 15a.[35]  
 
Encouraged by these positive results, Ir-PHOX catalysts were investigated for the asymmetric 
hydrogenation of unfunctionalized olefins. Again the initial results using olefin 16 were very 
promising as enantiomeric excess up to 97% could be obtained (scheme 1.6).[36] However, 
catalyst deactivation during the reaction led to incomplete conversions. Therefore, relatively 
high catalyst loadings (>4 mol%) were required, in order to achieve reasonable yield of 
hydrogenation product. Attempts to increase the catalyst activity by variation of the hydrogen 
pressure, temperature, solvent or concentration failed. The use of additives such as halides, 
amines or carboxylates was also not succesfull, due to catalyst poisoning. After extensive 
experimental studies, a relatively simple solution to avoid catalyst deactivation was found. By 
changing the counterion from PF6
− to a bulky, apolar, weakly coordinating anion like 
tetrakis[3,5-bis(trifluoromethyl)phenyl]borate (BArF),
[37] full conversions could be achieved 
even at low catalyst loadings (0.3 mol%, scheme 1.6).[36, 38] 
 
 
Scheme 1.6: Ir-catalyzed asymmetric hydrogenation of unfunctionalized olefin 16 using PHOX 
ligands.[36] 
 
 
1.3.2 The Counterion Effect 
As already mentioned, the initially high catalyst loading for the asymmetric hydrogenation of 
unfunctionalized olefins was required due to the catalyst deactivation during the 
hydrogenation. Such a deactivation pathway was already reported R. Crabtree for his achiral 
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catalyst.[30] An irreversibly formed trinuclear iridium species was identified as the inactive 
form of the catalyst. Similar species were also observed by 1H-NMR analysis in the Pfaltz 
group for the deactivation of the Ir-PHOX 15 catalyst. However, the final proof was achieved 
when the trinuclear hydride-bridged-complex 18 was isolated and fully characterized (scheme 
1.7). All attempts to use complex 18 for hydrogenation or to generate the active catalyst from 
this species failed.[39]  
 
 
Scheme 1.7: Formation of H-bridged trinuclear Ir-complex 18.[39] 
 
As mentioned above, the solution to the deactivation problem was the change of the 
counterion to BArF. By using this virtually non-coordination anion Ir-complexes showed 
higher stability under the hydrogenation conditions and were less sensitive to moisture. 
Moreover, the purification of the pre-catalyst by column chromatography became possible.[36]  
A systematic screening of several anions in combination with kinetic studies showed that 
tetrakis(perfluoro-tertbutoxy)aluminate and tetrakis(pentafluorophenyl)borate were 
performing with essentially same efficiency as BArF in the hydrogenation reaction, whereas 
more coordinating anions like PF6 or BF4 gave slow reactions and incomplete conversion or 
even inhibit (triflate) the reaction (scheme 1.8).[40] From these kinetic studies a first order rate 
dependence on catalyst and hydrogen gas concentration in solution was obtained for both 
counterions (PF6 and BArF). Also a first order dependence on olefin concentration was found 
for the PF6-complex, whereas the rate dependence for the corresponding BArF-complex was 
close to zero. This implies that the olefin is involved in the turnover-limiting step for the PF6-
complex, but not for the BArF-complex. The explanation for this discrepancy is the different 
stability of the bishydride-intermediates. These bishydride-intermediates form a tighter ion-
pair between the metal center and PF6. As a consequence the substrate is competing with the 
counterion to access the metal center. In this respect, the deactivation observed occurs 
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presumably under the hydrogenation conditions. Whereas the metal center remains “naked” 
with BArF and the olefin can access the metal faster. Therefore, the hydrogenation pathway 
predominates over the deactivation pathway.[38, 40] 
 
Scheme 1.8: Counterion effect in the Ir-catalyzed hydrogenation of unfunctionalized olefins.[40] 
 
 
1.3.3 NMR Study on Catalyst Activation 
Despite the remarkable progress over the last fifteen years in the field of iridium-catalyzed 
asymmetric hydrogenation, the catalytic cycle of this reaction is not yet fully understood. On 
the basis of Crabtree’s work,[41] where olefin dihydride intermediates were identified and 
characterized by NMR, A. Pfaltz and co-workers performed complementary NMR studies 
using the PHOX derived complex 15d (scheme 1.9).[42] 
Addition of dihydrogen to a solution of complex 15d in THF at −40 °C gave already after 5 
min the COD-dihydride intermediates 19a-d, which were characterized by NMR 
spectroscopy. Because of its coordinating properties, THF had to be used as solvent for this 
study to observe clean spectra, whereas the standard solvent for the Ir-catalyzed 
hydrogenation, dichlormethane gave complex reaction mixtures. Two new hydride signals 
appeared in the high field region of the 1H-NMR spectrum (at −1β.7 and −15.6 ppm), which 
were assigned to complex 19c. Like in intermediate 19d, one of the hydride is trans to the N 
donor, which is electronically favored over the trans orientation to the P donor found in 
intermediates 19a and 19b. These observations are in agreement with previous work obtained 
with Crabtree’s catalyst.[41] The predominance of 19c over 19d is explained by steric strain 
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between the COD ligand and isopropyl group in the oxazoline and the pseudoaxial phenyl 
rings on phosphorus atom found in 19d. After increasing the temperature to 0 °C under 
hydrogen atmosphere the signals assigned the COD ligand slowly disappeared. Two new 
hydrides were observed, which were assigned to the isomers 20c and 20d. Again both 
complexes contain the hydrides trans to the nitrogen atom and cis to phosphorus atom. These 
complexes are considered as the potential first active intermediates in the catalytic cycle. In a 
next step the complexes 20c and 20d should substitute one of the solvent molecule by the 
olefin in order to form again an olefin-metal complex. However, all attempts to gain more 
information about other possible intermediates being involved in the catalytic cycle by NMR 
spectroscopy failed so far.[38, 43] 
 
Scheme 1.9: Activation of the pre-catalyst 15d with dihydrogen gas and formation intermediates 19 
and 20 (the BArF counterions were omitted for clarity).
[43] 
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1.3.4 Catalytic Cycle 
Two different catalytic cycles, either via Ir(I)/Ir(III) (left) or via Ir(III)/Ir(V) (right) intermediates, 
which have been proposed are shown in scheme 1.10.[44] In analogy to the established cycle 
found for Rh-diphosphine complexes,[45] P. Chen and R. Dietiker postulated the Ir(I)/Ir(III) 
cycle (left). They suggested this pathway on the basis of experimental data obtained from 
electrospray ionization tandem mass spectrometry by investigating the hydrogenation of 
styrene using Ir-PHOX complex 15c.[43] As suggested by the NMR study, this pathway starts 
from the Ir(III)-dihydride intermediate A (scheme 1.9; labeled as 20c and 20d). The first step 
consists of a ligand exchange of the coordinating solvent for an alkene, to obtain the olefin-
dihydride intermediate B. Migratory insertion of the Ir-hydride into the C=C bond, together 
with coordination of a solvent molecule leads to an alkyl-hydride complex C, which releases 
the hydrogenation product upon reductive elimination leading to the Ir(I)-complex D. 
Oxidative addition of dihydrogen regenerates the active Ir(III)-dihydride intermediate A.  
 
 
Scheme 1.10: Postulated catalytic cycles for the Ir-catalyzed asymmetric hydrogenation. S = 
solvent.[44] 
 
However, this pathway is in contrast with DFT calculation studies performed by P. Brandt et 
al. where an Ir(III)/Ir(V) cycle was energetically favored.[46] In this case the solvent molecules 
are initially replaced by olefin and additional dihydrogen to generate the intermediate E. A 
step combining oxidative addition and migratory insertion was proposed to take place, leading 
to the complex with a polyhydride Ir(V) intermediate F. Again reductive elimination gives the 
Ir(III) intermediate G, which releases the hydrogenation product and reforms the dihydride-
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solvate complex A. However, since a very simplified model for the ligand (CH3-N-(CH)3-P-
(CH3)2) and substrate (ethylene) were used for these studies, which completely neglect 
important steric interaction, Ir(I)/Ir(III) cycle could not be completely ruled out.[38] However, 
recent studies using comprehensive quantum mechanical calculations and the active catalyst 
derived from Ir-PHOX 15c support the Ir(III)/Ir(V) cycle.[47]  
 
 
1.3.5 Selected N,P Ligands and Their Substrate Scope 
Soon after the first report on Ir-PHOX complexes as catalysts for asymmetric 
hydrogenation,[36] the investigation of new N,P ligand scaffolds started. Some selected ligands 
developed in the Pfaltz group are shown in figure 1.2. Like PHOX ligands, the majority of 
these systems is based on enantiopure molecules derived from the chiral pool, which are 
assembled to furnish a heterocyclic ring and connected to a phosphine or a phosphinite 
unit.[38b] Their application to the iridium-catalyzed asymmetric hydrogenation is discussed in 
the next sections.  
 
 
Figure 1.2: Selected N,P ligands developed in the Pfaltz group.[38b] 
 
One example of very successful ligands is ThrePHOX, which is obtained from the amino acid 
threonine.[48] Some of its Ir-complexes are commercially available named as UbaPHOX 21. 
These catalysts gave excellent enantioselectivities for several model substrates usually applied 
in the hydrogenation. Using catalyst 21a, for example, α-methylstilbene 7 was hydrogenated 
with 99% ee (scheme 1.11 top).[48] Furthermore, ThrePHOX derived catalysts were used in 
the hydrogenation of terminal C=C bonds[49] and they showed also high activity and 
selectivity in the hydrogenation of 2-alkyl and 2-aryl-4H-chromenes providing access to 
chiral flavenes like 23.[50]  
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Scheme 1.11: Selected applications of ThrePHOX derived Ir-catalysts 21 in asymmetric 
hydrogenations.[48] 
 
SimplePHOX ligands consist also of the oxazoline scaffold, which is accessible in one step 
from amino alcohols and 2-hydroxy-2-methylpropionic acid. These ligands are the first 
reported examples that provide high ees for functionalized olefins, like allylic alchol 24 using 
complex 26b (scheme 1.12).[51] Furthermore, the P-alkyl complexes 26j of this ligand family 
gave the best enatioselectivities in the hydrogenation of imines.[52]  
 
 
Scheme 1.12: Selected applications of Ir-SimplePHOX complexes 26 in asymmetric hydrogenation.[51] 
 
Their phosphine analogues, which were named NeoPHOX provided access to the important 
chiral tetraline motif. For example complex 30a was applied to the enantioselective (98% ee) 
four steps total synthesis of the antitumor natural product (R)-(+)-7-demethyl-2-
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methoxycalamenene 29 (scheme 1.13).[53] Furthermore, they were also used for the 
diastereoselective hydrogenation of polyene pyridine natural products.[54] 
 
 
Scheme 1.13: Selected application of Ir-NeoPHOX complexes 30 in asymmetric hydrogenation.[53] 
 
Phosphanylmethyloxazoline ligands were first reported by M. Sprinz and G. Helmchen in 
1993,[33a] but were not been used until recently in iridium catalysis. In contrast to previously 
described systems, they form a five-membered chelate ring with the metal center. Ir-
complexes such as 33a were successfully applied to the asymmetric hydrogenation of 
tetrasubstituted olefins. For example the tricyclic olefin 31 was hydrogenated generating two 
stereogenic centers in excellent selectivity (scheme 1.14).[55] 
 
 
Scheme 1.14: The application of Ir-phosphanylmethyloxazoline catalyst 33 for the hydrogenation of 
the tetrasubstitued olefin 31.[55] 
 
Despite the achievements made so far, asymmetric hydrogenation of purely alkyl substituted 
olefins remained challenging. With the development of bicyclic pyridine-phosphinite N,P 
ligands in the Pfaltz group even substrates like olefin 34 could be hydrogenated with high ee 
using complex 36d.[56] Even more remarkable was the performance of structurally similar 
catalyst 36e in the hydrogenation of the side chain of Ȗ-toco-trienylacetate 37 (scheme 1.15). 
In this reaction three C=C bonds were fully reduced and two new stereogenic centers created 
in high enantiomeric purity. 
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Scheme 1.15: Selected applications of byclic pyridine-phosphinite derived Ir-cataysts 36 in the 
asymmetric hydrogenation of purely alkyl substituted olefins 34 and 37.[56] 
 
Additionally, these catalysts provide also excellent ees in the hydrogenation of several 
trisubstituted model olefins.[57] Furthermore, they were also successfully applied to the 
hydrogenation of heterocyclic aromatic compounds, like furans[57] and indoles.[58] Finally, 
their potential was also demonstrated in the synthesis of several natural products, such as 
Mutisianthol,[59] Macrocidin A,[60] and (+)-Torrubiellone C.[54]  
Besides the ligands developed in the Pfaltz group, many N,P ligands were developed in other 
research groups for the asymmetric hydrogenation of C=C and C=N bonds. Among them 
most notable examples are the systems reported by P. G. Andersson and co-workers (figure 
1.3). For example the PHOX type catalysts 39 with three additional stereogenic centers were 
found to be useful for the reduction of imines,[61] enamines,[62] enol phosphinates,[63] 
vinylboronates,[64] α,ȕ-unsaturated esters[65] and unsaturated sulfones.[66] On the other hand, 
the rigid bicyclic thiozole complexes 40[67] were quite successful in the hydrogenation of 
terminal diaryl olefins,[68] vinylfluorides[69] and vinylphosphonates.[70] More recently P. G. 
Andersson and co-workers introduced pyrinoside phosphite-oxazoline Ir-complexes 41 for the 
asymmetric hydrogenation of minimally functionalized olefins.[71] Most remarkably these 
catalysts provided excellent enantioselectivities for the usually challenging terminal 
olefins.[72]  
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Figure 1.3: Selected Ir-complexes developed in the Anderssons’ research group and their use in 
asymmetric hydrogenation.  
 
Ligands that form larger than six-membered chelate rings with iridium were also introduced. 
Some, successful examples are shown in figure 1.4, for example the SpinPHOX ligands 42 
(seven-membered metal cycle)[73] or SIPHOX ligand 43 (nine-membered metal cycle).[74] 
Although N,P ligands still represent the most utilized mixed donor ligands for the iridium-
catalyzed asymmetric hydrogenation, C,N ligands 44[75] and O,P ligands 45[76] have also been 
successfully employed for this reaction. Both of them form a seven membered chelate ring 
within iridium complexes. While C,N ligand 44 provides unique results in the asymmetric 
hydrogenation of dienes,[77] all of these ligands were also successfully employed in the Ir-
catalyzed asymmetric hydrogenation of α,ȕ-unsaturated carbonyl compounds. SpinPHOX 42 
was reported to be useful for the reduction α,ȕ-unsaturated Weinreb amides,[78] while 
SIPHOX 43 gave excellent results in the hydrogenation of α,ȕ-unsaturated carboxylic 
acids.[74] On the other hand C,N ligand 44 and O,P ligands 45 were used for the hydrogenation 
of α,ȕ-unsaturated carboxylic esters[76, 79] and ketones.[76]  
 
 
Figure 1.4: Selected mixed donor ligands, which form larger than six-membered chelate rings with the 
metal.  
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1.3.6 Important Parameters in the Ir-Catalyzed Asymmetric Hydrogenation 
The proper choice of the reaction parameters is very important in order to achieve high 
enantioselectivities in the iridium-catalyzed asymmetric hydrogenation. As the exact catalytic 
cycle of this reaction has not been identified yet, the role of these parameters is also not fully 
understood. Some of the variable parameters are discussed herein: 
  Ligand / Complex   Solvent  Pressure  Temperature  Substrate geometry 
 
The outcome of the reaction strongly depends on the ligand structure. As rational tools for 
prediction of the enantioselectivity are not available yet, screening of different complexes is 
usually the first step. High-throughput screening might be helpful in order to cover a huge 
variety of ligands, but it also requires expensive automation equipments.[80] Therefore, 
traditional screening based on previous observations will still be continued.  
The activity and selectivity of an iridium catalyst strongly depends also on the solvent choice. 
Usually, the hydrogenations are carried out in weakly coordinating solvents like 
dichloromethane or 1,2-dichloroethane.[38, 81] Further apolar solvents, like toluene, 
chlorobenzene[82] or trifluorotoluene[68] have been also successfully employed. Usually the 
selectivity and reactivity drops down in strongly coordinating solvent, like THF, ethyl acetate 
or acetone,[81] however the use of propylene carbonate[83] and even methanol[74] have been 
reported with some success.  
Kinetic experiments revealed a first order dependence for dihydrogen in solution. Therefore, 
most of the hydrogenation are conducted at elevated hydrogen pressure (>5 bar) in order to 
accelerate the reaction. In contrast to the usually small influence of the pressure on the 
selectivity for trisbustitued olefins, for the hydrogenation of terminal and tetrasubstitued 
olefins lower pressures were found to have a distinctively positive influence. 
Furthermore, the temperature plays also an important role in the hydrogenation. In general, 
the enantioselectivity increases by lowering the temperature, whereas the activity is increased 
at higher temperature. 
The substrate geometry plays a major role in the Ir-catalyzed asymmetric hydrogenation. By 
changing the configuration at the double bond, opposite stereoisomers are obtained by using 
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the same catalyst. The hydrogenation of double isomers of farnesol 46a-d is clearly 
demonstrating this effect.[84] By proper choice of the double bond geometry all four 
stereosiomers of 47a-d could be obtained in high enantiomeric purity using catalyst (S)-36e. 
On the other hand, the preparation and purification of the substrates is becoming extremly 
important. In order to achieve high ees a high purity of each isomer of the olefin is required. 
Therefore, methods which exclusively allow the preparation of (E)- and (Z)-alkenes are 
receiving more interest.  
 
 
Scheme 1.16: Substrate geometry effect on the Ir-catalyzed asymmetric hydrogenation of farnesol 
isomers 46a-d. 
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1.4 Thesis Outline 
Iridium-catalyzed asymmetric hydrogenation is nowadays an established method in organic 
chemistry in order to prepare chiral compounds. In contrast to Rh- and Ru-catalysts, Ir-
complexes do not require the presence of coordinating groups adjacent to the double bond. 
Many N,P ligands have been successfully implemented for this reaction. However, as no 
ligand has a universal substrate scope, the development of new ligand scaffolds, which 
provide different activity and selectivity, is of great interest. The aim of this thesis is to study 
N,P ligands based on the rigid bicyclic pyridine scaffold. In the initial part a new synthetic 
pathway to such ligands is described. The next three chapters are dealing with the potential 
variations of the ligand scaffold in order to tune the reactivity and selectivity of their 
respective Ir-complexes. Furthermore, the application of N,P ligands to the hydrogenation of 
alkenyl boronic esters will be covered. During this study an unusual reactivity of imidazole-
phosphinite derived catalyst was observed, which will be discussed in the last chapter.  
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2.1 Introduction  
2.1.1 Bicyclic Pyridine-Phosphinite Ligands for Ir-Catalyzed Asymmetric 
Hydrogenation  
Bicyclic pyridine-phosphinites represent the most successful N,P ligand family developed so 
far for Ir-catalyzed asymmetric hydrogenation.[57] Their iridium complexes show high 
reactivity and are able to introduce very high enantioselectivity for several classes of 
trisubstitued olefins, as illustrated in the hydrogenation of Ȗ-toco-trienylacetate 37 (scheme 
2.1). In this reaction three C=C bonds were fully reduced and two new stereogenic centers 
were created in high enantiomeric purity (98% of the major RRR isomer). All the previously 
reported iridium catalysts failed to induce such a high level of enantioselectivity.[56] 
 
 
Scheme 2.1: Asymmetric hydrogenation of Ȗ-toco-trienylacetate 37 using an Ir-complex 36e derived 
from bicyclic pyridine-phosphinite ligand.[2] 
 
 
2.1.2 First Generation Synthesis of Pyridyl Alcohols 
The Ir-complex 36e shown in scheme 2.1 consist of N,P ligand, which is built from a pyridine 
unit. The pyridine moiety is connected to a phosphinite over a fused ring that also bears a 
stereogenic center. The phenyl group ortho to the pyridine nitrogen acts as the shielding group 
in the Ir-catalyst. As these ligands are of great value, generally applicable and highly modular 
syntheses of them are required. The synthetic route initially developed for the synthesis of the 
ligand backbone 54 is described in scheme 2.2. Acetophenone 48 is subjected to a Mannich 
reaction to afford 49, that is then reacted with enamine 50 to give the 1,5-diketone 51. 
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Treatment of 1,5-diketone 51 with hydroxylamine and subsequent dehydration furnishes 
pyridine 52, that can be transformed into the corresponding N-oxide 53. The N-oxides 
undergo a Boekelheide rearrangement[85] followed by subsequent hydrolysis to give the 
desired racemic pyridiyl alcohol rac.-54 in 14-20% overall yield over 7 steps.[57] This 
synthetic sequence is relatively long and does not allow for easy elaboration of the 
substituents at a late stage of the synthesis (the phenyl group is introduced in the 1st step).  
 
 
Scheme 2.2: First generation synthesis of racemic pyridyl alcohols 54.[57] 
 
 
2.1.3 Second Generation Synthesis of Pyridyl Alcohols 
To overcome some of the disadvantages of the synthetic sequence described in scheme 2.2, 
D. Woodmansee optimized a previously published synthetic route[86] to obtain pyridyl alcohol 
(scheme 2.3).[87] The idea of the new reaction pathway is to incorporate a chlorine atom in the 
pyridyl scaffolds 59, which would allow the introduction of various aryl groups by 
performing late stage Suzuki-Miyaura couplings on a common intermediate (i.e. 61, scheme 
2.3)  
The synthesis of the key chlorinated intermediates 59 was accomplished starting with the 
corresponding pyridone 58, that was obtained either via a condensation of ethyl acetoacetate 
56, cyclopentanone 55 and AcONH4,
[88] or by cyclization of 57 under acidic conditions.[89] 
Both procedures afforded the desired pyridones 58 in low yield. Chlorination using 
phenylphosphonic dichloride gave 59 in high yield.[90] After N-oxidation, Boekelheide 
rearrangement, subsequent hydrolysis and TBS protection, the chloro pyridines 61 were 
obtained. Late-stage Suzuki-Miyaura coupling and TBS deprotection gave the racemic pyridyl 
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alcohols rac.-54. However, it should be mentioned that enzymatic kinetic resolution is also 
possible of 2-chloro-pyridine derivatives prior to the TBS protection, giving access to 
enantiopure pyridyl alcohols 54. 
 
 
Scheme 2.3: Second generation synthesis of racemic pyridyl alcohols 54.[87] 
 
 
2.1.4 Formation of N,P Ligands and Their Ir-complexes 
The next problematic step is the preparation of P-Aryl phosphinite ligands 62. In fact, the 
choice of the base, that is required to enhance the nucleophilicity of the pyridyl alcohol, was 
difficult. The use of strong bases like n-BuLi resulted in partial racemization of the 
stereogenic center, whereas weaker bases like sodium hydride gave unsatisfactory results in 
the formation of the P-O bond. Therefore, S. Kaiser employed a mild method which is 
commonly used in nucleotide chemistry. Using an excess of 4,5-dichlorimidazole and of pre-
isolated diethylamino-phosphine the P-Aryl ligands 62 were formed in moderate to good 
yields (45-88%, scheme 2.4).[57] Unfortunately, since this procedure requires very long 
reaction times (up to 7 day to reach full conversion), it becomes impractical in handling such 
air-sensitive compounds. 
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Scheme 2.4: Preparation of P-aryl N,P ligands 62 and their Ir-complexes 36.[57] 
 
 
2.1.5 Objective of This Work 
Although the two described procedures give access to valuable N,P ligands, they are still far 
from being ideal. Therefore, the aim of this study was to develop an easy-to-handle and fast 
synthetic route for the generation of pyridyl alcohols 54, of their corresponding N,P ligands 
and iridium complexes. 
The idea for the synthesis of the pyridyl alcohol 54 was inspired by the work of K. Fagnou on 
Pd-catalyzed regioselective direct arylation of pyridine N-oxides 63.[91] The authors reported 
excellent yields (up to 90%) of arylated pyridines 65 employing a wide range of aryl bromides 
64 (scheme 2.5). 
 
 
Scheme 2.5: Palladium-catalyzed regioselective direct arylation of pyridine N-oxides 63.[91] 
 
For the formation N,P ligands the reaction conditions reported by Knochel and Liron are very 
attractive.[92] For their study on [3,3]-sigmatropic rearrangement reactions of acyclic allylic 
phosphinites 67 to allylic phosphine oxdides 68, the authors treated allylic alcohols 66 with 
chlorodiphenylphosphine in the presence of DMAP in diethyl ether. The reaction is completed 
within 30 min at room temperature and phosphinites 67 were obtained quantitatively (scheme 
2.6). 
 
New Synthetic Route to Bicyclic Pyridine-Phosphinite Ligands and Their Corresponding Ir-Complexes 
37 
 
Scheme 2.6: Formation of allylic phosphine oxdides 68 from allylic alcohols 66 via [3,3]-sigmatropic 
rearrangement reaction of arylphosphinites 67.[92]  
 
 
2.2 Development of the New Synthesis 
2.2.1 New Synthetic Route to Racemic Pyridyl Alcohols 
One of the disadvantages of the reaction sequence described by S. Kaiser lies within its low 
degree of modularity (scheme 2.2).[57] The important aryl residue on the pyridine ring that is 
required for shielding of the metal center is installed at the beginning of the sequence and in 
the next steps the pyridine ring is assembled. In order to overcome these issues, an attractive 
alternative reaction sequence would rely on a selective C−H arylation of pyridine N-oxides 
69a-b.[91]  
For this purpose the commercially available heterocycles 61a and 61b were converted to their 
N-oxides 69a-b. This oxidation can be performed either by using in situ generated peracetic 
acid[93] or by addition of MCPBA.[94] Both approaches provided the desired N-oxides 69a-b in 
good yields (72-90%). In the next step the ortho-selective arylation was explored. Employing 
the same conditions reported by K. Fagnou and co-workers, arylation products 53a-d were 
obtained in moderate yields (33-55%, Table 2.1).  
It should be mentioned that for the arylation reaction an excess of the N-oxides (3-4 eq.) is 
required, which is a clear drawback of the transformation. Moreover, another pitfall of this 
approach is that the scope of the arylhalides is limited to sterically non-hindered compounds. 
In fact, coupling reactions employing the bulky anthracene bromide or mesityl bromide were 
not successful. Nevertheless, this synthetic way is a straightforward approach to pyridyl 
alcohols 54, as the products obtained are advanced intermediates in the reaction sequence 
described by S. Kaiser.[57] Continuing this sequence (Boekelheide rearrangement[85] and 
hydrolysis), the racemic pyridyl alcohols rac.-54 were obtained in good yield (17-31% over 4 
steps).  
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Table 2.1: Preparation and Pd-catalyzed arylation of N-oxides 69a. 
 
Entry N-oxide Ar-Br Product 
Yield 
[%] 
1 
 
69a 
 
 
53a 55 
2 
 
69a 
 
 
53b 36 
3 
 
69b 
 
 
53c 33 
4 
 
69b 
 
 
53d 45 
 
 
Two possible ways have been developed in the Pfaltz group for the separation of the two 
enantiomers of pyridyl alcohols 54. One possibility is the chromatography-free enzymatic 
kinetic resolution optimized by M. Maywald.[95] Alternatively, separation by flash 
chromatography of the camphanic acid ester 50 is possible as shown by S. Gunzenhauser.[96] 
The two separation methods provide access to both enantiomers of 54 after hydrolysis of the 
corresponding esters on a multi-gram scale. However, it should be mentioned that these 
separations were not part of this work and the enatiopure materials were kindly provided by S. 
Gunzenhauser and M. Maywald.  
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Scheme 2.7: Formation of enantiopure alcohols 54 by resolution of racemates, which were obtained 
from 53 after Boekelheide rearrangement and hydrolysis.[95-96] 
 
 
2.2.2 Formation of N,P Ligands and Ir-Complexes 
Late-stage functionalization is one of the most important goals of any modular synthesis. 
Ideally, valuable intermediates should be quantitatively transformed into the desired target 
compounds. Moreover, fast reaction times are clearly advantageous when handling air- and 
moisture-sensitive compounds like phosphinites. The initially developed synthesis of N,P 
ligands did not fulfill these requirements and therefore careful optimization of this reaction 
sequence was the aim of this chapter. This study was performed in collaboration with E. 
Hörmann using the methodology developed by Knochel and co-workers for the formation of 
P-O-bonds.[92]  
As seen earlier (scheme 2.6), under the original conditions reported by P. Knochel and co-
workers the phosphinite is formed within 30 minutes by using an equal amount of a (vinyl)-
alcohol, chlorodiphenylphoshpine and DMAP in diethyl ether.[92] As pyridyl alcohols 54 
showed poor solubility in diethyl ether, a solvent screening was performed (scheme 2.8).  
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Scheme 2.8: Solvent screening for the formation of phosphinite rac.-62a. 
 
Figure 2.1: 31P-NMR analysis of the reaction mixture using different solvents for the formation of rac.-
62a. 
 
The course of the reaction was followed by 31P-NMR analysis and THF resulted as the best 
solvent for this transformation, giving the lowest amount of side-products compared to other 
solvents (figure 2.1; <20% total side products by integration of 31P signals). However, it 
should be noted that the reaction also works in ethereal solvent (diethyl ether or TBME; 
<30% total of side products) and to a lesser extent, in DCM (<35% total of side products).  
For further optimization studies THF was therefore selected as the solvent of choice and 
attempts to remove the precipitate from the reaction mixture (DMAP-hydrochloride) were 
investigated. Filtration through a disposable HPLC filter or a Celite® pad gave unsatisfactory 
results, as relatively low yield was obtained (approximately 40%) upon formation and 
isolation of the iridium complex 36a. A large amount (up to 50%) of a side product, whose 
THF 
 
 
Et2O 
 
 
TBME 
 
 
DCM 
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structure was tentatively assigned to the neutral iridium-chloride complex, was obtained. This 
observation indicates that even a relatively small amount of the hydrochloride salt strongly 
affects the BArF / chloride exchange and leads to a lower yield of the desired iridium-BArF 
complex. Therefore, a filtration over a pad of basic aluminum oxide (phosphinite ligands 62 
tend to decompose on silica gel) was investigated. Since the best solvent for elution was 
DCM, the reaction was run directly in that solvent. Moreover, the required filtration also 
allows the use of a small excess of chlorophosphine and DMAP (up to 1.1 eq.), as they could 
both be removed during the filtration. 
Further complexation studies showed that these ligands do not require additional heating to 
form the iridium complexes. Therefore, the solution containing ligand from filtration was 
directly added to a premix of [Ir(COD)Cl]2 (0.5 eq) and NaBArF (1.2 eq). The ligand (see 
figure 2.2 for the the cyclohexyl derivative (S)-62c, blue) was completely converted to the 
desired iridium complex (121.8 ppm; the signal at 126.2 ppm refers to the 
chlorodicyclohexylphosphine) within 1-2 hours.  
 
Figure 2.2: 
31P-NMR analysis of the formation of the ligand (S)-62c (pink) and of the corresponding Ir-
complex (S)-36c (blue reaction mixture, green the isolated complex after flash chromatography). 
 
After removal of the solvent and purification by flash chromatography the desired iridium 
complexes were obtained in high yields (≥60%, table β.β). Following this procedure, the Ir-
catalyst 36a was prepared for the first time (entry 1). Initially it was reported that the ligand 
62a forms a stable but catalytically inactive [Ir(L)2]BArF-complex.
[57b] However, during this 
work such complex was not observed and the 36a showed high catalytic activity. 
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Furthermore, catalyst 36a showed promising results in the hydrogenation of furan 
derivatives.[82]  
To demonstrate that this reaction setup is also amenable to the sterically demanding ortho-
tolyl substituents on the phosphorus atom, complexes 36b (on 0.5 mmol scale, entry 2) and 
36e (entry 4) were prepared in good yields.  
 
Table 2.2: New synthetic access to the phosphinite-pyridine derived complexes 36. 
 
Entry n R 
Scale 
[µmol] 
Ligand 
31
P-Ligand 
[ppm] 
Complex 
31
P-Complex 
[ppm] 
Yield 
[%] 
1 1 Ph 139 62a 108.5 (S)-36a 99.5 67 
2 1 o-Tol 500 62b 101.3 (S)-36b 113.6 60 
3 1 Cy 453 62c 147.6 (S)-36c 121.8 66 
4 2 o-Tol 110 62e 99.8 (S)-36e 99.3 66 
 
 
2.3 Crystal Structure Analysis 
Complexes (S)-36a, (S)-36b, and (S)-36e were crystallized by overlaying a saturated ethereal 
solution of the iridium compound with n-pentane. They were obtained as red ((S)-36a, (S)-
36a) and orange ((S)-36e) plates, which were subjected to crystal structure analysis. Mercury 
sticks representations are shown in figures 2.3-2.5. Selected structural parameters are given in 
tables 2.2-2.5, whereas the full crystallization parameters can be found in the appendix 
(chapter 9.1). Crystal structures of 36c, 36g and 36f obtained by S. Kaiser[57a] showed very 
similar structure to those obtained during this study. 
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Figure 2.3: Crystal structure of (S)-36a with COD ligand (left) and without COD ligand (right); BArF 
counter-ion was omitted for clarity. 
 
 
 
Figure 2.4: Crystal structure of (S)-36b with COD ligand (left) and without COD ligand (right). The 2nd 
molecule inside the unit cell and BArF counter-ion were omitted for clarity. 
 
In all complexes the Ir atom displays a square planar geometry. The unit cell of (S)-36a 
contains one molecule (figure 2.3). One of the phenyl groups on the phosphorus atom can 
occupy two different orientations. In the unit cell of (S)-36b two molecules were found (figure 
2.4 only one molecule is shown). The differences between bond lengths and angles of the two 
structures within the same unit cell are significant (see table 2.3). Comparison of these 
structures with the P-alkyl complex 36c revealed a shorter Ir-P bond, while the Ir-N distance 
remains unchanged. These small differences are reflected in smaller bite angles (table 2.3).  
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Table 2.3: Selected bond lengths and bite angles of Ir-complexes having a 5-atoms-membered 
carbocyclic ring. 
 
 
(S)-36a 
 
(S)-36b 
 
36c
[57a] 
Ir-P [Å]: 2.2529(9) 2.2569(9) / 2.3071(8) 2.2794(10) / 2.2808(11) 
Ir-N [Å]: 2.121(2) 2.146(2) / 2.094(2) 2.1241(4) / 2.132(3) 
P-O [Å]: 1.619(2) 1.626(2) / 1.641(2) 1.635(3) / 1.627(4) 
Ir-C13 or Ir-C27 [Å]: 3.221 3.253 / 3.254  
 P-Ir-N [°]: 86.27(7) 87.21(6) / 84.62(5) 88.26(10) / 88.14(10) 
 
Similar trends were observed for the complexes bearing a tetrahydroquinoline unit. Complex 
(S)-36e has again a shorter Ir-P distance and a smaller bite angle, when compared to the P-
alkyl complexes 36g and 36f (table 2.4). 
Ir(I)-complexes embedded in a six membered chelate ring adopt a characteristic boat 
conformation, and this is also valid for all the complexes described in this study. For 
complexes having a 5-membered carbocyclic ring (S)-36a and (S)-36b this boat conformation 
is less distinctive compared to the more flexible systems with a 6-atoms-membered 
carbocyclic ring (S)-36e. A parameter that is directly reflecting that conformation is the 
distance between the metal center and the stereogenic carbon atom. While this distance was 
found to be 3.22-3.25 Å long for catalysts (S)-36a and (S)-36b, the same distance is 3.11-3.16 
Å long in tetrahydroquinoline-based complexes.  
 
  
Figure 2.5: Crystal structure of (S)-36e with COD ligand (left) and without COD ligand (right). The 
BArF counter ion was omitted for clarity. 
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Table 2.4: Bond lengths and bite angles of Ir-complexes with a tetrahydroquinoline scaffold. 
 
 
(S)-36e 
 
36g
[57a]
 
 
36f
[57a]
 
Ir-P [Å]: 2.2794(4) 2.2881(7) 2.3522(9) / 2.3403(9) 
Ir-N [Å]: 2.118(1) 2.132(2) 2.117(3) / 2.107(4) 
P-O [Å]: 1.631(1) 1.625(2) 1.631(3) / 1.625(3) 
Ir-C14 [Å]: 3.162 3.150 3.107 / 3.106 
 P-Ir-N [°]: 84.11(4) 87.49(6) 87.23(8) / 86.7(1) 
 
The crystal structures are clearly showing the structural characteristics of each precatalyst in 
the solid state. However, once activated, the metal is found in different oxidation state (Ir(III) 
or Ir(V)) and the COD ligand is replaced by a substrate, hydride, dihydrogen or a solvent 
molecule. Therefore, it is difficult to draw direct conclusions regarding the structures of the 
actual catalysts.  
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2.4 Summary 
In summary a concise synthetic route toward pyridyl alcohols 54 was implemented. The key 
step for the installment of the desired functionality was a regioselective C−H functionalization 
of simple and readily available starting materials. Following this procedure pyridyl alcohols 
54 (n = 1, 2) were obtained in high yield (up to 31% prior to the resolution; scheme 2.9).  
 
 
Scheme 2.9: Regioselective C−H functionalization strategy for the fast preparation of pyridyl alcohols 
and formation of pyridine-phosphinite based N,P ligands and their Ir-complexes.  
 
Furthermore the synthetic protocol herein developed for the preparation of phosphinite 
ligands and their Ir-complexes is operationally simple and represents an efficient way to 
obtain valuable Ir-catalysts in high yields (≥60%) and reduced reaction times.  
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3.1 Introduction 
3.1.1 Model of Stereoinduction 
The excellent performance of iridium complexes bearing bicyclic-pyridine-phosphinite 
ligands 62 in the asymmetric hydrogenation of a broad range of substrates prompted a 
detailed investigation into the structural characteristics of the ligand scaffold.[57] This scaffold 
contains four important structural parts:  
  a phosphinite as the P donor  a pyridine as the N donor   a fused bicycle connecting the two parts and 
bearing the stereogenic center  a variable group in ortho-position of the 
pyridine ring 
 
Systematic variation of the residues on the “soft” P-ligand showed huge influence on the 
enantioselectivity in the Ir-catalyzed asymmetric hydrogenation. Most remarkably ortho-tolyl 
and tert-butyl residues were found to perform more efficiently compared to phenyl and 
cyclohexyl groups. Most likely, those residues have an electronic influence on the phosphorus 
atom and may direct the orientation of the other parts of the ligands and the substrate by steric 
effects.  
In order to mimic the structure of Crabtree’s catalyst ([Cy3P)Ir(pyridine)(COD)]PF6)[30] the 
pyridine part was used as the “hard” N donor. However, the electronic properties of this unit 
have not been investigated systematically in this particular system. The fused bicycle bears 
the stereogenic information of the ligand core and combines the two parts of the ligand 
structure. Systematic variations of the ring size revealed in general higher activity and 
selectivity for the smallest ring (n = 1). Finally the role of the substituents on the pyridine ring 
was investigated. The incorporation of an aryl group in ortho position of pyridine led to 
significant better enantioselectivity compared to unsubstituted systems.[57]  
In order to rationalize the enantioselectivity of a catalyst, a simple quadrant selectivity model 
was implemented for the rhodium-catalyzed asymmetric hydrogenation.[17, 21] This model 
shows the spatial arrangement around the metal along the plane formed by the coordinating 
atoms and the metal center itself. Based on this model Andersson and co-workers[67] 
suggested an iridium-adapted version for the hydrogenation of trisubstituted olefins. The view 
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along the plane formed by phosphorus-iridium-nitrogen atoms can be divided into four 
quadrants. Ideally, two of these quadrants remain open, whereas one of them is blocked by a 
bulky ligand substituent. The last quadrant should be semi-hindered.  
Based on these ideas, the quadrant model for the active bicylclic-pyridine-phosphinite derived 
catalyst (after dihydrogen addition and reduction of COD) is drawn in figure 3.1. Consistent 
with Andersson’s model, the N,P ligand is expected to completely block one of the quadrants 
by means of the aryl residues in the ortho-position to the pyridine nitrogen. The semi-
hindered quadrant would be occupied by a residue on the phosphorus atom. Now a 
trisubstitued olefin (for example (E)-α-methylstilbene) has two possibilities to approach and 
coordinate to the metal center in order to minimize the steric interactions with the ligand. The 
olefin will orientate with the bulky residues (phenyl groups) towards the open quadrants. The 
smallest part of the olefin (H atom on the C=C bond) will point towards the hindered 
quadrant, while the methyl group will occupy the semi-hindered quadrant. Coordination from 
the Si-face would give (S)-configured product, while the (R)-enantiomer would be obtained by 
attack from the Re-face. Experimental observations revealed that the catalyst derived from the 
(R)-configured-N,P ligand gives predominantly the hydrogenation product with (R)-
configuration (up to 99% ee), therefore the graphic on the right side of figure 3.1 seems to be 
more realistic than the one on the left side. This orientation of the substrate is also consistent 
with DFT calculation reported by P. G. Andersson et al.[38c, 46] 
 
 
Figure 3.1: Quadrant model rationalizing the enantioselectivity in the Ir-catalyzed asymmetric 
hydrogenation.[67] 
New N,P Ligands with a Quaternary Stereogenic Center and Their Ir-Complexes 
51 
Figure 3.2 shows the same model in an attempted 3D-view (Ir atom dark blue, N,P ligand blue 
and (E)-α-methylstilbene green). This picture reveals that the phenyl group next to the 
pyridine ring is oriented out of the pyridine plane and acts as a shielding group. Indeed, this 
orientation is observed in the crystal structures of the precatalysts.  
 
Figure 3.2: Possible substrate coordination of (E)-α-methylstilbene apon generation of the active 
catalyst.  
 
 
3.1.2 Cyclometallation and Formation of Inactive Ir(III)-Complexes 
Although the phenyl substituent on the pyridine ring in ligand 62 is important to achieve 
highly enantioselective hydrogenations, the activity of certain catalysts is relatively low. This 
observation could be explained with an undesired deactivation of the active catalyst. Such 
deactivation would arise from cyclometallation at the 2-phenyl position to form an Ir(III)-
complex bearing a tridentate C,N,P ligand. These oxidative addition reactions are known for 
late stage d8-metals like iridium or rhodium and have been systematically studied for C−H 
activation reactions.[97] Indeed, studies of the reaction mechanism of the hydrogenation of 
dienes using pyridine-phosphinite Ir-complex 36f showed the formation of a very stable 
dimeric Ir(III)-complex 71 (scheme 3.1).[98]  
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Scheme 3.1: Deactivation of pyridine-phosphinite derived Ir-catalyst 36f by formation of a stable 
Ir(III)-complex 71. 
 
To avoid this undesired cyclometallatoin the installation of blocking-groups on the aromatic 
residue (anthracene or mesitylene; scheme 3.2) was carried out by D. Woodmansee.[87] 
Furthermore, the selectivity of these new generation pyridine-phosphinite derived complexes 
improved for selected substrates. The most remarkable improvement in enantioselectivity was 
obtained in the hydrogenation of the cyclic olefin 72. The catalyst derived from ligands 62e 
having a phenyl group gave 73 with a good ee of 87%, whereas the new generation catalyst 
derived from ligand 74 afforded enantiomerically pure tetralin 73 (>99% ee, scheme 3.2).  
 
 
Scheme 3.2: Optimization of the pyridine-phosphinite ligand structure in order to avoid catalyst 
deactivation and improve the selectivity in the Ir-catalyzed asymmetric hydrogenation.  
 
 
3.1.3 Objective of This Work 
It should be noted that, if on one hand the presence of a mesityl or an anthracenyl group in the 
ortho-position of the pyridine ring is useful to avoid catalyst deactivation via 
cyclometallation, on the other hand the presence of these highly hindered groups mighty 
reduce the accessibility of the substrates to the metal center. To overcome this potential 
problem, a different approach for the synthesis of new bicyclic pyridine-based N,P ligands 
was sought. After close scrutiny of the model presented in figure 3.2, it was assumed that a 
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substituent at the stereogenic center of the ligand might have an appreciable influence on the 
substrate orientation. Therefore, the synthesis of a family of bicyclic pyridine-based N,P 
ligands bearing a tertiary alcohol was planned. In this case it was assumed that the installation 
of a residue on the sterogenic center and the removal of the substituent in the ortho-position 
of the pyridine ring (figure 3.3 left) would result in a different mode of approach of the 
substrate to the catalyst, according to the quadrant model depicted in figure 3.3 (right). The 
idea of using bicyclic pyridine-based N,P ligands with a quaternary stereogenic center was 
further supported by the success in the Ir-catalyzed asymmetric hydrogenation of other 
systems bearing a tertiary alcohol (e.g. ThrePHOX and SimplePHOX, see chapter 1).  
 
 
Figure 3.3: New N,P ligands having a quaternary stereogenic center and predicted coordination of 
(E)-α-methylstilbene using the quadrant model.  
 
As the precursors for such new phosphinite ligands 75 the pyridyl ketones 76a-b were 
selected. Furthermore phosphine 77 systems should be easely accessible starting from the 
same precursor as well (scheme 3.3).  
 
 
Scheme 3.3: Retrosynthetic analysis to N,P ligand 75 and 77 via the key intermediate pyridyl ketones 
76a and 76c. 
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3.2 Synthesis 
3.2.1 Ligand Core 
Two practical and fast methods were found which gave the pyridyl ketones 76a and 76c from 
commercially available starting materials. One possibility is to use the same strategy 
described by S. Kaiser for the preparation pyridine-phosphnite ligands (chapter 2, scheme 
2.2).[57, 99] After formation of N-oxides by pyridine oxidation with MCPBA or in situ 
generated peracetic acid, pyridyl alcohols 78a and 78b were obtained after Boekelheide 
rearrangement[85] and subsequent hydrolysis. Oxidation under Swern conditions[100] gave the 
corresponding ketones 76a and 76c (46-50% yield over four steps). Alternatively, the same 
products could be obtained from ozonolysis of olefins 79a and 79b, which were prepared by 
condensation of benzaldehyde with fused bicyclic pyridines 61 as described by R. Thummel 
and co-workers.[101] The yields obtained following this second approach were up to 10% 
higher, as only two steps are required (scheme 3.4).  
 
 
Scheme 3.4: Synthesis of pyridyl ketones 76a and 76c. 
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3.2.2 Phosphinite Ligands and Their Ir-Complexes 
In order to prepare the phosphinite ligands the tertiary alcohol 80 was required. For initial 
experiments a racemic synthesis of 80 was conducted. Simple Grignard addition to 76c did 
not lead to the product in an efficient way. Even in the presence of a Lewis acid like cerium 
trichloride[102] only 41% of the desired tertiary alcohol 80 was obtained. In order to improve 
the outcome of this transformation other reaction conditions were explored (table 3.1). The 
best result in terms of product yield and purity was obtained using methyl magnesium 
chloride in the presence of zinc chloride (entry 2).[10γ] Although alkylation using methyl 
lithium gave similar results, the isolated product contained some impurities, which were 
difficult to separate (entries 4-5).  
 
Table 3.1: Optimization of the prepartion of tertiary alcohol 80.  
 
Entry Reagent Additive
 
 Solvent Yield [%] 
1 MeMgCl (1.8 eq.) CeCl3
 
(1.5 eq.) THF 41 
2[103] MeMgCl (1.5 eq.) ZnCl2 (0.1 eq.) THF 63 
3 MeMgCl (1.5 eq.) ZnCl2 (0.1 eq.) / LiBr (1.0 eq.) THF 67 
4[104] MeLi (2.0 eq.) LiBr (1.0 eq.) Et2O 76 
5[105] MeLi (1.2 eq.) - Et2O / DME 1:1 79 
 
With the tertiary alcohol 80 in hand, the preparation of the phosphinite ligand and the 
corresponding Ir-complex was attempted (scheme 3.5). Indeed, using a strong base (n-BuLi) 
and chlorodiphenylphosphine, the formation of the ligand was observed by 31P-NMR 
spectroscopy. Despite of working under strictly inert conditions (degassed solvent, dry flasks) 
and purified reagents, several unidentified side products and decomposition products were 
obtained. Unfortunately, purification of the crude N,P ligand was not possible due to its 
decomposition on silica gel and aluminum oxide. Therefore, the use of the crude ligand 75 for 
the preparation of the corresponding iridium complex was investigated. Using the established 
procedure for the complexation of N,P ligands a complex product mixture was obtained.[36] 
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Analysis of the reaction mixture by 31P-NMR spectroscopy revealed the formation of a 
complex at room temperature, but decomposition at elevated temperature (50 °C). To 
suppress this decomposition the complex was formed at room temperature and isolated as a 
pale-yellow solid. 31P-NMR and MS analysis suggested formation of the expected bidentate 
Ir(I)-complex, but the observed color and careful analysis of the 1H-NMR shifts, revealed the 
presence of the cyclometalled tridentate C,N,P-derived Ir(III)-complex 81. The 31P-NMR 
spectrum of 81 shows a singlet at 100.17 ppm (figure 3.4). The 1H-NMR spectrum displays a 
doublet in the high-filed region at −15.88 ppm (2JPH,cis = 9.2 Hz). The signals of the 
diastereotopic nuclei of the methylene group (IrCH2) appear as a double doublet at 3.41 ppm 
(1JHH = 15.2 Hz, 
2
JHH = 8.0 Hz) and as a double triple doublet at 2.68 ppm (
1
JHH = 15.2 Hz, 
2
JHH = 8.0 Hz, 
3
JPH = 6.2 Hz). Crystal structure analysis of 81 revealed an insertion of iridium 
into the methyl C-H bond (for crystal structure see chapter 3.4). Such insertion reactions are 
generally strongly thermodynamically favored for platinum group metals, like iridium.[97] 
Nevertheless, this is one of the rare examples of cyclometallation into relatively inert sp3 
carbon-hydrogen bonds which lead to a formation of tridentate ligand.[106] 
 
 
Scheme 3.5: Formation of the tridentate Ir(III)-complex 81. 
 
The obtained Ir-complex 81 showed no catalytic activity in the hydrogenation of 
(E)-α-methylstilbene. For this reason and the fact that other substituents on the quaternary 
center (i-Pr, t-Bu, Ph) should have a similar influence on cyclometallation the synthesis of 
these phosphinite-derived ligands was not further investigated.  
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Figure 3.4: 31P- and 1H-NMR spectra of the cyclometallated Ir(III)-complex 81. 
 
 
3.2.3 Phosphine Ligands and Their Ir-Complexes 
A modification of the strategy was required in order to prepare the phosphine based ligands. 
Instead of treating the carbonyl compound 76 with a Grignard-reagent, a lithiated methyl-
phosphine was added (scheme 3.6). In order to increase the acidity of the methyl group of 82, 
a phosphine-BH3-adduct was pre-formed. For this purpose commercially available 
diphenylmethylphosphine was treated with BH3∙THF adduct, which gave the desired product 
84 in quantitative yield. All other BH3-protected methylphosphines were prepared by reacting 
the chlorophosphines 83 with methyl lithium or methyl magnesium bromide and subsequent 
protection with BH3∙THF (scheme 3.4).  
In the next step deprotonation of the methyl group of 84 and nucleophilic attack to the ketones 
76a and 76c in the presence of LiBr gave the racemic phosphines 85. It should be noted that 
the P-bound BH3-group for ortho-tolyl derivatives 85b and 85e was removed during the 
work-up. All other phosphines 85 were isolated in low to moderate yield as their BH3-
adducts. The enantiopure tertiary alcohols 85 were obtained after resolution by 
semipreparative HPLC using a chiral stationary phase (OD). Because of the low solubility of 
pyridyl alcohol 85d in apolar solvents and incomplete separation of the enantiomers of, the 
Chapter 3 
58 
BH3-group was removed prior to the resolution. For the dicyclohexylphosphine derivative 
85c, conditions for the separation of the enantiomers by HPLC on chiral stationary phase were 
not found.  
 
 
Scheme 3.6: Preparation of tertiary alcohols 85a-e by nucleophilic addition to ketones 76a and 76c. 
 
 
Table 3.2: Alcohol protection, phosphine deprotection and preparation of the Ir-complexes 87. 
 
Entry Ir-complex n R
1
 R
2
 
31
P-NMR 
(L) [ppm] 
31
P-NMR 
[ppm] 
Yield 
[%][a] 
1 (+)-87a 1 Ph TBS ‒27.0 10.4 73 
2 rac.-87b 2 Ph TMS −25.7 7.5 71 
3 (+)-87c 2 Ph TBS ‒26.4 6.5 53 
4 (−)-87d 2 Ph TIPS ‒25.1 7.8 70 
5 (−)-87e 2 o-Tol TBS ‒49.0 11.7 76 
[a]: Isolated yields of the Ir-complexes 87 after flash chromatography over silica gel. 
 
In order to prepare the iridium complexes 87 the tertiary alcohols 85 were protected as 
silylethers and the P-bound BH3-groups were removed using diethyl amine. Following this 
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approach, five iridium complexes having different electronically and sterically properties 
were prepared using established conditions (table 3.2).[36] It should be mentioned, that the 
TMS complex 87b was prepared in racemic form. Furthermore, complex having ortho-tolyl 
groups on the phosphorus atom 87e was obtained as mixtures of rotamers, due to the 
restricted rotation of the sterically demanding groups. Preparation of Ir-complexes using the 
free alcohols 85d failed.  
 
 
3.3 Hydrogenation Results  
3.3.1 Studies Using Racemic Catalysts 
In order to evaluate the activity of the new catalysts, initial hydrogenations using the racemic 
TMS protected Ir-complex 87b were performed. Using 2 mol% of catalyst loading and 50 bar 
hydrogen pressure, only 41% conversion for the terminal olefin 88 was observed (scheme 
3.8). Furthermore, GC analysis of the reaction mixture showed only 5% of the desired product 
89 and mainly isomerization to the more stable trisubstituted olefins 90 and 91. In order to 
exclude pressure induced isomerization, a control experiment without the catalyst was 
performed. Indeed, no isomerization of the terminal C=C bond of 88 was observed at 50 bar 
hydrogen pressure within 24 hours.  
 
 
Scheme 3.7: Hydrogenation studies using terminal olefin 88 and Ir-catalyst 87b. 
 
One explanation for the low product formation could be found in a hampered coordination of 
the substrate to the iridium due to the TMS group. However, this does not explain the 
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isomerization of 88 to olefins 90 and 91. A more reasonable explanation would be cleavage 
and decomposition of catalyst. It was independently proved by M. Maywald[107] and K. 
Burgess and co-workers[108] that iridium hydride species, once formed upon catalyst 
activation, are strong Brønsted acids. Such an acidic metal complex can lead to the cleavage 
of the acid labile TMS protecting group. Indeed, NMR experiments using activated Ir-
complex 87b indicated that such decomposition occurs. Furthermore, iridium hydrides 
themselves can promote olefin isomerization as well.  
To avoid the undesired TMS cleavage, acid stable protecting groups were installed. 
Performing the hydrogenation experiment under the same conditions described in scheme 3.8 
but now using the TBS protected Ir-catalyst 87c, full consumption of the starting material was 
observed (scheme 3.9). GC analysis of the reaction mixture revealed 99% product formation 
and only traces of isomerization product.  
 
 
Scheme 3.8: Hydrogenation studies using terminal olefin 88 and Ir-catalyst 87c. 
 
Hydrogenation of the trisubstituted olefins 90 and 91 would probably be slower than in the 
case of 88 as traces of the isomerization product were detected. To support this hypothesis, 
experiments using a mixture of isomeric substrates with the same catalyst were performed and 
analyzed by GC (see table 3.3).  
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Table 3.3: Hydrogenation studies using mixtures of isomeric substrates and Ir-catalyst 87c. 
 
Entry Substrate mixture 89 [%][a] 88 [%][a] (E)-90 [%][a] (Z)-91 [%][a] 
1 88 / (E)-90 1:1 32 3 65 0 
2 88 / (E)-91 1:1 39 0 6 55 
3 88 / (E)-90 / (Z)-91 1:1:1 26 0 36 38 
4 (E)-90 / (Z)-91 1:1 2 0 49 49 
[a]: Determined by GC analysis of the reaction mixture after removal of the catalyst. 
 
Indeed, using only 1 mol% of Ir-catalyst 87c and a 1:1 mixture of terminal olefin 88 and 
(E)-olefin 90, 32% of the hydrogenation product 89 was obtained (table 3.2, entry 1). While 
only 3% of the unreacted terminal olefin 88 remained untouched, 65% of the more stable 
trisubstituted olefin (E)-90 was obtained. Preforming the same experiment using only olefins 
(Z)-91 and 88 in a 1:1 ratio, again partial isomerization was observed (entry 2). Using all three 
isomers of the alkene in a 1:1:1 ratio only 26% hydrogenation product was obtained, while 
partial isomerization to both trisubstitued olefins was observed. In a last experiment only the 
trisubstituted olefins (E)-90 and (Z) -91 were mixed in a 1:1 ratio and reaction of both gave 
only traces of product (2%).  
These results clearly showed an isomerization pathway, which is competing with the desired 
hydrogenation. The isomerization favors the more stable E olefin (thermodynamically 
controlled). Ir-catalyst 87c is highly selective towards the hydrogenation of terminal C=C 
bonds, as only traces of hydrogenation products were obtained using a 1:1 mixture of (E)-90 
and (Z)-91 alkenes.  
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3.3.2 Asymmetric Hydrogenation of Terminal Olefins 
In order to evaluate the level of enantioselectivity that could be obtained with of the newly 
designed Ir-catalysts, hydrogenation studies using model substrate 88 were performed. For 
this purpose important reaction parameters, like hydrogen pressure and reaction time, were 
varied. The results of this study are shown in table 3.4.  
 
Table 3.4: Asymmetric hydrogenation of model substrate 88 using the newly developed Ir-catalysts. 
 
Entry Ir-catalyst 
p 
[bar] 
T 
[h] 
Conv. 
[%][a] 
89 
[%][a] 
ee 
[%][b] 
Isomerization 
(E)-90 
[%][a] 
(Z)-91 
[%][a] 
1 
 
(+)-87c 
1 1 24 5 n.d. 19 n.o. 
2 5 5 98 88 75 (R) 10 n.o. 
3 50 1 99 79 66 (R) 18 2 
4 100 1 >99 99 rac. <1 n.o. 
5 
 
(−)-87d 
5 5 45 42 62 (S) 3 n.o. 
6 50 1 55 31 27 (S) 23 n.o. 
7 100 1 >99 93 69 (S) 6 1 
8 
 
(−)-87e 
5 5 78 69 36 (R) 9 n.o. 
9 50 1 97 54 49 (R) 41 1 
10 
 
(+)-87a 
1 1 95 95 78 (R) n.o. n.o. 
11 5 5 >99 >99 45 (R) n.o. n.o. 
12 50 1 >99 >99 42 (R) n.o. n.o. 
[a]: Determined by GC analysis of the reaction mixture after removal of the catalyst. [b]: Determined by GC 
analysis on a chiral stationary phase. 
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The best result in terms of enantioselectivity was obtained applying lower hydrogen pressure 
(<5 bar). This is not very surprising as terminal olefins are known to react with higher 
enantioselectivity at lower pressure with iridium catalysts.[49] The highest enantiomeric excess 
achieved was 78% using catalyst 87a (entry 10). The structurally similar catalyst 87c having a 
six-membered fused bicycle gave a comparable ee of 75%, but also a significant amount of 
isomerization product was detected (entry 2). Increasing steric hindrance around the 
phosphorus atom and the oxygen atoms led to lower reactivity and enantioselectivity (entries 
2, 5 and 8).  
Furthermore, a preliminary study of the substrate scope with three terminal olefins having 
different electronic properties and the imine model substrate 13 with catalyst 87a was 
performed (see scheme 3.10). Model substrates which are frequently applied in Rh-catalyzed 
asymmetric hydrogenations were chosen and N-(1-phenyl-vinyl)-acetanilide 92 gave full 
conversion and moderate 74% ee, whereas diethyl itaconate 93 was reduced with 53% 
conversion and 44% ee. The hydrogenation product of substrate 94 proceeded with almost full 
conversion (97%) but very low enantioselectivity (28% ee) were obtained. Surprisingly, 
catalyst 87a showed full conversion in the hydrogenation of trisubstituted imine 13. This 
results indicate that the hydrogenation of C=N bonds follows a different mechanistic pathway, 
which is currently under investigation.[109] 
 
 
Scheme 3.9: Hydrogenation results obtained with selected terminal olefins and an imine using Ir-
complex 87a. [a]: Determined by GC analysis of the reaction mixture after removal of the catalyst; [b]: 
Determined by GC analysis on a chiral stationary phase.  
  
Chapter 3 
64 
3.4 Crystal Structure Analysis 
The crystal structure of Ir(III)-complex 81 is directly compared to the structurally similar Ir(I)-
complex 95 (figure 3.5 and table 3.4). Due to the rigid structure of 81, different bond lengths 
and a different bite angle were expected. While the Ir-P bond in complex 81 is slightly shorter 
compared to complex 95, the Ir-N bond is significantly longer (>0.1 Å). Nevertheless, the bite 
angle given by P-Ir-N atoms remains almost the same (86.2 ± 0.1°). Ir(III)-complex 81 has as 
well a boat-like conformation, which is tighter when compared to 95 (0.3 Å shorter distances 
between Ir and benzylic carbon atom C9).  
 
 
 
Figure 3.5: Crystal structures of 81 (left) and of 95 (right); BArF counterions were omitted for clarity. 
 
Table 3.5: Selected bond lengths and bond angles of Ir-complexes 81 and 95. 
 
 
81 
 
95
[57a] 
Ir-P [Å]: 2.252(2) 2.2758(2) 
Ir-N [Å]: 2.217(6) 2.1078(2) 
P-O [Å]: 1.619(5) 1.6273(19) 
Ir-C9 [Å]: 2.851 3.159 
 P-Ir-N [°]: 86.27(7) 86.23(7) 
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The differences between the phosphine derived complexes 87b and 96 are more pronounced 
(figure 3.6 and table 3.5). The installation of a quaternary carbon atom leads to longer 
coordination bonds (Ir-N and Ir-P). Therefore, the bite angle of 87b is also larger than in the 
case of 96 (∆ = 2.2 °), which is close to the bite angles found in phosphinite derived 
complexes (see 81). Due to the steric hindrance of the silyl group the boat conformation in 
87b is less distinctive when compared to complex 96.  
 
  
Figure 3.6: Mirror images of crystal structures of 87b (left) and 96 (right); BArF counterions were 
omitted for clarity. 
 
Table 3.6: Selected bond lengths and bond angles of Ir-complexes 87b and 96. 
 
 
87b 
 
96
[57a] 
Ir-P [Å]: 2.306(1) 2.2869(17) 
Ir-N [Å]: 2.153(4) 2.103(6) 
P-C [Å]: 1.839(5) 1.836(7) 
Ir-C6 [Å]: 3.346  3.278 
 P-Ir-N [°]: 86.2(1) 83.96(16) 
 
Although the crystal structures give some insight into the conformational preferences of the 
ligand complexes, direct conclusions concerning the structures of the active catalysts are not 
possible due to the very different coordination spheres resulting after removal of the COD 
group. 
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3.5 Summary 
In summary new pyridine derived N,P ligands containing a quaternary stereogenic center 
were synthesized from commercially available heterocycles 61 and converted into their 
Ir-complexes. While the phosphinite derived N,P ligand 75 was found to undergo an 
irreversible cyclometalation to give an air-stable, but catalytically inactive Ir(III)-complex 81, 
the phosphine derived complexes 87 were isolated as desired Ir(I)-complexes.  
 
 
Scheme 3.10: Preparation of pyridyl ketones 76a and 76c for the synthesis of pyridine-phosphinite 
and pyridine-phosphine ligands having a quaternary stereogenic center and their Ir-complexes. 
 
Applying these new Ir-complexes to the hydrogenation of olefins, a high selectivity towards 
the reduction of terminal versus tricyclic C=C bonds was found. These are first examples of 
Ir-complexes which are able to chemoselectivly reduce a terminal C=C bond in the presence 
of a trisubstitued C=C bond even at elevated pressure. However, the enatioselectivities 
achieved for model substrate 88 were clearly lower compared to previously developed 
catalysts, like Ir-TrePHOX 21[49] or the pyrinoside based Ir-complexes 41.[71] Furthermore, a 
preliminary study of the substrate scope revealed again low enantioselectivties for several 
terminal olefins.  
 
  
 
Chapter 4  
 
New Pyridine–Phosphinite Based Ligands for Iridium-
Catalyzed Asymmetric Hydrogenation 
4.1 Introduction 71 
4.1.1 N,P Ligands without Fused Bicycles Motif 71 
4.1.2 Objective of This Work 72 
4.2 Synthesis 73 
4.2.1 Synthesis of Chiral Pyridyl Alcohols by Enzymatic Kinetic Resolution 73 
4.2.2 Synthesis of Chiral Pyridyl Alcohols from the Chiral Pool 74 
4.2.3 Formation of N,P Ligands 76 
4.2.4 Formation of the Iridium Complexes 77 
4.3 Hydrogenation Results 78 
4.4 Summary 87 
 
  
  
 
New Pyridine–Phosphinite Based Ligands for Ir-Catalyzed Asymmetric Hydrogenation 
69 
4.1 Introduction 
4.1.1 N,P Ligands without Fused Bicyclic Motif 
The structural features that are important for the excellent performances of iridium complexes 
bearing bicyclic pyridine-phosphinite ligands 62 in the asymmetric hydrogenation of a broad 
range of substrates, have been discussed in previous chapters. Additionally, it should be 
noted, that the effect of the size of the cyclic backbone of the fused ring in the ligand scaffold 
was investigated as well. Ligands containing a fused ring consisting of five atoms were found 
to be the most active and selective for most of the tested model olefins.[57]  
Prior to the work on bicyclic pyridine phosphinite ligands A. Pfaltz and co-workers 
investigated structurally similar bidentate N,P ligands lacking a fused ring.[110] The 
selectivities obtained with ligand 97 for example were higher for most of the model substrates 
compared to the fused bicyclic ligand 62h. However, the installation of a phenyl group at the 
ortho-position of the pyridine ring into the ligand scaffold had a remarkably strong beneficial 
effect on the performance of bicyclic ligands in the hydrogenation reaction. The 
enantioselectivity obtained with ligand 62e was in all cases significantly higher compared to 
62h and 97 (scheme 4.1). 
 
 
 
 
  
 
 
 7 72 24 98 
(S)-97 >99% conv. 
95% ee (S) 
>99% conv. 
76% ee (R) 
>99% conv. 
95% ee (S) 
70% conv. 
22% ee (S) 
(R)-62h >99% conv. 
74% ee (R) 
>99% conv. 
69% ee (S) 
>99% conv. 
92% ee (R) 
>99% conv. 
46% ee (R) 
(R)-62e >99% conv. 
>99% ee (R) 
>99% conv. 
87% ee (S) 
>99% conv. 
97% ee (R) 
>99% conv. 
96% ee (R) 
Scheme 4.1: Comparison of selectivity of pyridine-phosphinite derived N,P ligands in the iridium-
catalyzed asymmetric hydrogenation of model olefins.[57, 110] 
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Furthermore, as mentioned in the introduction, P. G. Andersson and co-workers developed 
N,P ligands 100 based on the rigid thiazole ligand scaffold,[67] which are enantioselective for a 
broad range of substrates. In later studies, they built an open-chain version of the thioazole 
core in order to obtain a more flexible ligand scaffold, which might be beneficial for some 
substrates. Applying these new N,P ligands 101 to the iridium-catalyzed asymmetric 
hydrogenation, similar results for many model olefins were obtained as with the rigid scaffold 
(scheme 4.2). Only for the cyclic olefin 72 ligand 101 led to significantly lower ee.[111] 
 
 
 
 
  
 
 
 7 72 24 98 
(S)-100 >99% conv. 
>99% ee (S) 
>99% conv. 
93% ee (R) 
>99% conv. 
99% ee (S) 
>99% conv. 
98% ee (S) 
(R)-101 >99% conv. 
>99% ee (R) 
>99% conv. 
57% ee (S) 
>99% conv. 
91% ee (R) 
>99% conv. 
98% ee (R) 
Scheme 4.2: Comparison of selectivity of thiazole derived N,P ligands 100 and 101 in the iridium-
catalyzed asymmetric hydrogenation of model olefins.[67, 111] 
 
 
4.1.2 Objective of This Work 
Here the development of pyridine-phosphinite ligands without a rigid bicyclic ring system 
based on structure 102 is aimed. This ligand scaffold provides a unique opportunity to study 
various substitution patterns. First of all, the incorporation of substituents like Me, Et or Ph at 
the ortho-position of the pyridine ring (R1) could have beneficial stereoshielding effect, on the 
basis of what has been observed for the bicyclic N,P ligands 62e. As substituents on the 
stereogenic center (R2), Me and Ph groups were selected for investigation. Moreover, the 
orientation at this R2-residue should be influenced by putting a Me residue at the R3 position. 
By changing the R4 substituents, the electronic properties of the N donor can be tuned. And 
finally, the activity and selectivity of the ligands can be tuned by employing various 
substituents (R5) on the P donor. 
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Figure 4.1: New pyridine-phosphinite based ligands 102 aimed to develop for this study.  
 
 
4.2 Synthesis  
4.2.1 Synthesis of Chiral Pyridyl Alcohols by Enzymatic Kinetic Resolution 
Starting from commercially available 2,6-dibromopyridine 103 the racemic pyridyl alcohol 
104 was obtained after lithium-halogen exchange and subsequent trapping with acetaldehyde 
in excellent yield following the procedure described by C. Bolm and coworkers.[112] 
 
 
Scheme 4.3: Preparation of the racemic 6-bromo pyridyl alcohol 104. 
 
The enzymatic kinetic resolution of pyridyl alcohols using various lipases has been 
investigated by the research group of J. Uenishi and K. Nakamura.[113] Among all the systems 
tested CAL (Candida antarctica lipase) gave the best results. Under optimized conditions (6 h 
at 25 °C) they converted 104 into acetate (R)-105 with 46% yield and 97% ee, whereas the 
recovered alcohol (S)-104 was isolated in 49% yield and 93% ee. However, running the same 
reaction under the reported reaction conditions, only 18% conversion was obtained after 17 
hours. Nevertheless, as sufficient quantities of enantiopure alcohol (R)-104 were obtained 
after hydrolysis under weak basic conditions, this sequence was not further optimized.  
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Scheme 4.4: Enzymatic kinetic resolution of the 6-bromo pyridyl alcohol 104. 
 
In the next step the enantiopure pyridyl alcohol (R)-104 was subjected to a Suzuki−Miyaura 
reaction in order to install a phenyl group onto the pyridine ring. The coupling product (R)-
106 was obtained in 78% yield using reported reaction conditions.[86] 
 
 
Scheme 4.5: Suzuki−Miyaura coupling to obtain (R)-106.[86] 
 
 
4.2.2 Synthesis of Chiral Pyridyl Alcohols from the Chiral Pool 
C. Eidamshaus and H.-U. Reissig recently reported a flexible and rapid approach towards 
highly functionalized enantiopure pyridyl alcohols.[114] Starting from readily available 
ȕ-ketoenamines 108 and enantiopure α-hydroxy carboxylic acids 107 derived from the chiral 
pool, 4-pyridone 110 were obtained via a TMSOTf mediated cyclocondensation (scheme 4.6). 
ȕ-Ketoenamides 109 derived from mandelic acid 107a (R2 = Ph) were performing best in the 
cyclization sequence, whereas alkyl substitued α-hydroxy carboxylic acid 107b-c gave lower 
yields (R2 = i-Pr) or no cyclization product 110 (R2 = t-Bu). Furthermore, the cyclization was 
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also sensitive to the steric properties of the ȕ-ketoenamides, which allowed only small 
residues to be incorporated at the double bond (R1 = Me, Et). 
 
 
Scheme 4.6: Reissig’s route to enantipure protected 4-pyridones 110.[114] 
 
The 4-pyridones 110 are in equilibrium with their 4-hydroxy tautomers. In this context an O-
selective functionalization strategy was developed to obtain pyridyl alcohols 111 with 
different electronic and steric properties. Methylation of 110 with methyl iodide and TBS 
cleavage gave electron-rich pyridyl alcohols 111a in moderate to excellent yields (scheme 
4.7).  
Alternatively, the formation of pyrid-4-yl nonaflate (R)-112, which is an excellent reaction 
partner in cross-coupling reactions, was achieved. Using (R)-112 in combination with a Pd-
catalyst defunctionalization towards (R)-111b was achieved in the presence of formic acid.  
 
 
Scheme 4.7: Selective O-functionalization strategy to obtain pyridyl alcohols 111a-b with different 
electronic and steric properties.[114] 
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As some of these pyridyl alcohols showed promising results in asymmetric transformations, 
for example in the alkylation or alkynylation of aldehydes, in the asymmetric copper-
catalyzed Henry reaction and in the asymmetric allylation of benzaldehyde with 
allyl(trichloro) silane,[115] C. Eidamshaus and H.-U. Reissig kindly provided the enantiopure 
pyridyl alcohols 111a-b for the formation of N,P ligands and their iridium complexes.  
 
 
4.2.3 Formation of N,P Ligands  
For the formation of the corresponding aryl phosphinite ligands the optimized conditions for 
the bicyclic-pyridine arylphosphinites (see chapter 2) were employed. Using enantiopure 
pyridyl alcohols 106 and 111a-b, a small excess of chloro-arylphosphine (up to 1.1 eq.) and 
N,N-dimethylaminopyridine (up to 1.1 eq.) arylphosphinite ligands 102 were obtained after 
filtration over basic aluminum oxide under an inert atmosphere (scheme 4.8). The ligands 
were not isolated or further purified, and directly converted into the corresponding iridium 
complexes.  
 
 
Scheme 4.8: Formation P-aryl phosphinite ligands 102 from monocyclic pyridyl alcohols. 
 
For the formation of the P-alkyl phosphinite ligands a modification of the procedure described 
by S. Kaiser for the bicyclic phosphinite ligands was investigated. Instead of using sodium 
hydride in a THF/DMF (9:1) mixture at high dilution (0.05 M), the reaction was performed 
with an excess of potassium hydride in the presence of THF only but at higher concentration 
(0.5-0.1 M; scheme 4.9). The reaction progress was monitored by 31P-NMR spectroscopy and 
revealed full conversion within 15 h. After complete conversion, the solvent was replaced by 
toluene in order to remove the excess of KH and KCl by filtration.[116] Again, the ligands were 
neither isolated nor purified.  
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Scheme 4.9: Formation P-alkyl phosphinite ligands 102 from monocyclic pyridyl alcohols. 
 
 
4.2.4 Formation of the Iridium Complexes 
The iridium complexes of N,P ligands 102 were obtained using our standard procedure.[36] 
Heating was not required as the formation of complex could be checked by 31P-NMR. After 
counter ion exchange from chloride to BArF
− the desired iridium complexes were formed in 
low to good yields (table 4.1, 13-69% over two steps). It is important to mention that the 
complexes 113f, 113g and 113h are not stable towards silica gel flash chromatography using 
ethereal solvent (diethyl ether or tert-butyl methyl ether). The best way to obtain them in high 
purity was using flash chromatography on basic aluminum oxide and recrystallization from 
diethyl ether / n-pentane mixture, yet still <6% of an identified impurity could be detected by 
31P- and by 1H-NMR. This impurity is not resulting from any cyclometalation reaction of 
iridium with the aromatic protons, as no Ir-H signals were detected in the 1H-NMR spectra in 
the high-field region (between −10 and −50 ppm).  
 
Table 4.1: Formation of the iridium complexes 113 derived from monocyclic pyridine-phosphinite 
ligands 102. 
 
Entry Ir-complex R
1
 R
2
 R
3
 R
4
 R
5
 
31
P-NMR  
(L) [ppm] 
31
P-NMR 
[ppm] 
Yield [%][a]  
(2 steps) 
1 (R)-113a Ph Me H H o-Tol 94.7 96.5 (br s) 13 
2 (R)-113b Ph Me H H t-Bu 154.9 133.8 34 
3 (R)-113c Me Ph H H Ph 111.5 98.9 21 
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4 (R)-113d Me Ph H H o-Tol 98.6 108.6 (br s) 53 
5 (R)-113e Me Ph H H t-Bu 165.6 138.3 43 
6 (S)-113f Et Ph Me OMe Ph 111.6 98.9 26[b] 
7 (S)-113g Et Ph Me OMe o-Tol 99.0 107.4 (br s) 69[c] 
8 (S)-113h Et Ph Me OMe t-Bu 167.1 140.0 46[d] 
[a]: Isolated yields of the Ir-complexes 113 after flash chromatography over silica gel; [b]: contains according to 
1H-NMR 5% of an unidentified impurity after flash chromatography and recrystallization; [c]: contains according to 
1H-NMR 2% of an unidentified impurity after flash chromatography and recrystallization; [d]: contains according to 
1H-NMR 6% of an unidentified impurity after flash chromatography and recrystallization.  
 
 
4.3 Hydrogenation Results 
The new pyridine–phosphinite based ligands were evaluated in the iridium-catalyzed 
asymmetric hydrogenation of model substrates. The set of these model substrates includes 
trisubstituted unfunctionalized olefins with various substitution patterns and different double 
bond geometry 7, 90 and 91, a terminal olefin 88, an endocyclic olefin 72, two selected 
functionalized olefins (an allylic alcohol 24, an α,ȕ-unsaturated ester 98) and a ketimine 13 
(figure 4.2). Furthermore, their performances were compared to those of structurally similar 
catalysts 114 derived from ligand 97[110] and to the best result obtained with bicyclic pyridine-
phosphinite based catalysts. 
 
 
Figure 4.2: Model substrates used for the Ir-catalyzed asymmetric hydrogenation. 
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Table 4.2: Hydrogenation of (E)-α-methylstilbene (7). 
 
Entry Ir-catalyst R Conv. [%][a] ee [%][b] 
1 
 
(R)-113a o-Tol 7 n.d. 
2 (R)-113b t-Bu 7 n.d. 
3 
 
(R)-113c Ph 5 n.d. 
4 (R)-113d o-Tol 31 94 (R) 
5 (R)-113e t-Bu >99 96 (R) 
6 
 
(S)-113f Ph 7 n.d. 
7 (S)-113g o-Tol 2 n.d. 
8 (S)-113h t-Bu 12 95 (S) 
9[110] 
 
(R)-114a t-Bu >99 95 (R) 
10[57] 
 
(R)-36b o-Tol >99 >99 (R) 
[a]: Determined by GC analysis of the reaction mixture after removal of the catalyst; [b]: Determined by HPLC 
analysis on a chiral stationary phase.  
 
Iridium complexes (R)-113a, (R)-113b and (R)-113c with monocyclic pyridine-phosphinite 
ligands, proved to be not suitable for the asymmetric reduction of stilbene 7 as low 
conversions (<7%) were observed (table 4.2, entries 1-3). Catalyst (R)-113e having sterically 
bulky tert-butyl groups on the phosphorus atom performed best among tested complexes, 
providing full conversion and 96% ee (entry 5). On the other hand, complexes with an 
electron-rich pyridine ring were not very active (entries 6-8), albeit in certain cases high ee 
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could be obtained (entry 8). The results obtained are comparable to those obtained with 
previously known monocyclic pyridine-phosphinite iridium complexes like (R)-114b (entry 
9), but they cannot compete with bicyclic pyridine-phosphinite based catalysts like (R)-36b 
(entry 10).  
 
Table 4.3: Hydrogenation of (E)-2-(4-methoxyphenyl)-2-butene (90). 
 
Entry Ir-catalyst R Conv. [%][a] ee [%][b] 
1 
 
(R)-113a o-Tol 71 95 (R) 
2 (R)-113b t-Bu 82 30 (R) 
3 
 
(R)-113c Ph 99 84 (R) 
4 (R)-113d o-Tol >99 92 (R) 
5 (R)-113e t-Bu >99 93 (R) 
6 
 
(S)-113f Ph 13 6 (R) 
7 (S)-113g o-Tol 16 6 (S) 
8 (S)-113h t-Bu 69 92 (S) 
9[110] 
 
(R)-114b Ph >99 87 (R) 
10[57] 
 
(R)-36b o-Tol >99 >99 (R) 
[a]: Determined by GC analysis of the reaction mixture after removal of the catalyst; [b]: Determined by GC 
analysis on a chiral stationary phase.  
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In the hydrogenation of trisubstituted (E)-olefin 90 many of the catalysts tested showed high 
activity (table 4.3). The best result in terms of enantioselectivity was obtained with catalyst 
(R)-113a, altough the reaction did not reach full conversion within two hours (entry 1). Full 
conversions and only slighthly lower enantioselectivities (92% and 93% respectively) were 
obtained with (R)-113d and (R)-113e (entries 4 and 5). As already seen in the hydrogenation 
of stilbene 7, the electron-rich pyridine unit has a strong negative influence on the catalytic 
activity and selectivity of the iridium catalyst (entries 6-8). The best ee obtained with the new 
catalysts is higher compared to the highest previously reported values with monocyclic 
catalysts, like (S)-114b (entry 7). However, these values are clearly lower compared to those 
obtained with the rigid bicyclic ligand complex (R)-36b (entry 10). 
 
Table 4.4: Hydrogenation of (Z)-2-(4-methoxyphenyl)-2-butene (91). 
 
Entry Ir-catalyst R Conv. [%][a] ee [%][b] 
1 
 
(R)-113c Ph 44 87 (S) 
2 (R)-113d o-Tol 85 87 (S) 
3 (R)-113e t-Bu >99 86 (S) 
4 
 
(S)-113f Ph 35 8 (S) 
5 (S)-113g o-Tol 19 rac. 
6 (S)-113h t-Bu 25 86 (R) 
7[110] 
 
(R)-114b Ph >99 90 (S) 
8[57] 
 
(R)-36b o-Tol >99 98 (S) 
[a]: Determined by GC analysis of the reaction mixture after removal of the catalyst; [b]: Determined by GC 
analysis on a chiral stationary phase.  
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In general, the newly developed catalysts showed poor activity towards the hydrogenation of 
simple trisubstituted (Z)-olefin 91 (table 4.4). Only with catalyst (R)-113e, having bulky tert-
butyl groups on phosphorus, full conversion was achieved with 86% ee (entry 3). Similar 
enationselectivites but clearly lower activities were measured for catalysts with P-aryl groups 
(entries 1 and 2). Catalysts having electron-rich pyridines performed poorly in terms of 
activity (entries 4-6). Again these catalysts gave similar enantioselectivities those obtained 
with previously reported monocyclic ligand complexes (R)-114b (entry 7). However, they 
were significantly less selective than bicyclic pyridine-phosphinite based Ir-complexes, like 
(R)-36b (entry 8). 
 
Table 4.5: Hydrogenation of 2-(4-methoxyphenyl)-1-butene (88). 
 
Entry Ir-catalyst R Conv. [%][a] ee [%][b] 
1 
 
(R)-113a o-Tol 23 70 (S) 
2 (R)-113b t-Bu 38 59 (S) 
3 
 
(R)-113c Ph >99 36 (S) 
4 (R)-113d o-Tol >99 44 (S) 
5 (R)-113e t-Bu >99 26 (S) 
6 
 
(S)-113f Ph 47 7 (S) 
7 (S)-113g o-Tol 67 17 (R) 
8 (S)-113h t-Bu >99 40 (R) 
9[57] 
 
(R)-36b o-Tol >99 80 (S) 
[a]: Determined by GC analysis of the reaction mixture after removal of the catalyst; [b]: Determined by GC 
analysis on a chiral stationary phase.  
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For the hydrogenation of the terminal double bond in substrate 88 full conversions with 
moderate ee were only achieved with catalysts (R)-113c, (R)-113d, (R)-113e and (S)-113h 
(table 4.5, entries 3-5 and 8). In terms of enantioselectivity, catalysts with a phenyl group at 
the ortho-position of the pyridine performed better, but they did not show high activity 
(entries 1 and 2). Again the results obtained cannot compete with the best results reported 
using catalyst (R)-36b (entry 9).  
 
Table 4.6: Hydrogenation of 7-methoxy-1,2-dihydro-naphthalene (72). 
 
Entry Ir-catalyst R Conv. [%][a] 115 [%][a] ee [%][b] 
1 
 
(R)-113a o-Tol 89 38 56 (S) 
2 (R)-113b t-Bu 99 20 22 (S) 
3 
 
(R)-113c Ph 35 n.o. 59 (S) 
4 (R)-113d o-Tol 93 2 87 (S) 
5 (R)-113e t-Bu >99 1 86 (S) 
6 
 
(S)-113f Ph 44 1 rac. 
7 (S)-113g o-Tol 46 1 3 (R) 
8 (S)-113h t-Bu 66 1 80 (R) 
9[110] 
 
(R)-114b Ph >99 n.o. 87 (S) 
10[57] 
 
(S)-36d t-Bu >99 n.o. 92 (R) 
[a]: Determined by GC analysis of the reaction mixture after removal of the catalyst; [b]: Determined by HPLC 
analysis on a chiral stationary phase.  
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For substrate 72 having an endocyclic double bond, catalysts (R)-113d and (R)-113e reached 
high conversions with reasonably good enantioselectivities (table 4.6, entries 4 and 5). 
Catalysts with an electron-rich pyridine ring were not very active (entries 5-8). Surprisingly, 
iridium catalysts with a phenyl group at the ortho-position of the pyridine ring (R)-113a and 
(R)-113b performed poorly in terms of selectivity and a significant amount of the side product 
115 was obtained (entries 1-2). Catalyst (R)-113e was as enantioselective as the previously 
reported catalyst (R)-114b, but both complexes performed worse than the bicyclic complex 
(S)-36d.  
 
Table 4.7: Hydrogenation of (E)-2-methyl-3-phenylprop-2-en-1-ol (24). 
 
Entry Ir-catalyst R Conv. [%][a] ee [%][b] 
1 
 
(R)-113a o-Tol 29 55 (S) 
2 
 
(R)-113d o-Tol 76 83 (S) 
3 (R)-113e t-Bu 27 62 (S) 
4 
 
(S)-113f Ph 12 rac. 
5 (S)-113g o-Tol 2 n.d. 
6 (S)-113h t-Bu 2 n.d. 
7[110] 
 
(S)-114c o-Tol >99 95 (R) 
8[57] 
 
(R)-36b o-Tol >99 97 (S) 
[a]: Determined by GC analysis of the reaction mixture after removal of the catalyst; [b]: Determined by HPLC 
analysis on a chiral stationary phase.  
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The newly developed iridium catalysts proved to be not particularly suitable for the 
hydrogenation of allylic alcohols, like 24. Only catalyst (R)-113d gave conversion over 50% 
with an acceptable ee of 83% (table 4.7, entry 2). This is in clear contrast to the previously 
developed monocyclic pyridine-phosphinite catalyst (R)-114c and to the bicyclic pyridine-
phosphinite catalyst (R)-36b that aforded the desired product 25 with excellent 
enantioselectivities of up 97% and full conversion (entries 7-8).  
 
Table 4.8: Hydrogenation of (E)-ethyl 3-phenylbut-2-enoate (98). 
 
Entry Ir-catalyst R Conv. [%][a] ee [%][b] 
1 
 
(R)-113a o-Tol 5 n.d. 
2 (R)-113b t-Bu 6 n.d 
3 
 
(R)-113d o-Tol 19 30 (R) 
4 (R)-113e t-Bu 89 76 (R) 
5 
 
(S)-113f Ph 92 12 (R) 
6 (S)-113g o-Tol 10 16 (S) 
7 (S)-113h t-Bu 31 22 (S) 
8[110] 
 
(R)-114a t-Bu >99 95 (R) 
9[57] 
 
(R)-36b o-Tol >99 96 (R) 
[a]: Determined by GC analysis of the reaction mixture after removal of the catalyst; [b]: Determined by HPLC 
analysis on a chiral stationary phase.  
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The enantioselectivity of the newly developed catalysts in the hydrogenation of the α,ȕ-
unsaturated ester 98 was poor. Only catalyst (R)-113e gave a moderate 76% ee at 86% 
conversion (table 4.8, entry 4). Most of the complexes tested showed poor activity and 
selectivity, which is again in clear contrast to previously reported, structurally similar 
catalysts like (R)-114a and to the bicyclic pyridine-phosphinite catalysts like (R)-36b which 
gave up to 96% ee (entries 8-9).  
 
Table 4.9: Hydrogenation of (E)-N-(1-phenylethylidene)aniline (13). 
 
Entry Ir-catalyst R 
Conv. 
[%][a] 
14 
[%][a] 
48 + 116 
[%][a] 
ee 
[%][b] 
1 
 
(R)-113c Ph 84 58 25 28 (R) 
2 (R)-113d o-Tol 97 85 11 17 (R) 
3 (R)-113e t-Bu >99 >99 n.o. 23 (S) 
4 
 
(S)-113f Ph >99 98 1 12 (R) 
5 (S)-113g o-Tol 88 79 9 15 (S) 
6 (S)-113h t-Bu 85 44 41 rac. 
8[57b] 
 
(R)-36b o-Tol >99 >99 n.o. 82 (S) 
[a]: Determined by GC analysis of the reaction mixture after removal of the catalyst; [b]: Determined by HPLC 
analysis on a chiral stationary phase.  
 
In general, pyridine-phosphinite derived ligands showed moderate enantioselectivity towards 
the model substrate 13.[57, 87] The catalysts developed in this study showed high activity but 
low enantioselectivity (table 4.9). For most of the developed catalysts a significant amount of 
hydrolysis products (acetophenone 48 and aniline 116) was obtained.  
 
 
  
New Pyridine–Phosphinite Based Ligands for Ir-Catalyzed Asymmetric Hydrogenation 
85 
4.5 Summary  
In summary, the synthesis of differently substituted enantiopure pyridyl alcohols 106 and 
111a-b using different approaches was described (scheme 4.10). One synthetic pathway starts 
from commercially available 2,6-dibromopyridine 103, which gave racemic pyridyl alcohol 
104 after lithium-halogen exchange and subsequent trapping with acetaldehyde. Enzymatic 
kinetic resolution provided the secondary pyridyl alcohol 104, which was further modified by 
Suzuki−Miyaura coupling to give 106. Alternatively, enantiopure pyridyl alcohols 111a-b 
were obtained from ȕ-ketoenamine 108 and mandelic acid 107 by a sequence including ring 
cyclization and O-selective functionalization. Formation of N,P ligands and Ir-complexes 113 
was achieved following previously established conditions. 
 
 
Scheme 4.10: Synthesis of enantiopure pyridyl alcohol 106 and 111a-b for the formation of new 
monocyclic pyridine-phosphinite derived iridium complexes 113 for asymmetric hydrogenation.  
 
Applying these Ir-complexes to the asymmetric hydrogenation of unfunctionalized olefins up 
to 96% ee were obtained. Nevertheless, these complexes cannot compete with catalysts based 
on the rigid bicyclic framework. For partially functionalized olefins and imines low activity 
and selectivity were obtained  
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5.1 Introduction  
5.1.1 Electronic Properties of N,P Ligands 
As seen in the previous chapters small changes of the ligand scaffold can have a huge impact 
on the enantioselectivity and conversion of asymmetric hydrogenations. For example, 
employing the structurally similar α-pinene derived N,P ligands 117 (phosphine) and 118 
(phosphinite) in the iridium-catalyzed asymmetric hydrogenation of the cyclic olefin 72 
higher activity and selectivity was obtained using the catalyst derived from 117 (scheme 
5.1).[117] The only difference between the two ligands is the atom which links the P-donor to 
the N-donor. As both structures should have similar steric properties, their electronic 
properties must clearly be different.  
 
 
Scheme 5.1: Iridium-catalyzed asymmetric hydrogenation of model substrate 72 using structurally 
similar N,P ligands 117 and 118.[117] 
 
A further example, which demonstrates the importance of the electronic properties of a 
catalyst, is shown in scheme 5.2.[69] Employing Ir-complexes for the hydrogenation of vinyl 
fluorides 119a an ideal catalyst should provide the hydrogenation product 120a in high 
enantiomeric purity while avoiding a competitive defluorination that would afford the side-
product 121a. A preliminary screening revealed iridium complexes derived from 
aminophosphine-ligands 122 and 123 as the most active and chemoselective catalysts for this 
substrate. On the other hand iridium complexes derived from phosphine ligand 100 or 
phosphinite ligand 124 showed lower activities and, moreover, gave significant amounts of 
the side-product 121a.  
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Scheme 5.2: Comparison of reactivity and chemoselectivity of selected N,P ligands in the iridium-
catalyzed asymmetric hydrogenation of fluorinated olefin 119a.[69] 
 
As Ir-complexes derived from ligands 100 and 124 were known to induce higher level of ees 
for other trisubstituted olefins the authors considered to introduce an aminophosphine unit 
into the ligand scaffold. Therefore, they developed iridium catalyst 125 consisting of a 
thiazole-aminophosphine ligand which was very efficient in the hydrogenation of fluorinated 
allylic alcohol 119b and allylic acetate 119c (scheme 5.3). Only small amounts (<5%) of 
defluorinated side-products 121 were detected, moreover the hydrogenation products 120b 
and 120c were obtained in excellent enantiomeric excess (99%).[69]  
 
 
Scheme 5.3: Asymmetric hydrogenation of fluorinated olefins 119b and 119c using Ir-catalyst 125.[69] 
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5.1.2 Phosphine vs. Phosphinite Derived N,P Ligands 
Taking into account the unrivaled success of bicyclic pyridine phosphinite ligands in 
asymmetric hydrogenations, structural variations of these systems would be the next logical 
step. Indeed, in parallel to the development of phosphinite derived ligands, S. Kaiser prepared 
as well their phosphine analogs.[57a] When the performance of both ligand structures in 
hydrogenation was compared, opposite trends to those observed by J. Verendel and P. G. 
Andersson (see scheme 5.1) were found for unfunctionalized olefins.[117] While both ligands 
showed comparable reactivity, the phosphinite ligand 62i gave always higher, or at least 
equal, enantioselectivity compared to the phosphine ligand 126a in the reduction of 
unfunctionalized olefins like 7 and 72 (Figure 5.1). However, for the functionalized alkenes 
like the allylic alcohol 24, the phosphine ligand 126a was more active but less selective, 
whereas for the α,ȕ-unsaturated ester 98 ligand 126a showed higher activity and 
selectivity.[57a]  
 
 
 
 
  
 
 
 7 72 24 98 
(S)-62i >99% conv. 
91% ee (S) 
>99% conv. 
78% ee (R) 
26% conv. 
89% ee (R) 
24% conv. 
26% ee (R) 
(S)-126a >99% conv. 
88% ee (S) 
>99% conv. 
53% ee (R) 
>99% conv. 
79% ee (R) 
>99% conv. 
82% ee (R) 
Figure 5.1: Comparison of selectivity and activity of phosphinite and phosphine derived ligand in the 
iridium-catalyzed asymmetric hydrogenation of selected olefins.[57a] 
 
Encouraged by these promising results, D. Woodmansee attempted the synthesis of phosphine 
ligands having the desired aryl substitution on the pyridine ring in the scaffold. As seen in 
chapter 3 this substitution plays an important role, in order to obtain very high selectivity. 
However, ligand 126b with a phenyl group in this position could only be converted into the 
corresponding iridium(I) complex with the PF6
− counter ion 127a, but not with the more active 
BArF
− anion 127b.[87b] It was suggested that a competitive cyclometallation reaction produced 
a stable, but unreactive, Ir(III)-complex 128.  
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Scheme 5.4: Complexation study of bicyclic pyridine phosphine derived ligands 126.[97] 
 
Interestingly, as already discussed in chapter 3 (scheme 3.1), such a cyclometallation does not 
occur in the phosphinite derived Ir-complexes. Only under reaction conditions that lead to an 
irreversible removal of the COD ligand, the cyclometallated species 71 could be isolated 
starting from 36f (scheme 5.5).[98] 
 
Scheme 5.5: Cyclometallation of phosphinite derived Ir-complex 36f occurring under hydrogenation 
conditions.[98] 
 
 
5.1.3 Objective of This Work 
Although the bicyclic pyridine-phosphinite derived iridium complexes showed high activities 
and selectivities over a broad range of substrates, the development of new N,P ligands is still 
important. In the initial part of this chapter the importance of small variations of the ligand 
scaffold was shown in order to obtain hydrogenation catalysts for specific substrates (vinyl 
fluorides). In this section the development of new bicyclic pyridine-aminophosphine derived 
complexes is desribed. Initially, these new N,P ligands were applied to the iridium-catalyzed 
hydrogenations. But ideally if these new ligands showed promising results, they might found 
also find application in many other metal-catalyzed asymmetric transformations. Due to the 
smaller bond-length between phosphorus and nitrogen atoms these ligands should also be 
more stable towards air and moisture, when compared to the phosphite ligands (figure 5.2). 
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Figure 5.2: Comparison of different bicyclic pyridine derived N,P ligands.  
 
 
5.2 Synthesis  
5.2.1 Methods Described in the Literature 
Basically three different methods are available to obtain enantioenriched pyridyl amines 136, 
which are required for the preparation of the aminophosphine ligands 141: 
  Reduction of oximes / imines  Substitution of protected alcohols  Resolution of racemic amines 
 
The asymmetric reduction of oximes or imines seems very attractive at first glance. The 
required oximes or imines could be easily obtained from the pyridyl ketones that were 
described in chapter 3. Several boron based catalysts were reported for the asymmetric 
reduction of oximes.[118] One such example is shown on the left in scheme 5.6. Ketoxime 
ethers 130 are reduced to the desired amines 131 using spiroborate catalyst 132. Excellent ees 
up to 99% were reported for several amines 131 having at least one aromatic or 
heteroaromatic residue. Unfortunately, the authors reported low enantioselectivities for 2-
substitued pyridine oxime ether 130a due to an uncatalyzed background reduction that takes 
place by hydride transfer from pyridine-borane-adduct 133. Even using a stoichiometric 
amount of the catalyst, a modest result of 73% ee was obtained.[118b] Therefore, this approach 
was not used in this study.  
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Scheme 5.6: Synthesis of enantiopure (hetero)aromatic amines 131 by asymmetric reduction of 
ketoxime ethers 130 using spiroborate catalyst 132 (left); Uncatalyzed background reduction of 2-
pyridine derived ketoxime ether 130a, which gives low enantioselecitivity for this substrate (right).[118b] 
 
Despite the numerous reports on the asymmetric reduction of imines,[119] only one example 
employing pyridyl imines as substrates for this transformation was found in the literature.[120] 
As very low enantiomeric excess was reported for this substrate, this approach was not 
applied this course. 
Enantiopure pyridyl amines (S)-131a or (S)-135 could also be obtained by SN2 reaction from 
enantiopure pyridyl alcohols using a suitable leaving group. Interestingly, J. Uenishi and co-
workers used the enantiopure mesylate (R)-134 for the preparation of primary amines 131a 
and secondary amines 135 (scheme 5.7). The latter were obtained by direct substitution with 
benzylamine and cyclohexylamine respectivelyby whereas the primary amine 131a was 
obtained by using sodium azide with subsequent reduction (scheme 5.7).[121] As the synthesis 
of enantiopurey bicyclic pyridyl alcohols has been investigated and optimized in the Pfaltz 
research group (chapter 2),[95-96] this strategy seems to be very attractive. But due to the 
explosive nature of azides this approach was not investigated.[122]  
 
Scheme 5.7: Synthesis of enantiopure pyridyl amines by nucleophilic substitution using 134.[121] 
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Probably, the fastest way to obtain enantiopure pyridyl amines 136 would be the resolution of 
enantiomers by semiprepartive HPLC (most likely as their acetamide derivatives) or by 
recrystallization of diastereomeric salts formed from cheap and readily available chiral acids 
(e.g. tartaric acid or mandelic acid).[123] However, as an asymmetric synthesis was preferred, 
such a resolution would only serve as a back-up plan. Enzymatic kinetic resolution of pyridyl 
amines is a reasonable approach in order to obtain enantioenriched pyridyl amines 136. 
Indeed, the required reaction has been investigated by industrial scientists, as these important 
heterocyclic amines are useful building blocks in medicinal chemistry.[124] Following this 
approach researchers at AnorMED developed robust process for the synthesis of a CXCR4 
chemokine receptor antagonist 138 for the treatment of HIV (scheme 5.8).[125] 
 
 
Scheme 5.8: Enzymatic kinetic resolution of pyridyl amine 136c for the preparation of the drug 138 for 
treatment of HIV.[125]  
 
 
5.2.2 Synthesis of Racemic Pyridyl Amines 
In order to obtain racemic pyridyl amines 136 the synthesis via pyridyl oximes 139 was 
selected. The most straightforward way to obtain pyridyl oximes 139 is shown in scheme 5.9. 
The synthesis started from the commercially available bicyclic heterocycle 61b and gave, 
after deptronation with LDA and subsequent trapping with isoamyl nitrite, the desired oxime 
139c (R1 = H, n = 2) in moderate yield of 33%. However, isolation and purification of the 
product by crystallization was very difficult as it was obtained as a sticky oil.  
Therefore, pyridyl oximes 139 were prepared from pyridyl ketones 76 (see chapter 3.2) by 
condensation using hydroxylamine. The oximes precipitated directly out of the reaction 
mixture and therefore their isolation was more convenient. Reduction of oximes 139 with 
hydrogen gas in the presence of palladium on charcoal gave racemic amine 136 in excellent 
yields (88-97%).  
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Scheme 5.9: Synthesis of racemic pyridiyl amines 136. 
 
 
5.2.3 Preparation of Enantiopure Pyridyl Amines 
The enzymatic kinetic resolution route was selected for the preparation of the enantiomers 
(S)-136 and (R)-137 as this pathway provides both enantiomers in high enantiomeric purity 
using a readily available enzyme. Employing the published conditions124] using immobilized 
enzyme CAL-B, ethyl acetate as acylating agent and diisopropyl ether, longer reaction times 
then those reported were required for substrates 136c-d (scheme 5.8).[124] After six hours 
(instead of four hours) at 60 °C 50% conversion was obtained as determined by 1H-NMR 
spectroscopy by integration of the signals of the protons at the stereogenic center (δ = 4.91 
ppm for the amide and 3.99 ppm for the amine; scheme 5.10). Separation of the two products 
was readily achieved by flash chromatography. Under these conditions the pyridyl amides 
(R)-137c-d were obtained in 96-98% ee. Recrystallization from ethyl acetate gave the amides 
in perfect enantiomeric purity (>99% ee). Hydrolysis under acid conditions provided the 
pyridyl amines (R)-136c-d.  
After separation from the amides (R)-137c-d the remaining amines (S)-136c-d were directly 
crystallized as tartaric acid salts (SRR)-140c-d. The products were found to have an ee 
between 85-94%, which was again increased by recrystallization to >99%.  
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Scheme 5.10: Enzymatic kinetic resolution of pyridyl amines 136c-d with a six membered carbocyclic 
ring. [a] The ee was determined of the free amine (S)-136c-d. 
 
The conditions described above were not applicable to the enzymatic kinetic resolution of 
pyridyl amines 136a-b with a five membered carbocyclic ring (scheme 5.11) as these 
substrates showed low solubility in diisopropyl ether. Therefore, the reaction was run directly 
in ethyl acetate as solvent. Already after 3.5 hours 55-60% conversion was obtained. 
Therefore, the enantiomeric purity of the pyridyl amides (R)-137a-b was only moderate (75-
79% ee). The ee of (R)-137b could only be increased to 85% by recrystallization. However, 
due to the higher conversion the ee of pyridyl amines (S)-136a-b was already >99%. 
 
 
Scheme 5.11: Enzymatic kinetic resolution of pyridyl amines 136a-b with a five membered carbocyclic 
ring.  
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5.2.4 Formation of N,P Ligands and Their Ir-Complexes 
The phosphorus nitrogen bond could not be formed using the conditions applied in the 
synthesis of phosphinites (chapter 2). Therefore, several different conditions were 
investigated (table 5.1). Standard conditions for the formation of P-N bonds in toluene or THF 
as solvents in the presence of a weak base (triethyl amine or DIPEA) gave only small amounts 
of the product 141 (entries 1-3). Using stronger base (for example NaH) a higher yield of the 
product 141 was obtained, however a significant amount of impurities were obtained as well 
(entries 4-5). These impurities could not be separated by filtration through silica gel or 
aluminium oxide due to decomposition of the product 141. The successful conditions 
employed for the formation of phosphinites (chapter 2; DCM and DMAP) led to the desired 
products but good yields were obtained only for the ortho-tolyl derivative (entries 6-9).  
 
Table 5.1: Formation of phosphorus nitrogen bond using chlorophosphines. 
 
Entry Solvent Base R2PCl Purification 
Yield
[a] 
[%] 
Comment 
1 toluene Et3N Ph2PCl SiO2 traces 
decomposition on silica 
gel 
2 toluene Et3N Ph2PCl Al2O3 8  
3 toluene DIPEA Ph2PCl Al2O3 0  
4 THF/DMF 9:1 NaH (t-Bu)2PCl Al2O3 74 
impure mixture, which also 
gave impure Ir-complex 
5 THF/DMF 9:1 NaH Cy2PCl Al2O3 25  
6 DCM DMAP Ph2PCl Al2O3 20  
7 DCM DMAP 
Ph2PCl 
(>2 eq.) 
Al2O3 n.d. side products 
8 DCM DMAP (o-Tol)2PCl Al2O3 65  
9 DCM DMAP Cy2PCl Al2O3 20  
[a]: Isolated yield of the N,P ligand 141. 
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Due to these difficulties a similar approach to that reported by B. Breit and J. Wieland was 
used.[126] Instead of using the commercially available chlorophosphines, 
diethylaminophosphines were used as phosphorus source. Diethylaminophosphines have been 
synthesized from the chlorophosphines and diethylamine in toluene using an excess of 
triethylamine.[57a, 127] Their purification was possible by distillation, which gave the desired 
materials in good yield and purity. Diethylaminophosphines were then used in a nucleophilic 
substitution with the chiral pyridyl amine 136. The only side product formed was 
diethylamine, that could be removed under a stream of inert gas (argon). The ligands obtained 
using this method were pure and could directly be converted to their iridium complexes using 
our standard procedure.[36] Moreover, using this method for the formation of N,P bonds, the 
yields of the desired Ir-complexes were higher (entries 1-3, 6-7) compared to the approach 
using chlrorophosphines (entries 4 and 5). However, it should be noted that the preparation of 
N,P ligands having a di-tert-butyl-phosphino group failed as the diethylamino-di-tert-butyl-
phosphine could not be prepared.  
 
Table 5.2: Formation of Ir-complexes 142 using diethylaminophosphine for the prepration of N,P 
ligands 141. 
 
Entry Ir-complex n R
1
 R
2
 
31
P-NMR  
(L) [ppm] 
31
P-NMR  
[ppm]  
Yield 
[%][a] (2 steps) 
1 (S)-142a 1 Ph Ph 33.9 49.7 70 
2 (S)-142b 1 Ph o-Tol 18.9 55.9 (br s) 67 
3 (S)-142c 2 H Ph 33.4 51.1 52 
4 (R)-142d 2 H o-Tol 13.5 54.7 21[b] 
5 (R)-142e 2 H Cy 45.8 61.5 11[b] 
6 (S)-142f 2 Ph Ph 34.3 40.8 42 
7 (S)-142g 2 Ph o-Tol 19.3 43.4 46 
[a]: Isolated yields of the Ir-complexes 142 after flash chromatography over silica gel; [b]: Isolated yield of Ir-
complex (R)-142d and (R)-142e where the N,P ligands were obtained from chlorophosphines (table 5.1, entries 
8-9).  
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5.3 Crystal Structure Analysis 
From the complexes (S)-142a and (S)-142c suitable crystals for X-ray analysis were obtained 
by overlaying a saturated ethereal solution with n-pentane. They were obtained as red and 
yellow blocks, respectively. Mercury sticks representations are shown in figures 5.3 and 5.4. 
Selected structural parameters are given in tables 5.3 and 5.4, whereas the full 
characterization parameters can be found in the appendix (chapter 8.9). Crystal structures of 
the phosphine and phosphinite derived complexes 95 and 96 obtained by the work of S. 
Kaiser
[57a] are compared to the complexes obtained in this study.  
 
   
Figure 5.3: Crystal structures of various bicyclic pyridine derived Ir-complexes: 96 (left) (S)-142c 
(center) and mirror image of 95 (right); All BArF counterions were omitted for clarity. 
 
Table 5.3: Selected bond lengths and bite angle of Ir-complexes 96, (S)-142c and 95. 
 
 
96
[57a] 
 
(S)-142c 
 
95
[57a] 
Ir-P [Å]: 2.2869(17) 2.2784(5) 2.2758(2) 
Ir-N [Å]: 2.103(6) 2.103(2) 2.1078(2) 
P-X [Å]: 1.836(7) 1.669(2) 1.6273(19) 
Ir-C8 [Å]: 3.278 3.044 3.159 
 P-Ir-N [°]: 83.96(16) 85.18(5) 86.23(7) 
 
In all complexes the Ir atom adopts a square planar geometry. The Ir-P distance is slightly 
longer in the phosphine complex 96 (∆0.01 Å), compared to the phosphinite 95 and 
aminophosphine (S)-142c complexes. As expected, the P−X distance (X = C, N or O) showed 
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significant differences between the three complexes. The distances decrease with the 
electronegativity of the neighbor atom starting from 1.84 Å (C−P), 1.67 Å (N−P) to 1.6γ Å 
(O−P). The opposite trend can be observed for the bite angle given by the coordination atoms 
N-Ir-P, which increases from 84.0° (96), 85.2° (142c), to 86.2° (95). Somehow surprisingly, 
complex (S)-142c revealed a more characteristic boat conformation, which is reflected by the 
shortest distance found between Ir and C8.  
 
The unit cell of (S)-142a contains two molecules (only one of them is shown in figure 5.4). 
Comparison of this crystal structure to those of complex (S)-36a (chapter 2.4) revealed again 
the similarity of these two complexes. The most significant difference is the longer distance 
between the phosphorus atom and its neighbor atom, which is 0.05 Å longer for the 
aminophosphine derived complex (S)-142a.  
 
  
Figure 5.4: X-ray crystal structures of bicyclic pyridine derived Ir-complexes (S)-142a (left) and 
(S)-36a (right). Both BArF counterions were omitted for clarity. 
 
Table 5.4: Selected bond lengths and bite angle of Ir-complexes having a 5-atoms-membered 
carbocyclic ring. 
 
 
(S)-142a 
 
(S)-36a 
Ir-P [Å]: 2.2737(8) / 2.2644(7) 2.2529(9) 
Ir-N [Å]: 2.111(2) / 2.148(2) 2.121(2) 
P-X [Å]: 1.663(2) / 1.659(2) 1.619(2) 
Ir-C7 [Å]: 3.255 / 3.226 3.221 
 P-Ir-N [°]: 86.92(6) / 86.03(6) 86.27(7) 
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5.4 Hydrogenation Results 
5.4.1 Potential Cyclometallation 
Before starting the investigation of the new bicyclic pyridine amino-phosphine derived 
ligands in Ir-catalyzed asymmetric hydrogenations, potential cyclometallation of complexes 
(S)-142f and (S)-142g was evaluated. For this purpose the same experiment described in 
scheme 5.5 was performed using complex (S)-142f instead of the phosphinite derived 
complex 36f (scheme 5.12).  
 
  
Scheme 5.12: Activation of aminophosphine derived iridium complex (S)-142f with hydrogen gas 
(left). High-field region of the NMR spectra obtained from the product mixture (right). 
 
After purification by flash chromatography a mixture of at least two different components was 
obtained. ESI-MS analysis indicates a mixture of mononuclear, binuclear and even trinuclear 
iridium species. NMR data are neither in agreement with an H-bridged trinuclear complex nor 
with the cyclometallaed binuclear complex similar to 71. The integration ratio of the hydride 
signals for the H-bridged trinuclear complex should be 1:2:2 rather than 1:1:1, and the signal 
observed at −7.55 ppm would be a quartet rather than a double doublet. The integral ratio of 
1:1:1 would be in agreement with a binuclear complex, similar to 71. However, the chemical 
shifts and the signal splittings are completely different. Unfortunately, no crystal suitable for 
X-ray crystal analysis could be obtained from the mixture of these components. Therefore, the 
nature of the degradation products remains unclear. 
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5.4.2 Hydrogenation of Model Substrates 
Table 5.5: Hydrogenation of (E)-α-methylstilbene (7). 
 
Entry Ir-catalyst R Conv. [%][a] ee [%][b] 
1 
 
(S)-142a Ph >99 98 (S) 
2 (S)-142b o-Tol >99 98 (S)  
3 
 
(S)-142c Ph 96 86 (S) 
4 (R)-142d o-Tol >99 77 (R) 
5 (R)-142e Cy >99 91 (R) 
6 
 
(S)-142f Ph 1 n.d. 
7 (S)-142g o-Tol 10 17 (R) 
8[57b] 
 
(R)-36b o-Tol >99 >99 (R) 
[a]: Determined by GC analysis of the reaction mixture after removal of the catalyst; [b]: Determined by HPLC 
analysis on a chiral stationary phase.  
 
Most of the aminophosphine pyridine derived iridium complexes that were tested proved to be 
very active in the hydrogenation of methylstilbene 7. Only catalysts (S)-142f and (S)-142g 
gave very low conversions (table 5.5, entries 6 and 7). Catalyst (R)-142e provided a 
respectable 91% ee (entry 5). However, the most selective catalysts are (S)-142a and (S)-
142b, giving the hydrogenation product with 98% ee (entries 1 and 2). This is close to the ee 
achieved with the best phosphinite derived Ir-complex (R)-36b (entry 8). 
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Table 5.6: Hydrogenation of (E)-2-(4-methoxyphenyl)-2-butene (90). 
 
Entry Ir-catalyst R Conv. [%][a] ee [%][b] 
1 
 
(S)-142a Ph >99 94 (S)  
2 (S)-142b o-Tol >99 86 (S) 
3 
 
(S)-142c Ph >99 77 (S) 
4 (R)-142d o-Tol >99 64 (R) 
5 (R)-142e Cy >99 58 (R) 
6 
 
(S)-142f Ph 68 90 (S) 
7 (S)-142g o-Tol >99 38 (S) 
8[57b] 
 
(R)-36b o-Tol >99 >99 (R) 
[a]: Determined by GC analysis of the reaction mixture after removal of the catalyst; [b]: Determined by GC 
analysis on a chiral stationary phase.  
 
Again almost all the Ir-complexes showed high activity in the hydrogenation of the (E)-olefin 
90. In terms of enantioselectivity catalyst (S)-142a performed best, giving the product with 
94% ee (table 5.6, entry 1). However, this is clearly lower, compared to the structurally 
similar phosphinite derived catalyst (R)-36b which gave >99% ee (entry 8). In contrast to the 
trend observed with the phosphinite-derived catalyst, the sterically more demanding ortho-
tolyl groups gave in this case lower enantioselectivities (entries 1 vs. 2, 3 vs. 4, 6 vs. 7).  
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Table 5.7: Hydrogenation of (Z)-2-(4-methoxyphenyl)-2-butene (91). 
 
Entry Ir-catalyst R Conv. [%][a] ee [%][b] 
1 
 
(S)-142a Ph >99 96 (R) 
2 (S)-142b o-Tol >99 87 (R) 
3 
 
(S)-142c Ph 82 76 (R) 
4 (R)-142d o-Tol >99 80 (S) 
5 (R)-142e Cy >99 37 (S) 
6 
 
(S)-142f Ph 60 86 (R) 
7 (S)-142g o-Tol 73 32 (R) 
8[57b] 
 
(R)-36b o-Tol >99 98 (S) 
[a]: Determined by GC analysis of the reaction mixture after removal of the catalyst; [b]: Determined by GC 
analysis on a chiral stationary phase.  
 
Catalysts (S)-142c, (S)-142f and (S)-142g did not give full conversion in the hydrogenation of 
the (Z)-alkene 91 (table 5.7, entries 3, 6 and 7). In terms of enantioselectivity again catalyst 
(S)-142a performed best (entry 1). The ee of 96% is very close to the best result obtained with 
the phosphinite catalyst (R)-36b (entry 8). This time a clear trend in the influence of the P-
substituents was not observed. While (R)-142d bearing ortho-tolyl groups gave higher ee than 
(S)-142c (entries 3 vs. 4), catalyst (S)-142b was performing worse than (S)-142a (entries 1 vs. 
2). 
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Table 5.8: Hydrogenation of 2-(4-methoxyphenyl)-1-butene (88). 
 
Entry Ir-catalyst R Conv. [%][a] ee [%][b] 
1 
 
(S)-142a Ph >99 10 (R) 
2 (S)-142b o-Tol >99 24 (R) 
3 
 
(S)-142c Ph >99 32 (R) 
4 (R)-142d o-Tol >99 25 (S) 
5 (R)-142e Cy >99 38 (S) 
6 
 
(S)-142f Ph >99 55 (S) 
7 (S)-142g o-Tol >99 rac. 
8[57b] 
 
(R)-36b o-Tol >99 80 (S) 
[a]: Determined by GC analysis of the reaction mixture after removal of the catalyst; [b]: Determined by GC 
analysis on a chiral stationary phase.  
 
Although all the aminophosphine derived catalysts showed high activity in the hydrogenation 
of terminal olefin 88, enantioselectivities were only low to moderate (table 5.8). Surprisingly, 
the best result (55% ee, entry 6) was achieved using catalyst (S)-142f which performed poorly 
with the previously tested olefins. Electronic effects seem to play a crucial role for the 
selectivity. While the phosphinite derived catalyst (R)-36b produced 80% ee (entry 8), the 
aminophosphine catalyst (S)-142b gave only 24% ee (entry 2).  
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Table 5.9: Hydrogenation of 7-methoxy-1,2-dihydro-naphthalene (72). 
 
Entry Ir-catalyst R Conv. [%][a] 21 [%] ee [%][b] 
1 
 
(S)-142a Ph >99 n.o. 89 (R) 
2 (S)-142b o-Tol >99 n.o. 87 (R) 
3 
 
(S)-142c Ph 98 3 60 (R) 
4 (R)-142d o-Tol >99 n.o. 60 (S) 
5 (R)-142e Cy >99 n.o. 27 (S) 
6 
 
(S)-142f Ph 41 6 22 (R) 
7 (S)-142g o-Tol 71 18 19 (R) 
8[57b] 
 
(R)-36b o-Tol >99 n.o. 87 (S) 
[a]: Determined by GC analysis of the reaction mixture after removal of the catalyst; [b]: Determined by HPLC 
analysis on a chiral stationary phase.  
 
As seen already in the previous chapters (for example chapter 4), the cyclic olefin 72 can be a 
very challenging substrate because it is prone to oxidation leading to the aromatic naphthalene 
derivative 115. This side reaction was only observed for catalysts that showed poor activity 
(table 5.9, entries 3, 6 and 7). All the other catalysts gave selectively the hydrogenation 
product. The best enantioselectivity was again achieved with catalyst (S)-142a (89% ee, entry 
1). The enantioselectivity is even higher ee than that previously obtained with the phosphinite 
derived catalyst (R)-36b (entry 8). 
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Table 5.10: Hydrogenation of (E)-2-methyl-3-phenylprop-2-en-1-ol (24). 
 
Entry Ir-catalyst R Conv. [%][a] 
Product 
[%][a] 
ee [%][b] 
1 
 
(S)-142a Ph >99 >99 84 (R) 
2 (S)-142b o-Tol >99 >99 86 (R) 
3 
 
(S)-142c Ph >99 85 60 (R) 
4 (R)-142d o-Tol >99 >99 81 (S) 
5 (R)-142e Cy >99 88 49 (S) 
6 
 
(S)-142f Ph 90 50 27 (R) 
7 (S)-142g o-Tol >99 75 8 (R) 
8[57b] 
 
(R)-36b o-Tol >99 >99 97 (S) 
[a]: Determined by GC analysis of the reaction mixture after removal of the catalyst; [b]: Determined by HPLC 
analysis on a chiral stationary phase.  
 
The allylic alcohol 24 is a challenging substrate too, as often unpredictable side reactions 
(oxidation, isomerization, polymerization) can occur. Therefore, the yield of product that was 
determined by GC is given in the column next to the conversion in table 5.10, whereas 
conversion is termed to the consumption of starting material. Again the less reactive 
complexes gave also significant amount of side products (not identified) whereas the more 
active catalysts led to clean hydrogenation. In contrast to the previously described substrates, 
the most selective catalyst in this case was (S)-142b with the ortho-tolyl groups on 
phosphorus atom (entry 2). However, the enantioselectivity obtained with this catalyst is 
clearly lower than the value achieved with the structurally related phosphinite derived catalyst 
(R)-36b (entry 2 vs. 8).  
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Table 5.11: Hydrogenation of (E)-ethyl 3-phenylbut-2-enoate (98). 
 
Entry Ir-catalyst R Conv. [%][a] ee [%][b] 
1 
 
(S)-142a Ph >99 46 (S) 
2 (S)-142b o-Tol >99 86 (S) 
3 
 
(S)-142c Ph 40 41 (S) 
4 (R)-142d o-Tol 93 76 (R) 
5 (R)-142e Cy >99 92 (R) 
6 
 
(S)-142f Ph 1 n.d. 
7 (S)-142g o-Tol 16 25 (S) 
8[57b] 
 
(R)-36b o-Tol >99 96 (R) 
[a]: Determined by GC analysis of the reaction mixture after removal of the catalyst; [b]: Determined by HPLC 
analysis on a chiral stationary phase.  
 
In the hydrogenation of the α,ȕ-unsaturated ester 98 catalysts (S)-142f and (S)-142g showed 
poor activity (table 5.11, entries 6 and 7). Only three of the eight complexes tested gave full 
conversion. The best result in terms of enantioselectivity was obtained with catalyst (R)-142e, 
which provided the product with 92% ee (entry 5). For this substrate the sterically more 
demanding bis-ortho-tolyl phosphine induced as well significantly higher enantioselectivities 
than the diphenylphosphine ligands (entries 1 vs. 2, and 3 vs. 4).  
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Table 5.12: Hydrogenation of (E)-N-(1-phenylethylidene)aniline (13). 
 
Entry Ir-catalyst R Conv. [%][a] ee [%][b] 
1 
 
(S)-142a Ph 51 19 (R) 
2 (S)-142b o-Tol 31 63 (R) 
3 
 
(S)-142c Ph 51 4 (R) 
4 (R)-142d o-Tol 44 rac. 
5 (R)-142e Cy >99 39 (R) 
6 
 
(S)-142f Ph 5 n.d. 
7 (S)-142g o-Tol 1 n.d. 
8[57b] 
 
(R)-36b o-Tol >99 82 (S) 
[a]: Determined by GC analysis of the reaction mixture after removal of the catalyst; [b]: Determined by HPLC 
analysis on a chiral stationary phase.  
 
In the hydrogenation of imine 13 most of the applied catalysts did not lead to reach full 
conversion within the given reaction time (2 hours, table 5.12) and the chiral amine 14 was 
obtained with a maximum ee of 63% (entry 2). 
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5.5 Summary and Outlook 
In summary, a synthetic route towards enantiopure pyridyl amines 136 was developed. The 
key step, to obtain enantiomerically pure ligands, was an enzymatic kinetic resolution of 
primary pyridyl amines (scheme 5.11). Furthermore, an efficient approach for the formation 
of N,P ligands was developed. After complexation to iridium seven different air-stable 
complexes with various electronic and steric properties were obtained (Scheme 5.13).  
 
 
Scheme 5.13: Synthesis of aminophosphine derived iridium precatalyst 142 for the asymmetric 
hydrogenations.  
 
Applying these complexes to the asymmetric hydrogenation of several model substrates 
excellent enatioselectivies were obtained for weakly functionalized olefins (up to 98% ee). 
For olefins with coordinating groups (like carbonyl) very good enantioselectivies (up to 92% 
ee) were obtained, whereas these catalysts performed poorly in the hydrogenation of 
acetophenone imine.  
Future work might be dedicated to the development of N,P ligands 143, 144 and 145. By 
installing various substituents on the P-bound nitrogen atom, a more direct approach to 
control the electronic properties of the ligands could be achieved (Scheme 5.14).  
 
 
Scheme 5.14: Proposed ligands 143, 144 and 145 for Ir-catalyzed asymmetric hydrogenation. 
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6.1 Introduction 
6.1.1 Chiral Boronic Acids and Esters 
Chiral boronic acids are highly versatile building blocks in organic synthesis,[128] since 
carbon-boron bonds can be readily converted into C–O, C–N and C–C bonds in a 
stereospecific manner.[129] Furthermore, boronic acids can act as surrogates of carboxylic 
acids[128] and are thus interesting motifs for drug design.[130] For example, α-amino boronic 
acids serve as building blocks for unnatural peptides, which are getting increasing attention as 
new anti-cancer drugs.[131] Hence, enantioselective routes to these compounds are of great 
value. The most widely used method for the synthesis of enantioenriched chiral boronic esters 
is the hydroboration of C=C bonds with chiral hydroboranes pioneered by H. Brown (scheme 
6.1a).[132] The method works particularly well with 1,2-disubstituted cis olefins, while the 
corresponding trans isomers and trisubstituted olefins usually react with much lower 
enantioselectivity.[129a-c]  
 
 
Scheme 6.1: Enantioselective routes to chiral secondary alkyl boronates. 
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On the other hand, the homologation reaction involving a stereoselective migration-
displacement process, originally developed by D. Matteson[133] and further investigated by V. 
Aggarwal,[134] yields chiral secondary boron compounds directly from α-haloboronic esters or 
primary alcohols (scheme 6.1b). 
Although these approaches have proved very useful in complex molecule synthesis, it was 
desirable to develop catalytic methods that do not require stoichiometric quantities of chiral 
reagents. The discovery of D. Männig and H. Nöth that rhodium complexes catalyze the 
addition of catecholborane to alkenes paved the way toward enantioselective catalytic 
hydroboration.[135] Subsequently, rhodium,[136] and to a lesser extent other transition metal 
complexes with chiral ligands have been successfully used as catalysts to prepare chiral 
organoboranes in high enantiomeric purity.[129d, 137] However, the substrate scope of these 
reactions is still limited. With few exceptions, high enantio- and regioselectivities are only 
obtained with aryl-substituted alkenes.  
 
 
6.1.2 Hydrogenation of Boronic Esters Described in the Literature 
The asymmetric hydrogenation of alkenylboronic esters is attractive, because it avoids the 
regioselectivity problems often encountered in catalytic and stoichiometric hydroborations. 
Moreover, asymmetric hydrogenation is one of the best established reactions in organic 
synthesis with a wide range of potential catalysts available. The first report using 
alkenylboronic ester 146g for asymmetric hydrogenation was published in 2002 by N. 
Miyaura and co-workers. The chiral boronate (S)-147g was not isolated, but rather oxidized to 
1-phenyl-1-ethanol (148). Using Rh-complexes in combination with diphosphine ligands in 
general low catalytic activity and selectivity were achieved. The highest ee (80%) was 
obtained using BINAP 6 as chiral ligand after seven days reaction time (scheme 6.2).[138] 
 
 
Scheme 6.2: First reported Rh-BINAP mediated asymmetric hydrogenation of alkenylboronic ester 
146g.[138]  
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Two years later J. Morgan and J. Morken reported on the enantioselective Rh-catalyzed 
hydrogenation of 1,2-bis(boronates) 149 mediated by bisphosphine ligands.[139] The best 
results in terms of activity and selectivity were achieved using Walphos[140] ligand 151 
(scheme 6.3). It should be mentioned that the hydrogenation products 150 were again directly 
oxidized to the enantioenriched diols rather than isolated. However, a relatively narrow 
substrate scope was reported, but nevertheless high enantioselectivities (86-93%) were 
achieved for various residues. 
 
 
Scheme 6.3: Rh-Walphos-catalyzed asymmetric hydrogenation of alkenyl-1,2-bis(boronates) 149.[139]  
 
Two years later and W. Moran and J. Morken successfully employed alkenyl boronic esters 
146 for the Rh-catalyzed asymmetric hydrogenation, using again Walphos ligand 151 
(scheme 6.4).[141] In general, full conversions and high ees (81-97%) for several alkenyl 
boronic esters were achieved. However, relatively high catalyst loading loadings of 5 mol% 
and long reaction times were required. Furthermore, the authors demonstrated the usefulness 
of the hydrogenation products (R)-147. For example chiral secondary amine (R)-152 could be 
obtained after a sequence involving the cleavage of the pinacole group, treatment with benzyl 
azide and subsequent rearrangement with release of nitrogen gas. On the other hand, they 
obtained the chiral primary alcohol (R)-153 after homologenation with lithiated 
chloromethane and oxidation with hydrogen peroxide.  
 
Chapter 6 
118 
 
Scheme 6.4: Rh-Walphos-catalyzed asymmetric hydrogenation of alkenylboronate 146 and potential 
applications of the hydrogenation product (R)-147h.[141]  
 
More recently, P. G. Andersson and co-workers found that iridium complexes with chiral N,P 
ligands are more active catalysts in reactions of this type, giving full conversion with only 0.5 
mol% catalyst loading (scheme 6.5). With certain alkenylboronates, for example 146g, 149h 
and 149p, high ees were achieved, while analogous alkyl-substituted substrates, like 146a 
gave unsatisfactory enantiomeric excesses.[64, 71a]  
 
 
Scheme 6.5: First reported Ir-catalyzed asymmetric hydrogenation of alkenyl boronic esters 
hydrogenation 146 or 149.[64, 71a] 
 
Parallel to the studies described herein, a new report on the Ir-catalyzed asymmetric 
hydrogenation of alkenyl boronic esters was published recently (scheme 6.6).[142] In this case, 
the authors achieved the challenging hydrogenation of boronic esters 154, which have a 
chlorine atom at the vinylic position. In analogy to the hydrogenation of vinyl fluorides 
described in chapter 5.1, the challenge with substrates 154 is to find efficient hydrogenation 
conditions, while avoiding dehalogenation to the side-product 156. The valuable 
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hydrogenation products 155 were obtained using an Ir-catalyst derived from ferrocenyl 
imidazoline N,P ligand 157. 
 
 
Scheme 6.6: Ir-catalyzed asymmetric hydrogenation of (1-chloro-1-alkenyl) boronic esters 154.[142] 
 
 
6.1.3 Objective of This Study 
Overall, the scope of these Rh- and Ir-catalyzed hydrogenations is still limited, so the search 
for other catalysts that enhance the application range will continue. The hydrogenation of the 
aliphatic boronate 146a, which so far had given unsatisfactory results with Ir-catalysts, served 
as a starting point for this study (scheme 6.7).  
 
 
Scheme 6.7: Results obtained in Rh- and Ir-catalyzed asymmetric hydrogenations of alkyl substituted 
vinylic boronic esters 146a.[64, 71a, 141] 
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6.2 Synthesis of Substrates 
6.2.1 Synthesis of Terminal Boronic Esters 
The boronic ester substrates bearing a terminal double bond were obtained by two different 
procedures both starting from commercially available alkynes 157 (table 6.1). Addition of 
boron tribromide to alkynes led to 2-bromo-alkenylboranes, which were hydrolyzed in the 
presence of acetic acid to give 2-bromo-alkenyl intermediates 159. Lithium halogen exchange 
from 159 with t-BuLi and subsequent trapping with (pin)BO(i-Pr) provided access to most of 
the substrates 146 (entries 1-2 and 5-8).[141] Since substrates 146c, 146d and 146i could not be 
obtained by this approach, they were synthesized via the corresponding vinyl iodides 160 as 
described by Y. Ishii et al.[143] By using a mixture of TMSCl, NaI and water, hydrogen iodide 
was generated in situ. Under these conditions HI adds to the C≡C bond with complete cis-
selectivity in a Markovnikov fashion, to give 160. Vinyl iodides 160 were used with 
bis(pinacolato)diboron for C−B Miyaura-coupling-reaction, to obtain vinyl boronates 146c, 
146d and 146i (entries 3, 4 and 9).[144] Both approaches provide the substrates in poor to 
moderate yields (14-56%).  
 
Table 6.1: Preparation of terminal alkenyl boronic esters 146. 
 
Entry Alkyne 
Methods 
used 
Intermediate Substrate 
Yield
[a] 
[%] 
1 1-octyne (158a) A1 & B1 159a 
 
146a 31 
2 1-hexyne (158b) A1 & B1 159b 
 
146b 29 
3 6-chloro-1-hexyne (158c) A1 & B2 159c 
 
146c 26 
4 propargyl alcohol (158d) A2 & B2 160a 
 
146d
[a]
 58 
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5 4-phenyl-1-butyne (158e) A1 & B1 159d 
 
146e 36 
6 
3-phenyl-1-propyne 
(158f) 
A1 & B1 159e 
 
146f 14 
7 --- --- --- 
 
146g ---[b] 
8 
cyclohexylacetylene 
(158g) 
A1 & B1 159f 
 
146h 24 
9 
3,3-dimethyl-1-butyne 
(158h) 
A2 & B2 160b 
 
146i 36 
[a] The TBS protecting group was not stable under the reaction conditions applied for methods A1 and A2, but 
had to be introduced prior installation of the boron group.[145] Therefore, the free alcohol was protected using 
TBSCl (1.1 eq.) and DMAP (1.1 eq.) in DCM (0.1 M) solution after halogenation. [b] 1-Phenylvinylboronic acid 
pinacol ester (146g) was purchased from Aldrich (659193). 
 
 
6.2.2 Synthesis of Trisubstituted Boronic Esters 
In order to achieve high levels of enantioselectivities, the synthesis of substrates with perfect 
E and Z selectivity is important. Therefore alkynes were reacted with bis-pinacolato diboron 
using a platinum catalyst to obtain trisubstited cis-1,2-bis(boryl)alkenes 149a-c obtained in 
good yields 74-83% (table 6.2, entries 1-3). 1,2-Bis-boronates 149a-d were used as substrates 
for the hydrogenation. 
 
Table 6.2: Preparation of trisubstitued cis-1,2-bis(boryl)alkenes 149a-d. 
 
Entry Alkyne Products  
Yield 
[%] 
1 cyclohexylacetylene (158g) 
 
149a 83 
2 1-octyne (158a) 
 
149b 74 
3 3,3-dimethyl-1-butyne (158h) 
 
149c 83 
4 --- 
 
149d ---[a] 
[a] (E)-α,ȕ-Styrenediboronic acid bis(pinacol) ester (149d) was purchased from Alfa Aesar (L19651) and used as 
received. 
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Furthermore, they are also versatile precursors for the preparation of alkenyl-monoboronic 
esters with a trisubstituted C=C bond by Suzuki−Miyaura coupling occurring selectively at 
the more reactive terminal boronate group.[146] In this way a series of alkenylboronates 
149e-n, in which the terminal boron substituent had been replaced by different groups (table 
6.3, entries 1-9) was prepared in generally good yield (60-73%). Only for the purely alkyl 
substituted alkenylboronate 149n the yield dropped down to 19% (entry 10).  
 
Table 6.3: Preparation of trisubstitued alkenyl boronic esters 149e-o. 
 
Entry 
1,2-
bis(boryl)alkenes 
R
2
-Br Substrate Yield
 [%] 
1 149a 4-bromotoluene 
 
149e 60 
2 149b 4-bromotoluene 
 
149f 62 
3 149c 4-bromotoluene 
 
149g 66 
4 --- --- 
 
146h ---[a] 
5 149a bromobenzene 
 
149i 73 
6 149a 4-bromoanisole 
 
149j 64 
7 149a 
4-bromo-
trifluorotoluene 
 
149k 64 
8 149a 
1-bromo-3-
fluorobenzene 
 
149l 75 
9 149a benzyl bromide 
 
149m 78 
10 149a ethyl bromide 
 
149n 19 
11 --- --- 
 
146p ---[a] 
[a] Stilbeneboronic acid pinacol ester (146h) and Methyl (E)-oct-2-enoate-3-boronic acid pinacol ester (146p) 
were purchased from Alfa Aesar (L19651) respectively from Aldrich (540625) used as received. 
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Finally, substrate 149o was obtained by a zirconocene-mediated regioselective coupling with 
ethylene gas from 2-phenyl-1-ethynylboronic acid pinacol ester 158 in moderate yield 
(scheme 6.8).  
 
 
Scheme 6.8: Zirconocene mediated regioselective preparation of substrate 149o.[142] 
 
 
6.3 Hydrogenation Results 
6.3.1 Hydrogenation of Terminal Boronic Esters 
As already mentioned the hydrogenation of the aliphatic boronate 146a, which so far had 
given unsatisfactory results with Ir-catalysts, served as a starting point for this study. In a 
series of chiral N,P ligand complexes that were screened in this reaction,[38b] complex 162c 
derived from an imidazoline-phosphinite ligand stood out as the most promising catalyst, 
providing an enantiomeric excess of 68% at 50 bar hydrogen pressure (scheme 6.9).[147]  
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Scheme 6.9: Catalyst screening for the hydrogenation of boronic ester 146a.  
[a]: Determined by GC analysis of the reaction mixture after removal of the catalyst; [b]: Determined by GC 
analysis on a chiral stationary phase.  
 
In a next step important reaction parameters were systematically varied, in order to increase 
the enantioselectivity. Since terminal olefins are known to react with higher enantioselectivity 
at lower pressure with iridium catalysts of this type,[49] the hydrogenation of 146a was 
performed at 2 bar hydrogen pressure. Indeed, the ee increased to 86% while full conversion 
was still achieved. The reaction was also proceeding with a standard hydrogen ballon with the 
same enantioselectivity, but somehow slower reaction rate. Therefore, the pressure of 2 bar H2 
was kept, in order to achieve full conversion. Furthermore, the solvent influence was 
investigated, since hydrogenation with rhodium complexes showed a remarkably high solvent 
dependence for substrates of this type.[141] However, in this case the solvent influence proved 
to be weak. In DCM, DCE, toluene and chlorobenzene an ee of 86% was obtained, while only 
slightly lower enantioselectivities were recorded in more polar solvents like cyclopentyl 
methyl ether (83% ee), ethyl aceate (81% ee) or trifluoroethanol (78% ee). No special 
precautions to exclude oxygen and moisture were found to be necessary when setting up the 
hydrogenation, so the reaction solutions could be conveniently prepared in the laboratory 
atmosphere without rigorous purification of the solvents.  
Next, the steric and electronic effects of the substituents at the stereogenic center and the 
nitrogen atom of the imidazoline ring and at the phosphorus atom of the ligand were studies. 
As shown in table 6.4 the sterically demanding tert-butyl group on the imidazole ring is 
Ir-Catalyzed Enantioselective Hydrogenation of Alkenylboronic Esters 
125 
necessary for achieving high enantioselectivity (entry 1 vs. 2). The introduction of electron 
donor or acceptor substituents in the N-phenyl group led to lower ee values (entries 3-5). 
Replacement of the P-phenyl groups by P-ortho-tolyl groups also lowered the 
enantioselectivity (entry 6), whereas the more electron-donating dicyclohexylphosphino group 
improved the ee to 91% (entry 7). The sterically more demanding di-tert-butylphosphino 
group, on the other hand, caused a decrease of the ee to 77% (entry 8). Thus, catalyst 162h 
that seemed to have an optimal balance between electronic and steric properties was selected 
for further studies.  
 
Table 6.4: Catalyst optimization performed in the hydrogenation of vinyl boronate 146a. 
 
Entry [Ir-cat.] R
1
 R
2
 R
3
 Conv. [%][b] ee [%][b] 
1 (R)-162a Ph i-Pr Ph >99 46 (R) 
2 162c Ph t-Bu Ph >99 86 
3 162d Ph t-Bu o-Tol >99 79 
4 162e Ph t-Bu p-F3C-C6H4 >99 80 
5 162f Ph t-Bu 3,5-(MeO)2-C6H3 >99 59 
6 162g o-Tol t-Bu Ph >99 81 
7 162h Cy t-Bu Ph >99 91 
8 162i t-Bu t-Bu Ph >99 77 
[a]: Determined by GC analysis of the reaction mixture after removal of the catalyst; [b]: Determined by GC 
analysis on a chiral stationary phase.  
 
The enantioselectivity of catalyst 162h could be further improved by lowering the 
temperature. The best result was achieved at –20 °C with an ee of 96%, while still 
maintaining full conversion (table 6.5 and figure 6.1). For the di-tert-butylphosphino-
imidazoline ligand complex 162i the temperature had a similar effect with an increase in ee 
from 68% at 40 °C to 81% at –20 °C. Remarkably, the di-ortho-tolyl analogue 162g showed a 
strikingly different behavior. In this case, the enantioselectivity dropped from 81% ee to 15% 
ee when the temperature was lowered from 25 °C to –20 °C. The enantioselectivity of the 
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corresponding catalyst 162a with a diphenylphosphino group, on the other hand, remained in 
a narrow range of 80 to 85% ee between –20 and 40 °C.  
 
 
Figure 6.1: Temperature influence in the hydrogenation of terminal vinyl boronate 146a using 
phosphinite-imidazoline derived catalyst 162c and 162g-i. 
 
A series of experiments at different catalyst loadings and a reaction time of 4 h demonstrated 
that 0.1 mol% catalyst are sufficient to achieve full conversion and retain the ee at 96% (table 
6.5, entries 17-20). Lower catalyst loadings led to incomplete conversion although the 
enantioselectivity was not affected (entry 21).  
 
Table 6.5: Reaction parameters optimization performed in the hydrogenation of vinyl boronate 146a. 
 
 
Entry [Ir-cat] R
1 
Ir-cat.  
[mol%] 
Time  
[h] 
T 
[°C] 
Conv. 
[%][a] 
ee 
[%][b] 
1 162c Ph 1.00 12 40 >99 80 
2 162c Ph 1.00 12 25 >99 86 
3 162c Ph 1.00 12 0 >99 79 
4 162c Ph 1.00 12 −20 >99 82 
5 162g o-Tol 1.00 12 40 >99 63 
6 162g o-Tol 1.00 12 25 >99 81 
7 162g o-Tol 1.00 12 0 >99 42 
8 162g o-Tol 1.00 12 −20 >99 15 
9 162h Cy 1.00 12 40 >99 77 
10 162h Cy 1.00 12 25 >99 91 
11 162h Cy 1.00 12 0 >99 95 
12 162h Cy 1.00 12 −20 >99 96 
13 162i t-Bu 1.00 12 40 >99 68 
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14 162i t-Bu 1.00 12 25 >99 77 
15 162i t-Bu 1.00 12 0 >99 82 
16 162i t-Bu 1.00 12 −20 >99 83 
17 162h Cy 1.00 4 −20 >99 96 
18 162h Cy 0.50 4 −20 >99 96 
19 162h Cy 0.25 4 −20 >99 96 
20 162h Cy 0.10 4 −20 >99 96 
21 162h Cy 0.05 4 −20 58 96 
[a]: Determined by GC analysis of the reaction mixture after removal of the catalyst; [b]: Determined by GC 
analysis on a chiral stationary phase.  
 
Having established the optimal conditions for substrate 146a, the scope of catalyst 162h in the 
hydrogenation of boronic esters with a terminal C=C bond was investigated (scheme 6.10). 
All substrates having a CH2 group next to the double bond were well tolerated. Excellent 
activity and enantioselectivity were obtained for a variety of different substrates having 
additional functional groups (chloride 146c, OTBS 146d or phenyl groups 146e-f). Sterically 
more demanding substituents next to the C=C bond (146g-i) required higher catalyst loadings 
(1 mol%) and longer reaction times (>12 h) to achieve full conversion, and a dramatic drop in 
enantioselectivity was observed. In this respect, catalyst 162h strongly differed from 
Andersson's Ir-catalysts 39a that gave 89% ee with substrate 146g, but only 18% ee with 
146a.[64]  
 
 
Scheme 6.10: Substrate scope of the hydrogenation of terminal boronic esters 146.  
[a] Determined by GC analysis of the reaction mixture after removal of the catalyst; [b] Determined by GC 
analysis on a chiral stationary phase; [c] Reaction time 12 hours. 
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In order to figure out which catalysts might provide reasonable ees in the hydrogenation 
aromatic and branched substrates 146g and 146h, more catalyst screenings were performed. 
For the styrene-based substrate 146g the best result was obtained using the bicyclic pyridine-
phosphinite derived Ir-catalyst 36e (scheme 6.11, 78% ee). However, all attempts to further 
increase the selectivity by variation of the catalyst structure or by changing the reaction 
conditions failed.  
 
 
 
 
 
Scheme 6.11: Catalyst screening for the hydrogenation of boronic ester 146g.  
[a] Determined by GC analysis of the reaction mixture after removal of the catalyst; [b] Determined by HPLC 
analysis on a chiral stationary phase. 
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For the cyclohexyl-substituted olefin 146h the optimized reaction conditions (2 bar, and 
−20 °C) for the hydrogenation of 146a were applied. As shown in scheme 6.10, the 
imidazolyl-dicyclohexyl-phosphinite-catalyst 162h gave only 33% ee (scheme 6.10). 
However, using the sterically more demanding imidazolyl-di-tert-butyl-phosphinite-catalyst 
162i an ee of 67% could be achieved (scheme 6.12). This is approximately in the same range 
as the values obtained with one of the ThrePHOX derived Ir-catalysts 21b (69% ee), but 
lower than that achieved with one member of the Ir-NeoPHOX family 30b (85% ee). 
However, the best results (91% ee) for the hydrogenation of substrate 146h was achieved 
using a phosphanyl-methyl-oxazoline derived catalyst 33d. Nevertheless, this value is still 
clearly lower than the one reported with Rh-Walphos catalyst.[141]  
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Scheme 6.12: Catalyst screening for the hydrogenation of boronic ester 146h.  
[a] Determined by GC analysis of the reaction mixture after removal of the catalyst; [b] Determined by GC 
analysis on a chiral stationary phase. 
 
 
6.3.2 Hydrogenation of Trisubstituted Boronic Esters 
The next substrates targeted were bisboronic esters 149a-d (table 6.2, entries 1-4). However, 
for this substrate class the phosphinite-imidazoline ligand complex 162h gave poor 
enantioselectivities (only 13% ee for substrate 149a). In a brief catalyst screening (scheme 
6.13) the pyridine-phosphinite complexes[56, 57b] 36d and 36e emerged as the most promising 
catalysts for substrates of this type.  
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Scheme 6.13: Catalyst screening for the hydrogenation of bis-boronic ester 149a.  
[a] Determined by GC analysis of the reaction mixture after removal of the catalyst; [b] Determined by GC 
analysis on a chiral stationary phase. 
 
Catalyst 36e having a 6-membered carbocyclic ring showed higher ee for substrate 149a than 
the more rigid catalyst 36d. But the activity of catalyst 36d in the hydrogenation of different 
1,2-bisboronic esters 149a-d showed a broader substrate scope (scheme 6.14). Various 
substituents (cyclohexyl, n-hexyl, tert-butyl, and phenyl) at the C=C bond were tolerated, 
giving high conversions for all substrates. The cyclohexyl- and phenyl-substitued 
bisboronates 149a and 149d reacted with excellent enantioselectivities of 95 and 98% ee, 
while the sterically less demanding n-hexyl derivative gave 72% ee. On the other hand, 
catalyst 36e gave even higher ee for substrate 149d, but clearly lower activity for 149c and 
lower selectivity for 149c. 
 
 
 
 
   
 149b 149c 149c 
(S)-36d 
>99% conv. 
72% ee (+) 
97% conv. 
85% ee (+) 
>99% conv. 
98% ee (+) 
(R)-36e 
>99% conv. 
59% ee (−) 
20% conv. 
n.d. ee (−) 
>99% conv. 
>99% ee (−) 
Scheme 6.14: Comparison of selectivity and activity of pyridine-phosphinite derived Ir-complexes 36d 
and 36e for the asymmetric hydrogenation of 1,2-bisboronic esters 149b-d.  
 
Therefore, the hydrogenation of trisubstitued mono boronic esters 149e-p was performed 
using iridium catalyst 36d. Generally, excellent selectivities from 95% up to >99% ee were 
achieved. With the exception of the sterically demanding tert-butyl derivative 149g, all other 
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substrates gave >98% conversion. Electron donor or acceptor groups at the aryl substituent 
had no significant effect on ee and conversion. Aryl substituents at the C=C bond are not 
essential for achieving high enantioselectivity, as shown by the hydrogenation of the merely 
alkyl-substituted substrates 149m and 149n. Substrate 149o[148] bearing a boronic ester 
residue at the less substituted olefinic C atom reacted with lower, but still very good 
enantioselectivity yielding the corresponding primary alkylboronate with full conversion and 
90% ee. 
 
 
 
 
 
Scheme 6.15: Substrate scope of the hydrogenation of trisubstitued boronic esters 149.  
[a] Determined by GC analysis of the reaction mixture after removal of the catalyst; [b] Determined by GC or 
HPLC analysis on a chiral stationary phase. 
 
Furthermore, the hydrogenation of substrate 146p which has a coordinating carbonyl group 
adjacent to the C=C bond was investigated. Initial screening revealed complex 26a derived 
from SimplePHOX ligand as the most promising catalyst for this substrate (84% ee; scheme 
6.16).  
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Scheme 6.16: Catalyst screening for the hydrogenation of trisbustituted boronic ester 146p having a 
coordinating carbonyl group adjacent on the C=C bond.  
[a] Determined by GC analysis of the reaction mixture after removal of the catalyst; [b] Determined by GC 
analysis on a chiral stationary phase. 
 
In a next step, variation of the catalyst structure 26 was investigated in order to improve the 
enantioselectivity for this substrate. For this purpose the substituent on phosphorus, on the 
oxazoline moiety and the bridging unit were modified (table 6.6). This variation revealed that 
phenyl and cyclohexyl groups were well tolerated as substituents on the phosphorus atom, 
while o-Tol, t-Bu or 3,5-CF3-C6H3 groups gave significantly lower ees (entries 1-6). 
Modification of the bridging unit, which allows the installation of an additional stereogenic 
center,[98] did not give any improvement in ee (entries 7-9). Finally, by replacing the 
substituent on the oxazoline to phenyl the highest ee of 90% was obtained (entry 13).  
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Table 6.6: Catalyst structure optimization performed for the hydrogenation of trisbustituted boronic 
ester 149p. 
 
Entry [Ir-cat] R
1 R2 R3 R4 
Conv. 
[%][a] 
ee 
[%][b] 
1 26a Ph t-Bu CH3 CH3 >99 84 
2 26a Ph t-Bu CH3 CH3 70
[c] 83 
3 26b o-Tol t-Bu CH3 CH3 41
[c] 60 
4 26j Cy t-Bu CH3 CH3 >99
[c] 82 
5 26k t-Bu t-Bu CH3 CH3 >99
[c] 55 
6 26d 3,5-CF3-C6H3 t-Bu CH3 CH3 78
[d] 20 
7 26e[e] Ph t-Bu Ph H >99 78 
8 26f[e] Ph t-Bu H Ph >99 19 
9 26g[e] o-Tol t-Bu Ph H >99 70 
10 26c Ph i-Pr CH3 CH3 >99 86 
11 26l Cy i-Pr CH3 CH3 >99 79 
12 26m t-Bu i-Pr CH3 CH3 >99 77 
13 26h Ph Ph CH3 CH3 >99 90 
14 26i Ph Bn CH3 CH3 >99 86 
[a]: Determined by GC analysis of the reaction mixture after removal of the catalyst; [b]: Determined by GC 
analysis on a chiral stationary phase; [c]: Experiment performed at 5 bar H2 pressure; [d]: Experiment performed 
using 2 mol% [Ir-cat.]; [e] Ir-complexes 26e-g were kindly provided by A. Schumacher.[98]  
 
 
6.4 Summary and Outlook 
In summary, the preparation of terminal vinyl boronates 146 from commercially available 
alkynes was achieved in acceptable yields. Furthermore, starting from alkynes, 1,2-bisboronic 
ester 149a-d were obtained by Pt-catalyzed addition of bis(pinacolato)diboron in good yields. 
Those 1,2-bisboronic esters 149a-d were then used for the chemoselective preparation of 
trisubstited mono-boronic esters 149a-o.  
The alkenyl boronic acid esters obtained were applied in the Ir-catalyzed asymmetric 
hydrogenation. While an Ir-complex derived from phosphinoimidazoline ligand 162h was 
identified as highly efficient for the enantioselective hydrogenation of terminal vinyl boronic 
esters 146, trisubstituted bis- and monoboronates 149 could be reduced with high activity and 
excellent selectivity employing a pyridine-phosphinite derived Ir-complex 36d. Furthermore, 
alkenyl boronic esters which gave low selectivity with these two catalysts could also be 
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efficiently reduced by other Ir-complexes, but required additional screening and optimization 
studies (scheme 6.17).  
 
 
Scheme 6.17: Ir-catalyzed asymmetric hydrogenation of alkenyl boronic eter 146 and 149.  
 
Future work might be dedicated to the development of asymmetric hydrogenation of 
tetrasubstitued boronic esters. This would allow installing two stereogenic centers in one step 
and would therefore have a very high synthetic relevance. Tetrasubstituted bis-boronic esters 
could be obtained from symmetrical alkynes and then modified by Suzuki−Miyaura coupling 
to target substrates.  
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7.1 Introduction 
7.1.1 Objective of This Work 
During the investigations on the asymmetric hydrogenation of alkenyl boronic esters (chapter 
6) a SimplePHIM Ir-complex 162h bearing cyclohexyl groups at the phosphorus atom, was 
identified as the most suitable catalyst for terminal vinyl boronates 146. Furthermore 
regarding the asymmetric hydrogenation of trisubstituted boronic esters substrate 146p having 
a carbonyl group adjacent to the C=C bond, the best ee of 90% was obtained using Ir-
SimplePHOX derived catalyst 26h (scheme 7.1). These two complexes are examples of Ir-
catalysts, which were synthesized for specific substrates in order to optimize the 
enantioselectivity. Therefore, the aim of this study was to develope the synthesis of those Ir-
complexes and to explore the general potential for the asymmetric hydrogenation of olefins. 
  
 
Scheme 7.1: Selected results obtained in Iridium-catalyzed asymmetric hydrogenation of alkenyl 
boronic esters. 
 
 
7.1.2 Ir-SimplePHIM Complexes Prior to This Work 
Complex 162h belongs to the structural family of Ir-SimplePHIM complexes previously 
developed by F. Menges.[147] However, prior to the work on asymmetric hydrogenation of 
alkenyl boronic esters only P-aryl derived Ir-SimplePHIM complexes 162a-g were known. 
Complexes 162a-g showed encouraging results in the asymmetric hydrogenation of model 
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olefins, like α-methylstilbene 7, (Z)-olefin 91 and α,ȕ-unsaturated ester 98 and in the 
hydrogenation of farnesol 46a (scheme 7.2).[84, 147]  
 
 
   
 
7 91 98 46a 
(R)-162b (S)-162a (R)-162b (S)-162a 
>99% conv. 
87% ee (S) 
>99% conv. 
94% ee (R) 
>99% conv. 
91% ee (S) 
>99% conv. 
79% (3S,7S), 99% ee 
Scheme 7.2: Ir-SimplePHIM complexes 162a-b previously used in the asymmetric hydrogenation.[84, 
147]  
 
The synthetic route towards the P-aryl SimplePHIM Ir-complexes 162a-g starts with the 
esterfication of oxalyl chloride 165 with isopropanol. Coupling of 166 with amino alcohols 
167 gave amides 168, which were converted to the ȕ-chloroimidoyl chloride 169 using 
thionyl chloride. The subsequent cyclization with anilines afforded imidazolinyl esters 170, 
which gave upon addition of methyl Grignard reagent tertiary alcohols 171.  
 
 
Scheme 7.3: Synthesis of imidazolyl alcohols 171.[147] 
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These imidazolinyl alcohols 171 served as starting materials for the preparation of 
arylphosphinites 172a-g and the corresponding Ir-complexes 162a-g.[147]  
 
 
Scheme 7.4: Synthesis of P-aryl Ir-SimplePHIM complexes 162a-g.[147] 
 
 
7.1.3 Ir-SimplePHOX Complexes Prior to This Work 
In contrast to Ir-SimplePHIM complexes, the Ir-SimplePHOX complex family is based on the 
oxazoline as N-donor. P-aryl complexes 26a-d were first investigated by S. Smidt and F. 
Menges,[51] while M. Schrems reported the synthesis of P-alkyl Ir-SimplePHOX complexes 
26j-m.[53] In general, the synthetic sequence leading to complexes 26 is simple and short. 
Condensation of 2-hydroxyisobutyric acid 172 with amino alcohols 167a-b provides the 
oxazolinyl alcohols 173a-b in low yield (scheme 7.5).  
 
 
Scheme 7.5: Synthesis of oxazolyl alcohol 173a-b.[51] 
 
Deprotonation of the alcohols 173a-b using n-BuLi and subsequent trapping with aryl-chloro-
phosphines furnishes P-aryl ligands 174a-d, which can be directly converted to the Ir-
complexes 26a-d (scheme 7.6).[51]  
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Scheme 7.6: Synthesis of P-aryl Ir-SimplePHOX complexes 26a-d.[51] 
On the other hand, P-alkyl Ir-SimplePHOX complexes 26j-m were prepared using sodium 
hydride in concentrated solution of THF/DMF 9:1 (scheme 7.7). Both P-Aryl and P-Alkyl Ir-
SimplePHOX complexes showed high activity and selectivity in the hydrogenation of C=C 
and C=N bonds.[51, 116] 
 
 
Scheme 7.7: Synthesis of P-Alkyl Ir-SimplePHOX complexes 26j-m.[116]  
 
However, Ir-SimplePHOX complexes having aromatic R1 gropus on the oxazoline ring have 
not been reported so far. As such residues were required for the hydrogenation of trisubstitued 
boronic esters, their synthesis and performance in the asymmetric hydrogenation of model 
olefins is described herein. 
 
 
7.2 Synthesis  
7.2.1 P-Alkyl Ir-SimplePHIM Complexes 
Imidazolinyl alcohols 171 were required for the formation of P-alkyl Ir-SimplePHIM 
complexes. They were obtained following the same procedure as described by F. Menges 
(scheme 7.3).[147] The formation of P-alkyl Ir-SimplePHIM complexes 162h-k was achieved 
in 24-62% yield (table 7.1, entries 1-4) employing similar conditions as implemented by M. 
Schrems for 26j-m (scheme 7.7).[116] Rather than using sodium hydride in THF/DMF 9:1, an 
excess of potassium hydride in pure THF was used.  
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Table 7.1: Formation of Ir-complexes 162h-k starting from imidazolyl alcohols 171. 
 
Entry R
1
 R
3
 Ir-complex 
31
P-NMR 
(L) [ppm] 
31
P-NMR  
126h-k 
[ppm] 
31
P-NMR 
175 
[ppm] 
Ratio  
162 : 175 
Yield [%]  
(2 steps) 
1 t-Bu Cy (S)-162h 129.8 109.2 n.o. -- 25 
2 t-Bu t-Bu (S)-162i 144.2 138.7 n.o. -- 55 
3 i-Pr Cy (S)-162j 122.3 112.9 
145.8 
(175a) 
2.3:1[a] 24[b] 
4 i-Pr t-Bu (S)-162k 143.8 133.2 
146.0 
(175b) 
1:1.9[a] 62[b] 
[a]: The ratio between both Ir-species formed was calculated from the inegrals of 31P-NMR signals; [b]: Isolated 
yields of the mixture of Ir-complex 162j-k and 175a-b after flash chromatography over silica gel. 
 
 
7.2.2 Cyclometalled P-Alkyl Ir-SimplePHIM Complexes 
Complexes 162j and 162k containing isopropyl residues on the imidazoline ring were isolated 
as a mixture of two different Ir-species. Both species were inseparable by flash 
chromatography or recrystallization. NMR analysis showed signals in the high field region 
(between −15 and −β0 ppm) which are characteristic for Ir-hydrides, similar to those 
described in chapter 3. Indeed a more detailed investigation revealed an unusual insertion of 
the iridium into one of the sp3 C−H bonds of the geminal methyl group. The extent of 
cyclometallation depends on the substitution of the P-donor as 31P-NMR spectra revealed a 
2:1 ratio in favour of the non-cyclometallated form for 162k, while the cyclometalled form 
175b was predominantly found in complex 162k (1:2 ratio). Furthermore, crystals suitable for 
X-ray diffraction analysis were obtained from the cyclometallated 175b (see chapter 7.3 for 
crystal structure analysis). Taking the obtained crystals of 175b back again in solution a ratio 
of 1:2 between 162k and 175b was observed by 31P-NMR. This indicates a reversible 
formation of both complexes in solution, whereas the cyclometalled form 175b is more 
favored in solid structure.  
The tendency to undergo cyclometallation depends also on the substitution pattern at the N-
donor, as cyclometallation does not occur for complexes 162h and 162i, which bear a tert-
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butyl group on the imidazoline ring. Cyclometallated species derived from complexes 162a-b, 
which have the isopropyl group on the imidazoline part, but contain aromatic groups on the 
phosphorus atom are also not found. Structurally similar P-alkyl Ir-SimplePHOX complexes 
26j-m as well showed no tendency to form cyclometalled species. 
 
Table 7.2: Temperature dependence on the equilibrium between the Ir-SimplePHIM complex 162k 
and its cyclometalled form 175b. 
 
T [°C] 
Ratio 
175b : 162k 
 
−60 2.4 : 1 
−40 2.3 : 1 
25 1.9 : 1 
60 
 
1.3 : 1 
 
 
 
The reversibility of the C−H insertion observed in complex 162k was also confirmed by 31P-
NMR spectra recorded at different temperatures. While at elevated temperature (60 °C) the 
ratio of both components 162k and 175b is close to 1:1, at rt and lower temperatures the 
cyclometallated species 175b predominates over 162k (>2:1).  
Interestingly, upon treating the mixture of 162k and 175b in a sealed NMR tube at −γ0 °C in 
d8-THF with dihydrogen gas for 16 h, clean formation of only the cyclometalled form 175b 
was observed (scheme 7.8 and figure 7.1). The NMR spectra remained nearly unchanged 
when the sample was left to reach room temperature (only traces of addition Ir-H signals were 
found).  
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Scheme 7.8: Reaction of equilibrium mixture of Ir-SimplePHIM complex 162k and its cyclometalled 
form 175b with dihydrogen. 
 
 
 
Figure 7.1: 
31P-NMR spectra recorded before (left) and after (right) reaction of Ir-SimplePHIM complex 
162k and its cyclometalled form 175b with dihydrogen. 
 
 
7.2.3 SimplePHOX Derived Complexes 
The required oxazolinyl alcohols (173b, R1 = t-Bu) and 173c, R1 = Ph) were kindly provided 
by E. Hörmann or they were obtained (173d, R1 = Bn) by condensation hydroxy-isobutyric 
acid 172 with amino alcohol 167d (R1 = Bn) following the described procedure (scheme 7.5). 
The N,P ligands and their Ir-complexes 26d and 26h-i were formed in low to moderate yields 
applying the outlined conditions.[51] In this case no cyclometallation was observed. 
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Table 7.3: Synthesis of Ir-SimplePHOX complexes 26d and 26h-i.[51]  
 
Entry R
1
 Ar Ir-Complex 
31
P-NMR 
(L) [ppm] 
Yield 
[%] 
31
P-NMR 
[ppm] 
Yield 
[%] (2nd steps) 
1 t-Bu 3,5-CF3-C6H3 (S)-26d 83.3 38 96.6 67 
2 Ph Ph (S)-26h 95.5 8 101.8 45 
3 Bn Ph (S)-26i 94.8 9 102.0 98 
 
 
7.3 Crystal Structure Analysis 
The crystal structure of the cyclometallated form of Ir(III)-complex 175b was obtained by 
overlaying an etheral solution of 162k and 175b with n-pentane. The cyclometallated species 
appears to be the more stable form of the P-alkyl Ir-SimplePHIM complexes in the crystalline 
state and thus crystalizes preferentially.  
This crystal structure is compared to two previously obtained structures of Ir-SimplePHIM 
complexes 162l and Ir-SimplePHOX complex 26m (figure 7.2 and table 7.4). Complex 162l 
was selected to get insights into the coordination sphere of the Ir(I)-SimplePHIM complexes. 
In respect of steric and electronic properties complex 162l significantly differs from the 
obtained Ir(III)-complex 175b. On the hand Ir-SimplePHOX complex 26m is closely matching 
the steric properties found in the non-cyclometalled complex 162k.  
The substituents on the P-donor and the N-donor were found to orientate almost in parallel 
fashion in Ir(I)-complexes 162l and 26m in contrary to the cyclometallated Ir(III)-complex 
175b. In this case a switch of the boat chelating conformation is pushing these substitutes 
away from each other.  
Although this crystal structure gives some insights in the complex geometry of the 
cyclometallated species 175b the coordination in solution might be completely different, since 
an equilibrium is observed between 162k and 175b. Therefore, direct conclusions concerning 
the structures of the active catalyst are not possible due to the very different coordination 
spheres resulting after removal of the COD ligand.  
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Figure 7.2: Crystal structures of complexes 175b, 162l and 26m; all COD ligands and counterions 
were omitted for clarity. 
 
Table 7.4: Selected bond lengths and bond angles of Ir-complexes 175b, 162l and 26m. 
 
 
  
 175b 162l
[147a]
 26m
[116]
 
Ir-P [Å]: 2.311(1) / 2.310(1) 2.2348(15) 2.3033(8) 
Ir-N [Å]: 2.212(4) / 2.210(5) 2.088(5) 2.107(2) 
 P-Ir-N [°] 87.6(1) / 87.3(1) 85.2(1) 88.74(7) 
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7.4 Hydrogenation Results 
Table 7.5: Hydrogenation of (E)-α-methylstilbene (7). 
 
Entry Ir-catalyst R
1
 R
2
 Conv. [%][a] ee [%][b] 
1 
 
(S)-162h t-Bu Cy 36 55 (R) 
2 (S)-162i t-Bu t-Bu 22 29 (R) 
3 (S)-162j i-Pr Cy 96 91 (R) 
4 (S)-162k i-Pr t-Bu >99 95 (R) 
5[147a] (R)-162b i-Pr o-Tol >99 87 (S) 
6 
 
(S)-26h Ph Ph >99 51 (R) 
7 (S)-26i Bn Ph 98 89 (R) 
8 (S)-26d t-Bu 3,5-CF3-C6H3 >99 88 (R) 
9[116] (S)-26k t-Bu t-Bu >99 >99 (R) 
[a]: Determined by GC analysis of the reaction mixture after removal of the catalyst; [b]: Determined by HPLC 
analysis on a chiral stationary phase.  
 
Ir-SimplePHIM complexes bearing tert-butyl groups on imidazoline scaffold provided poor 
activity in the hydrogenation of methylstilbene 7 (table 7.5, entries 1-2). Complexes (S)-162j 
and (S)-162k derived from the less expensive valinol scaffold displayed higher activities and 
selectivies (entries 3 and 4). The same trend was also previously observed for the P-Aryl 
SimplePHIM complexes 162a-g.[147a] The best result was achieved using catalyst (S)-162k 
(entry 4), which is superior to complex (R)-162b. Variations of the SimplePHOX scaffold led 
to a decrease in selectivity, when compared to the best reported value (entries 6-9).  
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Table 7.6: Hydrogenation of (E)- and (Z)-2-(4-methoxyphenyl)-2-butene (90 and 91). 
 
Entry Substrate Ir-catalyst R
1
 R
2
 Conv. [%][a] ee [%][b] 
1 (E)-90 
 
(S)-162h t-Bu Cy 83 72 (R) 
2 (E)-90 (S)-162i t-Bu t-Bu >99 81 (R) 
3 (E)-90 (S)-162j i-Pr Cy >99 88 (R) 
4 (E)-90 (S)-162k i-Pr t-Bu >99 90 (R) 
5[147a] (E)-90 (R)-162b i-Pr o-Tol >99 91 (S) 
6 (Z)-91 
 
(S)-162h t-Bu Cy 60 71 (S) 
7 (Z)-91 (S)-162i t-Bu t-Bu 13 rac. 
8 (Z)-91 (S)-162j i-Pr Cy >99 85 (S) 
9 (Z)-91 (S)-162k i-Pr t-Bu 95 80 (S) 
10[147a] (Z)-91 (S)-162a i-Pr Ph >99 94 (S) 
[a]: Determined by GC analysis of the reaction mixture after removal of the catalyst; [b]: Determined by GC 
analysis on a chiral stationary phase.  
 
In the hydrogenation of the (E)-olefin 90 and (Z)-olefin 91 complexes derived from the less 
expensive valinol scaffold performed better than the tert-leucinol derivatives (table 7.6, 
entries 1-2 vs. 3-4, 6-7 vs. 8-9). Moderate enantioselectivities (up to 90%) were achieved 
using the newly developed P-alkyl Ir-SimplePHIM complexes. These values are lower, when 
compared to the P-aryl derived complexes.  
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Table 7.7: Hydrogenation of 2-(4-methoxyphenyl)-1-butene (88). 
 
Entry Ir-catalyst R
1
 R
2
 Conv. [%][a] ee [%][b] 
1 
 
(S)-162h t-Bu Cy >99 39 (S) 
2 (S)-162i t-Bu t-Bu >99 83 (S) 
3 (S)-162j i-Pr Cy >99 47 (S) 
4 (S)-162k i-Pr t-Bu >99 80 (R) 
5[147a] (S)-162a i-Pr Ph >99 44 (S)[c] 
6 
 
(S)-26h Ph Ph >99 45 (S) 
7 (S)-26i Bn Ph >99 52 (S) 
8 (S)-26d t-Bu 3,5-CF3-C6H3 99 86 (S) 
9[51] (S)-26a t-Bu Ph >99 78 (S) 
[a]: Determined by GC analysis of the reaction mixture after removal of the catalyst; [b]: Determined by GC 
analysis on a chiral stationary phase; [c]: Result obtained at 50 bar H2 pressure.  
 
In contrast to the trisubstited olefins 90 and 91 the installation of electron-rich phosphinites 
(P-alkyl residues) had a beneficial effect on the enantioselectivity in the hydrogenation of 
terminal C=C bond, found in 88. The best result of 83% ee was achieved using catalyst 
(S)-162j (table 7.7, entry 2). Furthermore, the electron-poor phosphinite unit found in 
SimplePHOX-complex (S)-26d showed also a positive influence on the hydrogenation of 
terminal olefin 88. In this case an ee of 86% was achieved (entry 8), which is clearly higher 
than previously reported (entry 9). 
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Table 7.8: Hydrogenation of 7-methoxy-1,2-dihydro-naphthalene (72). 
 
Entry Ir-catalyst R
1
 R
2
 Conv. [%][a] 115 [%][a] ee [%][b] 
1 
 
(S)-162h t-Bu Cy 57 1 86 (S) 
2 (S)-162i t-Bu t-Bu 14 1 77 (S) 
3 (S)-162j i-Pr Cy 78 1 78 (S) 
4 (S)-162k i-Pr t-Bu 98 1 79 (S) 
5[147a] (S)-162a i-Pr Ph >99 n.o. 88 (S) 
6 
 
(S)-26h Ph Ph 42 3 86 (S) 
7 (S)-26i Bn Ph 24 6 75 (S) 
8 (S)-26d t-Bu 3,5-CF3-C6H3 44 19 n.d. 
9[51] (S)-25b t-Bu o-Tol >99 n.o. 95 (R) 
[a]: Determined by GC analysis of the reaction mixture after removal of the catalyst; [b]: Determined by HPLC 
analysis on a chiral stationary phase.  
 
For the challenging cyclic substrate 72 none of the newly obtained complexes gave full 
conversion within two hours (table 7.8). While the most active complex (S)-162k gave 
moderate 79% ee (entry 4), the less active complex (S)-162h provided 86% ee. All of the new 
SimplePHOX complexes displayed poor activity and moderate selectivity (entries 6-8).  
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Table 7.9: Hydrogenation of (E)-2-methyl-3-phenylprop-2-en-1-ol (24). 
 
Entry Ir-catalyst R
1
 R
2
 Conv. [%][a] ee [%][b] 
1 
 
(S)-162h t-Bu Cy >99 62 (S) 
2 (S)-162i t-Bu t-Bu >99 7 (S) 
4[147a] (S)-162a i-Pr Ph >99 96 (S) 
4 
 
(S)-26h Ph Ph 98 81 (S) 
5 (S)-26i Bn Ph 98 89 (S) 
6 (S)-26d t-Bu 3,5-CF3-C6H3 >99 77 (S) 
7[51] (S)-25b t-Bu o-Tol >99 97 (S) 
[a]: Determined by GC analysis of the reaction mixture after removal of the catalyst; [b]: Determined by HPLC 
analysis on a chiral stationary phase.  
 
In general, low enantioselectivities were obtained using P-alkyl Ir-SimplePHIM complexes in 
the hydrogenation of allylic alcohol 24 (Table 7.9, entries 1-2). On the other hand 
SimplePHOX derived catalysts led to full conversion, but no improvement in 
enantioselectivity compared to the previously reported complexes (entries 4-6 vs. 7).  
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Table 7.10: Hydrogenation of (E)-ethyl 3-phenylbut-2-enoate (98). 
 
Entry Ir-catalyst R
1
 R
2
 Conv. [%][a] ee [%][b] 
1 
 
(S)-162h t-Bu Cy >99 5 (R) 
2 (S)-162i t-Bu t-Bu 46 42 (R) 
3 (S)-162j i-Pr Cy 98 40 (R) 
4 (S)-162k i-Pr t-Bu >99 83 (R) 
5[147a] (R)-162b i-Pr o-Tol >99 91 (S) 
6 
 
(S)-26h Ph Ph >99 82 (R) 
7 (S)-26i Bn Ph 75 85 (R) 
8 (S)-26d t-Bu 3,5-CF3-C6H3 9 77 (R) 
9[116] (S)-26k t-Bu t-Bu >99 >99 (R) 
[a]: Determined by GC analysis of the reaction mixture after removal of the catalyst; [b]: Determined by HPLC 
analysis on a chiral stationary phase.  
 
The introduction of P-alkyl residues did not give any improvement in ee in the hydrogenation 
of the α,ȕ-unsaturated ester 98 (table 7.10, entries 1-4). However, these complexes 
demonstrate the beneficial effect of an isopropyl residue compared to tert-butyl group on the 
imidazoline ring (entries 1 vs. 3, 2 vs. 4). The new SimplePHOX (S)-26h-i complexes showed 
moderate enantioselectivities (entries 6-8). Furthermore, the installation of electron-poor 
phosphinite (26k) reduced the activity significantly (entry 8).  
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Table 7.11: Hydrogenation of (E)-N-(1-phenylethylidene)aniline (13). 
 
Entry Ir-catalyst R
1
 R
2
 Conv. [%][a] ee [%][b] 
1 
 
(S)-162h t-Bu Cy 16 61 (R) 
2 (S)-162i t-Bu t-Bu 30 25 (R) 
3 (S)-162j i-Pr Cy >99 85 (R) 
4 (S)-162k i-Pr t-Bu 85 64 (R) 
5 
 
(S)-26h Ph Ph >99 44 (R) 
6 (S)-26i Bn Ph >99 32 (R) 
7 (S)-26d t-Bu 3,5-CF3-C6H3 >99 45 (R) 
8[116] (S)-26l Cy i-Pr >99 88 (R) 
[a]: Determined by GC analysis of the reaction mixture after removal of the catalyst; [b]: Determined by HPLC 
analysis on a chiral stationary phase.  
 
Beside complex (S)-162j, most of the newly Ir-SimplePHIM complexes did not reach full 
conversion in the hydrogenation of acetophenone imine 13. However, the most active catalyst 
(S)-162j provided a respectable 85% ee. All of the SimplePHOX derivatives gave full 
conversion, but significantly lower ee (entries 5-7), as obtained with best complex of this 
family (entry 8).  
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7.5 Summary 
In summary, the synthesis of P-alkyl Ir-SimplePHIM complexes 162h-k starting from 
imidazolinyl alcohol 171 is described (scheme 7.9A). Complexes having P-Alkyl substituents 
and an isopropyl group on the imidazoline were found to undergo a reversible cyclomellation 
reaction, furnishing a tridentate C,N,P complex 175a-b (scheme 7.9B). Furthermore, the Ir-
SimplePHOX family was extended with three new members 26d, 26h and 26i (scheme 7.9C).  
 
 
Scheme 7.9: Synthesis of P-alkyl SimplePHIM derived Ir-complexes 162h-k and three new members 
of the Ir-SimplePHOX family.  
 
Applying these new complexes in the hydrogenation of model olefins high activities but 
moderate enantioselectivities were obtained. For methylstilbene and acetophenone imine the 
obtained enantioselectivities were higher compared to those previously reported for P-aryl 
SimplePHIM complexes 162a-g. Although the P-alkyl Ir-SimplePHIM complexes 162l-k 
bearing isopropyl group on imidazoline were found to stay in equilibrium with their 
cyclometallated form 175a-b, they were more active in the hydrogenation compared to the 
complexes having tert-butyl groups on the N-donor. The newly obtained Ir-SimplePHOX 
complexes (26d, 26h and 26i) did not provide any significantly improved enantioselectivity 
compared to previously prepared SimplePHOX catalysts.  
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8.1 Working Techniques 
Commercially available reagents were purchased from Acros, Aldrich, Alfa-Aesar, Fluka, 
Frontier Scientific, Strem or TCI and used as received. The solvents were collected from a 
purification column system (PureSolv, Innovative Technology Inc.)[149] or purchased from 
Aldrich or Fluka in sure/sealedTM bottles over molecular sieves. Column chromatographic 
purifications were performed on Merck silica gel 60 (particle size 40-63 nm) according to the 
procedure published by Still and Mitra.[150] The eluents were of technical grade and distilled 
prior to use. The hydrogenation experiments were obtained in air. 
 
 
8.2 Analytical Methods 
Thin Layer Chromatography (TLC): TLC plates were obtained from Macherey-Nagel 
(Polygram SIL/UV254, 0.2 mm silica with fluorescence indicator). UV light (254 nm) or 
basic permanganate solution were used to visualize the respective compounds.  
NMR-Spectroscopy: NMR spectra were measured either on a Bruker DPX-NMR (400 
MHz), on a Bruker BZH-NMR (250 MHz) or a Bruker Avance DRX-NMR (500 MHz) 
spectrometer equipped with BBO broadband probe heads. Chemical shifts (δ) are reported in 
parts per million (ppm) relative to residual solvent peaks and coupling constants (J) are 
reported in Hertz (Hz). Deuterated NMR solvents were obtained from Cambridge Isotope 
Laboratories, Inc. (Andover, MA, USA). The measurements were performed at 25 °C, if 
nothing else is reported. The chemical shift δ values were corrected to 7.26 ppm (1H NMR) 
and 77.16 ppm (13C NMR) for CHCl3, 5.32 ppm (
1H NMR) and 54.0 ppm (13C NMR) for 
CH2Cl2.
19F NMR spectra relative to CFCl3 (δ = 0 ppm) and 11B NMR spectra relative to 
BF3·OEt2 (δ = 0 ppm) as external standards. 13C, 19F and spectra were recorded 1H-decoupled. 
Carbon atoms directly attached to the boron were not detected in 13C spectra (quadrupole 
relaxation) for the alkynyl boronic esters.[141, 151] The assignment of 1H and 13C signals was 
partly made by 2D-NMR, namely COSY, HMQC, HMBC and NOSY. Multiplicities are 
reported as follows: s=singlet, d=doublet, t=triplet, q=quartet, quin=quintet, m=multiplet and 
b=broad.  
Mass Spectrometry (MS): Mass spectra were measured by Dr. H. Nadig (Department of 
Chemistry, University of Basel) on a VG70-250 (electron ionization (EI)) mass spectrometer 
or a MAR 312 (fast atom bombardment (FAB)) mass spectrometer. FAB was performed with 
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3-nitrobenzyl alcohol (NBA) as matrix. The signals are given in mass to charge ratio (m/z). 
The fragment and intensities are given in brackets. All values are rounded to the nearest 
whole number.  
High Resolution Mass Spectrometry (HRMS): High Resolution Mass spectra were 
measured by the group of Dr. Xiangyang Zhang (Department of Chemistry, ETH Zürich) on a 
Micromass (Waters) AutoSpec Ultima. 
Infrared Spectroscopy (IR): The IR spectra were recorded on a Shimadzu FTIR-8400S 
Fourier Transform spectrometer with ATR/Golden Gate technology. The absorption bands are 
given in wave numbers ῦ (cm−1). The peak intensity is assigned with s (strong), m (medium) 
and w (weak). The index br stands for broad.  
Optical Rotations ([α]D20): Optical rotations were measured on a Perkin Elmer Polarimeter 
341 (1 dm cylindrical cell) or on a Jasco P-2000 Polarimeter (1 dm cylindrical cell) at 589 
nm. The concentration (c) is given in g/100 mL. 
Elemental Analysis (EA): Elemental analyses were measured by Mr. W. Kirsch and Sylvie 
Mittelheiser (Department of Chemistry, University of Basel) on a Leco CHN-900 or a Vario 
Micro Cube by Elementar (C-, H-, N-detection). The data are indicated in mass percent. 
Melting Points (m.p.): Melting points were determined on a Büchi B-545 apparatus and were 
not corrected.  
High Performance Liquid Chromatography (HPLC): HPLC analysis was measured on 
Shimadzu Class-VP Version 5.0 systems with SCL-10A system controller, LC-10AD pump 
system, SIL-10AD auto injector, CTO-10AC column oven, DGU-14A degasser and SPD-
M10A diode array- or UV/VIS detector or on Shimadzu LC-20A prominence with LC-20AD 
pump system, SIL-20AHT auto injector, CTO-10AS column oven, SPD-M20A diode array, 
DGU-20A3 degasser. Chiral columns Chiralcel AD-H, IC, OD-H, or OJ-H (4.6 mm × 250 
mm) from Daicel Chemical Industries were used.  
Gas Chromatography (GC): Gas chromatograms were recorded on a Carlo Erba HRGC 
Mega2 Series 800 (HRGS Mega2) or a GC-2010 Plus von Shimadzu instruments. Achiral 
separations were performed on a Restek Rtx®-1701 column (30 m × 0.25 mm × 0.25 μm) 
using helium as carrier gas. For the separations of enantiomers Chiraldex G-TA, Ȗ–
cyclodextrin TFA column (30 m × 0.25 mm × 0.25 μm), Macherey-Nagel Hydrodex-ß-3P 
(25 m × 0.25 mm × 0.25 µm), Brechbühler SE54 ß-cyclodextrin DEtTButSil (25 m × 0.25 
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mm × 0.25 μm), Varian CP-Chiralsil-dex CB (25 m × 0.25 mm × 0.25 μm) Varian CP-Sil 88 
(25 m × 0.25 mm × 0.25 μm) were used with H2 as carrier gas.  
Gas Chromatography-Mass Spectrometry (GC-MS): The GC-MS spectra were recorded 
on a HP5890 gas chromatograph with a HP5970A detector equipped with a Macherey and 
Nagel Optima5 (5% polyphenylmethylsiloxane column, 25 m × 0.2 mm × 35 μm), a HP5890 
gas chromatograph with a HP5971 detector equipped with a Agilent HP1 (1% 
dimethylsiloxane column, 15 m × 0.2 mm × 33 μm). For both instruments the flow was set to 
1 mL/min with 20:1 split ratio. A Shimadzu GCMS-QP2010 SE equipped with a Restek Rtx®-
5MS (30 m × 0.2 mm × 0.2 µm) was used too. For this instrument the carrier pressure (He) 
was set to 100 kPa with 40:1 split ratio.  
 
 
8.3 Development of a New Synthetic Route to Bicyclic Pyridine-Phosphinite 
Ligands and Their Corresponding Ir-Complexes 
8.3.1 Formation of N-Oxides 
 
 
 
6,7-Dihydro-5H-cyclopenta[1]pyridine-N-oxide (69a) 
 
6,7-dihydro-5H-cyclopenta[1]pyridine (10.0 g, 83.9 mmol, 1.0 eq.) was added to 
a solution of MCPBA (24.8 g, 101 mmol, 1.2 eq.) in DCM (100 mL) at 0 °C. The 
reaction mixture was allowed to warm to rt and stirring was continued for 
additional 1.5 h. The reaction mixture was again cooled down to 0 °C and NaOH 2 M aq. 
solution (100 mL) was added. The layers were separated and the aq. phase was extracted with 
with DCM (5×250 mL). Combined organic layers were washed with brine (200 mL), dried 
over MgSO4 and the solvent was removed under reduced pressure. The obtained crude 
N-oxide was purified by recrystallization from a boiling mixture of n-heptane (7 mL) and 
toluene (4 mL) to obtain the title compound 69a as a pale yellow solid (8.16 g, 60.4 mmol, 
72%). The analytical data match the reported values.[57b] 
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C8H9NO (135.16 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 8.05 (dd, J = 7.3, 1.8 Hz, 1H, HAr), 7.13 (d, J = 7.8 Hz, 1H, 
HAr), 7.08 (dd, J = 7.3, 7.8 Hz, 1H, HAr), 3.18 (t, J = 7.6 Hz, 2H, CH2), 3.03 (t, J = 7.6 Hz, 
2H, CH2), 2.19 (pentet, J = 7.6 Hz, 2H, CH2) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): 
δ = 153.5 (CAr), 142.6 (CAr), 137.7 (HCAr), 124.2 (HCAr), 122.9 (HCAr), 32.0 (CH2), 29.9 
(CH2), 22.4 (CH2) ppm. m.p.: 119–120°C; lit. 117 °C.[57b] 
 
 
5,6,7,8-Tetrahydroquinoline-N-oxide (69b) 
 
Hydrogen peroxide 30 w% solution (26.0 mL, 23.5 g, 255 mmol, 3.4 eq), was 
added to a solution of 5,6,7,8-tetrahydroquinoline (10.3 mL, 10.0 g, 75.1 mmol, 
1.0 eq.) and acetic acid (48.5 mL, 50.9 g, 847 mmol, 11.3 eq.). The reaction 
mixture was stirred at 80 °C for 18 h. The reaction mixture was cooled down to 0 °C and 
NaOH 3 M aq. solution (200 mL) was added. The mixture was extracted with DCM 
(5×250 mL). The combined organic layers were washed with brine (200 mL), dried over 
MgSO4 and the solvent was removed under reduced pressure. The obtained crude N-oxide 
was purified by flash chromatography (SiO2, 6 cm × 10 cm, cyclohexane / ethyl acetate 1:4) 
to obtain the title compound 69b as a pale yellow solid (9.10 g, 61.0 mmol, 81%). The 
analytical data match the reported values.[57b] 
 
C9H11NO (149.19 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 8.09 (d, J = 7.5 Hz, 1H, HAr), 7.0β‒6.96 (m, βH, HAr), 2.90 
(t, J = 6.2 Hz, 2H, CH2), 2.73 (t, J = 6.2 Hz, 2H, CH2), 1.91‒1.81 (m, βH, CH2), 1.79‒1.68 
(m, 2H, CH2) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 147.2 (CAr), 137.3 (CAr), 136.8 
(HCAr), 126.7 (HCAr), 122.4 (HCAr), 29.0 (CH2), 25.1 (CH2), 22.2 (CH2), 22.0 (CH2) ppm. 
m.p.: 80–81 °C; lit. 83 °C.[57b] TLC (SiO2, cyclohexane / ethyl acetate 1:4): Rf = 0.10. 
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8.3.3 Arylations of N-oxides 
 
 
General Procedure A: A solution of aryl bromide (1.0 eq.) in toluene (0.3 M) was slowly 
added to a mixture of N-oxide (3.0 eq.), Pd(OAc)2 (5 mol%), (t-Bu)3P·HBF4 (5 mol%), 
K2CO3 (2.0 eq.) in toluene (0.3 M). The reaction mixture was stirred for 15-18 hours at 125 
°C. After cooling down to rt the reaction mixture was filtered over a pad of Celite® and rinsed 
with DCM (50-150 mL). Water (100 mL) was added to the obtained filtrated and the mixture 
was extracted with DCM (5×100-150 mL). The combined organic layers were dried over 
MgSO4, filtered and the solvent was removed under reduced pressure. The crude product was 
purified by flash chromatography.  
 
 
2-Phenyl-6,7-dihydro-5H-cyclopenta[1]pyridine-N-oxide (53a) 
 
The title compound 53a was obtained following the general procedure A 
using phenyl bromide (388 mg, 2.47 mmol, 1.0 eq) in toluene (8.0 mL), 
69a (1.00 g, 7.40 mmol, 3.0 eq.), Pd(OAc)2 (27.7 mg, 123 μmol, 5 mol%), 
(t-Bu)3P·HBF4 (35.8 mg, 123 μmol, 5 mol%), K2CO3 (682 mg, 4.93 mmol, 2.0 eq.) in toluene 
(8.0 mL) and after purification by flash chromatography (SiO2, 3 cm × 15 cm, ethyl acetate) 
as a pale yellow solid (285 mg, 1.35 mmol, 55%). The analytical data match the reported 
values.[57b] 
 
C14H13NO (211.26 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 7.73 (dd, J = 7.7, 1.1 Hz, 2H, HAr), 7.40‒7.γ4 (m, γH, HAr), 
7.18 (d, J = 7.7 Hz, 1H, HAr), 7.07 (d, J = 7.7 Hz, 1H, HAr), 3.14 (t, J = 7.1 Hz, 2H, CH2), 2.99 
(t, J = 7.1 Hz, 2H, CH2), β.β0‒β.10 (m, βH, CH2) ppm. 13C{1H}-NMR (101 MHz, CDCl3): 
δ = 154.2 (CAr), 148.0 (CAr), 141.9 (CAr), 133.4 (CAr), 129.8 (HCAr), 129.5 (HCAr), 128.5 
(HCAr), 125.7 (HCAr), 122.5 (HCAr), 32.1 (CH2), 30.5 (CH2), 22.7 (CH2) ppm. m.p.: 123–
124 °C; lit. 125 °C.[57b] TLC (SiO2, ethyl acetate): Rf = 0.15.  
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2-(3,5-Di-tert-butyl-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[1]pyridine-N-oxide 
(53c) 
 
The title compound 53c was obtained following the general 
procedure A using 5-bromo-1,3-di-tert-butyl-2-methoxybenzene 
(2.20 g, 7.66 mmol, 1.0 eq.), 69a (3.11 g, 23.0 mmol, 3.0 eq.), 
Pd(OAc)2 (86.1 mg, 390 μmol, 5 mol%), (t-Bu)3P·HBF4 (111 mg, 390 μmol, 5 mol%), K2CO3 
(2.12 g, 15.3 mmol, 2.0 eq.) in toluene (50 mL) and after purification by flash 
chromatography (SiO2, 3 cm × 19 cm, DCM  DCM / MeOH 98:2) as a black solid (960 mg, 
2.72 mmol, 36%).  
 
C23H31NO2 (353.50 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 7.67 (s, 2H, HAr), 7.18 (d, J = 7.3 Hz, 1H, HAr), 7.06 (d, J = 
7.3 Hz, 1H, HAr), 3.65 (s, 3H, OCH3), 3.16 (t, J = 7.5 Hz, 2H, CH2), 2.98 (t, J = 7.5 Hz, 2H, 
CH2), 2.15 (pentet, J = 7.5 Hz, 2H, CH2), 1.38 (s, 18H, (CH3)3C) ppm. 
13
C{
1
H}-NMR 
(101 MHz, CDCl3): δ = 160.7 (CAr), 154.1 (CAr), 148.2 (CAr), 143.5 (CAr), 140.1 (CAr), 128.6 
(HCAr), 127.5 (CAr), 125.6 (HCAr), 122.5 (HCAr), 64.7 (OCH3), 36.3 (CH3)3C), 32.5 (CH3)3C), 
32.1 (CH2), 30.6 (CH2), 22.7 (CH2) ppm. TLC (SiO2, DCM / MeOH 98:2): Rf = 0.26. 
 
 
2-Phenyl-5,6,7,8-tetrahydroquinoline-N-oxide (53b) 
 
The title compound 53b was obtained following the general procedure A 
using 5-bromo-1,3-di-tert-butyl-2-methoxybenzene (2.20 g, 7.66 mmol, 
1.0 eq.), 69b (3.43 g, 23.0 mmol, 3.0 eq.), Pd(OAc)2 (27.7 mg, 123 μmol, 
5 mol%), (t-Bu)3P·HBF4 (35.8 mg, 123 μmol, 5 mol%), K2CO3 (682 mg, 4.93 mmol, 2.0 eq.) 
in toluene (50 mL) and after purification by flash chromatography (SiO2, 3 cm × 16 cm, ethyl 
acetate) as a pale yellow solid (184 mg, 0.817 mmol, 33%). The analytical data match the 
reported values.[57b] 
 
C15H15NO (225.28 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 7.70 (dd, J = 7.1, 1.2 Hz, 2H, HAr), 7.40‒7.β8 (m, γH, HAr), 
7.14 (d, J = 7.1 Hz, 1H, HAr), 6.97 (d, J = 7.1 Hz, 1H, HAr), 2.92 (t, J = 7.8 Hz, 2H, CH2), 2.74 
(t, J = 7.8 Hz, 2H, CH2), 1.90‒1.8β (m, βH, CH2), 1.74‒1.68 (m, βH, CH2) ppm. 
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13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 149.7 (CAr), 147.1 (s, CAr),135.3 (CAr), 134.1 (CAr), 
129.8 (HCAr), 129.4 (HCAr), 128.5 (HCAr), 126.1 (HCAr), 123.8 (HCAr), 29.1 (CH2), 25.6 
(CH2), 22.5 (CH2), 22.1 (CH2) ppm. m.p.: 129–130 °C; lit. 137 °C.[57b] TLC (SiO2, ethyl 
acetate): Rf = 0.25. 
 
 
2-(3,5-Di-tert-butyl-4-methoxyphenyl)-5,6,7,8-tetrahydroquinoline-N-oxide (53d) 
 
The title compound 53d was obtained following the general 
procedure A using phenyl bromide (388 mg, 2.47 mmol, 1.0 eq) in 
toluene (8.0 mL), 69b (1.10 g, 7.40 mmol, 3.0 eq.), Pd(OAc)2 (27.7 
mg, 123 μmol, 5 mol%), (t-Bu)3P·HBF4 (35.8 mg, 123 μmol, 5 
mol%), K2CO3 (2.12 g, 15.3 mmol, 2.0 eq.) in toluene (50 mL) and after purification by flash 
chromatography (SiO2, 3 cm × 18 cm, cyclohexane / DCM 1:1  cyclohexane / DCM / ethyl 
acetate 5:5:2) as a black solid (184 mg, 0.817 mmol, 33%). 
 
C24H33NO2 (367.52 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 7.70 (s, 2H, HAr), 7.21 (d, J = 7.7 Hz, 1H, HAr), 7.01 (d, J = 
7.7 Hz, 1H, HAr), 3.72 (s, 3H, OCH3), 3.05–2.94 (m, 2H, CH2), 2.82–2.74 (m, 2H, CH2), 
1.93–1.87(m, 2H, CH2), 1.85–1.76 (m, 2H, CH2), 1.45 (s, 18H, (CH3)3C) ppm. 13C{1H}-NMR 
(101 MHz, CDCl3): δ = 160.6 (CAr), 149.5 (CAr), 147.5 (CAr), 143.5 (CAr), 134.3 (CAr), 128.6 
(HCAr), 128.2 (HCAr), 126.1 (HCAr), 123.7 (HCAr), 64.7 (OCH3), 36.3 (CH3)3C), 32.5 
(CH3)3C), 29.1 (CH2), 25.7 (CH2), 22.6 (CH2), 22.1 (CH2) ppm. TLC (SiO2, cyclohexane / 
DCM / ethyl acetate 5:5:2): Rf = 0.20. 
 
 
8.3.4 Boekelheide Rearrangement and Hydrolysis  
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General Procedure B: Trifluoroacetic anhydride (2.5 eq.) or acetic anhydride (2.5 eq.) was 
slowly added to a solution of the N-oxide (1 eq.) in DCM (0.9‒1.0 M) at 0 °C. After stirring 
for 3-12 h at RT, the volatiles were removed under in vacuo. The crude acetate was dissolved 
in MeOH / water 1:1 mixture (0.3 M) and hydrolyzed with K2CO3 (>2.5 eq.). After stirring for 
additional 12-16 h at RT, the reaction mixture was extracted with DCM (3×20-50 mL). 
Combined organic layers were dried over MgSO4, and the solvent was removed under 
reduced pressure. The crude product was purified by flash chromatography or by 
recrystallization. 
 
6,7-Dihydro-5H-cyclopenta[1]pyridin-7-ol (78a) 
 
The title compound 78a was obtained following the general procedure B using 
69a (1.18 g, 8.73 mmol, 1.0 eq.) in DCM (10 mL), acetic anhydride (2.0 mL, 
2.16 g, 21.2 mmol, 2.5 eq.) during 4 h; subsequent hydrolysis using K2CO3 
(2.80 g, 20.3 mmol, 2.4 eq.) in MeOH / water 1:1 (30 mL) during 16 h at rt and purification 
by flash chromatography (SiO2, 3.5 cm × 40 cm, ethyl acetate / cyclohexane 20:1 1:0) as a 
slightly yellow solid (325 mg, 2.40 mmol, 28%). The analytical data match the reported 
values.[57b] 
 
C8H9NO (135.16 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 7.44‒7.4β (m, 1H, HAr), 7.57 (dd, J = 7.6, 1.1 Hz, 1H, HAr), 
7.15 (dd, J = 7.6, 4.9 Hz, 1H, HAr), 5.24 (t, J = 6.8 Hz, 1H, CH), 4.49 (br s, 1H, OH), γ.09‒
3.02 (m, 1H, CH2), β.87‒β.80 (m, 1H, CH2), β.60‒β.5β (m, 1H, CH2CH(OH)), β.11‒β.0β (m, 
1H, CH2CH(OH)) ppm.  
 
 
2-Phenyl-6,7-dihydro-5H-cyclopenta[1]pyridin-7-ol (54a) 
 
The title compound 54a was obtained following the general procedure B 
using 53a (280 mg, 1.33 mmol, 1.0 eq.), DCM (5.0 mL), TFAA (443 µL, 
696 mg, 3.31 mmol, 2.5 eq.); subsequent hydrolysis using MeOH (2.0 
mL) and K2CO3 1 M aq. solution (20 mL) and purification by flash chromatography (SiO2, 1.5 
cm × 19 cm, cyclohexane / ethyl acetate 1:1) as a slightly yellow solid (220 mg, 1.04 mmol, 
79%). The analytical data match the reported values.[57b] 
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C14H13NO (211.26 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 7.95 (dd, J = 7.2 Hz, 1.3 Hz, 2H, HAr), 7.65‒7.58 (m, 2H, 
HAr), 7.47‒7.γ5 (m, γH, HAr), 5.β9‒5.β1 (m, 1H, CH), 3.60 (br s, 1H, OH), γ.05‒β.99 (m, 1H, 
CH2), β.85‒β.70 (m, 1H, CH2), β.54‒β.48 (m, 1H, CH2), β.1β‒1.97 (m, 1H, CH2) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 165.1 (CAr), 157.0 (CAr), 139.9 (CAr), 135.2 (CAr), 
134.2 (HCAr), 129.1 (HCAr), 127.4 (HCAr), 120.5 (HCAr), 75.2 (CH), 33.5 (CH2), 27.6 (CH2) 
ppm. m.p.: 118‒119°C; lit. 119 °C.[57b] TLC (SiO2, cyclohexane / ethyl acetate 1:1): 
Rf = 0.70. 
 
 
5,6,7,8-Tetrahydroquinolin-8-ol (78b) 
 
The title compound 78b was obtained following the general procedure B using 
69b (7.93 g, 53.2 mmol, 1.0 eq.), DCM (100 mL), TFAA (20 mL, 29.6 g, 
141 mmol, 2.6 eq.); subsequent hydrolysis using K2CO3 (14.0 g, 101 mmol, 1.9 
eq.) in MeOH / water 1:1 mixture (150 mL) and purification by recrystallization from boiling 
TBME (10 mL) as a pale yellow solid (5.46 g, 36.6 mmol, 69%). The analytical data match 
the reported values.[57b] 
 
C9H11NO (149.19 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 8.45‒8.γ4 (m, 1H, HAr), 7.44‒7.γ8 (m, 1H, HAr), 7.12 (dd, 
J = 7.7, 4.8 Hz, 1H, HAr), 4.71 (t, J = 7.0 Hz, 1H, CH), 4.21 (s, 1H, OH), β.89‒β.7γ (m, βH, 
CH2), β.γγ‒β.ββ (m, 1H, CH2), β.06‒1.95 (m, 1H, CH2), 1.87‒1.74 (m, βH, CH2) ppm. MS 
(FAB NBA) m/z (%): 150 ([M+H]+, 100, 132 (34). EA: calc. (%) C 72.46, H 7.43, N 9.39; 
found C 72.23, H 7.30, N 9.41. m.p.: 67‒68°; lit. 65 °C.[57b] 
 
 
2-Phenyl-5,6,7,8-tetrahydroquinolin-8-ol (54b) 
 
The title compound 54b was obtained following the general procedure B 
using 53b (180 mg, 800 μmol, 1.0 eq.), DCM (5 mL), TFAA (279 µL, 
421 mg, 2.00 mmol, 2.5 eq.); subsequent hydrolysis using MeOH (2.0 
mL) and K2CO3 1 M aq. solution (20 mL) and purification by by flash chromatography (SiO2, 
1.5 cm × 16 cm, cyclohexane / ethyl acetate 1:1) as a slightly yellow solid (112 mg, 497 
μmol, 62%). The analytical data match the reported values.[57b] 
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C15H15NO (225.28 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 7.92 (dd, J = 7.1, 1.2 Hz, 2H, HAr), 7.50 (d, J = 7.7 Hz, 1H, 
HAr), 7.4β‒7.γ5 (m, γH, HAr), 7.γ4‒7.γ0 (m, 1H, HAr), 4.68‒4.65 (m, 1H, CH), 4.26 (s, 1H, 
OH), β.79‒β.7β (m, βH, CH2), β.γβ‒β.β5 (m, 1H, CH2), 1.96‒1.89 (m, 1H, CH2) 1.87‒1.75 
(m, 2H, CH2) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 158.1 (CAr), 154.7 (CAr), 139.3 
(CAr), 138.1 (HCAr), 130.3 (CAr), 129.3 (HCAr), 129.1 (HCAr), 127.1 (HCAr), 119.6 (HCAr), 
69.6 (CH), 31.1 (CH2), 28.4 (CH2), 20.1 (CH2) ppm. m.p.: 80‒81 °C; lit. 8β °C.[57b] TLC 
(SiO2, cyclohexane / ethyl acetate 1:1): Rf = 0.54. 
 
 
8.3.5 Formation of N,P Ligands From Pyridyl Alcohols and Subsequent 
Complexation with Iridium  
 
 
 
General Procedure C: A Schlenk flask was charged with pyridyl alcohol (1.0 eq.) and 
4-dimethylaminopyridine (1.0 eq.). The Schlenk flask was evacuated three times and each 
time backfilled with argon. The mixture was dissolved in DCM (0.5 mL) and was treated with 
the corresponding chlorophosphine (1.0 eq.). The reaction was stirred at room temperature for 
30-60 minutes, until 31P-NMR shows full conversion. A second Schlenk flask was filled with 
[Ir(COD)Cl]2 (0.5 eq.), NaBArF (1.2 eq.) and assembled with a Schlenk fritt. The Schlenk fritt 
was charged with basic aluminum oxide (brockman activity 1, d×h, 2 cm × 1 cm). The 
equipment was evacuated three times and each time backfilled with argon. The ligand 
containing solution was filtered over the aluminum oxide layer and rinsed with DCM (5-
10 mL). The new obtained reaction mixture was stirred at room temperature for 1-2 hours 
until 31P-NMR shows full conversion. Afterwards the solvent was removed under reduced 
pressure. The crude Ir-complex was purified by flash chromatography. First side products 
were separated by elution with TBME and then the desired Ir-complex was washed down 
with DCM (collecting the orange-red band). If required the Ir-complex was recrystallized by 
overlaying a saturated etheral solution with n-pentane.  
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(S)-(+)-[η4-1,5-Cyclooctadiene-7-(2-phenyl-6,7-dihydro-5H-[1]pyrindine)-
diphenylphosphinite-iridium(I)]-tetrakis-(3,5-bis-(trifluoromethyl)-phenyl)-borate (36a)  
 
Ir-complex 36a was obtained following the general procedure C using 
pyridyl alcohol (S)-54a (29.4 mg, 139 µmol, 1.0 eq.), DMAP (17.0 mg, 
139 µmol, 1.0 eq.), chlorodiphenylphosphine (25.0 µL, 30.7 mg, 
139 µmol, 1.0 eq.), DCM (0.5 mL), [Ir(COD)Cl]2 (47.0 mg, 70.0 µmol, 
0.5 eq.), NaBArF (148 mg, 167 µmol, 1.2 eq.), after purification by flash chromatography 
(SiO2, 1.5 cm × 20 cm) and recrystallization from diethyl ether (2 mL) / n-petane (50 mL) as 
an orange solid (137 mg, 87.8 µmol, 63%). Suitable crystals for X-ray analysis were obtained 
by overlaying a concentrated etheral solution with n-pentane. 
 
31
P{
1
H}-NMR of Ph2PCl (162 MHz, CD2Cl2): δ = 79.1 (s) ppm. 
31
P{
1
H}-NMR of the ligand (162 MHz, CD2Cl2): δ = 108.5 (s) ppm. 
 
C66H46BF24IrNOP (1559.06 g/mol): 
1
H-NMR (500 MHz, CD2Cl2): δ = 7.88 (d, J = 8.0 Hz, 1H, HAr), 7.82–7.74 (m, 10H, BArF-H, 
HAr), 7.73–7.67 (dd, J = 11.4 Hz, 7.6, 3H, HAr), 7.65 (d, J = 8.0 Hz, 1H, HAr), 7.63–7.55 (m, 
6H, BArF-H, HAr), 7.55–7.41 (m, 8H, HAr), 6.43–6.46 (m, 1H, CHOP), 4.69–4.59 (br s, 1H, 
CH COD), 4.37 (mc, J = 2.7 Hz, 1H, CH COD), 3.32–3.20 (m, 1H, Ar-CH2), 3.18–3.07 (m, 
2H, Ar-CH2, CH2CH2CH), 3.04–2.90 (m, 2H, CH COD), 2.70–2.57 (m, 1H, CH2CH2CH), 
2.32–2.23 (m, 2H, CH2 COD), 2.18 (ddd, J = 16.4, 10.0, 5.3 Hz, 1H, CH2 COD), 2.07 (dd, J = 
15.4, 7.8 Hz, 1H, CH2 COD), 1.89 (dt, J = 13.6, 9.2 Hz, 1H, CH2 COD), 1.43–1.16 (m, 3H, 
CH2 COD) ppm.
 13
C{
1
H}-NMR (126 MHz, CD2Cl2): δ = 162.4 (q, JBC = 50 Hz, CAr BArF), 
161.5 (d, JPC = 4 Hz, CAr), 161.3 (s, CAr), 139.3 (d, JPC = 14 Hz, CAr), 137.7 (s, HCAr), 136.3 
(s, CAr), 135.8 (s, CAr), 135.4 (s, HCAr BArF), 132.7 (d, JPC = 2 Hz, HCAr), 132.3 (s, HCAr), 
131.8 (s, CAr), 130.9 (d, JPC = 14 Hz, HCAr), 130.1 (s, HCAr), 130.0 (d, JPC = 11 Hz, HCAr), 
129.8 (d, JPC = 11 Hz, HCAr), 129.6 (d, JPC = 11 Hz, HCAr), 129.5 (qq, JFC = 31 Hz, JBC = 3 Hz, 
CAr BArF), 128.1 (s, HCAr), 127.7 (s, HCAr), 125.2 (q, JFC = 272 Hz, CF3 BArF), 118.1 (septett, 
JFC = 4 Hz, HCAr BArF), 100.4 (d, JPC = 10 Hz, CH COD), 91.8 (d, JPC = 14 Hz, CH COD), 
86.0 (s, CHOP), 70.0 (s, CH COD), 63.6 (s, CH COD), 37.1 (s, CH2 COD), 34.4 (s, CH2 
COD), 30.7 (d, JPC = 10 Hz, CH2CH2CH), 28.9 (s, CH2 COD), 28.1 (s, Ar-CH2), 25.2 (s, CH2 
COD) ppm. 31P{1H}-NMR (202 MHz, CD2Cl2): δ = 99.5 (s) ppm. MS (FAB NBA) m/z (%): 
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696 ([Ir(L)(COD)]+, 100), 586 (19) EA: calc. (%) C 50.85, H 2.97, N 0.90; found C 50.70, H 
3.06, N 0.78. m.p.: 15β‒15γ °C. [α]D20: +23 (c = 1.19, CHCl3). 
 
 
(S)-(+)-[η4-1,5-Cyclooctadiene-7-(2-phenyl-6,7-dihydro-5H-[1]pyrindine)di-(ortho-
tolyl)phosphinite-iridium(I)]-tetrakis-(3,5-bis-(trifluoromethyl)-phenyl)-borate (36b)  
 
Ir-complex 36b was obtained following the general procedure C 
using pyridyl alcohol (S)-54a (106 mg, 500 µmol, 1.0 eq.), DMAP 
(61.1 mg, 500 µmol, 1.0 eq.), chloro-di-ortho-tolyl-phosphine 
(124 mg, 500 µmol, 1.0 eq.), DCM (1.0 mL), [Ir(COD)Cl]2 
(168 mg, 250 µmol, 0.5 eq.), NaBArF (532 mg, 600 µmol, 1.2 eq.) and after purification by 
flash chromatography (SiO2, 3 cm × 12 cm) and recrystallization from diethyl ether (2 mL) 
and n-petane (50 mL) as an orange solid (479 mg, 302 µmol, 60%). Suitable crystals for X-
ray analysis were obtained by overlaying a concentrated etheral solution with n-pentane. The 
analytical data match the reported values.[57b] 
 
31
P{
1
H}-NMR of (o-Tol) 2PCl (162 MHz, CD2Cl2): δ = 75.3 (s) ppm. 
31
P{
1
H}-NMR of the ligand (162 MHz, CD2Cl2): δ = 101.3 (s) ppm. 
 
C68H50BF24IrNOP (1587.11 g/mol):  
1
H-NMR (500 MHz, CD2Cl2): δ = 8.08 (br s, 1H, HAr), 7.91 (br s, 2H, HAr), 7.84 (d, J = 8.0 
Hz, 1H, HAr), 7.78 (br s, 8H, BArF-H), 7.73 (mc, J = 7.4 Hz, 1H, HAr), 7.67 (mc, J = 7.3 Hz, 
2H, HAr), 7.63 (d, J = 7.9 Hz, 1H, HAr), 7.59 (br s, 4H, BArF-H), 7.48–7.37 (m, 4H, HAr), 
7.36–7.27 (br s, 1H, HAr), 7.15 (mc, J = 2.1 Hz, 1H, HAr), 6.71 (mc, J = 8.0 Hz, 1H, HAr), 6.36 
(mc, J = 8.6 Hz, 1H, CHOP), 4.73 (br s, 1H, CH COD), 4.22 (br s, 1H, CH COD), γ.β6‒γ.14 
(m, 1H, Ar-CH2), γ.1β‒β.95 (m, γH, Ar-CH2, CH2CH2CH, CH COD), 2.84 (br s, 4H, Ar-CH3, 
CH COD) 2.56–2.17 (m, 6H, CH2CH2CH, Ar-CH3, CH2 COD), 2.13 (mc, J = 15.0, 7.9 Hz, 
1H, CH2 COD), 2.07–1.90 (m, 2H, CH2 COD), 1.44–1.26 (m, 2H, CH2 COD), 1.25–1.16 (m, 
1H, CH2 COD) ppm.
 13
C{
1
H}-NMR (126 MHz, CD2Cl2): δ = 162.4 (q, JBC = 50 Hz, CAr 
BArF), 161.5 (s, CAr), 161.3 (d, JPC = 3 Hz, CAr), 141.5 (d, JPC =8 Hz, CAr), 139.2 (d, JPC = 9 
Hz, CAr), 137.4 (s, HCAr), 135.2 (s, HCAr BArF), 135.1 (s, CAr), 134.7 (s, CAr), 133.3 (d, JPC = 
7 Hz, HCAr), 133.0 (s, HCAr), 132.5 (s, HCAr), 132.4 (s, HCAr), 131.9 (s, HCAr), 131.6 (s, 
HCAr), 131.4 (s, HCAr), 129.7 (s, HCAr), 129.3 (qq, JFC = 31 Hz, JBC = 3 Hz, CAr BArF), 128.3 
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(s, HCAr), 126.7 (d, JPC = 11 Hz, HCAr), 125.0 (q, JFC = 273 Hz, CF3 BArF), 117.9 (septett, JFC 
= 4 Hz, HCAr BArF), 99.1 (br s, CH COD), 90.0 (br s, CH COD), 83.9 (s, CHOP), 69.0 (s, CH 
COD), 67.1 (br s, CH COD), 36.7 (s, CH2 COD), 34.4 (s, CH2 COD), 30.5 (d, JPC = 9 Hz, 
CH2CH2CH), 28.4 (s, CH2 COD), 27.5 (s, Ar-CH2), 24.9 (s, CH2 COD), 23.2 (d, JPC = 5 Hz, 
Ar-CH3), 22.7 (br s, Ar-CH3) ppm. 
31
P{
1
H}-NMR (162 MHz, CD2Cl2): δ = 113.6 (br s) ppm. 
MS (FAB NBA) m/z (%): 724 ([Ir(L)(COD)]+, 100), 612 (35), 194 (14). EA: calc. (%) 
C 51.46, H 3.18, N 0.88; found C 51.46, H 3.18, N 0.84. m.p.: 1γ1‒1γβ °C; lit. 84 °C.[57b]. 
[α]D20: +21 (c = 1.01, CHCl3); lit. −10 (c = 1.01, CHCl3) for (R)-enantiomere.[57b] 
 
 
(S)-(+)-[η4-1,5-Cyclooctadiene-7-(2-phenyl-6,7-dihydro-5H-[1]pyrindine)-dicyclohexyl-
phosphinite-iridium(I)]-tetrakis-(3,5-bis-(trifluoromethyl)-phenyl)-borate (36c)  
 
Ir-complex 36c was obtained following the general procedure C 
using pyridyl alcohol (S)-54a (95.7 mg, 453 µmol, 1.0 eq.), DMAP 
(55.3 mg, 453 µmol, 1.0 eq.), chlorodicyclohexylphosphine (100 µL, 
105 mg, 453 µmol, 1.0 eq.), DCM (1.0 mL), [Ir(COD)Cl]2 (152 mg, 
226 µmol, 0.5 eq.), NaBArF (482 mg, 544 µmol, 1.2 eq.) and after purification by flash 
chromatography (SiO2, 3 cm × 12 cm) and recrystallization from diethyl ether (2 mL) and n-
pentane (50 mL) as an orange solid (469 mg, 299 µmol, 66%). Suitable crystals for X-ray 
analysis were obtained by overlaying a concentrated etheral solution with n-pentane. The 
analytical data match the reported values.[57b] 
 
 
31
P{
1
H}-NMR of Cy2PCl (162 MHz, CD2Cl2): δ = 126.7 (s) ppm. 
31
P{
1
H}-NMR of the ligand (162 MHz, CD2Cl2): δ = 147.6 (s) ppm. 
 
C66H58BF24IrNOP (1571.16 g/mol): 
1
H-NMR (500 MHz, CD2Cl2): δ = 8.32 (d, J = 7.4 Hz, 2H, HAr), 7.89 (d, J = 8.0 Hz, 1H, 
HAr), 7.80–7.70 (m, 10H, BArF-H, HAr), 7.68 (t, J = 7.5 Hz, 2H, HAr), 7.56 (m, 4H, BArF-H), 
5.80–5.74 (m, 1H, CHOP), 4.89–4.82 (m, 1H, CH COD), 4.66–4.59 (m, 1H, CH COD), 3.58–
3.48 (m, 1H, CH COD), 3.18–3.09 (m, 1H, Ar-CH2), 3.05–2.95 (m, 1H, Ar-CH2), 2.85–2.75 
(m, 1H, CH2CH2CH), 2.68–2.58 (m, 1H, CH COD), 2.49–2.02 (m, 7H, CH2), 2.01–1.74 (m, 
7H, CH2), 1.72–1.20 (m, 12H, CH2), 1.17–0.98 (m, 4H, CH2), 0.63–0.49 (m, 1H, CH2) ppm. 
13
C{
1
H}-NMR (126 MHz, CD2Cl2): δ = 162.3 (q, JBC = 50 Hz, CAr BArF), 162.0 (d, JPC = 3 
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Hz, CAr), 160.3 (s, CAr), 139.1 (s, CAr), 139.0 (s, CAr), 137.6 (s, HCAr), 135.4 (s, HCAr BArF), 
132.3 (s HCAr), 130.3 (s, HCAr), 129.4 (qq, JFC = 32 Hz, JBC = 3 Hz, CAr BArF), 128.8 (s, 
HCAr), 127.4 (s, HCAr), 125.2 (q, JFC = 272 Hz, CF3 BArF), 118.0 (septett, JFC = 4 Hz, HCAr 
BArF), 95.6 (d, JPC = 8 Hz, CH COD), 85.4 (d, JPC = 15 Hz, CH COD), 85.2 (s, CHOP), 69.6 
(s, CH COD), 66.2 (s, CH COD), 39.2 (d, JPC = 31 Hz, CH Cy), 37.8 (d, JPC = 3 Hz, CH2), 
36.8 (d, JPC = 31 Hz, CH Cy), 35.4 (s, CH2), 30.1 (d, JPC = 9 Hz, CH2CH2CH), 28.7 (s, CH2), 
28.3 (s, CH2), 28.2 (s, CH2), 27.4 (s, Ar-CH2), 27.3 (d, JPC = 3 Hz, CH2), 27.2 (s, CH2), 27.1 
(s, CH2), 27.0 (s, CH2), 26.7 (s, CH2), 26.6 (d, JPC = 2 Hz, CH2), 26.5 (s, CH2), 26.4 (s, CH2), 
26.3 (s, CH2), 25.5 (s, CH2), 24.5 (d, JPC = 2 Hz, CH2) ppm.
 31
P{
1
H}-NMR (202 MHz, 
CD2Cl2): δ = 121.8 (s) ppm. MS (FAB NBA) m/z (%): 708 ([Ir(L)(COD)]+, 100), 596 (25), 
432 (16), 194 (13). EA: calc. (%) C 50.45, H 3.72, N 0.89; found C 50.60, H 3.71, N 0.71. 
m.p.: 169‒171 °C; lit. 175 °C.[57b]. [α]D20: −44 (c = 1.04, CHCl3); lit. +41 (c = 1.09, CHCl3) 
for (R)-enantiomere.[57b] 
 
 
(S)-(+)-[η4-1,5-Cyclooctadiene-8-(2-phenyl-5,6,7,-tetrahydrochinolinyl)-di-(ortho-
tolyl)phosphinite-iridium(I)]-tetrakis-(3,5-bis-(trifluoromethyl)-phenyl)-borate (36e)  
 
Ir-complex 36e was obtained following the general procedure C 
using pyridyl alcohol (S)-54c (25 mg, 111 µmol, 1.0 eq.), DMAP 
(13.6 mg, 111 µmol, 1.0 eq.) chloro-di-ortho-tolyl-phosphine 
(27.6 mg, 111 µmol, 1.0 eq.), DCM (0.5 mL), [Ir(COD)Cl]2 
(37.3 mg, 55.5 µmol, 0.5 eq.) and NaBArF (118 mg, 133 µmol, 
1.2 eq.), after purification by flash chromatography (SiO2, 1.5 cm × 15 cm) and 
recrystallization from diethyl ether (2 mL) and n-pentane (50 mL) was isolated as an orange 
solid (118 mg, 73.4 µmol, 66%). Suitable crystals for X-ray analysis were obtained by 
overlaying a concentrated etheral solution with n-pentane. The analytical data match the 
reported values.[57b] 
 
31
P{
1
H}-NMR of (o-Tol) 2PCl (162 MHz, CD2Cl2): δ = 75.3 (s) ppm. 
31
P{
1
H}-NMR of the Ligand (162 MHz, CD2Cl2): δ = 99.8 (s) ppm. 
 
C69H52BF24IrNOP (1601.14 g/mol):  
1
H-NMR (500 MHz, CD2Cl2): δ = 7.90‒7.65 (m, 1βH, HAr, BArF-H), 7.65‒7.50 (m, 7H, HAr, 
BArF-H), 7.48‒7.γ9 (m, γH, HAr), 7.γ9‒7.γ1 (m, βH, HAr), 7.β9‒7.βγ (m, 1H, HAr), 7.20 (t, J 
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= 6.3 Hz, 1H, HAr), 6.96‒6.85 (m, 1H, HAr), 6.γ1‒6.β4 (m, 1H, CHOP), 4.71 (br s, 1H, CH 
COD), 4.49 (br s, 1H, CH COD), 3.24 (br s, 1H, CH COD), 3.06–2.96 (m, 1H, CH2), 2.89 (s, 
3H, Ar-CH3), 2.87–2.74 (m, 2H, CH COD, CH2), 2.68–2.59 (m, 1H, CH2), 2.49 (s, 3H, Ar-
CH3), 2.45–2.30 (m, 2H, CH2), β.16‒1.95 (m, γH, CH2), 1.9γ‒1.79 (m, γH, CH2), 1.4β‒1.γ1 
(m, 1H, CH2), 1.30‒1.18 (m, 1H, CH2), 1.15‒1.04 (m, 1H, CH2) ppm. 13C{1H}-NMR 
(126 MHz, CD2Cl2): δ = 162.3 (q, JBC = 50 Hz, CAr BArF), 160.8 (s, CAr), 141.5 (s, HCAr), 
139.6 (s, CAr), 136.7 (s, CAr), 135.4 (s, HCAr BArF), 134.8 (s, CAr), 134.4 (s, CAr), 133.0 (d, JPC 
= 8 Hz, HCAr), 132.8 (s, HCAr), 132.7 (s, HCAr), 132.1 (s, HCAr), 132.0 (d, JPC = 14 Hz, HCAr), 
130.4 (s, HCAr), 129.5 (qq, JFC = 32 Hz, JBC = 3 Hz, CAr BArF), 128.2 (s, HCAr), 127.0 (d, JPC 
= 11 Hz, HCAr), 126.4 (s, HCAr), 125.2 (q, JFC = 273 Hz, CF3 BArF), 118.1 (septett, JFC = 4 
Hz, HCAr BArF), 94.8 (br s, CH COD), 83.1 (br s, CH COD), 76.7 (s, CHOP), 70.4 (s, CH 
COD), 70.2 (br s, CH COD), 36.5 (d, JPC = 2 Hz, CH2), 35.2 (s, CH2), 31.2 (d, JPC = 10 Hz, 
CH2), 29.3 (s, CH2), 29.0 (s, CH2), 24.2 (s, CH2), 23.3 (d, JPC = 7 Hz, Ar-CH3), 22.5 (d, JPC = 
57 Hz, Ar-CH3), 19.0 (s, CH2) ppm. 
31
P{
1
H}-NMR (162 MHz, CD2Cl2): δ = 99.3 (br s) ppm. 
MS (FAB NBA) m/z (%): 738 ([Ir(L)(COD)]+, 100), 628 (58), 534 (11), 419 (11), 218 (16). 
EA: calc. (%) C 51.76, H 3.27, N 0.87; found C 51.92, H 3.30, N 0.71. m.p.: 158‒159 °C; lit. 
163 °C.[57b] [α]D20: +33 (c = 0.985, CHCl3); lit. +41 (c = 1.0, CHCl3).[57b] 
 
 
8.4 New N,P Ligands with a Quaternary Stereogenic Center and Their 
Iridium-Complexes 
8.4.1 Preparation of Ligand Precursors 
(E)-7-benzylidene-6,7-dihydro-5H-cyclopenta[1]pyridine (79a)  
 
A mixture of 6,7-dihydro-5H-cyclopenta[1]pyridine (5.0 mL, 5.15 g, 
43.2 mmol), benzaldehyde (6.6 mL, 6.93 g, 65.3 mmol, 1.5 eq.) and acetic 
anhydride (7.8 mL, 8.42 g, 82.5 mmol, 1.9 eq.) was stirred at 180 °C for 
13 h. All volutiles were then removed under reduced pressure at 100 °C. 
Ice cold water (40 mL) was added to the obtained black residue and the mixture was made 
basic (pH > 10) with aqueous NaOH 2 M solution (40 mL) and then extracted with DCM 
(4×50 mL). Combined organic layers were dried over MgSO4, filtered and the solvent was 
removed under reduced pressure. The residue was purified by Kugelrohr distillation (150‒
160 °C / 0.2 mbar). Recrystallization from n-hexanes (10 mL) gave the title compound 79a 
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(6.60 g, 31.8 mmol, 74%) as a colorless solid. The analytical data match the reported 
values.[101a] 
 
C15H13N (207.27 g/mol): 
1
H-NMR (500 MHz, CDCl3): δ = 8.40 (d, J = 4.7 Hz, 1H, HAr), 7.51‒7.47 (m, γH, HAr), 7.44 
(s, 1H, CH), 7.32 (t, J = 7.7 Hz, 2H, HAr), 7.18 (t, J = 7.4 Hz, 1H, HAr), 7.02 (dd, J = 7.5, 
4.9 Hz, 1H, HAr), γ.09‒γ.08 (m, βH, CH2), γ.0γ‒γ.00 (m, βH, Ar-CH2) ppm. 13C{1H}-NMR 
(101 MHz, CDCl3): δ = 160.7 (CAr), 148.4 (HCAr), 141.2 (C=CH), 138.9 (CAr), 137.6 (CAr), 
133.0 (HCAr), 129.0 (HCAr), 128.4 (HCAr), 126.9 (HCAr), 122.3 (HCAr), 122.1 (C=CH), 28.7 
(CH2), 28.2 (Ar-CH2) ppm. MS: (FAB NBA) m/z (%): 208 ([M+H]
+, 100), 130 (5), 117 (6), 
91 (9), 77 (109, 63 (5), 51 (6), 39 (7). IR: ṽ = 2986 (w), 2938 (w), 1596 (w), 1575 (m), 1490 
(m), 1446 (m), 1430 (s), 1415 (s), 1263 (m), 1202 (w), 1163 (m), 1106 (w), 1079 (s), 1006 
(m), 965 (w), 916 (s), 881 (m), 817 (m), 798 (s), 774 (m), 750 (s), 692 (s) cm-1. EA: calc. (%) 
C 86.92, H 6.32, N 6.76; found C 86.72, H 6.37, N 6.82. m.p.: 75‒76 °C; lit. 74‒75 °C.[101a] 
 
 
(E)-8-Benzylidene-5,6,7,8-tetrahydroquinoline (79b)  
 
A mixture of 5,6,7,8-tetrahydroquinoline (5.0 mL, 5.15 g, 38.7 mmol), 
benzaldehyde (6.0 mL, 6.30 g, 59.4 mmol, 1.5 eq.) and acetic anhydride (7.0 
mL, 7.56 g, 74.1 mmol, 1.9 eq.) was stirred at 180 °C for 15 h. The volutiles 
were removed under reduced pressure at 100 °C. Ice cold water (40 mL) was 
added to the obtained black residue and the mixture was made distinctly basic (pH > 10) with 
aq. NaOH 2 M solution (5 mL) and then extracted with DCM (4×50 mL). Combined organic 
layers were dried over MgSO4, filtered and the solvent was removed under reduced pressure. 
The residue was purified by Kugelrohr distillation (150‒160 °C / 0.2 mbar). Recrystallization 
from n-hexane (25 mL) gave the title compound 79b (6.40 g, 28.9 mmol, 75%) as a colorless 
solid. The analytical data match the reported values.[101a] 
 
C16H15N (221.30 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 8.48 (dt, J = 4.4, 0.8 Hz, 1H, HAr), 7.98 (s, 1H, CH), 7.γ6‒
7.46 (m, 5H, HAr), 7.26 (tt, J = 7.2, 1.2 Hz, 1H, HAr), 7.09 (dd, J = 7.6, 4.6 Hz, 1H, HAr), 
β.90‒β.9γ (m, βH, ArCH2), 2.86 (t, J = 6.2 Hz, 2H, CH2C(O)), 1.86 (p, J = 6.2 Hz, 2H, 
CH2CH2CH2) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 152.9 (CAr), 147.2 (HCAr), 137.9 
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(C=CH), 136.9 (CH), 135.3 (CAr), 132.6 (CAr), 129.6 (HCAr), 128.0 (HCAr), 126.9 (HCAr), 
126.7 (HCAr), 121.9 (HCAr), 29.8 (CH2), 28.0 (CH2), 22.7 (CH2) ppm. MS (EI, 70 eV, ca. 
50 °C) m/z (%): 220 ([M]+, 100). IR: ṽ = 2946 (m), 2928 (w), 2915 (w), 2834 (w), 1580 (w), 
1563 (m), 1485 (m), 1456 (w), 1435 (s), 1419 (m), 1182 (w), 1116 (m), 1072 (w), 1057 (w), 
1029 (w), 926 (s), 918 (w), 901 (w), 887 (m), 864 (m), 847 (w), 832 (m), 826 (w), 792 (s), 
772 (s), 757 (s), 715 (m), 699 (s) cm-1. EA: calc. (%) C 86.84, H 6.83, N 6.33; found C 86.70, 
H 6.92, N 6.23. m.p.: 66‒67 °C; lit. 6β‒64 °C.[101a] 
 
 
8.4.2 Preparation Pyridyl Ketones  
 
 
 
Swern Oxidation, General Procedure D: 
A solution of DMSO (2.5 eq.) in DCM (β.5‒5 M) was slowly added to a solution of oxalyl 
chloride (1.2 eq.) in DCM (0.5‒0.6 M) at ‒78 °C. After stirring for 15 min, a solution of 
pyridyl alcohol (1.0 eq.) in DCM (1 M) was slowly added. After stirring for additional 20 min, 
triethylamine (>5 eq.) was added to the reaction mixture. The cooling bath was removed and 
the reaction mixture was allowed to reach RT. The volutiles were removed in vacuo. The 
residue was dissolved in DCM (20 mL), and washed with water (10 mL) and with brine 
(10 mL). After drying over MgSO4, the solvent was removed under reduced pressure. The 
obtained ketone was purified by flash chromatography or by Kugelrohr distillation.  
 
Ozonolysis, General Procedure E: 
A solution of olefin (1.0 eq.) in MeOH (0.2 M) was treated with ozone (40 L / min) at ‒40 °C 
for 2 h. Afterwards the reaction mixture was purged with N2. Dimethyl sulfide (3.0 eq.) was 
then added. The mixture was stirred for 0.5 h at ‒40 °C, before it was allowed to warm to rt 
overnight. The solvent was removed under reduced pressure. The obtained ketone was 
purified by flash chromatography or by Kugelrohr distillation.  
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5H-Cyclopenta[1]pyridin-7(6H)-one (76a) 
 
The title compound 76a was obtained following the general procedure D using 
oxalyl chloride (0.29 mL, 429 mg, 3.38 mmol, 1.2 eq.), DCM (7.5 mL), DMSO 
(0.53 mL, 583 mg, 7.37 mmol, 2.5 eq.), DCM (3.0 mL), 78a (393 mg, 2.91 mmol, 
1.0 eq.), DCM (3.0 mL), triethylamine (2.1 mL, 1.53 g, 15.1 mmol, 5.2 eq.), after purification 
by flash chromatography (SiO2, 3 cm × 10 cm, TBME / cyclohexane 1:1  1:0) and by 
Kugelrohr distillation (1β5‒1γ0 °C, 0.1 mbar) as a slightly yellow solid (297 mg, 2.23 mmol, 
77%).  
Alternativly the title compound 76a was prepared following the general procedure E using 
79a (9.45 g, 45.6 mmol, 1.0 eq.), MeOH (200 mL), ozone, dimethyl sulfide (10 mL, 8.40 g, 
135 mmol, 3.0 eq.), after purification by Kugelrohr distillation (1β5‒1γ0 °C, 0.1 mbar) as 
brown solid (4.34 g, 32.6 mmol, 72%). The analytical data match the reported values.[101a] 
 
C8H7NO (133.05 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 8.77‒8.76 (m, 1H, HAr), 7.90‒7.87 (m, 1H, HAr), 7.44 (dd, 
J = 7.9 Hz, 4.5 Hz, 1H, HAr), 3.17 (m, 2H, CH2CO), β.78‒β.75 (m, βH, CH2) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 205.3 (C=O), 154.0 (CAr), 150.6 (HCAr), 149.5 (CAr), 
135.3 (HCAr), 127.3 (HCAr), 34.8 (CH2C(O)), 23.4 (ArCH2) ppm. MS (EI, 70 eV, RT) m/z 
(%): 133 ([M]+, 100), 104 (57), 78 (23), 51 (10). IR: ṽ = 3185 (m br), 2963 (w), 2925 (w), 
2876 (w), 1578 (s), 1449 (m), 1426 (m), 1331 (m), 1289 (m), 1187 (w), 1117 (w), 1082 (s), 
1053 (m), 1001 (s), 969 (s), 949 (m), 884 (m), 830 (m), 799 (s,) 780 (m), 724 (w), 689 (s br) 
cm-1. EA: calc. (%) C 72.17, H 5.30, N 10.52; found C 72.08, H 5.39, N 10.51. m.p.: 117‒
118 °C; lit. 118‒1β0 °C.[101a] 
 
 
2-Phenyl-5,6,7,8-tetrahydroquinolin-8-on (76b) 
 
The title compound 76b was obtained following the general procedure D 
using oxalyl chloride (1.0 mL, 1.48 g, 11.6 mmol, 1.2 eq.), DCM (30 mL), 
DMSO (1.8 mL, 1.98 g, 25.4 mmol, 2.3 eq.), DCM (10 mL), 54a (2.30 g, 
10.9 mmol, 1.0 eq.), DCM (10 mL), triethylamine (7.7 mL, 5.54 g, 54.8 mmol, 5.0 eq.), after 
purification by flash chromatography (SiO2, 3 cm × 20 cm, DCM / cyclohexane 1:1  1:0) as 
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pale greenish solid (422 mg, 1.90 mmol, 90%). The analytical data match the reported 
values.[152] 
 
C14H11NO (209.24 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 8.1γ‒7.99 (m, βH, HAr), 7.89 (q, J = 8.2 Hz, 2H, HAr), 
7.50‒7.γ4 (m, γH, HAr), γ.19‒γ.10 (m, βH, CH2), β.81‒β.7γ (m, βH, CH2) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 205.8 (CO), 158.7 (CAr), 154.2 (CAr), 148.4 (CAr), 
138.4 (CAr), 136.1 (HCAr), 129.7 (HCAr), 128.9 (HCAr), 127.5 (HCAr), 124.8 (HCAr), 35.5 
(CH2), 23.4 (CH2) ppm. MS (EI, 70 eV, ca. 200 °C) m/z (%): 209 ([M]
+, 100), 180 (42), 152 
(6), 140 (11), 115 (8), 77 (6). EA: calc. (%) C 80.36, H 5.30, N 6.69; found C 80.83, H 5.54, 
N 6.67. m.p.: 17β‒174 °C (dec.); lit. 167‒168 °C.[152] TLC (SiO2, DCM): Rf = 0.10. 
 
 
5,6,7,8-Tetrahydroquinolin-8-on (76c) 
 
The title compound 76c was obtained following the general procedure D using 
oxalyl chloride (1.0 mL, 1.48 g, 11.7 mmol, 1.1 eq.), DCM (20 mL), DMSO 
(1.8 mL, 1.98 g, 25.0 mmol, 2.4 eq.), DCM (5.0 mL), 78b (1.51 g, 10.6 mmol, 
1.0 eq.), DCM (10 mL), triethylamine (7.5 mL, 5.48 g, 54.1 mmol, 5.1 eq.), after purification 
by Kugelrohr distillation (150‒160 °C, 0.1 mbar) to give the title compound 76c as a slightly 
yellow solid (1.50 g, 10.2 mmol, 96%).  
Alternativly the title compound 76c was prepared following the general procedure E using 
79b (10.0 g, 47.0 mmol, 1.0 eq.), MeOH (170 mL), ozone, dimethyl sulfide (10.3 mL, 8.76 g, 
141 mmol, 3.0 eq.), after purification by recrystallization from a mixture of diisopropyl ether 
(55 mL) and acetone (10 mL) as a slightly yellow solid (4.50 g, 31 mmol, 66%). The 
analytical data match the reported values.[101a] 
 
C9H9NO (147.07 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 8.70 (dd, J = 4.5, 0.8 Hz, 1H, HAr), 7.65 (dd, J = 7.8, 
0.8 Hz, 1H, HAr), 7.38 (dd, J = 7.8, 4.5 Hz, 1H, HAr), 3.03 (t, J = 6.1 Hz, 2H, ArCH2), 2.81 (t, 
J = 6.6 Hz, 2H, CH2C(O)), 2.20 (p, J = 2.4 Hz, 2H, CH2CH2CH2) ppm. 
13
C{
1
H}-NMR 
(101 MHz, CDCl3): δ = 196.7 (CO), 149.0 (HCAr), 148.1 (CAr), 140.7 (CAr), 137.5 (HCAr), 
126.9 (HCAr), 39.6 (CH2C=O), 29.0 (ArCH2), 22.6 (CH2CH2CH2) ppm. MS (EI, 70 eV, ca. 
50 °C) m/z (%): 147 ([M]+, 73), 118 (39), 91 (100), 64 (18), 55 (28), 51 (11), 39 (21). IR: ṽ = 
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3354 (w), 3165 (w), 3049 (w), 2941 (m), 2880 (w), 1686 (s), 1582 (w), 1562 (m), 1435 (w), 
1421 (m), 1350 (w), 1329 (m), 1294 (s), 1271 (w), 1196 (m), 1184 (m), 1148 (w), 1111 (m), 
1088 (m), 1055 (w), 1036 (m), 1001 (w), 906 (m), 897 (s), 862 (m), 818 (m), 800 (s), 773 (w), 
704 (w), 689 (m), 648 (m) cm-1. EA: calc. (%) C 73.45, H 6.16, N 9.52; found C 73.06, 
H 6.24, N 9.45. m.p.: 8β‒87 °C; lit: 98‒100 °C.[101a] 
 
 
2-Phenyl-5,6,7,8-tetrahydroquinolin-8-on (76d) 
 
The title compound 76d was obtained following the general procedure D 
using oxalyl chloride (0.20 mL, 296 mg, 2.33 mmol, 1.1 eq.), DCM 
(5.0 mL), DMSO (0.35 mL, 385 mg, 2.33 mmol, 2.3 eq.), DCM (1.0 mL), 
54b (478 mg, 2.12 mmol, 1.0 eq.), DCM (2.0 mL), triethylamine (1.5 mL, 1.10 g, 10.8 mmol, 
5.1 eq.) after purification by flash chromatography (SiO2, 3 cm × 15 cm, ethyl acetate / 
cyclohexane 1:4  1:1  1:0) as a colorless solid (422 mg, 1.90 mmol, 90%). The analytical 
data match the reported values.[152] 
 
C15H13NO (223.27 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 8.06‒8.0γ (m, βH, HAr), 7.81 (d, J = 8.1 Hz, 1H, HAr), 7.70 
(br d, J = 8.2 Hz, 1H, HAr), 7.48‒7.γ8 (m, γH, HAr), 3.03 (t, J = 6.1 Hz, 2H, ArCH2), β.84‒
2.79 (m, 2H, CH2C(O)), 2.20 (t, J = 6.4 Hz, 2H, CH2CH2CH2) ppm. 
13
C{
1
H}-NMR 
(101 MHz, CDCl3): δ = 196.8 (CO), 156.8 (CAr), 148.0 (CAr), 139.3 (CAr), 138.6 (CAr), 138.5 
(HCAr), 129.4 (HCAr), 128.8 (HCAr), 127.3 (HCAr), 124.0 (HCAr), 40.0 (CH2C=O), 29.1 
(ArCH2), 22.8 (CH2CH2CH2) ppm. MS (EI, 70 eV, ca. 150 °C) m/z (%): 223 (100, [M]
+), 194 
(40), 167 (66). EA: calc. (%) C 80.69, H 5.87, N 6.27; found C 80.68, H 5.86, N 6.17. m.p.: 
1γ5‒1γ7 °C; lit. 145‒146 °C.[152] TLC (SiO2, EtOAc): Rf = 0.67. 
 
 
8-Methyl-5,6,7,8-tetrahydroquinolin-8-ol (80)  
 
Methylmagnesium chloride 3 M solution in THF (3.0 mL, 9.0 mmol, 1.3 eq.) was 
slowly added to a suspension of zinc chloride (100 mg, 734 μmol, 0.1 eq.) and 
76c (1.02 g, 6.92 mmol, 1.0 eq.) in THF (20 mL) at 0 °C. After stirring for 2 h 
under ice bath control, the reaction was quenched by addition of a ½-sat. aq. NH4Cl solution 
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(50 mL). Extraction with DCM (3×50 mL), drying with MgSO4 and evaporation of solvent 
under reduced pressure offered the crude product. Purification by flash chromatography 
(SiO2, 1.5 cm × 12 cm, cyclohexane / TBME 10:1) gave the title compound 80 (712 mg, 
4.36 g, 63%) as a colorless solid. The analytical data match the reported values.[104]  
 
C10H13NO (163.22 g/mol):  
1
H-NMR (400 MHz, CDCl3): δ = 8.40 (dd, J = 4.7, 0.7 Hz, 1H, HAr), 7.36 (dd, J = 7.7, 
0.7 Hz, 1H, HAr), 7.07 (dd, J = 7.7, 4.7 Hz, 1H, HAr), 3.93 (s, 1H, OH), β.85‒β.7β (m, 2H, 
ArCH2), β.07‒1.91 (m, γH, CH2CH2C(OH)), 1.86‒1.76 (m, 1H, CH2C(OH)), 1.53 (s, 3H, 
CH3) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 160.9 (CAr), 147.0 (HCAr), 136.8 (HCAr), 
130.5 (CAr), 122.1 (HCAr), 70.7 (C(OH)), 36.8 (CH2), 30.5 (CH3), 28.7 (CH2), 19.7 (CH2) 
ppm. MS (FAB NBA) m/z (%): 164 ([M+H]+, 100), 146 (66), 136 (9), 107 (8), 89 (10), 77 
(14), 51 (8); (FAB NBA + KCl) m/z (%): 202 ([M+K]+, 12), 164 ([M+H]+, 100), 146 (6), 107 
(10), 89 (10), 77 (19), 63 (9), 51 (10). IR: ṽ = 3292 (w br), 3053 (w), 2935 (m) , 2866 (w), 
1576 (m), 1454 (m), 1441 (s), 1421 (m), 1389 (m), 1364 (m), 1329 (m), 1294 (m), 1269 (w), 
1200 (m), 1190 (m), 1177 (w), 1144 (s), 1107 (m), 1077 (s), 1055 (w), 1047 (m), 1016 (w), 
995 (w), 984 (w), 972 (w), 935 (s), 899 (w), 870 (w), 847 (m), 837 (m), 816 (m), 799 (s), 719 
(w), 682 (s), 669 (m), 621 (w) cm-1. EA: calc. (%) C 73.59, H 8.03, N 8.03, O 9.80; found 
C 73.36, H 7.79, N 8.40. m.p.: 58‒60 °C; lit: 7β‒7γ °C.[104] 
 
 
8.4.3 Preparation Methyl-Phosphines-BH3-Adducts 
 
Diphenyl-methyl-phosphine-borane adduct (84a)  
 
BH3-THF-adduct 1 M solution (16.0 mL, 6.00 mmol, 1.2 eq.) was slowly 
added to a solution of methyldiphenylphosphine (1.00 g, 4.99 mmol, 1.0 eq.) 
in THF (15 mL) at 0 °C. The reaction mixture was stirred for 2 h at RT. All 
volatiles were removed in vacuo to obtain the title compound 84a (1.08 g, 5.06 mmol, quant.) 
as a colorless solid. The analytical data match the reported values.[153] 
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C13H16BP (214.05 g/mol):  
1
H-NMR (400 MHz, CDCl3): δ = 7.68–7.64 (m, 4H, HAr), 7.52–7.42 (m, 6H, HAr), 1.87 (d, 
JPH = 10.1 Hz, 3H, PCH3), 0.99 (br q, JBH = 85 Hz, 3H, BH3) ppm. 
31
P{
1
H}-NMR (162 MHz, 
CDCl3): δ = 7.3 (q, JBP = 51 Hz) ppm. m.p.: 48‒49°C; lit 55 °C.[153] 
 
 
Methyl-di-ortho-tolylphosphine-borane adduct (84b) 
 
Methyllithium 1.6 M solution in diethyl ether (5.0 mL, 8.00 mmol, 1.0 eq.) 
was added to a solution of chloro-methyl-di-ortho-tolylphosphine (1.99 g, 
8.00 mmol, 1.0 eq.) in diethyl ether (15 mL) at 0 °C. The reaction mixture 
was stirred overnight at RT. BH3·THF 1 M solution (10 mL, 10.0 mmol, 1.3 eq.) was added at 
0 °C, and the reaction mixture was stirred for additional 5 h at RT. The reaction mixture was 
quenched with ½-sat. aq. NH4Cl-solution (20 mL) at 0 °C and extracted with DCM 
(3×15 mL). The combined organic layers were washed with water (20 mL), brine (20 mL) 
and dried over MgSO4. After removing the solvent under reduced pressure the title compound 
84b (0.782 g, 3.23 mmol, 40%) was obtained as a colorless solid. 
  
C15H20BP (242.10 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 7.85–7.74 (m, 2H, HAr), 7.39 (tt, J = 7.5, 1.6 Hz, 2H, HAr), 
7.31 (t, J = 7.5 Hz, 2H, HAr), 7.16 (dd, J = 7.5, 3.6 Hz, 2H, HAr), 2.10 (s, 6H, ArCH3), 1.93 (d, 
JPH = 9.8 Hz, 3H, PCH3), 1.38 (br q, JBH = 85 Hz, 3H, BH3) ppm. 
13
C{
1
H}-NMR (101 MHz, 
CDCl3): δ = 142.0 (d, JCP = 6 Hz, CAr), 132.7 (d, JCP = 13 Hz, HCAr), 131.8 (d, JCP = 8 Hz, 
HCAr), 128.8 (d, JCP = 53 Hz, CAr), 126.6 (d, JCP = 11 Hz, HCAr), 21.6 (d, JCP = 5 Hz, ArCH3), 
12.1 (d, JCP = 42 Hz, CH3P) ppm. 
31
P{
1
H}-NMR (162 MHz, CDCl3): δ = 6.90 (q, 
JBP = 36 Hz) ppm. m.p.: 118–119 °C. 
 
 
Dicyclohexyl-(methyl)-phosphine-BH3-adduct (84c) 
 
Methylmagnesium chloride 3.0 M solution in THF (3.0 mL, 8.0 mmol, 
1.0 eq.) was added to a solution of chloro-dicyclohexyl-methylphosphine 
(1.86 g, 8.00 mmol, 1.0 eq.) in THF (7 mL) at 0 °C. The reaction mixture was 
stirred for 4 hours at RT. BH3·THF 1 M solution (10 mL, 10.0 mmol, 1.3 eq.) was added at 
0 °C, and the reaction mixture was stirred overnight at RT. The reaction mixture was 
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quenched with ½-sat. aq. NH4Cl-solution (10 mL) at 0 °C and extracted with DCM 
(3×25 mL). The combined organic layers were washed with water (20 mL), brine (20 mL) 
and dried over MgSO4. The solvent was removed under reduced pressure. The crude product 
was purified by flash chromatography (SiO2, 1.5 cm × 25 cm, cyclohexane / ethyl acetate 9:1) 
to obtain the title compound 84c (1.45 g, 6.41 mmol, 80%) as a colorless solid. 
 
C13H28BP (226.15 g/mol):  
1
H-NMR (400 MHz, CDCl3): δ = 1.94‒1.77 (m, 6H, Cy), 1.7β‒1.61 (m, 6H, Cy), 1.41‒1.14 
(m, 10H, Cy), 1.10 (d, JPH = 9.8 Hz, 3H, PCH3), 0.76‒0.β0 (br q, JBH = 86 Hz, 3H, BH3). 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 31.4 (d, JCP = 34 Hz, CH), 27.0 (CH2), 26.9 (d, 
JCP = 2 Hz, CH2), 26.7 (CH2), 26.3 (d, JCP = 3 Hz, CH2), 26.2 (d, JCP = 1 Hz, CH2), 3.8 (d, 
JCP = 35 Hz, CH3P) ppm. 
31
P{
1
H}-NMR (162 MHz, CDCl3): δ = 17.6 (q, JBP = 55 Hz) ppm. 
m.p.: 77–78 °C. TLC (SiO2, cyclohexane / ethyl acetate 9:1): Rf = 0.72. 
 
 
Di-ortho-methoxyphenyl-methyl-phosphan-BH3-adduct (84d) 
 
Methyllithium 1.6 M solution in diethyl ether (5.0 mL, 8.00 mmol, 1.0 eq.) 
was slowly added to a solution of chloro-di-ortho-methoxyphenyl-methyl-
phosphine (3.98 g, 14.2 mmol, 1.0 eq.) in diethyl ether (20 mL) at 0 °C. 
The reaction mixture was stirred overnight at RT. BH3·THF 1 M solution (10 mL, 10.0 mmol, 
1.3 eq.) was added at 0 °C, and the reaction mixture was stirred overnight at RT. The reaction 
mixture was quenched with ½-sat. aq. NH4Cl-solution (20 mL) at 0 °C and extracted with 
DCM (3×15 mL). The combined organic layers were washed with water (20 mL), brine 
(20 mL) and dried over MgSO4. After removing the solvent under reduced pressure the crude 
product was purified by flash chromatography (SiO2, 1.5 cm × 25 cm, cyclohexane / ethyl 
acetate 3:1) to obtain the title compound 84d (1.15 g, 3.23 mmol, 30%) as a colorless solid.  
 
C15H20BO2P (274.10 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 7.59 (ddd, J = 13.1, 7.6, 1.6 Hz, 2H, HAr), 7.48–7.41 (m, 
2H, HAr), 7.00 (tdd, J = 7.5, 1.7, 1.0 Hz, 2H, HAr), 6.88 (dd, J = 8.1, 3.8 Hz, 2H, HAr), 3.69 (s, 
6H, ArCH3), 1.96 (d, JPH = 10.8 Hz, 3H, PCH3), 1.38 (br q, JBH = 87 Hz, 3H, BH3). 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 161.4 (CAr), 134.3 (d, JCP = 11 Hz, HCAr), 132.8 
(HCAr), 120.9 (d, JCP = 11 Hz, HCAr), 118.7 (d, JCP = 58 Hz, CAr), 111.4 (d, JCP = 5 Hz, HCAr), 
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55.6 (s, OCH3), 11.2 (d, JCP = 43 Hz, CH3P) ppm.
31
P{
1
H}-NMR (162 MHz, CDCl3): δ = 7.44 
(q, JBP = 41 Hz) ppm. 
 
 
8.4.4 Addition of Phosphines 
 
 
 
General Procedure F: A 1.6 M solution of n-BuLi (1.1 eq.) was added to a solution of 
phosphine-borane adduct (1.1 eq.) in THF (0.3-0.4 M) at 0 °C. The reaction mixture was 
stirred for 1-2 h at RT. A mixture of ketone (96.8 mg, 727 µmol, 1.0 eq.), lithium bromide 
(63.2 mg, 727 µmol, 1.0 eq.) and THF (0.6-0.7 M) was slowly added to the reaction mixture at 
0 °C. The reaction mixture was stirred overnight at RT. The reaction mixture was quenched 
by the addition of ½-sat. aq. NH4Cl-solution (5-10 mL) and it was extracted with TBME 
(2×5-10 mL). The combined organic layers were washed with water (5-10 mL), and brine (5-
10 mL), and dried over MgSO4. The crude product was purified by flash chromatography or 
by recrystallization. 
 
Note: For phosphines having ortho-tolyl residues the BH3 protecting group was removed 
during the work-up.  
 
7-((Diphenylphosphino)methyl)-6,7-dihydro-5H-cyclopenta[1]pyridin-7-ol-BH3-adduct 
(85a) 
 
The title compound 85a was obtained following the general procedure F 
using 84a (171 mg, 800 µmol, 1.1 eq.), THF (2.0 mL), n-BuLi (0.5 mL, 
800 µmol, 1.1 eq.), ketone 76a (96.8 mg, 727 µmol, 1.0 eq.), LiBr (63.2 mg, 
727 µmol, 1.0 eq.), THF (1.0 mL) and after purification by flash 
chromatography (SiO2, 1.5 cm × 25 cm, cyclohexane / ethyl acetate 1:1) as a colorless solid 
(120 mg, 346 µmol, 48%). Enantiomers were separated by semi-preparative HPLC (chiral, 
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Daicel Chiracel OD (2 cm × 25 cm), n-hexane: i-PrOH 97:3, 6.0 mL / min, Tc: 40 °C, 20 mg 
loading, tR 56‒6β min (+) and 67‒78 min (−)). 
 
C21H23BNOP (347.20 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 8.40 (dd, J = 4.8, 0.6 Hz, 1H, HAr), 7.79‒7.7γ (m, 4H, HAr), 
7.53 (dd, J = 7.6, 0.9 Hz, 1H, HAr), 7.50‒7.40 (m, 6H, HAr), 7.13 (dd, J = 7.6, 4.9 Hz, 1H, 
HAr), 3.49 (dd, J = 15.0, 9.9 Hz, 1H, CH2P), 3.33 (br s, 1H, OH), γ.04‒β.96 (m, 1H, ArCH2), 
β.69‒β.67 (m, βH, CH2P, ArCH2), 2.29 (ddd, J = 13.6, 8.1 Hz, 4.2 Hz, 1H, CCH2CH2), ), 2.15 
(ddd, J = 13.8, 8.4, 6.9 Hz, 1H, CCH2CH2), 1.70‒0.70 (br s, γH, BH3) ppm. 13C{1H}-NMR 
(101 MHz, CDCl3): δ = 164.7 (d, JCP = 10 Hz, CAr), 146.1 (HCAr), 136.1 (CAr), 133.3 (HCAr), 
132.4 (d, JCP = 9 Hz, HCAr), 131.9 (d, JCP = 9 Hz, HCAr), 131.3 (d, JCP = 3 Hz, HCAr), 131.0 
(d, JCP = 2 Hz, HCAr), 130.2 (d, JCP = 37 Hz, CAr), 129.7 (d, JCP = 35 Hz, CAr), 128.9 (d, 
JCP = 6 Hz, HCAr), 128.8 (d, JCP = 6 Hz, HCAr), 123.4 (HCAr), 80.6 (C(OH)), 38.2 (d, 
JCP = 2 Hz, CCH2CH2), 36.2 (d, JCP = 34 Hz, CH2P), 27.3 (ArCH2). 
31
P{
1
H}-NMR 
(162 MHz, CDCl3): δ = 6.1 (br d, JPB = 62 Hz) ppm. MS (FAB NBA) m/z (%): 348 ([M+H]+, 
57), 334 ([M-H-BH3]
+, 40), 316 (41), 185 (100), 132 (61), 107 (21), 89 (30), 77 (40), 69 (26), 
57 (42), 51 (21), 39 (33). IR: ṽ = 3148 (w br), 2835 (m), 1590 (w), 1483 (w), 1437 (s), 1410 
(m), 1313 (w), 1246 (w), 1180 (w), 1105 (m), 1085 (m), 1064 (w), 1054 (s), 1001 (m), 969 
(m), 953 (m), 821 (m), 800 (s), 763 (w), 747 (m), 731 (s), 703 (s), 689 (s br), 670 (w). EA: 
calc. (%) C 72.65, H 6.68, N 4.03; found C 72.47, H 6.67, N 3.84. m.p.: 122–123 °C (dec.). 
TLC (SiO2, cyclohexane / ethyl acetate 1:1): Rf = 0.18. HPLC (chiral, Daicel Chiracel OD-H, 
0.46 cm × 25 cm, n-heptane / i-PrOH, 0.9 mL/min, 40 °C): tR = 24.7 min (+), 28.6 min (−). 
[α]D20: +10.2 (c = 1.02, CHCl3), −9.7 (c = 1.03, CHCl3). 
 
 
7-((Di-ortho-tolylphosphino)methyl)-6,7-dihydro-5H-cyclopenta[1]pyridin-7-ol (85b) 
 
The title compound 85b was obtained following the general procedure F 
using 84b (310 mg, 1.28 mmol, 1.1 eq.), THF (4.0 mL), n-BuLi (0.8 mL, 
1.28 mmol, 1.1 eq.), 76a (155 mg, 1.16 mmol, 1.0 eq.), LiBr (101 mg, 
1.16 mmol, 1.0 eq.), THF (5.0 mL), after purification by flash chromatography (SiO2, 1.5 cm 
× 23 cm, cyclohexane / ethyl acetate 1:1) as a slightly reddish oil (118 mg, 0.326 mmol, 
28%). 
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C23H24NOP (361.42 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 8.38 (dd, J = 5.7 Hz, 1H, HAr), 7.75 (d, J = 7.7 Hz, 1H, 
HAr), 7.γβ‒7.β7 (m, 1H, HAr), 7.ββ‒6.90 (m, 8H, HAr), 5.55 (dd, J = 7.9, 4.2 Hz, 1H, CH2P), 
4.12 (br s, 1H, OH) γ.β4‒γ.10 (m, 1H, CH2P), β.84‒β.70 (m, βH, ArCH2), 2.43 (s, 3H, 
ArCH3), 2.39 (s, 3H, ArCH3), β.γγ‒β.08 (m, βH, CH2) ppm. 31P{1H}-NMR (162 MHz, 
CDCl3): δ = ‒51.1 ppm. MS (EI, 70 eV, ca. 200 °C) m/z (%): 361 ([M]+, 23), 343 (93), 328 
(18), 252 (53), 227 (100), 220 (28), 213 (50), 207 (21), 196 (18), 179 (17), 165 (23), 148 (19), 
130 (56), 121 (17), 105 (14), 91 (21), 78 (24). TLC (SiO2, cyclohexane / ethyl acetate 1:1): Rf 
= 0.13. 
 
 
7-((Dicyclohexylphosphino)methyl)-6,7-dihydro-5H-cyclopenta[1]pyridin-7-ol (85c) 
 
The title compound 85c was obtained following the general procedure F 
using 84c (289 mg, 1.28 mmol, 1.1 eq.), THF (5.0 mL), n-BuLi (0.8 mL, 
1.28 mmol, 1.1 eq.), ketone 76a (155 mg, 1.16 mmol, 1.0 eq.), LiBr (101 mg, 
1.16 mmol, 1.0 eq.), THF (2.0 mL), after purification by flash 
chromatography (SiO2, 1.5 cm × 22 cm, cyclohexane / ethyl acetate 1:1) as a slightly red solid 
(108 mg, 0.301 mmol, 26%).  
 
C21H35BNOP (359.29 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 8.42 (dd, J = 4.9, 0.7 Hz, 1H, HAr), 7.54 (dd, J = 7.4, 
0.6 Hz, 1H, HAr), 7.12 (dd, J = 7.6, 4.9 Hz, 1H, HAr), 3.42 (br s, 1H, OH), 3.03 (td, J = 15.2, 
7.5 Hz, 1H, ArCH2), β.8β‒β.70 (m, βH, ArCH2, CH2P), 2.49 (ddd, J = 13.5, 8.1, 4.2 Hz, 1H, 
CH2C), 2.35 (ddd, J = 13.8, 8.3, 7.0, 1H, CH2C), β.0β‒1.69 (m, 13H, Cy, CH2P), 1.51‒1.γ7 
(m, 2H, Cy), 1.β9‒1.14 (m, 8H, Cy), 1.10‒0.10 (br d, J = 114 Hz, 3H, BH3) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 165.0 (d, JCP = 10 Hz, CAr), 148.2 (HCAr), 136.2 (CAr), 
133.3 (HCAr), 123.2 (HCAr), 80.4 (C(OH)), 39.7 (CH2C), 33.0 (d, JCP = 34 Hz, CH Cy), 32.6 
(d, JCP = 34 Hz, CH Cy), 27.0 (d, J = 8 Hz, CH2P), 26.8 (d, J = 4 Hz, CH2 Cy), 26.7 (d, J = 12 
Hz, CH2 Cy), 26.4 (s, CH2 Cy), 26.3 (d, J = 3 Hz, CH2 Cy), 25.9 (ArCH2) ppm. 
31
P{
1
H}-NMR (162 MHz, CDCl3): δ = 16.4 (br d, JPB = 58 Hz) ppm. MS (EI, 70 eV, ca. 
150 °C) m/z (%): 359 ([M]+, 6), 345 (5), 328 (10), 262 (100), 244 (10), 199 (8), 180 (36), 162 
(27), 132 (45), 83 (6), 55 (12), 41 (6); (FAB NBA + KCl) m/z (%): 398 ([M+K]+, 42), 356 
(100), 346 (34), 328 (59), 262 (23), 180 (18), 162 (15), 132 (80), 115 (25), 81 (24), 77 (12), 
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55 (35), 39 (26). IR: ṽ = 3475 (w), 2922 (s), 2851 (s), 2381 (s br), 1740 (w), 1586 (m), 1443 
(s), 1420 (m), 1363 (w), 1320 (w), 1220 (w), 1190 (w), 1142 (w), 1064 (s), 1041 (m), 1000 
(m), 930 (w), 891 (m), 853 (m), 830 (w), 795 (m), 750 (w). EA: calc. (%) C 70.20, H 9.82, 
N 3.90; found C 69.91, H 9.64, N 3.72. TLC (SiO2, cyclohexane / ethyl acetate 1:1): 
Rf = 0.26. 
 
 
8-((Diphenylphosphino)methyl)-5,6,7,8-tetrahydroquinolin-8-ol-BH3-adduct (85d-BH3) 
 
The title compound 85d-BH3 was obtained following the general procedure F 
using diphenyl-methyl-phosphine-borane adduct 84a (310 mg, 1.45 mmol, 
1.1 eq.), THF (5.0 mL), n-BuLi (0.5 mL, 800 µmol, 1.1 eq.), 76c (193 mg, 
1.31 mmol, 1.0 eq.), LiBr (114 mg, 1.31 mmol, 1.0 eq.), THF (2.0 mL), after 
recrystallization from boiling acetone (7.0 mL) as a colorless solid (285 mg, 0.79 mmol, 
60%).  
 
C22H25BNOP (361.18 g/mol): 
1
H-NMR (500 MHz, CDCl3): δ = 8.26 (dd, J = 3.5, 1.0 Hz, 1H, HAr), 7.85‒7.81 (m, βH, HAr), 
7.6β‒7.59 (m, βH, HAr), 7.48‒7.4β (m, γH, HAr), 7.40 (dd, J = 7.2, 1.4 Hz, 1H, HAr), 7.γ6‒
7.33 (m, 3H, HAr), 7.05 (dd, J = 7.7, 4.7 Hz, 1H, HAr), 3.39 (br s, 1H, OH), 3.26 (dd, J = 14.8, 
11.9 Hz, 1H, CH2P), 2.93 (dd, J = 14.8, 10.8 Hz, 1H, CH2P), β.79‒β.69 (m, βH, ArCH2), 
β.γγ‒β.β7 (m, 1H, CH2C), β.08‒β.04 (m, 1H, CH2C), 1.9γ‒1.85 (m, 1H, CH2CH2CH2), 1.79‒
1.71 (m, 1H, CH2CH2CH2), 1.50‒0.60 (br s, γH, BH3) ppm. 13C{1H}-NMR (126 MHz, 
CDCl3): δ = 158.3 (d, JCP = 6 Hz, CAr), 148.4 (HCAr), 147.1 (HCAr), 137.1 (HCAr), 132.2 (d, 
JCP = 9 Hz, HCAr), 132.1 (d, JCP = 9 Hz, HCAr), 131.8 (CAr), 130.9 (d, JCP = 40 Hz, CAr), 130.8 
(d, JCP = 3 Hz, HCAr), 130.7 (d, JCP = 2 Hz, HCAr), 130.4 (d, JCP = 57 Hz, CAr), 128.6 (d, 
JCP = 10 Hz, HCAr), 128.5 (d, JCP = 10 Hz, HCAr), 122.9 (HCAr), 72.7 (d, JCP = 1 Hz, C(OH)), 
38.2 (d, JCP = 32 Hz, CH2P), 35.5 (d, JCP = 2 Hz, CH2C), 27.3 (ArCH2), 19.1 (CH2) ppm. 
31
P{
1
H}-NMR (202 MHz, CDCl3): δ = 9.5 (br d, JPB = 66 Hz) ppm. MS (FAB NBA) m/z (%): 
362 ([M+H]+, 65), 348 (50), 330 (13), 270 (11), 252 (12), 199 (42), 185 (62), 176 (19), 165 
(10), 155 (10), 146 (100), 136 (32), 124 (14), 115 (11), 107 (27), 91 (29), 77 (39), 65 (19), 51 
(10), 39 (10). IR: ṽ = 3194 (w br), 3066 (w), 2941 (w), 2940 (w), 2915 (w), 2397 (m), 2380 
(m), 1580 (w), 1575 (w,) 1447 (m), 1434 (s), 1409 (m) 1386 (w), 1333 (w), 1302 (w), 1278 
(w), 1234 (m), 1184 (w), 1134 (w), 1103 (s), 1093 (s), 1062 (s), 1039 (w), 1023 (s), 976 (s), 
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944 (w), 908 (m), 888 (s), 859 (m), 813 (s), 801 (s), 775 (w), 762 (w), 748 (s), 738 (s), 698 
(s), 688 (s) cm-1. m.p.: 140–141 °C (dec.). TLC (SiO2, cyclohexane / DCM 1:1): Rf = 0.31. 
 
Note: The BH3 protecting group of 85d-BH3 was removed prior the silylation of the alcohol, 
because of the better separation of enanatiomers by semi-preparative HPLC.  
 
 
8-((Diphenylphosphino)methyl)-5,6,7,8-tetrahydroquinolin-8-ol (85d) 
 
A solution of 85d-BH3 (52 mg, 144 µmol, 1.0 eq.) in diethyl amine (2 mL, 
1.42 g, 19.3 mmol, 134 eq.) was stirred for 2 h. After complete converstion, 
the volatiles were removed in vacuo to give the title compound 85d (44.0 mg, 
144 µmol, 88%). Enantiomers were separated by semi-preparative HPLC (chiral, Daicel 
Chiracel OD (2 cm × 25 cm), n-hexane : i-PrOH 95:5, 6.0 mL/min, Tc: 25 °C, 5 mg loading, 
tR γ8‒48 min (+) and 5β‒6γ min (−). 
 
C22H22NOP (347.39 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 8.34‒8.26 (m, 1H, HAr), 7.53‒7.45 (m, 2H, HAr), 7.41‒7.23 
(m, 9H, HAr), 7.02 (dd, J = 7.7, 4.7 Hz, 1H, HAr), 3.64 (br s, 1H, OH), 2.94 (dd, J = 14.4, 
3.8 Hz, 1H, CH2P), 2.77 (t, J = 6.1 Hz, 2H, ArCH2), 2.67 (dd, J = 14.4, 2.2 Hz, 1H, CH2P), 
2.49‒2.30 (m, 1H, CH2C), 2.11‒1.96 (m, 1H, CH2C), 1.91‒1.77 (m, 2H, CH2) ppm. 
31
P{
1
H}-NMR (1622 MHz, CDCl3): δ = −β8.9 (s) ppm. m.p.: 112–113 °C. HPLC (chiral, 
Daicel Chiracel OD-H, 0.46 cm × 25 cm, n-heptane / i-PrOH 95:5, 0.5 mL/min, 20 °C): 
tR = 18.2 min (+), 23.6 min (−). [α]D20: +21.2 (c = 1.25, CHCl3), −18.0 (c = 1.20, CHCl3). 
 
 
8-((Di-ortho-tolylphosphino)methyl)-5,6,7,8-tetrahydroquinolin-8-ol (85e) 
 
The title compound 85e was obtained following the general procedure F 
using 84b (348 mg, 1.44 mmol, 1.1 eq.), THF (5.0 mL), n-BuLi (0.9 mL, 
1.44 mmol, 1.1 eq.), 76c (193 mg, 1.31 mmol, 1.0 eq.), LiBr (114 mg, 
1.31 mmol, 1.0 eq.), THF (2.0 mL), after purification by flash chromatography (SiO2, 1.5 cm 
× 22 cm, cyclohexane / DCM 5:1  1:1  0:1) and by recrystallization from boiling iso-
propanol (1.0 mL) as a yellow solid (143 mg, 0.38 mmol, 29%). Enantiomers were separated 
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by semi-preparative HPLC (chiral, Daicel Chiracel OD (2 cm × 25 cm), n-hexane : i-PrOH 
98:2, 6.0 mL/min, Tc: 35 °C, 30 mg loading, tR γ4‒40 min (+) and 4β‒51 min (−). 
 
C24H26NOP (375.44 g/mol): 
1
H-NMR (500 MHz, CDCl3): δ = 8.28 (d, J = 4.6 Hz, 1H, HAr), 7.45‒7.4β (m, 1H, HAr), 7.40 
(d, J = 7.6 Hz, 1H, HAr), 7.βγ‒7.08 (m, 6H, HAr), 7.05‒7.01 (m, βH, HAr), 3.72 (br s, 1H, OH), 
2.93 (dd, J = 14.7 Hz, J = 3.0 Hz, 1H, CH2P), β.81‒β.78 (m, βH, ArCH2), β.51‒β.44 (m, 5H, 
CH2C, CH2P, ArCH3), 2.37 (s, 3H, ArCH3), β.09‒β.04 (m, 1H, CH2C), 1.94‒1.87 (m, 1H, 
CH2CH2CH2), 1.86‒1.77 (m, 1H, CH2CH2CH2) ppm. 13C{1H}-NMR (126 MHz, 
CDCl3): δ = 160.2 (d, JCP = 3 Hz, CAr), 147.0 (HCAr), 142.3 (d, JCP = 24 Hz, CAr), 142.0 (d, 
JCP = 25 Hz, CAr), 137.9 (d, JCP = 13 Hz, CAr), 137.5 (d, JCP = 13 Hz, CAr), 137.0 (HCAr), 
132.4 (HCAr), 131.1 (CAr), 131.0 (HCAr), 130.1 (d, JCP = 5 Hz, HCAr), 130.0 (d, JCP = 5 Hz, 
HCAr), 128.3 (HCAr), 128.1 (HCAr), 126.0 (HCAr), 125.9 (HCAr), 122.4 (HCAr), 72.7 (d, 
JCP = 14 Hz, C(OH)), 41.3 (d, JCP = 17 Hz, CH2P), 35.4 (d, JCP = 10 Hz, CH2C), 28.9 
(ArCH2), 21.5 (d, JCP = 2 Hz, ArCH3), 21.3 (ArCH3), 19.5 (CH2CH2CH2) ppm. 
31
P{
1
H}-NMR (202 MHz, CDCl3): δ = ‒48.1 ppm. MS (EI, 70 eV, ca. 150 °C) m/z (%): 375 
([M]+, 1), 285 (11), 266 (7), 227 (21), 213 (8), 146 (100), 91 (5); (FAB NBA) m/z (%):414 
([M+K]+, 6), 376 ([M+H]+, 26), 213 (19), 39 (12). EA: calc. (%) C 76.78, H 6.98, N 3.73; 
found C 72.42, H 6.97, N 3.60. m.p.: 110–111 °C. TLC (SiO2, cyclohexane / DCM 5:1): 
Rf = 0.31. HPLC (chiral, Daicel Chiracel OD-H, 0.46 cm × 25 cm, n-heptane / i-PrOH 98:2, 
0.5 mL / min, 25 °C): tR = 19.4 min (+), 25.4 min (−). [α]D20: +19.7 (c = 0.80, CHCl3), −β0.γ 
(c = 1.02, CHCl3). 
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8.4.5 Silylation of the Alcohol and Deprotection of Phosphine 
 
 
 
(+)-7-((tert-Butyldimethylsilyl)oxy)-7-((diphenylphosphino)methyl)-6,7-dihydro-5H-
cyclopenta[1]pyridine (86a) 
 
Tert-butyldimethylsilyl trifluoromethanesulfonate (20 µl, 23 mg, 87 µmol, 
3.8 eq.) was slowly added to a solution of 85a (8.0 mg, 23 µmol, 1.0 eq.) and 
2,6-lutidine (20 µl, 18 mg, 172 µmol, 7.5 eq.) in DCM (0.5 mL) at 0 °C. The 
reaction mixture was allowed to warm to rt and stirring was continued for 2 h at RT. Water 
(1.0 mL) was added to the reaction mixture, fallowed by extraction with DCM (2×1.0 mL). 
The combined organic layers were dried over MgSO4, filtered and the solvent was removed 
under reduced pressure. Diethyl amine (1 mL) was added to the crude product and the 
reaction mixture was stirred overnight at RT. All volatiles were removed in vacuo and the 
crude product was purified by flash chromatography (SiO2, 0.5 cm × 5 cm, cyclohexane / 
TBME 19:1) to obtain the title compound 86a as a colorless solid (8 mg, 92.3 µmol, 56%). 
 
C27H34NOPSi (447.62g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 8.44 (dd, J = 4.8, 0.7 Hz, 1H, HAr), 7.57‒7.5γ (m, βH, HAr), 
7.48 (dd, J = 7.6, 0.7 Hz, 1H, HAr), 7.4β‒7.γ8 (m, βH, HAr), 7.γβ‒7.β4 (m, 6H, HAr), 7.10 (dd, 
J = 7.6, 4.9 Hz, 1H, HAr), 3.18 (dd, J = 14.3, 3.2 Hz, 1H, CH2P), β.91‒β.98 (m, 1H, ArCH2), 
2.72 (ddd, J = 16.3, 8.5, 4.5 Hz, 1H, ArCH2), 2.55 (dd, J = 14.3, 3.5 Hz, 1H, CH2P), β.γ6‒
2.28 (m, 1H, CCH2CH2), β.βγ‒β.17 (m, 1H, CCH2CH2), 0.74 (s, 9H, (CH3)3CSi), ‒0.05 (s, 
3H, CH3Si), ‒0.54 (s, 3H, CH3Si) ppm. 13C{1H}-NMR (101 MHz, CDCl3): δ = 165.8 (d, 
JCP = 4 Hz, CAr), 148.2 (HCAr), 140.6 (d, JCP = 13 Hz, CAr), 139.8 (d, JCP = 13 Hz, CAr), 133.4 
(d, JCP = 20 Hz, HCAr), 136.9 (CAr), 133.0 (HCAr), 132.9 (d, JCP = 21 Hz, HCAr), 128.4 (dd, 
JCP = 7 Hz, 4 Hz HCAr), 123.1 (HCAr), 128.2 (HCAr), 84.1 (d, JCP = 16 Hz, C(OH)), 41.3 (d, 
JCP = 16 Hz, CH2P), 39.8 (d, JCP = 9 Hz, CCH2CH2), 27.3 (ArCH2), 26.0 (CH3)3CSi), 18.2 
((CH3)3CSi), ‒β.8 (CH3Si), ‒γ.9 (CH3Si) ppm. 31P{1H}-NMR (162 MHz, CDCl3): δ = ‒
27.0 ppm. TLC (SiO2, cyclohexane / TBME 19:1): Rf = 0.27. [α]D20: = +22.6 (c = 1.40, 
CHCl3). 
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8-((Diphenylphosphino)methyl)-8-((trimethylsilyl)oxy)-5,6,7,8-tetrahydroquinoline (86b) 
 
Trimethylsilyl chloride (30 µl, 25.7 mg, 236 µmol, 1.4 eq.) was added to a 
solution of alcohol 85d (58 mg, 166 µmol, 1.0 eq.), triethyl amine (35 µl, 
24 mg, 236 µmol, 1.4 eq.) and potassium iodide (5.0 mg, 30.0 µmol, 0.2 eq.) 
in THF (1.0 mL) at 0 °C. After stirring for overnight at RT, water (1 mL) was added. The 
reaction mixture was extracted with TBME (3×1 mL). Combined organic layers were dried 
over MgSO4, filtered, and the solvent was removed under reduced pressure. The crude 
product was purified by flash chromatography (SiO2, 0.5 cm × 5 cm, DCM / cyclohexane 2:1) 
to give the title compound 86b (40 mg, 92.3 µmol, 56%) as a colorless solid.  
 
C25H30NOPSi (419.57 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 8.43 (dd, J = 4.6, 1.6 Hz, 1H, HAr), 7.61 (dt, J = 7.7, 
1.7 Hz, 2H, HAr), 7.4β‒7.γ1 (m, 6H, HAr), 7.β9‒7.β0 (m, γH, HAr), 7.09 (dd, J = 7.7, 4.6 Hz, 
1H, HAr), 3.16 (dd, J = 14.0, 5.4 Hz, 1H, CH2P), 3.06 (dd, J = 14.1, 3.1 Hz, 1H, CH2P), β.79‒
2.75 (m, 2H, ArCH2), β.1γ‒β.06 (m, βH, CH2CH2CH2), β.04‒1.9γ (m, 1H, CH2C), 1.76‒1.68 
(m, 1H, CH2C), 0.21 (s, 9H, CH3Si) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 159.9 (d, 
JCP = 3 Hz, CAr), 147.0 (HCAr), 139.8 (d, JCP = 12 Hz, CAr), 139.3 (d, JCP = 12 Hz, CAr), 136.8 
(HCAr), 133.1 (HCAr), 132.9 (HCAr), 132.8 (HCAr), 132.6 (HCAr), 131.1 (CAr), 128.27 (HCAr), 
128.24 (HCAr), 128.21 (HCAr), 128.19 (HCAr), 128.16 (HCAr), 122.6 (HCAr), 76.3 (d, 
JCP = 19 Hz, C(OSi)), 42.4 (d, JCP = 15 Hz, CH2P), 38.1 (d, JCP = 12 Hz, CH2C), 26.9 
(ArCH2), 18.6 (CH2CH2CH2), 1.6 (CH3Si) ppm. 
31
P{
1
H}-NMR (162 MHz, CDCl3): δ = 
−25.7 ppm. TLC (SiO2, DCM / cyclohexane 2:1): Rf = 0.20. 
 
 
8-(tert-Butyldimethylsilyloxy)-8-((diphenylphosphino)methyl)-5,6,7,8-
tetrahydroquinoline (86c) 
 
Tert-butyldimethylsilyl trifluoromethanesulfonate (66 µl, 76.1 mg, 288 
µmol, 4.0 eq.) was slowly added to a solution of 85d (25.0 mg, 72.0 µmol, 
1.0 eq.) and 2,6-lutidine (50 µl, 46.2 mg, 432 µmol, 6.0 eq.) in DCM 
(1.0 mL). The reaction mixture was allowed to warm to rt and stirring was continued for 1.5 h 
at RT. Afterwards all volutiles were removed under reduced pressure. The crude product was 
purified by flash chromatography using a Schlenk fritt (SiO2, 2 cm × 4 cm, cyclohexane / 
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ethyl acetate 4:1) to obtain the title compound 86c as a colorless solid (23.0 mg, 49.8 µmol, 
69%). 
 
C28H36NOPSi (461.65 g/mol): 
1
H-NMR (400 MHz, CD2Cl2): δ = 8.39 (dd, J = 4.5, 0.9 Hz, 1H, HAr), 7.55 (dt, J = 7.5, 
1.6 Hz, 2H, HAr), 7.γ9‒7.β9 (m, 6H, HAr), 7.βγ‒7.β1 (m, γH, HAr), 7.09 (dd, J = 7.7, 4.6 Hz, 
1H, HAr), 3.14 (dd, J = 14.0, 3.8 Hz, 1H, CH2P), 3.00 (dd, J = 14.0, 4.9 Hz, 1H, CH2P), β.78‒
2.72 (m, 2H, ArCH2), β.0γ‒1.91 (m, γH, CH2C, CH2CH2CH2), 1.68‒1.6β (m, 1H, CH2C), 
0.77 (s, 9H, (CH3)3CSi), 0.08 (s, 3H, CH3Si), ‒0.70 (s, γH, CH3Si) ppm. 13C{1H}-NMR 
(101 MHz, CD2Cl2): δ = 158.5 (d, JCP = 2 Hz, CAr), 146.7 (HCAr), 141.2 (d, JCP = 14 Hz, CAr), 
140.2 (d, JCP = 13 Hz, CAr), 137.0 (HCAr), 133.4 (d, JCP = 20 Hz, HCAr), 132.9 (d, JCP = 2 Hz, 
CAr), 132.8 (d, JCP = 19 Hz, HCAr), 128.9 (HCAr), 128.4 (d, JCP = 3 Hz, HCAr), 128.2 (d, 
JCP = 7 Hz, HCAr), 127.9 (HCAr), 122.7 (HCAr), 76.2 (d, JCP = 21 Hz, C(OSi)), 42.2 (d, 
JCP 15 Hz, CH2P), 38.5 (d, JCP = 10 Hz, CH2C), 29.3 (ArCH2), 25.8 (CH3)3CSi), 18.7 
(CH2CH2CH2), 18.2 (d, JCP = 20 Hz, (CH3)3CSi), ‒β.8 (CH3Si), ‒4.5 (CH3Si) ppm. 
31
P{
1
H}-NMR (162 MHz, CD2Cl2): δ = ‒β6.4 ppm. 
 
 
8-((Diphenylphosphino)methyl)-8-(tri-iso-propylsilyloxy)-5,6,7,8-tetrahydroquinoline 
(86d) 
 
Tri-iso-propylsilyl trifluoromethanesulfonate (80 µl, 91.2 mg, 297 µmol, 
4.1 eq.) was slowly added to a solution of alcohol 85d (25.0 mg, 72.0 µmol, 
1.0 eq.) and 2,6-lutidine (50 µl, 46.2 mg, 432 µmol, 6.0 eq.) in DCM 
(1.0 mL) and. The reaction mixture was allowed to warm to rt and stirring 
was continued for 2 h at RT. Afterwards the volatiles were removed under reduced pressure. 
The crude product was purified by flash chromatography using a Schlenk fritt (SiO2, 2 cm × 
5 cm, cyclohexane / ethyl acetate 5:1) to obtain the title compound 86d (14.0 mg, 27.0 µmol, 
38%) as a colorless oil.  
 
C31H42NOPSi (503.73 g/mol): 
1
H-NMR (400 MHz, CD2Cl2): δ = 8.γ6‒8.γ5 (m, 1H, HAr), 7.58‒7.5γ (m, βH, HAr), 7.41‒
7.34 (m, 6H, HAr), 7.β8‒7.βγ (m, γH, HAr), 7.09 (dd, J = 7.7, 4.6 Hz, 1H, HAr), 3.52 (dd, 
J = 13.5, 4.1 Hz, 1H, CH2P), 2.87 (dd, J = 13.5, 5.1 Hz, 1H, CH2P), β.80‒β.76 (m, βH, 
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ArCH2), β.10‒β.0β (m, βH, CH2CH2CH2), 1.9γ‒1.89 (m, 1H, CH2C), 1.71‒1.61 (m, 1H, 
CH2C), 1.08‒0.91 (m, β1H, CH(CH3)3) ppm. 13C{1H}-NMR (101 MHz, CD2Cl2): δ = 158.5 
(d, JCP = 2 Hz, CAr), 146.7 (HCAr), 141.2 (d, JCP = 14 Hz, CAr), 140.2 (d, JCP = 13 Hz, CAr), 
137.0 (HCAr), 133.4 (d, JCP = 20 Hz, HCAr), 132.9 (d, JCP = 2 Hz, CAr), 132.8 (d, JCP = 19 Hz, 
HCAr), 128.9 (HCAr), 128.4 (d, JCP = 3 Hz, HCAr), 128.2 (d, JCP = 7 Hz, HCAr), 127.9 (HCAr), 
122.7 (HCAr), 76.2 (d, JCP = 21 Hz, C(OSi)), 42.2 (d, JCP 16 Hz, CH2P), 38.5 (d, JCP = 9 Hz, 
CH2C), 29.3 (ArCH2), 18.7 (CH2CH2CH2), 13.6 ((CH3)2CHSi), 13.5 ((CH3)2CHSi) ppm. 
31
P{
1
H}-NMR (162 MHz, CD2Cl2): δ = ‒β5.1 ppm.  
 
 
8-((tert-Butyldimethylsilyl)oxy)-8-((di-ortho-tolylphosphino)methyl)-5,6,7,8-
tetrahydroquinoline (86e) 
 
Tert-butyldimethylsilyl trifluoromethanesulfonate (100 µl, 115 mg, 
435 µmol, 3.9 eq.) was added to a solution of 85e (42.0 mg, 112 µmol, 
1.0 eq.) and 2,6-lutidine (80 µl, 73.8 mg, 689 µmol, 6.1 eq.) in DCM 
(1.0 mL). The reaction mixture was allowed to warm to rt and stirring was continued for 2 h 
at RT. Afterwards the volatiles were removed under reduced pressure. The crude product was 
purified by flash chromatography (SiO2, 0.5 cm × 5 cm, cyclohexane / ethyl acetate 19:1) to 
obtain the title compound 86e (36.0 mg, 73.5 µmol, 66%) as a colorless solid. 
 
C30H40NOPSi (489.70 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 8.40 (dd, J = 4.5, 1.4 Hz, 1H, HAr), 7.82 (ddd, J = 7.4, 3.8, 
1.0 Hz, 1H, HAr), 7.γ4‒7.β7 (m, βH, HAr), 7.23 (dt, J = 7.4, 1.4 Hz, 1H, HAr), 7.14‒6.99 (m, 
6H, HAr), 3.04 (dd, J = 14.3 Hz, 3.9 Hz, 1H, CH2P), β.86‒β.8β (m, 1H, CH2P), β.76‒β.7γ (m, 
2H, ArCH2), 2.46 (s, 3H, ArCH3), 2.25 (s, 3H, ArCH3), β.βγ‒β.17 (m, 1H, CH2C), β.05‒1.9γ 
(m, 2H, CH2CH2CH2, CH2C), 1.75‒1.67 (m, 1H, CH2CH2CH2), 0.75 (s, 9H, (CH3)3CSi), 0.09 
(s, 3H, CH3Si), ‒0.70 (s, γH, CH3Si) ppm. 13C{1H}-NMR (101 MHz, CDCl3): δ = 159.0 
(CAr), 147.0 (HCAr), 142.1 (d, JCP = 6 Hz, CAr), 141.9 (d, JCP = 4 Hz, CAr), 138.9 (d, 
JCP = 14 Hz, CAr), 138.0 (d, JCP = 14 Hz, CAr), 136.7 (HCAr), 132.9 (HCAr), 132.5 (CAr), 132.0 
(HCAr), 129.8 (dd, JCP = 9 Hz, 5 Hz, HCAr), 128.3 (HCAr), 128.0 (HCAr), 127.9 (HCAr), 125.8 
(HCAr), 122.5 (HCAr), 76.3 (d, JCP = 19 Hz, C(OH)), 40.2 (d, JCP = 17 Hz, CH2P), 38.5 (d, 
JCP = 10 Hz, CH2C), 29.6 (ArCH2), 26.0 (CH3)3CSi), 21.5 (d, JCP = 20 Hz, ArCH3), 21.3 (d, 
JCP = 19 Hz, ArCH3), 19.3 (CH2CH2CH2), 18.5 ((CH3)3CSi), ‒β.8 (CH3Si), ‒4.β (CH3Si) ppm. 
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31
P{
1
H}-NMR (162 MHz, CDCl3): δ = ‒49.0 ppm. MS (EI, 70 eV, ca. 150 °C) m/z (%): 489 
([M]+, 11), 432 (100), 398 (68), 357 (9), 276 (13), 262 (34), 227 (53), 213 (19), 205 (32), 148 
(8), 133 (5), 105 (5), 73 (15). EA: calc. (%) C 73.58, H 8.23, N 2.86; found 72.67, 8.17, 2.63. 
m.p.: 119‒1β1°C. TLC (SiO2, cyclohexane / TBME 9:1): Rf = 0.56.  
 
 
8.4.6 Preparation of the Ir-complexes  
 
 
 
General Procedure G: A solution of the N,P ligand (1.0 eq.) in DCM (0.02 M) was slowly 
added to a solution of [Ir(COD)Cl]2 (0.5 eq.) in DCM (0.04-0.05 M). The reaction mixture 
was stirred for 1 h at 50 °C. NaBArF (>1.1 eq.) was added after cooling down to RT. The 
reaction mixture was vigorously stirred for 0.5 h. Afterwards the solvent was removed under 
reduced pressure. The crude Ir-complex was purified by flash chromatography. First side 
products were separated by elution with TBME and then the desired Ir-complex was washed 
down with DCM (collecting the orange-red band). If necessary the Ir-complex was 
recrystallized by from DCM / n-pentane or diethyl ether / n-pentane.  
 
 
(+)-[η4-1,5-Cyclooctadiene-7-((tert-butyldimethylsilyl)oxy)-7-
((diphenylphosphino)methyl)-6,7-dihydro-5H-cyclopenta[1]pyridine-iridium(I)]-
tetrakis-[3,5-bis(trifluormethyl)phenyl]borate (87a) 
 
The title compound 87a was obtained following the general procedure G 
using [Ir(COD)Cl]2 (11.6 mg, 17.2 µmol, 0.5 eq.), DCM (0.5 mL), 
ligand 86a (14.0 mg, 31.3 µmol, 1.0 eq.), DCM (1 mL), NaBArF 
(30.5 mg, 34.4 µmol, 1.1 eq.), after purification by flash 
chromatography (SiO2, 1.5 cm × 15 cm) as an orange solid (37.0 mg, 23.0 µmol, 73%).  
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C67H58BF24IrNOPSi (1611.23 g/mol): 
1
H-NMR (500 MHz, CD2Cl2): δ = 8.46 (d, J = 5.7 Hz, 1H, HAr), 7.86–7.79 (m, 2H, HAr), 7.77 
(dd, J = 7.7, 0.8 Hz, 1H, HAr), 7.75 (s, 8H, BArF-H), 7.56 (s, 4H, BArF-H), 7.50–7.38 (m, 6H, 
HAr), 7.38–7.30 (m, 3H, HAr), 4.98 (p, J = 7.3 Hz, 1H, CH COD), 4.76 (q, J = 6.3 Hz, 1H, CH 
COD), 3.67–3.59 (m, 1H, CH COD), 3.18–3.09 (m, 1H, CH2), 2.96 (dd, J = 15.3, 9.1 Hz, 1H, 
CH2P), 2.92–2.83 (m, 1H, CH2 ) 2.80–2.70 (m, 2H, CH2 1H, CH COD 1H), 2.66–2.49 (m, 4H, 
CH2 1H, CH2 COD 3H), 2.38 (dd, J = 15.3, 10.5 Hz, 1H, CH2P), 2.37–2.29 (m, 1H, CH2 
COD), 2.27–2.19 (m, 1H, CH2 COD), 2.05–1.92 (m, 1H, CH2 COD), 1.69–1.57 (m, 1H, CH2 
COD), 1.45–1.33 (m, 1H, CH2 COD), 0.96 (s, 9H, (CH3)3CSi), 0.36 (s, 3H, CH3Si), 0.26 (s, 
3H, CH3Si) ppm. 
13
C{
1
H}-NMR (126 MHz, CD2Cl2): δ = 164.6 (d, JPC = 5 Hz, CAr), 162.3 (q, 
JBC = 50 Hz, CAr BArF), 149.5 (s, HCAr), 139.8 (s, CAr), 138.4 (s, HCAr), 135.6 (d, JPC = 13 
Hz, HCAr), 135.4 (s, HCAr BArF), 133.2 (d, JPC = 54 Hz, CAr), 132.7 (d, JPC = 10 Hz, HCAr), 
132.6 (d, JPC = 2 Hz, HCAr), 131.6 (d, JPC = 2 Hz, HCAr), 129.9 (d, JPC = 11 Hz, HCAr), 129.5 
(qq, JFC = 32 Hz, JBC = 3 Hz, CAr BArF), 129.1 (d, JPC = 10 Hz, HCAr), 128.5 (d, JPC = 54 Hz, 
CAr), 127.0 (s, HCAr), 125.2 (q, JFC = 272 Hz, CF3 BArF), 118.1 (septett, JFC = 4 Hz, HCAr 
BArF), 96.9 (d, JPC = 12 Hz, CH COD), 89.5 (d, JPC = 12 Hz, CH COD), 86.2 (s, COSi), 63.1 
(s, CH COD), 63.0 (s CH COD), 41.4 (s, CH2), 40.3 (s, CH2 COD), 38.8 (d, JPC = 30 Hz, 
CH2P), 36.9 (d, JPC = 4 Hz, CH2 COD), 31.9 (d, JPC = 2 Hz, CH2 COD), 29.3 (d, JPC = 3 Hz, 
CH2 COD), 27.4 (s, (CH3)3C), 27.3 (s, CH2), 19.4 (s, (CH3)3C), −0.9 (s, CH3Si), −1.6 (s, 
CH3Si) ppm. 
31
P{
1
H}-NMR (162 MHz, CD2Cl2): δ = 10.4 ppm. MS (FAB NBA) m/z (%): 
748 ([Ir(L)(COD)]+, 100), 668 (13), 568 (10). EA: calc. (%) C 49.94, H 3.63, N 0.87; found 
C 49.16, H 3.53, N 0.83. m.p.: 153–154 °C. [α]D20: +7.0 (c = 0.69, CHCl3). 
 
 
(±)-[η4-1,5-Cyclooctadiene-8-((diphenylphosphino)methyl)-8-(trimethylsilyloxy)-5,6,7,8-
tetrahydroquinoline-iridium(I)]-tetrakis-[3,5-bis(trifluormethyl)phenyl]borat (87b) 
 
The title compound 87b was obtained following the general procedure 
G using [Ir(COD)Cl]2 (26.4 mg, 39.3 µmol, 0.5 eq.), DCM (2 mL), 
ligand 86b (33.0 mg, 78.7 µmol), DCM (1 mL), NaBArF (69.7 mg, 
78.7 µmol, 1.0 eq.), after purification by flash chromatography (SiO2, 
1.5 cm × 10 cm) as an orange solid (88.0 mg, 55.6 µmol, 71%). Crystals suitable for X-ray 
analysis were obtained by overlaying a concentrated etheral solution with n-pentane.  
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C65H54BF24IrNOPSi (1583.18 g/mol): 
1
H-NMR (400 MHz, CD2Cl2): δ = 8.67 (d, J = 5.6 Hz, 1H, HAr), 7.91–7.83 (m, 2H, HAr), 7.75 
(s, 8H, BArF-H), 7.59 (d, J = 7.9 Hz, 1H, HAr), 7.57 (s, 4H, BArF-H), 7.52–7.40 (m, 6H, HAr), 
7.29 (ddd, J = 9.8, 6.6, 3.0 Hz, 2H, HAr), 7.24 (dd, J = 7.7, 5.7 Hz, 1H, HAr), 4.79–4.67 (m, 
1H, CH COD), 4.55 (q, J = 6.1 Hz, 1H, CH COD), 3.56 (q, J = 6.3 Hz, 1H, CH COD), 2.93 
(ddd, J = 16.2, 10.1, 5.5 Hz, 1H, CH2), 2.81–2.72 (m, 2H, CH2P 1H, CH2 1H), 2.67–2.43 (m, 
6H, CH2P 1H, CH2 1H, CH COD 1H, CH2 COD 3H), 2.35 (dd, J = 12.6, 6.6 Hz, 1H, CH2), 
2.33–2.20 (m, 2H, CH2 COD ), 2.14–1.92 (m, 2H, CH2 COD 1H, CH2 1H), 1.84–1.66 (m, 1H, 
CH2), 1.67–1.54 (m, 1H, CH2 COD), 1.43–1.31 (m, 1H, CH2 COD), 0.38 (s, 9H, CH3Si) ppm. 
13
C{
1
H}-NMR (126 MHz, CD2Cl2): δ = 162.3 (q, JBC = 50 Hz, CAr BArF), 160.2 (d, JPC = 3 
Hz, CAr), 150.5 (s, HCAr), 142.0 (s, HCAr), 136.7 (s, CAr), 135.5 (d, JPC = 13 Hz, HCAr), 135.4 
(s, HCAr BArF), 132.8 (d, JPC = 10 Hz, HCAr), 131.7 (s, CAr), 131.5 (d, JPC = 2 Hz, HCAr), 
131.2 (s, CAr), 129.8 (d, JPC = 11 Hz, HCAr), 129.5 (qq, JFC = 32 Hz, JBC = 3 Hz, CAr BArF), 
129.1 (d, JPC = 11 Hz, HCAr), 125.7 (s, HCAr), 125.2 (q, JFC = 272 Hz, CF3 BArF), 118.1 
(septett, JFC = 4 Hz, HCAr BArF), 97.1 (d, JPC = 11 Hz, CH COD), 85.0 (d, JPC = 5 Hz, CH 
COD), 78.2 (s, COSi), 61.2 (s, CH COD), 57.8 (s, CH COD), 41.8 (d, JPC = 8 Hz, CH2), 40.5 
(d, JPC = 32 Hz, CH2P), 36.8 (d, JPC = 3 Hz, CH2 COD), 31.5 (d, JPC = 2 Hz, CH2 COD), 30.8 
(s, CH2), 29.5 (d, JPC = 3 Hz, CH2 COD), 27.8 (s, CH2 COD), 20.8 (s, CH2), 3.6 (s, CH3) ppm. 
31
P{
1
H}-NMR (162 MHz, CD2Cl2): δ = 7.5 ppm. MS (ESI, c = 0.05 mg/mL, 50 °C, 15 
µL/min) m/z (%): 720 ([Ir(L)(COD)]+, 100). IR: ṽ = 2961 (w br), 1602 (w), 1440 (w), 1354 
(s), 1272 (s), 1181 (w), 1154 (m), 1116 (s br), 1074 (m), 1054 (m), 1034 (w), 1028 (w), 996 
(w), 897 (w), 886 (m), 838 (m), 743 (m), 715 (m), 696 (m), 682 (m) cm-1. m.p.: 163–164°C. 
 
 
(+)-[η4-1,5-Cyclooctadiene-8-(tert-butyldimethylsilyloxy)-8-
((diphenylphosphino)methyl)-5,6,7,8-tetrahydroquinoline-iridium(I)]-tetrakis-[3,5-
bis(trifluormethyl)phenyl]borate (87c) 
 
The title compound 87c was obtained following the general procedure G 
using [Ir(COD)Cl]2 (25.5 mg, 37.9 µmol, 0.5 eq.), DCM (2 mL), ligand 
86c (35.0 mg, 75.8 µmol, 1.0 eq.), DCM (1 mL), NaBArF (67.2 mg, 
83.4 µmol, 1.1 eq.), after purification by flash chromatography (SiO2, 
1.5 cm × 15 cm) as an orange solid (65.0 mg, 40.0 µmol, 53%).  
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C68H60BF24IrNOPSi (1625.26 g/mol): 
1
H-NMR (400 MHz, CD2Cl2): δ = 8.67 (d, J = 5.4 Hz, 1H, HAr), 7.90–7.79 (m, 2H, HAr), 7.75 
(s, 8H, BArF-H), 7.58 (s, 4H, BArF-H), 7.55 (d, J = 8.2 Hz, 1H, HAr), 7.49–7.35 (m, 6H, HAr), 
7.27–7.15 (m, 3H, HAr), 4.91–4.77 (m, 2H, CH COD), 3.47 (q, J = 6.0 Hz, 1H, CH COD), 
2.96–2.81 (m, 2H, CH2P 1H, CH2 1H), 2.78–2.61 (m, 4H, CH2P 1H, CH2 1H, CH COD 1H, 
CH2 COD 1H), 2.60–2.42 (m, 4H, CH2 2H, CH2 COD 2H), 2.36–2.19 (m, 2H, CH2 1H, CH2 
COD 1H, ), 2.17–1.97 (m, 2H, CH2 COD 1H, CH2 1H), 1.69–1.51 (m, 2H, CH2 COD), 1.46–
1.30 (m, 1H, CH2 COD), 0.87 (s, 9H, (CH3)3CSi), 0.53 (s, 3H, (CH3Si)), 0.51 (s, 3H, (CH3Si)) 
ppm. 13C{1H}-NMR (101 MHz, CD2Cl2): δ = 162.4 q, JBC = 50 Hz, CAr BArF), 160.0 (d, JPC 
= 4 Hz, CAr), 150.6 (s, HCAr), 142.2 (s, HCAr), 136.7 (s, CAr), 135.4 (s, HCAr BArF), 135.3 (s, 
HCAr), 132.6 (d, JPC = 2 Hz, HCAr), 132.5 (d, JPC = 10 Hz, HCAr), 131.6 (d, JPC = 2 Hz, HCAr), 
131.5 (s, CAr), 131.0 (s, CAr), 129.8 (d, JPC = 11 Hz, HCAr), 129.5 (qq, JFC=32, JBC=3, CAr 
BArF), 129.3 (d, JPC = 10 Hz, HCAr), 125.6 (s, HCAr), 125.2 (q, JFC=272, CF3 BArF), 118.1 
(septett, JFC=4, HCAr BArF), 99.1 (d, JPC = 11 Hz, CH COD), 87.3 (d, JPC = 14 Hz, CH COD), 
78.5 (s, COSi)), 60.6 (s, CH COD), 57.2 (s, CH COD), 42.1 (d, JPC = 9 Hz, CH2 COD), 40.6 
(d, JPC = 32 Hz, CH2P), 36.7 (d, JPC = 4 Hz, CH2 COD), 31.4 (d, JPC = 4 Hz, CH2), 30.4 (s, 
CH2), 29.6 (s, CH2), 27.8 (s, CH2), 27.5 (s, (CH3)3C), 21.2 (s, CH2), 19.8 (s, (CH3)3C), 1.5 (s, 
CH3Si), 0.3 (s, CH3Si) ppm. 
31
P{
1
H}-NMR (162 MHz, CDCl3): δ = 6.5 ppm. MS (ESI, 
c = 0.05 mg/mL, 50 °C, 20 µL/min) m/z (%): 762 ([Ir(L)(COD)]+, 100). IR: ṽ = 2967 (w br), 
2874 (w), 1611 (w), 1471 (w), 1436 (w), 1353 (s), 1272 (s), 1170 (m), 1115 (s br), 1078 (m), 
1054 (m), 1034 (m), 999 (w), 885 (m), 839 (m), 805 (w), 783 (w), 743 (w), 712 (m), 681 (s), 
669 (m) cm-1. EA: calc. (%) C 50.25, H 3.72, N 0.86; found C 50.29, H 3.70, N 0.77. m.p.: 
169–171°C. [α]D20: +12.8 (c = 0.35, CH2Cl2). 
 
 
(−)-[η4-1,5-Cyclooctadiene-8-((diphenylphosphino)methyl)-8-(tri-iso-propylsilyloxy)-
5,6,7,8-tetrahydroquinoline-iridium(I)]-tetrakis-[3,5-bis(trifluormethyl)phenyl]borate 
(87d) 
 
The title compound 87d was obtained following the general procedure 
G using [Ir(COD)Cl]2 (8.0 mg, 11.9 µmol, 0.5 eq.), DCM (1 mL), 
ligand 86d (12.0 mg, 23.8 µmol, 1.0 eq.), DCM (0.5 mL), NaBArF 
(23.2 mg, 26.2 µmol, 1.1 eq.), after purification by flash 
chromatography (SiO2, 1.5 cm × 10 cm) as an orange solid (28.0 mg, 17.8 µmol, 70%). 
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C71H66BF24IrNOPSi (1667.34 g/mol):  
1
H-NMR (400 MHz, CD2Cl2[M+H]): δ = 8.68 (d, J = 5.6 Hz, 1H, HAr), 7.83–7.75 (m, 2H, 
HAr), 7.72 (s, 8H, BArF-H), 7.55 (s, 4H, BArF-H), 7.53 (d, J = 8.0 Hz, 1H, HAr), 7.50–7.34 (m, 
6H, HAr), 7.28–7.18 (m, 3H, HAr), 4.96–4.81 (m, 2H, CH COD), 3.47 (q, J = 6.3 Hz, 1H, CH 
COD), 3.02 (dd, J = 15.3, 12.4 Hz, 1H, CH2), 2.90 (ddd, J = 18.1, 12.9, 5.7 Hz, 1H, CH2P), 
2.84–2.76 (m, 1H, CH COD), 2.74–2.63 (m, 2H, CH2P 1H, CH2 COD 1H), 2.62–2.33 (m, 5H, 
CH2 2H, CH2 COD 3H), 2.33–2.18 (m, 2H, CH2 1H, CH2 COD 1H), 2.13–1.98 (m, 2H, CH2 
1H, CH2 COD 1H), 1.68–1.56 (m, 2H, CH2 1H, CH2 COD 1H), 1.44–1.32 (m, 4H, CH2 COD 
1H, ((CH3)2CH)3Si 3H), 1.12 (d, J = 6.4 Hz, 9H, ((CH3)2CH)3Si), 1.12 (d, J = 7.5 Hz, 9H, 
((CH3)2CH)3Si) ppm. 
13
C{
1
H}-NMR (101 MHz, CD2Cl2): δ = 162.4 (q, JBC = 50 Hz, CAr 
BArF), 157.3 (s, CAr), 150.5 (s, HCAr), 142.3 (s, HCAr), 137.0 (s, CAr), 135.3 (s, HCAr BArF), 
135.2 (d, JPC = 12 Hz, HCAr), 132.6 (d, JPC = 5 Hz, HCAr), 132.5 (d, JPC = 3 Hz, HCAr), 131.7 
(d, JPC = 3 Hz, CAr), 130.9 (s, CAr), 129.8 (d, JPC = 11 Hz, HCAr), 129.5 (qq, JFC = 32 Hz, JBC = 
3 Hz, CAr BArF), 129.2 (d, JPC = 11 Hz, HCAr), 125.6 (s, HCAr), 125.1 (q, JFC = 272 Hz, CF3 
BArF), 118.0 (septett, JFC = 4 Hz, HCAr BArF), 99.4 (d, JPC = 11 Hz, CH COD), 87.8 (d, JPC = 
14 Hz, CH COD), 77.7 (s, COSi), 61.5 (s, CH COD), 57.6 (s, CH COD), 40.8 (d, JPC = 9 Hz, 
CH2P), 40.0 (d, JPC = 1 Hz, CH2), 36.4 (d, JPC = 3 Hz, CH2 COD), 31.0 (d, JPC = 2 Hz, CH2 
COD), 30.4 (s, CH2), 29.7 (d, JPC = 2 Hz, CH2 COD), 27.7 (s, CH2 COD), 21.1 (s, CH2), 19.0 
(s, (CH3)2CHSi), 18.9 (s, (CH3)2CHSi), 15.4 (s, (CH3)2CHSi) ppm. 
31
P{
1
H}-NMR (162 MHz, 
CD2Cl2): δ = 7.8 ppm. MS (ESI, c = 0.05 mg / mL, 50 °C, 15 µL / min) m/z (%): 804 
([Ir(L)(COD)]+, 100). IR: ṽ = 2944 (w br), 2863 (w), 1610 (w), 1470 (w), 1437 (w), 1352 (s), 
1272 (s), 1158 (m), 1119 (s br), 1102 (s), 1055 (m), 1047 (w), 1017 (w), 1000 (w), 896 (w), 
884 (m), 839 (m), 805 (w), 741 (w), 722 (w), 716 (m), 693 (w), 681 (s), 668 (s) cm-1. EA: 
calc. (%) C 51.72, H 4.16, N 0.83; found C 49.67, H 3.90, N 0.60. m.p.: 103–104 °C. [α]D20: 
−11.7 (c = 0.33, CH2Cl2). 
 
 
(−)-[η4-1,5-Cyclooctadiene-8-(tert-butyldimethylsilyloxy)-8-((di-ortho-
tolylphosphino)methyl)-5,6,7,8-tetrahydroquinoline-iridium(I)]-tetrakis-[3,5-
bis(trifluormethyl)phenyl]borate (87e) 
 
The title compound 87e was obtained following the general procedure 
G using [Ir(COD)Cl]2 (31.5 mg, 47.0 µmol, 0.5 eq.), DCM (2 mL), 
ligand 86e (46.0 mg, 93.9 µmol, 1.0 eq.), DCM (1 mL), NaBArF 
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(91.6 mg, 103 µmol, 1.1 eq.), after purification by flash chromatography (SiO2, 1.5 cm × 22 
cm) as an orange solid (119 mg, 72.0 µmol, 76%). This compound consists as a mixture of 
rotamers. The experimental data given below are given for the main diastereomer.  
 
C70H64BF24IrNOPSi (1653.31 g/mol): 
1
H-NMR (400 MHz, CD2Cl2): δ = 9.08 (br s, 1H, HAr), 8.67 (dd, J = 5.4 Hz, 1H, HAr), 7.90–
7.79 (m, 2H, HAr), 7.75 (s, 8H, BArF-H), 7.58 (s, 4H, BArF-H), 7.55 (d, J = 8.2 Hz, 1H, HAr), 
7.49–7.35 (m, 6H, HAr), 7.27–7.15 (m, 3H, HAr), 4.91–4.77 (m, 2H, CH2 COD), 3.47 (q, 
J = 6.0 Hz, 1H, CH2 COD), 2.96–2.81 (m, 2H, CH2), 2.78–2.59 (m, 4H, CH2), 2.69–2.42 (m, 
4H, CH2), 2.61–2.36 (m, 3H, CH2), 2.36–2.19 (m, 2H, CH2), 2.17–1.97 (m, 2H, CH2), 1.69–
1.51 (m, 2H, CH2), 1.46–1.30 (m, 1H, CH2), 0.87 (s, 9H, (CH3)3CSi), 0.53 (s, 3H, (CH3Si)), 
0.51 (s, 3H, (CH3Si)) ppm. 
31
P{
1
H}-NMR (162 MHz, CD2Cl2): δ = 11.7 ppm (rotamer 2.4 
ppm). MS (FAB NBA) m/z (%): 790 ([Ir(L)(COD)]+, 100), 606 (28), 546 (10), 202 (16), 146 
(11). IR: ṽ = 2962 (w br), 2893 (w), 1610 (w), 1481 (w), 1447 (w), 1352 (s), 1272 (s), 1159 
(m), 1115 (s br), 1070 (m), 1051 (m), 1032 (m), 1005 (w), 886 (m), 820 (w), 807 (w), 786 
(w), 744 (m), 723 (w), 710 (s), 681 (s), 668 (m) cm-1. EA: calc. (%) C 50.85, H 3.90, N 0.85; 
found C 50.87, H 3.85, N 0.69. m.p.: 83–84 °C. [α]D20: −0.9 (c = 0.42, CHCl3). 
 
 
(±)-[η4-1,5-Cyclooctadiene-8-methyl-8-(5,6,7,8-tetrahydoquinolinyl)diphenylphosphinite-
hydrido-iridium(III)]-tetrakis-[3,5-bis(trifluormethyl)phenyl]-borate (81) 
 
To a solution of 80 (95.0 mg, 582 µmol, 1.0 eq.) in THF (2.0 mL) was 
added a n-BuLi 1.6 M solution in hexanes (0.4 mL, 640 µmol, 1.1 eq.) at 
‒78 °C. The reaction mixture was stirred at 0 °C for 1 h, fallowed by 
slow addition of a solution of chlorodiphenylphosphine (120 µL, 
140 mg, 639 µmol, 1.0 eq.) in THF (1.0 mL). The cooling bath was 
removed and the reaction mixture was stirred for additional 2 h at RT. The solvent was 
removed under reduce pressure, following by addition of DCM (5.0 mL) and filtration 
through a HPLC syringe filter (CHROMAFIL® O-20/15 MS, pore size 20 µm). The syringe 
filter was purged with DCM (1.0 mL). The obtained solution was added to a solution of 
[Ir(COD)Cl]2 (97.0 mg, 145 µmol, 0.25 eq.) in DCM (1.0 mL) at 0 °C and stirred for an 
additional 1 h at 0 °C. NaBArF (284 mg, 321 µmol, 0.55 eq.) was added and stirring was 
continued for additional 30 min. The reaction mixture was washed with water (5.0 mL) and 
the aq. phase was re-extracted with DCM (5.0 mL). Combined organic layers were dried over 
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MgSO4, filtered and the solvent was removed under reduced pressure. Purification by flash 
chromatography (SiO2, 1.5 cm × 25 cm, TBME  DCM / cyclohexane 2:1) gave the title 
compound 81 (100 mg, 66.2 µmol, 11%) as pale grey solid. 
 
31
P{
1
H}-NMR of Ph2PCl (162 MHz, CD2Cl2): δ = 79.1 (s) ppm. 
31
P{
1
H}-NMR of the ligand (162 MHz, C6D6): δ = 86.9 (s) ppm. 
 
C62H46BF24IrNOP (1511.00 g/mol):  
1
H-NMR (500 MHz, CDCl3): δ = 8.31 (d, J = 5.2 Hz, 1H, HAr), 7.76 (dd, J = 13.3, 7.6 Hz, 
3H, HAr), 7.72 (s, 8H, BArF-H), 7.64–7.53 (m, 3H, HAr), 7.52 (s, 4H, BArF-H), 7.26–7.18 (m, 
2H, HAr), 7.12 (td, J = 7.7, 2.4 Hz, 2H, HAr), 6.42 (dd, J = 11.5, 7.7 Hz, 2H, HAr), 5.23–5.14 
(m, 1H, CH COD), 5.11 (t, J = 6.7 Hz, 1H, CH COD), 4.26–4.16 (m, 1H, CH COD), 3.58 (q, 
J = 7.2 Hz, 1H, CH COD), 3.41 (dd, J = 15.2, 8.0 Hz, 1H, CH2Ir), 2.99–2.90 (m, 1H, CH2), 
2.86–2.74 (m, 2H, CH2 1H, CH2 COD 1H), 2.68 (dtd, 1H, J = 15.2, 8.0, 6.2 Hz, 1H, CH2Ir), 
2.60–2.36 (m, 4H, CH2 COD 3H, CH2 1H), 2.15–1.99 (m, 2H, CH2 2H), 1.90–1.82 (m, 1H, 
CH2 COD), 1.81–1.70 (m, 1H, CH2 COD), 1.39–1.28 (m, 1H, CH2 COD), 0.96–0.87 (m, 2H, 
CH2 COD 1H, CH2 1H), −15.88 (d, J = 9.2 Hz, 1H, Ir-H) ppm. 13C{1H}-NMR (126 MHz, 
CDCl3): δ = 161.8 (q, JBC = 50 Hz, CAr BArF), 161.7 (d, JPC = 2 Hz, CAr), 150.5 (s, HCAr), 
140.4 (s, HCAr), 136.9 (s, CAr), 134.9 (s, HCAr BArF), 133.5 (d, JPC = 2 Hz, HCAr), 132.7 (d, 
JPC = 15 Hz, CAr), 132.1 (s, HCAr), 132.04 (d, JPC = 23 Hz, HCAr), 132.00 (s, HCAr), 131.8 (d, 
JPC = 2 Hz, HCAr), 131.4 (d, JPC = 47 Hz, CAr), 129.4 (d, JPC = 12 Hz, HCAr), 129.1 (qq, JFC = 
32 Hz, JBC = 3 Hz, CAr BArF), 129.0 (d, JPC = 11 Hz, HCAr), 127.9 (d, JPC = 11 Hz, HCAr), 
126.3 (s, HCAr), 124.7 (q, JFC = 272 Hz, CF3 BArF), 117.6 (septett, JFC = 4 Hz, HCAr BArF), 
96.8 (s, CO), 90.6 (d, JPC = 11 Hz, CH COD), 90.4 (d, JPC = 16 Hz, CH COD), 86.2 (s, CH 
COD), 83.7 (s, CH COD), 39.7 (d, JPC = 8 Hz, CH2Ir), 36.2 (d, JPC = 10 Hz, CH2 COD), 31.1 
(s, CH2 COD), 28.8 (s, CH2), 27.9 (s, CH2 COD), 25.7 (s, CH2 COD), 24.2 (d, JPC = 4 Hz, 
CH2), 20.9 (s, CH2) ppm. 
31
P{
1
H}-NMR (202 MHz, CDCl3): δ = 100.2 ppm. MS (FAB NBA) 
m/z (%): 648 ([Ir(L)(COD)]+, 89), 538 (19), 444 (30), 384 (21), 258 (20), 245 (20), 230 (21), 
166 (23), 149 (45), 107 (68), 89 (98), 77 (100), 65 (41), 51 (38), 39 (63). IR: ṽ = 2967 (w br), 
1609 (w), 1438 (w), 1353 (s), 1271 (s), 1090 (s br), 999 (w), 897 (w), 885 (m), 863 (w), 852 
(w), 838 (m), 811 (w), 788 (m), 768 (m), 743 (m), 714 (s), 708 (m), 681 (s), 667 (m) cm-1. 
EA: calc. (%) C 49.28, H 3.07, N 0.93; found C 49.64, H 3.32, N 0.79. 
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8.5 New Pyridine–Phosphinite Based Ligands for Iridium-Catalyzed 
Asymmetric Hydrogenation  
8.5.1 Preparation of the Ligand Precursers 
1-(6-Bromopyridin-2-yl)ethanol (104) 
 
A n-BuLi 1.6 M solution (5.0 mL, 8.00 mmol, 1.0 eq.) was slowly added to a 
solution of 2,5-dibromopyridine (1.90 g, 8.00 mmol, 1.0 eq.) in diethyl ether 
(40 mL) at −78 °C. After stirring for 1.5 h at −78 °C, acetaldehyde (1 mL, 
0.78 g, 17.7 mmol, β.β eq.) was added. The reaction mixture was stirred for β h at −78 °C, 
afterwards it was allowed to warm to RT. HCl 1 M aq. solution (15 mL) was added and the 
biphasic mixture was separated. The aqueous layer was extracted with TBME (3×10 mL). 
Combined organic layers were dried over MgSO4, filtered and the solvent was removed under 
reduced pressure. The title compound 104 was obtained after purification by Kugelrohr 
distillation (110–115 °C / 0.1 mbar) as a colorless oil (1.56 g, 7.72 mmol, 96%). The 
analytical data match the reported values.[112]  
 
C7H8BrNO (202.05 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 7.52 (t, J = 7.6 Hz, 1H, HAr), 7.35 (d, J = 7.6 Hz, 1H, HAr), 
7.28 (d, J = 7.6 Hz, 1H, HAr), 4.84 (q, J = 6.4 Hz, 1H, CH), 3.69 (br s, 1H, OH), 1.47 (d, 
J = 6.4 Hz, 3H, CH3) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 165.2 (CAr), 142.1 (CAr), 
139.2 (HCAr), 126.6 (HCAr), 118.5 (HCAr), 79.1 (CH), 24.1 (CH3) ppm. MS (EI, 70 eV, rt, m/z 
(%): 202 (5, [M+]), 186 (100), 158 (31), 106 (19), 78 (45), 51 (11). b.p.: 110‒115 °C / 0.1 
mbar).  
 
 
(R)-1-(6-Bromopyridin-2-yl)ethyl acetate (105) 
 
Vynyl acetate (2.0 mL, 1.89 mg, 21.7 mmol, 5.8 eq.) was added to a 
mixture of pyridyl alcohol 104 (750 mg, 3.71 mmol, 1.0 eq.) and CAL-B 
(300 mg) in diisopropyl ether (200 mL). The reaction mixture was stirred 
for 17 h at RT. The reaction mixture was filtered and washed with ethyl 
acetate (100 mL). The solvents were removed under reduced pressure. Separation of the two 
products was chieved by MPLC (SiO2, cyclohexane / ethyl acetate 95:5). The title compound 
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(R)-105 (165 mg, 682 μmol, 18%) was obtained as a colorless oil. The analytical data match 
the reported values.[112] 
 
C9H10BrNO2 (242.09 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 7.53 (t, J = 7.6 Hz, 1H, HAr), 7.38 (d, J = 8.0 Hz, 1H, HAr), 
7.28 (d, J = 7.6 Hz, 1H, HAr), 5.85 (q, J = 6.8 Hz, 1H, CH), 2.12 (s, 3H, CCH3), 1.57 (d, 
J = 6.4 Hz, 3H, CHCH3) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 170.1 (C=O), 161.9 
(CAr), 141.6 (CAr), 138.9 (HCAr), 127.1 (HCAr), 119.0 (HCAr), 72.4 (CH), 21.2 (CH3), 20.6 
(CH3) ppm. MS (EI, 70 eV, RT, m/z (%): 243 ([M
+], 0.2), 200 (100), 186 (23), 158 (8), 104 
(46), 78 (24), 43 (78). TLC: (SiO2, cyclohexane / ethyl acetate 95:5): Rf = 0.15. [α]D20: +74.2 
(c = 0.93, CHCl3); lit. +72 (c = 1.49, CHCl3).
[112]  
 
 
(S)-1-(6-Bromopyridin-2-yl)ethanol ((S)-104) 
 
The title compound (S)-104 was obtained by enzymatic kinetic resolution 
after the separation of the product by MPLC (SiO2, cyclohexane / ethyl 
acetate 95:5) as a colorless oil (507 mg, 2.51 mmol, 68%).  
 
TLC: (SiO2, cyclohexane / ethyl acetate 95:5) : Rf = 0.10. HPLC (chiral, Daicel Chiracel 
OD-H, (4.6 mm × 250 mm), n-heptane / i-PrOH 98:2, 0.5 mL / min, 25 °C: tR = 32.0 min (S), 
34.4 min (R), 30% ee. [α]D20: −γ.γ (c = 1.07, CHCl3); lit. −10.8 (c = 2.75, CHCl3).[112].  
 
 
(R)-1-(6-Bromopyridin-2-yl)ethanol ((R)-104) 
 
Water (5 mL) and K2CO3 (200 mg, 1.45 mmol, 2.1 eq.) were added to a 
solution of acetate (R)-105 (165 mg, 682 μmol, 1.0 eq.) in methanol (5 mL) 
and the reaciton mixture was stirred at rt over night. The reaction mixture was 
extracted with DCM (3×5 mL). Combined organic layers were dried over MgSO4, filtered and 
evaporated under reduced pressure. The title compound (R)-104 (108 mg, 535 µmol, 78%) 
was obtained as a colorless oil.  
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HPLC (chiral, Daicel Chiracel OD-H, (4.6 mm × 250 mm), n-heptane / i-PrOH 98:2, 0.5 mL 
/ min, 25 °C: tR = 33.0 min (S), 34.4 min (R), >99% ee. [α]D20: +7.1 (c = 0.78, CHCl3); lit. 
+11.0 (c = 1.49, CHCl3).
[112]  
 
 
(R)-1-(6-Bromopyridin-2-yl)ethanol ((R)-106) 
 
A degassed solution of phenylboronic acid (80.2 mg, 658 µmol, 1.2 eq.) in 
ethanol (1.5 mL) and a degassed solution of Na2CO3 (113 mg, 1.07 mmol, 
2.0 eq.) in water (1.5 mL) were added to a degassed solution of Pd(PPh3)4 
(6.50 mg, 5.63 µmol, 1 mol%) and pyridyl alcohol (R)-104 (108 mg, 535 µmol, 1.0 eq.) in 
toluene (1.5 mL). The reaction mixture was stirred for 15 h at 85 °C. After cooling down to 
RT, the layers were separated. The aquoues layer was extracted with DCM (2×1 mL). The 
combined organic layers were dried over over MgSO4, filtered and evaporated under reduced 
pressure. Purification by flash chromatography (SiO2, cyclohexane / ethyl acetate 4:1) gave 
the title compound (R)-106 as pale yellow oil (102 mg, 512 µmol, 96%).  
 
 
C13H13BrNO (199.25 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 8.04–8.02 (m, 2H, HAr), 7.38 (t, J = 7.6 Hz, 1H, HAr), 7.65 
(d, J = 8.0 Hz, 1H, HAr), 7.51–43 (m, 3H, HAr), 7.20 (d, J = 7.6 Hz, 1H, HAr), 4.95 (dd, 
J = 4.8, 1.6 Hz, 1H, CH), 4.77 (d, J = 4.4 Hz, 1H, OH), 1.55 (d, J = 6.4 Hz, 3H, CHCH3) 
ppm. TLC: (SiO2, cyclohexane / ethyl acetate 4:1): Rf = 0.30. HPLC (chiral, Daicel Chiracel 
OD-H, (0.46 cm × 25 cm), heptane / i-PrOH 90:10, 0.5 mL / min, 25 °C: tR = 15.8 min (S), 
19.2 min (R), >99% ee. [α]D20: −β7.5 (c = 1.20, CHCl3). 
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8.5.2 Preparation of Ir-complexes 
 
(R)-[η4-1,5-Cyclooctadiene-2-(ethyl-6-phenylpyridyl)-1-di-ortho-tolylphosphinite-
iridium(I)]-tetrakis-(3,5-bis-(trifluoromethyl)-phenyl)-borate ((R)-113a)  
 
The intermediate N,P ligand (R)-102a was obtained following the 
general procedure C using pyridyl alcohol (R)-106 (40 mg, 
201 µmol, 1.0 eq.), DMAP (25.0 mg, 201 µmol, 1.0 eq.), chloro-
diphenylphosphine (50.0 mg, 201 µmol, 1.0 eq.), THF (1.0 mL) and 
after filtration over silica gel SiO2, 1.5 cm × 5 cm, cyclohexane / TBME 5:1, degassed) under 
innert conditions as a colorless foam (24.0 mg, 58.3 µmol, 29%). The title compound (R)-
113a was obtained following general procedure G using the N,P ligand (R)-102a, 
[Ir(COD)Cl]2 (20.0 mg, 29.8 µmol, 0.5 eq.), DCM (1.5 mL) and NaBArF (58.0 mg, 
65.5 µmol, 1.2 eq.) after purification by flash chromatography (SiO2, 1.5 cm × 15 cm, TBME 
then DCM) was isolated as an orange foam (40 mg, 25.3 µmol, 13% over two steps).  
 
31
P{
1
H}-NMR of (o-Tol)2PCl (162 MHz, CD2Cl2): δ = 75.3 (s) ppm. 
31
P{
1
H}-NMR of the ligand (162 MHz, CD2Cl2): δ = 94.7 (s) ppm. 
 
C67H50BF24IrNOP (1575.08 g/mol): 
1
H-NMR (500 MHz, CD2Cl2): δ = 8.00 (t, J = 7.9 Hz, 1H, HAr), 7.76–7.68 (m, 11H, BArF-H, 
HAr), 7.68–7.59 (m, 3H, HAr), 7.56 (s, 4H, BArF-H), 7.52–7.39 (m, 4H, HAr), 7.38–7.34 (m, 
2H, HAr), 7.25–7.18 (m, 2H, HAr), 6.94 (dd, J = 12.5, 8.0 Hz, 1H, HAr), 6.33 (p, J = 6.6 Hz, 
1H, CHOP), 4.63–4.57 (m, 1H, CH COD), 4.52 (t, J = 6.3 Hz, 1H, CH COD), 3.38–3.24 (m, 
1H, CH COD), 2.93 (s, 3H, CH3), 2.79 (p, J = 7.4 Hz, 1H, CH COD), 2.49 (s, 3H, CH3), 2.36 
(ddd, J = 16.9, 10.9, 6.3 Hz, 1H, CH2 COD), 2.10 (d, J = 6.5 Hz, 3H, CHCH3), 1.92–1.71 (m, 
5H, CH2 COD), 1.41–1.32 (m, 1H, CH2 COD), 1.26–1.19 (m, 1H, CH2 COD) ppm. 
31
P{
1
H}-NMR (162 MHz, CD2Cl2): δ = 96.5 (br s) ppm.  
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Formation of P-alkyl N,P Ligands and Subsequent Complexation with Iridium  
 
 
General Procedure H: A Schlenk flask was charged with the pyridyl alcohol (1.0 eq.) and 
the corresponding chloro-alkylphosphine (>1 eq.). THF (>0.5 M) and KH (dry, >1 eq.) were 
added. The reaction mixture was stirred at rt until 31P-NMR revealed full conversion of the 
chlorophosphine (usually >12 h). After reaching full conversion the solvent was removed in 
vacuo. Toluene (1 mL) was added and the suspension was filtered over a plug of Celite® 
using a Schlenk (d×h, 2 cm × 1 cm). Toluene (2×1 mL) was used for purging. The obtained 
N,P ligands was converted to the corresponding Ir-complex following general procedure G. 
 
 
(R)-[η4-1,5-Cyclooctadiene-2-(ethyl-6-phenylpyridyl)-1-di-tert-butylphosphinite-
iridium(I)]-tetrakis-(3,5-bis-(trifluoromethyl)-phenyl)-borate ((R)-113a)  
 
The intermediate N,P ligand (R)-102b was obtained following the 
general procedure H using pyridyl alcohol (R)-106 (42.0 mg, 
211 µmol, 1.0 eq.), chloro-di-tert-butylphosphine (40 µL, 38.0 mg, 
211 µmol, 1.0 eq.), KH (10.2 mg, 253 µmol, 1.2 eq.), THF (1.0 mL) 
as a colorless foam (65.0 mg, 189 µmol, 90%).  
The title compound (R)-113a was obtained following the general procedure G using (R)-106b 
(65.0 mg, 189 µmol, 90%). [Ir(COD)Cl]2 (63.6 mg, 94.6 µmol, 0.5 eq.), DCM (3 mL), 
NaBArF (185 mg, 208 µmol, 1.1 eq.) and after purification by flash chromatography (SiO2, 
1.5 cm × 20 cm, TBME then DCM) as an orange solid (107 mg, 71.0 µmol, 34% over two 
steps).  
 
31
P{
1
H}-NMR of (t-Bu)2PCl (162 MHz, C6D6): δ = 146.4 (s) ppm. 
31
P{
1
H}-NMR of the ligand (162 MHz, C6D6): δ = 154.9 (s) ppm. 
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C61H54BF24IrNOP (1507.05 g/mol): 
1
H-NMR (500 MHz, CD2Cl2): δ = 8.27 (d, J = 7.4 Hz, 2H, HAr), 8.02 (t, J = 7.9 Hz, 1H, HAr), 
7.79 (t, J = 7.5 Hz, 1H, HAr), 7.76–7.68 (m, 11H, BArF-H, HAr), 7.63 (dd, J = 7.8, 1.0 Hz, 1H, 
HAr), 7.56 (s, 4H, BArF-H), 5.82 (dq, J = 9.6, 6.5 Hz, 1H, CHOP), 5.23 (t, J = 6.7 Hz, 1H, CH 
COD), 4.41 (t, J = 5.5 Hz, 1H, CH COD), 4.21 (p, J = 8.6 Hz, 1H, CH COD), 2.42 (p, J = 8.0 
Hz, 1H, CH COD), 2.24–2.13 (m, 2H, CH2 COD), 2.05–1.92 (m, 2H, CH2 COD), 1.92 (d, J = 
6.5 Hz, 3H, CH3), 1.71–1.61 (m, 2H, CH2 COD), 1.60 (br s, 9H, C(CH3)2), 1.05 (d, J = 14.4 
Hz, 9H C(CH3)2), 0.96–0.82 (m, 2H, CH2 COD) ppm. 13C{1H}-NMR (126 MHz, CD2Cl2): 
δ = 162.4 (d, JPC = 3 Hz, CAr), 162.3 (q, JBC = 50 Hz, CAr BArF), 160.0 (s, CAr), 140.8 (s, 
HCAr), 139.9 (s, CAr), 135.4 (s, HCAr BArF), 132.3 (s HCAr), 130.6 (s, HCAr), 129.7 (s, HCAr), 
129.4 (qq, JFC = 32 Hz, JBC = 3 Hz, CAr BArF), 126.6 (s, HCAr), 125.2 (q, JFC = 272 Hz, CF3 
BArF), 121.2 (s, HCAr), 118.0 (septett, JFC = 4 Hz, HCAr BArF), 88.7 (d, JPC = 5 Hz, CH 
COD), 79.3 (s, CHOP), 77.7 (d, JPC = 19 Hz, CH COD), 74.8 (s, CH COD), 63.6 (s, CH 
COD), 41.6 (d, JPC = 18 Hz, C(CH3)2), 40.2 (d, JPC = 19 Hz, C(CH3)2), 37.1 (s, CH2 COD), 
35.7 (s, CH2 COD), 28.64 (s, C(CH3)2), 28.59 (s, C(CH3)2), 28.3 (s, CH2 COD), 23.9 (s, CH2 
COD), 19.0 (d, JPC = 8 Hz, CH3) ppm. 
31
P{
1
H}-NMR (202 MHz, CD2Cl2): δ = 133.8 (s) ppm.  
 
 
(R)-(−)-[η4-1,5-Cyclooctadiene-((phenyl)methyl)-(6-methylpyridyl)-diphenylphosphinite-
iridium(I)]-tetrakis-(3,5-bis-(trifluoromethyl)-phenyl)-borate ((R)-113c)  
 
The intermediate N,P ligand (R)-102c was obtained following the 
general procedure C using (R)-(6-methylpyridin-2-yl)(phenyl)methanol 
(19.9 mg, 100 µmol, 1.0 eq.), DMAP (12.2 mg, 100 µmol, 1.0 eq.), 
chloro-diphenylphosphine (18 µL, 22.1 mg, 100 µmol, 1.0 eq.), DCM 
(1.0 mL), after filtration over aluminum oxide (d×h, 2 cm × 2 cm) and washing with DCM 
(10 mL). The N,P ligand solution was concentrated in vacuo up to 1 mL. The title compound 
(R)-113c was obtained following the general procedure G using the N,P ligand solution, 
[Ir(COD)Cl]2 (33.6 mg, 50 µmol, 0.5 eq.), DCM (2 mL), NaBArF (99.0 mg, 112 µmol, 
1.1 eq.), after purification by flash chromatography (SiO2, 3 cm × 10 cm, TBME then DCM) 
as an orange solid (33 mg, 21.3 µmol, 21% over two steps).  
 
31
P{
1
H}-NMR of Ph2PCl (162 MHz, CD2Cl2): δ = 79.1 (s) ppm. 
31
P{
1
H}-NMR of the ligand (162 MHz, CD2Cl2): δ = 111.5 (s) ppm. 
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C65H46BF24IrNOP (1547.03 g/mol): 
1
H-NMR (500 MHz, CD2Cl2): δ = 7.84 (d, J = 7.6 Hz, 1H, HAr), 7.76 (s, 8H, BArF-H), 7.64 
(ddt, , J = 9.5, 5.1, 3.8 Hz, 7H, HAr), 7.60 (m, 4H, BArF-H), 7.52–7.42 (m, 6H, HAr), 7.35–
7.29 (m, 2H, HAr), 7.22 (dd, J = 7.9, 1.0 Hz, 2H, HAr), 6.76 (d, J = 7.7 Hz, 1H, CHOP), 5.27 
(d, J = 8.4 Hz, 1H, CH COD), 4.59 (t, J = 6.5 Hz, 1H, CH COD), 4.40 (p, J = 7.5 Hz, 1H, CH 
COD), 3.15–3.10 (m, 1H, CH COD), 3.08 (s, 3H, CH3), 2.36 (ddt, J = 15.9, 10.1, 5.0 Hz, 1H, 
CH2 COD), 2.51–2.43 (m, 1H, CH2 COD), 2.35 (dd, J = 15.7, 7.8 Hz, 1H, CH2 COD), 2.31–
2.21 (m, 1H, CH2 COD), 2.11–2.00 (m, 1H, CH2 COD), 1.98–1.86 (m, 1H, CH2 COD), 1.77–
1.58 (m, 2H, CH2 COD) ppm.
 13
C{
1
H}-NMR (126 MHz, CD2Cl2): δ = 162.3 (q, JBC = 50 Hz, 
CAr BArF), 160.9 (s, CAr), 160.3 (s, CAr), 140.4 (s, HCAr), 135.4 (s, HCAr BArF), 133.2 (s 
HCAr), 132.5 (s HCAr), 132.0 (d, JPC = 16 Hz, HCAr), 130.5 (s, HCAr), 129.9 (s, HCAr), 129.8 
(s, HCAr), 129.4 (qq, JFC = 32 Hz, JBC = 3 Hz, CAr BArF), 127.8 (s, HCAr), 125.2 (q, JFC = 272 
Hz, CF3 BArF), 123.4 (s, HCAr), 118.0 (septett, JFC = 4 Hz, HCAr BArF), 102.7 (d, JPC = 9 Hz, 
CH COD), 92.17 (d, JPC = 14 Hz, CH COD), 85.2 (s, CHOP), 69.5 (s, CH COD), 66.5 (s, CH 
COD), 37.6 (s, CH2 COD), 34.6 (s, CH2 COD), 29.1 (s, CH3), 28.3 (s, CH2 COD), 25.9 (s, 
CH2 COD) ppm. 
31
P{
1
H}-NMR (202 MHz, CD2Cl2): δ = 98.9 (s) ppm. MS (FAB NBA) m/z 
(%): 684 ([Ir(L)(COD)]+, 100), 576 (22), 498 (12), 182 (31). EA: calc. (%) C 50.47, H 3.00, 
N 0.91; found C 50.46, H 2.92, N 1.01. m.p.: 1γ4‒1γ5 °C. [α]D20: −16.0 (c = 0.53, CHCl3). 
 
 
(R)-(+)-[η4-1,5-Cyclooctadiene-((phenyl)methyl)-(6-methylpyridyl)-di-ortho-
tolylphosphinite-iridium(I)]-tetrakis-(3,5-bis-(trifluoromethyl)-phenyl)-borate 
((R)-113d)  
 
The intermediate N,P ligand (R)-102d was obtained following the 
general procedure C using (R)-(6-methylpyridin-2-yl)(phenyl)-
methanol (39.9 mg, 200 μmol, 1.0 eq.), DMAP (25.7 mg, 210 μmol, 
1.06 eq.), chloro-di-ortho-tolylphosphine (52.2 mg, 210 μmol, 1.05 
eq.), DCM (1.0 mL), after purification by flash chromatography 
(SiO2, 2 cm × 10 cm, pentane / diethyl ether 10:1, Argon degassed). The filtrate was 
concentrated in vacuo to obtain the intermediate ligand (48 mg, 117 μmol, 58%) as a colorless 
solid. The title compound (R)-113d was obtained following the general procedure G using the 
N,P ligand (48 mg, 117 μmol, 58%), [Ir(COD)Cl]2 (39.2 mg, 58.3 μmol, 0.5 eq.), DCM (3 
mL), NaBArF (120 mg, 136 μmol, 1.2 eq.), purification by flash chromatography (SiO2, 3 cm 
× 10 cm, TBME then DCM) as a red solid (166 mg, 105 µmol, 53% over two steps).  
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31
P{
1
H}-NMR of (o-Tol) 2PCl (162 MHz, CD2Cl2): δ = 75.3 (s) ppm. 
31
P{
1
H}-NMR of the ligand (162 MHz, CD2Cl2): δ = 98.6 (s) ppm. 
 
C67H50BF24IrNOP (1575.08 g/mol): 
1
H-NMR (400 MHz, CD2Cl2): δ = 7.98 (br s, 1H, HAr), 7.83–7.71 (m, 9H, BArF-H, HAr), 
7.62–7.49 (m, 10H, BArF-H, HAr), 7.45–7.36 (m, 2H, HAr), 7.35–7.28 (m, 2H, HAr), 7.27–7.20 
(m, 2H, HAr), 7.16 (t, J = 7.3 Hz, 1H, HAr), 6.86–6.63 (m, 1H, HAr), 5.29 (br s, 1H, CHOP), 
4.51 (br s, 1H, CH COD), 4.19 (br s, 1H, CH COD), 3.23 (br s, 3H, Ar-CH3), 3.19–3.17 (m, 
1H, CH COD), 2.90 (br s, 1H, CH2 COD), 2.77–2.74 (m, 1H, CH2 COD), 2.52 (br s, 3H, Ar-
CH3), 2.44 (dd, J = 15.8, 9.2 Hz, 2H, CH2 COD), 2.35–2.17 (m, 5H, CH2 COD 2H, Ar-CH3), 
2.16–2.02 (m, 1H, CH2 COD), 1.92–1.79 (m, 1H, CH2 COD), 1.72–1.59 (m, 1H, CH2 COD) 
ppm. 13C{1H}-NMR (101 MHz, CD2Cl2): δ = 162.4 (q, JBC = 50 Hz, CAr BArF), 160.8 (s, CAr), 
160.3 (s, CAr), 141.4 (d, JPC = 11 Hz, CAr), 140.4 (s, HCAr), 135.4 (s, HCAr BArF), 134.9 (d, 
JPC = 11 Hz, CAr), 134.4 (s, CAr), 133.8 (s, CAr), 133.7 (s, HCAr), 133.2 (s, HCAr), 132.9 (s, 
HCAr), 132.7 (s, HCAr), 132.6 (s, HCAr), 131.0 (s, HCAr), 130.9 (s, HCAr), 130.4 (s, HCAr), 
130.0 (s, HCAr), 129.6 (qq, JFC = 32 Hz, JBC = 3 Hz, CAr BArF), 128.4 (s, HCAr), 127.9 (s 
HCAr), 127.1 (d, JPC = 12 Hz, HCAr), 126.1 (d, JPC = 17 Hz, HCAr), 125.3 (q, JFC = 272 Hz, 
CF3 BArF), 123.7 (s, HCAr), 118.1 (septett, JFC = 4 Hz, HCAr BArF), 101.1 (br s, CH COD), 
89.5 (br d, JPC = 12 Hz, CH COD), 84.2 (s CHOP), 69.6 (s, 2 × CH COD), 37.9 (s, CH2 
COD), 35.1 (s, CH2 COD), 28.8 (s, CH2 COD), 28.6 (s, CH3), 25.6 (s, CH2 COD), 22.4 (s, 
CH3), 22.3 (s, CH3) ppm. 
31
P{
1
H}-NMR (162 MHz, CD2Cl2): δ = 108.6 (br s) ppm. MS (FAB 
NBA) m/z (%): 712 ([Ir(L)(COD)]+, 100), 602 (21), 182 (28). EA: calc. (%) C 51.09, H 3.20, 
N 0.89; found C 51.18, H 3.14, N 1.02. [α]D20: +20.0 (c = 1.02, CHCl3). 
 
 
(R)-(+)-[η4-1,5-Cyclooctadiene-((phenyl)methyl)-(6-methylpyridyl)-di-tert-
butylphosphinite-iridium(I)]-tetrakis-(3,5-bis-(trifluoromethyl)-phenyl)-borate 
((R)-113e)  
 
The intermediate N,P ligand (R)-102e was obtained following the 
general procedure H using (R)-(6-ethyl-4-methoxy-3-methylpyridin-
2-yl)(phenyl)methanol (60 mg, 233 μmol, 1.0 eq.), chloro-di-tert-
butylphosphine (20 µL, 19.0 mg, 210 μmol, 1.1 eq.), KH (20.0 mg, 
499 μmol, 2.5 eq.), THF (0.5 mL) as a sticky oil (60.0 mg, 175 µmol, 
87%).The title compound (R)-113e was obtained following the general procedure G using the 
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N,P ligand (60.0 mg, 175 µmol, 87%), [Ir(COD)Cl]2 (63.6 mg, 94.6 µmol, 0.5 eq.), DCM (3 
mL),NaBArF (185 mg, 208 µmol, 1.1 eq.), after purification by flash chromatography (SiO2, 2 
cm × 18 cm, TBME then DCM) and recrystallization form diethyl ether (1 mL) and n-pentane 
(25 mL) as a red solid (113 mg, 75.0 µmol, 43% over two steps). 
 
31
P{
1
H}-NMR of (t-Bu)2PCl (162 MHz, C6D6): δ = 146.4 (s) ppm. 
31
P{
1
H}-NMR of the ligand (162 MHz, C6D6): δ = 165.6 (s) ppm. 
 
C61H54BF24IrNOP (1507.05 g/mol): 
1
H-NMR (400 MHz, CD2Cl2): δ = 7.79 (s, 8H, BArF-H), 7.64–7.40 (m, 9H, BArF-H, HAr), 
7.34 (d, J = 7.9 Hz, 1H, HAr), 7.05 (d, J = 9.9 Hz, 1H, HAr), 6.68 (d, J = 7.6 Hz, 1H, HAr), 
5.44–5.37 (m, 1H, CHOP), 4.95 (t, J = 8.4 Hz, 1H, CH COD), 4.22 (q, J = 8.5 Hz, 1H, CH 
COD), 3.36–3.26 (m, 4H, CH3, 1H, CH COD), 2.64 (dtd, J = 15.9, 10.2, 5.7 Hz, 1H, CH2 
COD), 2.48–2.30 (m, 2H, CH COD 1H, CH2 COD 1H ), 2.22 (dt, J = 13.8, 9.3 Hz, 1H, CH2 
COD), 2.13–1.95 (m, 2H, CH2 COD), 1.72–1.62 (m, 1H, CH2 COD), 1.61–1.50 (m, 2H, CH2 
COD), 1.41 (d, J = 13.8 Hz, 9 H, (CH3)3C), 1.06 (d, J = 14.9 Hz, 9 H, (CH3)3C) ppm.
 
31
P{
1
H}-NMR (202 MHz, CD2Cl2): δ = 138.3 (s) ppm. MS (FAB NBA) m/z (%): 644 
([Ir(L)(COD)]+, 100), 422 (22), 182 (14). EA: calc. (%) C 48.62, H 3.61, N 0.93; found C 
48.55, H 3.56, N 1.08. [α]D20: +37.6 (c = 0.52, CHCl3). 
 
 
(S)-(−)-[η4-1,5-Cyclooctadiene-((phenyl)methyl)-(6-ethyl-4-methoxy-3-methylpyridyl)-
diphenylphosphinite-iridium(I)]-tetrakis-(3,5-bis-(trifluoromethyl)-phenyl)-borate 
((S)-113f)  
 
The intermediate ligand (S)-102f was obtained following the general 
procedure C using (S)-(6-methylpyridin-2-yl)(phenyl)methanol (34.0 
mg, 132 µmol, 1.0 eq.), DMAP (17.8 mg, 145 µmol, 1.1 eq.), chloro-
diphenylphosphine (26 µL, 32.0 mg, 145 µmol, 1.0 eq.), DCM (1.0 
mL), after filtration over aluminum oxide (Al2O3, 2 cm × 2 cm) as a 
colorless oil (21 mg, 47.6 mmol, 36%). The title compound (S)-113f was obtained following 
the general procedure G using the N,P ligand (S)-102f (21 mg, 47.6 mmol, 36%), 
[Ir(COD)Cl]2 (16.0 mg, 23.4 µmol, 0.5 eq.), DCM (1.5 mL), NaBArF (45.0 mg, 50.8 µmol, 
1.1 eq.), after purification by flash chromatography (Al2O3, 2 cm × 10 cm, only DCM) and 
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recrystallization from diethyl ether (1 mL) and n-pentane (25 mL) as an orange solid 
(56.0 mg, 34.9 µmol, 26% over two steps).  
 
31
P{
1
H}-NMR of Ph2PCl (162 MHz, CD2Cl2): δ = 79.1 (s) ppm. 
31
P{
1
H}-NMR of the ligand (162 MHz, CD2Cl2): δ = 111.6 (s) ppm. 
 
C68H52BF24IrNO2P (1605.11 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 7.71 (s, 8H, BArF-H), 7.59–7.49 (m, 9H, HAr, BArF-H), 
7.48–7.40 (m, 4H, HAr), 7.34–7.28 (m, 4H, HAr), 6.62 (s, 1H, HAr), 6.86 (d, J = 27.5 Hz, 1H, 
HAr), 6.62 (s, 1H, HAr), 4.50–4.32 (m, 2H, CHOP, CH COD), 4.15 (dq, J = 11.2, 4.2 Hz, 1H, 
CH COD), 3.84 (s, 3H, OCH3), 3.42–3.24 (m, 1H, CH COD), 3.12 (dq, J = 14.8, 7.4 Hz, 1H, 
CH2 COD), 2.98 (tt, J = 6.8, 3.1 Hz, 1H, CH2 COD), 2.46–2.33 (m, 1H, CH2 COD), 2.29 (s, 
3H, ArCH3), 2.23–2.08 (m, 1H, CH2 COD), 1.99–1.78 (m, 2H, CH COD, CH2 COD), 1.49–
1.21 (m, 4H, CH2 COD), 0.90–0.82 (m, 1H, CH2 COD), 0.79 (t, J = 7.5 Hz, 3H, CH2CH3) 
ppm. 31P{1H}-NMR (162 MHz, CDCl3): δ = 98.9 (s) ppm. MS (FAB NBA) m/z (%): 742 
([Ir(L)(COD)]+, 71), 634 (20), 458 (12), 240 (100). EA: calc. (%) C 50.88, H 3.27, N 0.87; 
found C 51.01, H 4.15, N 1.04. m.p.: 177‒178 °C. [α]D20: −69.0 (c = 0.26, CHCl3). 
 
 
(S)-(−)-[η4-1,5-Cyclooctadiene-((phenyl)methyl)-(6-ethyl-4-methoxy-3-methylpyridyl)-di-
ortho-tolylphosphinite-iridium(I)]-tetrakis-(3,5-bis-(trifluoromethyl)-phenyl)-borate 
((S)-113g)  
 
The intermediate ligand (S)-102g was obtained following the general 
procedure C using (S)-(6-methylpyridin-2-yl)(phenyl)methanol (40.0 
mg, 155 μmol, 1.0 eq.), DMAP (21.2 mg, 173 μmol, 1.1 eq.), chloro-
di-ortho-tolylphosphine (40.0 mg, 161 μmol, 1.05 eq.), DCM (1.0 
mL), after filtration over aluminum oxide (Al2O3, 2 cm × 2 cm, 
DCM) as colerless foam (68 mg, 145 μmol, 94%). The title compound (S)-113g was obtained 
following general procedure G using the N,P ligand (S)-102g (68 mg, 145 μmol, 94%), 
[Ir(COD)Cl]2 (49.0 mg, 72.9 μmol, 0.5 eq.), DCM (3 mL), NaBArF (137 mg, 155 μmol, 1.1 
eq.), after purification by flash chromatography (Al2O3, 2 cm × 20 cm, only DCM) and by 
recrystilliazation form diethyl ether (1 mL) with n-pentane (25 mL) as a orange foam 
(175 mg, 107 µmol, 69% over two steps).  
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31
P{
1
H}-NMR of (o-Tol) 2PCl (162 MHz, CD2Cl2): δ = 75.3 (s) ppm. 
31
P{
1
H}-NMR of the ligand (162 MHz, CD2Cl2): δ = 99.0 (s) ppm. 
 
C70H56BF24IrNO2P (1633.16 g/mol): 
1
H-NMR (500 MHz, CD2Cl2): δ = (500 MHz, CD2Cl2): δ = 8.25 (d, J = 7.9 Hz, 1H, CHOP), 
7.73 (s, 8H, BArF-H), 7.56 (s, 4H, BArF-H), 7.54–7.51 (m, 1H), 7.50–7.43 (m, 3H), 7.39 (t, J 
= 7.3 Hz, 3H), 7.32–7.26 (m, 3H), 7.24–7.18 (m, 2H), 7.16–7.08 (m, 1H), 6.69 (br s, 1H, 
HAr), 5.45–5.35 (m, 1H, CH COD), 4.45–4.30 (m, 1H, CH COD), 4.20–4.09 (m, 1H, CH 
COD), 3.77 (m, 3H, OCH3), 3.55–3.35 (m, 1H, CH COD), 2.70–2.55 (m, 1H, CH2 COD), 
2.50–2.14 (m, 11H, CH2 COD 6H, CH2CH3 2H, Ar-CH3 3H), 1.81–1.72 (m, 1H, CH2 COD), 
1.60–1.17 (m, 9H, CH3, CH2CH3, Ar-CH3) ppm. 13C{1H}-NMR (126 MHz, CD2Cl2): 
δ = 168.4 (s, CAr), 164.2 (s, CAr), 162.3 (q, JBC = 50 Hz, CAr BArF), 155.0 (s, CAr), 137.2 (d, 
JPC = 7 Hz, CAr), 135.4 (s, HCAr BArF), 133.6 (s, HCAr), 133.3 (br s, HCAr), 133.1 (s, HCAr), 
132.8 (s, HCAr), 132.6 (s, HCAr), 132.1 (d, JPC = 16 Hz, CAr), 131.1 (br s, HCAr), 130.2 (br s, 
HCAr), 130.1 (s, HCAr), 129.6 (s, HCAr), 129.4 (qq, JFC = 32 Hz, JBC = 3 Hz, CAr BArF), 126.7 
(d, JPC = 11 Hz, CAr), 125.2 (q, JFC = 272 Hz, CF3 BArF), 123.6 (s, CAr), 118.0 (septett, JFC = 4 
Hz, HCAr BArF), 107.4 (s, HCAr), 100.1 (br s, CH COD), 88.4 (s, CH COD), 85.7 (s, CHOP), 
67.5 (br s, CH COD), 67.0 (br s, CH COD), 57.0 (s, OCH3), 38.1 (d, JPC = 3 Hz, CH2 COD), 
35.5 (d, JPC = 3 Hz, CH2 COD), 35.3 (s, CH2CH3), 28.7 (s, Ar-CH3), 25.4 (s, CH2 COD), 
22.03 (s, CH2 COD), 21.98 (s, Ar-CH3), 14.3 (CH2CH3), 11.3 (s, CH3) ppm. 
31
P{
1
H}-NMR 
(202 MHz, CD2Cl2): δ = 107.4 (br s) ppm. MS (FAB NBA) m/z (%): 770 ([Ir(L)(COD)]+, 65), 
662 (22), 240 (100). EA: calc. (%) C 51.48, H 3.46, N 0.86; found C 50.33, H 3.60, N 1.09. 
m.p.: 8γ‒84 °C. [α]D20: −γ9.7 (c = 0.70, CHCl3). 
 
 
(S)-(−)-[η4-1,5-Cyclooctadiene-((phenyl)methyl)-(6-ethyl-4-methoxy-3-methylpyridyl))-
di-tert-butylphosphinite-iridium(I)]-tetrakis-(3,5-bis-(trifluoromethyl)-phenyl)-borate 
((S)-113h)  
 
The intermediate ligand (S)-102h was obtained following the 
general procedure H using (S)-(6-methylpyridin-2-yl)(phenyl)-
methanol (60 mg, 233 μmol, 1.0 eq.), chloro-di-tert-
butylphosphine (44 µL, 42.1 mg, 233 μmol, 1.0 eq.), KH (14. 0 
mg, 349 μmol, 1.5 eq.), THF (1.0 mL) as a colorless foam (68.0 mg, 169 µmol, 73%). The 
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title compound (S)-113h was obtained following general procedure G using the N,P ligand 
(68.0 mg, 169 µmol, 73%), [Ir(COD)Cl]2 (57.36 mg, 85.3 µmol, 0.5 eq.) in DCM (3 mL), 
NaBArF (160 mg, 181 µmol, 1.1 eq.), after purification by flash chromatography (Al2O3, 3 cm 
× 14 cm, cyclohexane / DCM 2:1) and recrystallization from diethyl ether solution (1 mL) and 
n-pentane (25 mL) as a red solid (170 mg, 108 µmol, 46% over two steps). 
 
31
P{
1
H}-NMR of (t-Bu)2PCl (162 MHz, C6D6): δ = 146.4 (s) ppm. 
31
P{
1
H}-NMR of the ligand (162 MHz, C6D6): δ = 167.1 (s) ppm. 
 
C64H60BF24IrNO2P (1565.13 g/mol): 
1
H-NMR (500 MHz, CD2Cl2): δ = 7.73 (s, 8H, BArF-H), 7.57 (s, 4H, BArF-H), 7.56–7.05 (m 
5H, HAr), 6.87 (s, 1H, HAr), 5.28–5.21 (m, 1H, CH COD), 5.05–4.98 (m, 1H, CH COD), 4.04 
(d, J = 7.5 Hz, 1H, CH COD), 3.96 (dq, J = 14.9, 7.4 Hz, 1H, CH2CH3), 3.88 (m, 3H, OCH3), 
3.51 (dq, J = 14.9, 7.4 Hz, 1H, CH2CH3), 3.29 (p, J = 7.4 Hz, 1H, CH COD), 2.59 (dtd, J = 
15.9, 10.6, 5.7 Hz, 1H, CH2 COD), 2.31 (ddt, J = 15.3, 9.8, 5.3 Hz, 1H, CH2 COD), 2.23 (ddt, 
J = 15.7, 8.0 Hz, 1H, CH2 COD), 2.14 (dt, J = 13.9, 9.3 Hz, 1H, CH2 COD), 2.08–1.94 (m, 
2H, CH2 COD), 1.62–1.53 (m, 1H, CH2 COD), 1.56 (t, J = 7.4 Hz, 3H, CH2CH3), 1.50–1.40 
(m, 2H, CH2 COD), 1.39–1.31 (m, 12H, CH3, (CH3)3C), 1.01 (d, J = 14.8 Hz, 9H, (CH3)3C) 
ppm. 13C{1H}-NMR (126 MHz, CD2Cl2): δ = 168.6 (s, CAr), 164.3 (s, CAr), 162.3 (q, JBC = 50 
Hz, CAr BArF), 155.4 (s, CAr), 137.2 (d, JPC = 7 Hz, CAr), 135.4 (s, HCAr BArF), 130.1 (br s, 
HCAr), 129.7 (s, HCAr), 129.4 (qq, JFC = 32 Hz, JBC = 3 Hz, CAr BArF), 126.6 (s, CAr), 125.2 
(q, JFC = 272 Hz, CF3 BArF), 123.6 (s, CAr), 118.0 (septett, JFC = 4 Hz, HCAr BArF), 107.5 (s, 
HCAr), 93.5 (d, JPC = 6 Hz, CH COD), 87.4 (s, CHOP), 82.1 (d, JPC = 18 Hz, CH COD), 71.8 
(s, CH COD), 59.9 (s, CH COD), 57.1 (s, OCH3), 41.3 (d, JPC = 19 Hz, (CH3)3C), 40.0 (d, JPC 
= 19 Hz, (CH3)3C), 39.2 (d, JPC = 3 Hz, CH2 COD), 35.9 (s, CH2 COD), 35.4 (s, CH2CH3), 
29.0 (s, (CH3)3C), 28.9 (s, (CH3)3C), 28.5 (s, CH2 COD), 24.3 (d, JPC = 3 Hz, CH2 COD), 13.7 
(CH2CH3), 11.0 (s, CH3) ppm. 
31
P{
1
H}-NMR (162 MHz, CD2Cl2): δ = 140.0 (s) ppm. MS 
(FAB NBA) m/z (%): 702 ([Ir(L)(COD)]+, 100), 594 (11), 538 (28), 478 (33), 431 (14), 240 
(50). EA: calc. (%) C 49.11, H 3.86, N 0.89; found C 47.97, H 3.80, N 1.22. m.p.: 1βγ‒
124 °C. [α]D20: −40.1 (c = 0.50, CHCl3). 
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8.6 New Bicyclic Pyridine Amino-Phosphine Derived Ligands for Iridium-
Catalyzed Asymmetric Hydrogenations 
8.6.1 Formation of N-Oximies 
 
 
 
5H-Cyclopenta[1]pyridin-7(6H)-one oxime (139a) 
 
A mixture of ketone 76a (1.29 g, 9.69 mmol, 1.0 eq.), hydoxylamine 
hydrochloride (1.36 g, 19.6 mmol, 2.0 eq.), sodium acetate (2.76 g, 33.6 
mmol, 3.5 eq.), MeOH (15 mL) and water (5 mL) was stirred for 14 hours at 
RT. A precipitate is formed, which was separated by filtration, followed by washing with 
water (10 mL) and pentane (10 mL). The title compound 139a (1.08 g, 7.29 mmol, 75%) was 
isolated as a colorless solid.  
 
C8H8N2O (148.16 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 11.25 (s, 1H, N-OH), 8.47 (d, J = 3.1 Hz, 1H, HAr), 7.78 (d, 
J = 7.6 Hz, 1H, HAr), 7.30 (dd, J = 7.7, 4.7 Hz, 1H, HAr), 3.04–2.88 (m, 2H, CH2), 2.87–2.64 
(m, 2H, CH2) ppm.
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 159.6 (C=N), 155.2 (CAr), 149.9 
(HCAr), 141.9 (CAr), 133.8 (HCAr), 123.8 (HCAr), 25.4 (CH2), 24.4 (CH2) ppm. MS (EI, 70 
eV, ca. 200°C, m/z (%): 148 (97, [M+]), 130 (76), 117 (100), 104 (34), 91 (31), 79 (18), 63 
(13), 51 (16), 39 (14). m.p.: 245–246 °C (dec.). 
 
 
2-Phenyl-5H-cyclopenta[1]pyridin-7(6H)-one oxime (139b) 
 
A mixture of ketone 76b (500 mg, 2.39 mmol, 1.0 eq.), hydoxylamine 
hydrochloride (332 mg, 4.78 mmol, 2.0 eq.), sodium acetate (686 mg, 
8.36 mmol, 3.5 eq.), methanol (6.0 mL) and water (2.0 mL) was 
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stirred for 20 hours at RT. A precipitate is formed, which was separated by filtration, followed 
by washing with methanol-water 3:1 mixture (0.6 mL) and with pure n-pentane (5 mL) to 
obtain the title compound (536 mg, 2.39 mmol, quant.) as a pale green solid. 
 
C14H12N2O (224.26 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 11.20 (s, 1H, N-OH), 8.12–8.00 (m, 2H, HAr), 7.85 (q, 
J = 8.1 Hz, 2H, HAr), 7.56–7.28 (m, 3H, HAr), 3.04–2.93 (m, 2H, CH2), 2.90–2.76 (m, 2H, 
CH2) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 159.5 (C=N), 155.6 (CAr), 155.3 (CAr), 
140.8 (CAr), 138.6 (CAr), 134.7 (HCAr), 129.0 (HCAr), 128.7 (HCAr), 126.6 (HCAr), 120.6 
(HCAr), 25.3 (CH2), 24.7 (CH2) ppm. MS (EI, 70 eV, ca. 200°C, m/z (%): 224 (100, [M
+]), 
206 (62), 180 (19), 166 (17), 152 (10), 139 (7), 115 (9), 89 (7), 77 (8). EA: calc. (%) C 74.98, 
H 5.39, N 12.49; found C 71.63, H 5.60, N 11.50. m.p.: 235–236 °C 
 
 
(E)-6,7-dihydroquinolin-8(5H)-one oxime (139c) 
 
A mixtre of ketone 76b (1.00 g, 6.79 mmol, 1.0 eq.), of hydroxylamine 
hydrochloride (0.95 g, 13.6 mmol, 2.0 eq.), sodium acetate (1.85 g, 22.6 mmol, 
3.3 eq.), ethanol (6.0 mL) and water (2.0 mL) was stirred at 70 °C for 1 h. The 
reaction mixtue was cooled down to RT. Filtration, following by washing with 
water (4 mL) and n-heptane (5 mL) gave the title compound 139c (0.66 g, 4.09 mmol, 60%) 
as a slightly brown solid.  
 
Procedure directly starting from 5,6,7,8-tetrahydro-quinoline: 
A solution of 5,6,7,8-tetrahydro-quinoline (2.13 g, 16.0 mmol, 1.0 eq.) and diisopropylamine 
(1.62 g, 16.0 mmol, 1.0 eq.) TBME (10 mL) was stirred for 10 min, while dry nitrogen gas 
was purged through the solution. The solution was then cooled to −β0 °C and n-BuLi 1.6 M 
solution (β0 mL, γβ.0 mmol, β.0 eq.) was added, while the temperature was kept under −15 
°C. The obtained orange / red solution was transfered via cannula to a pre-cooled solution of 
isopentyl nitrite (6.4 mL, 5.6γ g, 48.1 mmol, γ.0 eq.) in TBME (6.0 mL) at −15 °C. The 
resulting mixture was stirred at −15°C for 1 h, then carefully quentched with water (β0 mL). 
The reaction mixture was allowed to reach RT, and then the phases were separated. The aq. 
phase re-extracted with TBME (2×15 mL). The aq. fraction was neutralized with HCl 1 M 
solution. The volume was concentrated in vacuo to approximantely ~10 mL. The resulting 
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slurry was cooled down to 0 °C. The N-oxime precipitates out and was collected by filtration. 
After washing with n-heptane (10 mL) the title compound 139c was obtained as a brown solid 
(756 mg, 4.66 mmol, 29%).  
 
C9H10N2O (162.19 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 10.2 (br s, 1H, N-OH), 8.48 (dd, J = 4.7, 1.7 Hz, 1H, HAr), 
7.46 (tdd, J = 7.7, 1.6 Hz, 0.6 Hz, 1H, HAr), 7.17 (dd, J = 7.7, 4.7 Hz, 1H, HAr), 2.91 (t, 
J = 6.7 Hz, 2H, CH2), 2.80 (t, J = 6.1 Hz, 2H, CH2), 1.90 (quin., J = 6.2 Hz, 2H, CH2) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 152.7 (C=N), 148.8 (CAr), 148.1 (HCAr), 136.7 
(HCAr), 134.6 (CAr), 123.5 (HCAr), 29.4 (CH2), 24.3 (CH2), 21.2 (CH2) ppm. MS (EI, 70 eV, 
ca. 150°C, m/z (%): 162 (100, [M+]). IR: ṽ = 3125 (m), 3072 (m), 2999 (m), 2936 (m), 2830 
(m br), 2084 (m), 1621 (w), 1575 (m), 1475 (s), 1423 (m), 1347 (w), 1311 (w), 1222 (w), 
1193 (m), 1185 (m), 1120 (w), 1089 (m), 1039 (w), 969 (s), 903 (m), 877 (s), 843 (m), 792 
(s), 730 (s) cm-1. EA: calc. (%) C 66.65, H 6.21, N 17.27; found C 66.51, H 6.16, N 17.17. 
m.p.: 171‒17β °C (dec.). 
 
 
(E)-2-phenyl-6,7-dihydroquinolin-8(5H)-one oxime (139d) 
 
A mixture of ketone 76d (800 mg, 3.58 mmol, 1.0 eq.), hydroxylamine 
hydrochloride (498 mg, 7.16 mmol, 2.0 eq.), sodium acetate (976 mg, 
11.9 mmol, 3.3 eq.), ethanol (10 mL) and water (3.0 mL) was stirred at 
70 °C for 18 h. After addition of water (5 mL) the reaction mixture 
was extracted with DCM (3×30 mL). After removal of the volatiles the title compound 139d 
was obtained as a slightly yellow solid (829 mg, 3.48 mmol, 97%).  
 
C15H14N2O (238.28 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 10.24 (br s, 1H, N-OH), 8.05 (d, J = 8.0 Hz, 2H, HAr), 7.65 
(d, J = 8.0 Hz, 1H, HAr), 7.55 (d, J = 8.0 Hz, 1H, HAr), 7.47 (t, J = 7.5 Hz, 2H, HAr), 7.43–7.37 
(m, 1H, HAr), 2.98 (t, J = 6.3 Hz, 2H, CH2), 2.85 (t, J = 5.7 Hz, 2H, CH2), 1.96 (pentet, 
J = 6.2 Hz, 2H, CH2) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 156.0 (C=N), 152.7 (CAr), 
148.6 (CAr), 130.4 (CAr), 137.8 (HCAr), 133.3 (CAr), 129.0 (HCAr), 128.8 (HCAr), 127.2 
(HCAr), 120.8 (HCAr), 29.0 (ArCH2), 24.2 (CH2C), 21.1 (CH2CH2CH2) ppm. MS (EI, 70 eV, 
ca. 200°C, m/z (%): 238 (100, [M+]), 221 (43), 206 (21), 194 (19), 167 (6), 128 (6), 115 (5). 
EA: calc. (%) C 75.61, H 5.92, N 11.76; found C 73.58, H 5.99, N 11.35. m.p.: 8β‒87 °C.  
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8.6.2 Reduction of N-Oximies  
 
 
 
General Procedure I: Pd/C (5% Pd, 1 w% to the oxime) was added to a solution of N-oxime 
(1.0 eq) in MeOH / ammonia 25 w% aq. solution (5:1, 0.4 M) in a glas vial. The reaction 
mixture was placed in an autoclave. Hydrogen pressure (5-10 bar) was applied and the 
mixture was stirred at rt for 12-15 hours. After complete reduction the catalyst was removed 
by filtration over a Celite® pad and washed with DCM (3×50 mL). After drying over MgSO4 
and filtration, the solvent was removed under reduced pressure. The crude product was 
purified by Kugelrohr distillation.  
 
Note: The pyridyl amines are not bench-stable. However, they can be stored for months 
inside a freezer (−18 °C) under innert conditions. 
 
 
6,7-Dihydro-5H-cyclopenta[1]pyridin-7-amine (136a) 
 
The title compound 136a was obtained following the general procedure I for 
the reduction of oximes using 139a (200 mg, 1.35 mmol, 1.0 eq.), methanol 
(2.0 mL), ammonia 25 w% aq. solution (0.5 mL), Pd/C (5%, 57.5 mg. 
267.0 µmol, 0.02 eq.) under 5 bar hydrogen gas during 14 hours, and purification by 
Kugelrohr distillation (0.2 mbar, 135–145 °C) as a brown oil (158 mg, 1.18 mmol, 87%).  
 
C8H10N2 (134.18 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 8.40 (d, J = 4.8 Hz, 1H, HAr), 7.50 (d, J = 7.6 Hz, 1H, HAr), 
7.08 (dd, J = 7.5, 4.9 Hz, 1H, HAr), 4.32 (t, J = 7.9 Hz, 1H, CH), 2.93 (ddd, J = 16.2, 8.9, 3.0 
Hz, 1H, CH2), 2.80 (dt, J = 16.4, 8.4 Hz, 1H, CH2), 2.55 (dtd, J = 12.8, 7.9, 3.1 Hz, 1H, CH2), 
2.24 (s, 2H, NH2), 1.74 (dq, J = 12.9, 8.6 Hz, 1H, CH2) ppm. b.p.: 135‒145 °C (0.2 mbar). 
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2-Phenyl-6,7-dihydro-5H-cyclopenta[1]pyridin-7-amine (136b) 
 
The title compound 136b was obtained following the general procedure 
I for the reduction of oximes using 139b (520 mg, 2.3 mmol, 1.0 eq.), 
methanol (5.0 mL), ammonia 25 w% aq. solution (1.0 mL), Pd/C (5%, 
98.7 mg. 46.4 µmol, 0.02 eq.) under 9 bar hydrogen gas during 14 hours, and purification by 
Kugelrohr distillation (0.2 mbar, 155–160 °C) as a brown oil (448 mg, 2.13 mmol, 92%).  
 
C14H14N2 (210.28 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 8.05–7.91 (m, 2H, HAr), 7.55 (dd, J = 19.2, 8.0 Hz, 2H, 
HAr), 7.50–7.43 (m, 2H, HAr), 7.42–7.36 (m, 1H, HAr), 4.38 (t, J = 7.9 Hz, 1H, CH), 2.97 (ddd, 
J = 16.3, 8.6, 2.5 Hz, 1H, CH2), β.78‒β.90 (m, 1H, CH2), 2.61 (dtd, J = 12.8, 7.8, 3.1 Hz, 1H, 
CH2), 1.93 (br s, 2H, NH2), 1.80 (ddd, J = 17.1, 12.8, 8.8 Hz, 1H, CH2) ppm. 
13
C{
1
H}-NMR 
(101 MHz, CDCl3): δ = 166.9 (CAr), 156.4 (CAr), 139.9 (CAr), 134.5 (CAr), 133.4 (HCAr), 
128.8 (HCAr), 128.7 (HCAr), 127.0 (HCAr), 119.2 (HCAr), 567.0 (CH), 34.4 (CH2), 27.6 (CH2) 
ppm. MS (EI, 70 eV, ca. 200 °C) m/z (%): 210 (100, [M+]), 195 (28), 182 (28), 169 (15), 155 
(10), 115 (6), 104 (5), 77 (5). EA: calc. (%) C 79.97, H 6.71, N 13.32; found C 78.87, H 6.96, 
N 12.88. b.p.: 155‒160 °C (0.2 mbar). 
 
 
5,6,7,8-Tetrahydroquinolin-8-amine (136c) 
 
The title compound 136c was obtained following the general procedure I for the 
reduction of oximes using 139c (660 mg, 4.07 mmol, 1.0 eq.), methanol (10 mL), 
ammonia 25 w% aq. solution (2 mL), Pd/C (5%, 225 mg. 0.11 mmol, 0.03 eq.) 
under 5 bar hydrogen gas during 18 hours, and purification by Kugelrohr distillation 
(0.1 mbar, 125–130 °C) as a colorless oil (544 mg, 3.67 mmol, 90%).  
 
Procedure B: 
Zinc dust (18.0 g, 275 mmol, 41 eq.) was added in portions to a mixture of 139c (1.10 g, 
6.78 mmol, 1.0 eq.) in glacial acetic acid (18.0 mL, 18.9 g, 315 mmol, 46 eq.) und ethanol 
(7.0 mL) under vigorous stirring. The reaction mixture was stirred over night (>14 h) at RT; 
before the insoluble material was removed by filtration over a Celite® pad and washing with 
ethanol (3×10 mL). After removing the solvent under reduced pressure the residue was 
extracted with DCM (15 mL) and aqueous NaOH 50% solution (20 mL). The water layer was 
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washed with DCM (3×20 mL). After drying over MgSO4 the solvent was removed under 
reduced pressure. The crude product was purified by Kugelrohr distillation (0.5 mbar, 150–
160 °C) to obtain the title compound 136c (980 mg, 6.56 mmol, 97%) as a slightly yellow oil.  
 
C9H12N2 (148.20 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 8.39 (dd, J = 4.7, 0.8 Hz, 1H, HAr), 7.35 (dd, J = 7.7, 
0.8 Hz, 1H, HAr), 7.04 (dd, J = 7.7, 4.7 Hz, 1H, HAr), 3.98 (t, J = 5.5 Hz, 1H, CH), β.90‒β.65 
(m, 2H, CH2), β.β0‒β.1γ (m, 1H, CH2), 2.01 (br s, 2H, NH2), 1.99‒1.89 (m, 1H, CH2), 1.81‒
1.64 (m, 2H, CH2) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 159.6 (CAr), 147.0 (HCAr), 
136.7 (HCAr), 131.5 (CAr), 121.6 (HCAr), 51.4 (CH), 32.0 (CH2), 29.0 (CH2), 19.9 (CH2) ppm. 
MS (EI, 70 eV, RT) m/z (%):148 ([M+], 84), 130 (28), 119 (90), 93 (54), 77 (7), 65 (8), 56 
(6), 51 (5), 39 (7). IR: ṽ = 3364 (w), 2925 (m), 2858 (m), 1746 (m), 1584 (m), 1569 (s), 1426 
(s), 1374 (m), 1352 (w), 1215 (w), 1116 (w), 928 (w), 880 (m), 849 (m), 821 (w), 784 (s) 
cm-1. EA: calc. (%) C 72.94, H 8.16, N 18.90; found C 72.21, H 8.19, N 18.49. b.p.: 1β5‒
130 °C (0.1 mbar).  
 
 
2-Phenel-5,6,7,8-tetrahydroquinolin-8-amine (136d) 
 
The title compound 136d was obtained following the general procedure I 
for the reduction of oximes using 139d (820 mg, 3.44 mmol, 1.0 eq.), 
methanol (10 mL), ammonia 25 w% aq. solution (2 mL) and Pd/C (5%, 
205 mg. 0.01 mmol, 0.03 eq.) under 5 bar hydrogen gas during 18 hours, and purification by 
Kugelrohr distillation (0.3 mbar, 150–155 °C) as a colorless oil (620 mg, 2.77 mmol, 80%). 
 
C15H16N2 (224.30 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 8.04–7.96 (m, 2H, HAr), 7.55–7.33 (m, 5H, HAr), 4.05 (dd, 
J = 8.6, 5.7 Hz, 1H, CH), β.90‒β.70 (m, βH, ArCH2), β.γ1‒β.ββ (m, 1H, CH2), 2.14 (br s, 2H, 
NH2), β.06‒1.91 (m, 1H, CH2), 1.88‒1.76 (m, 1H, CH2), 1.76‒1.64 (m, 1H, CH2) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 159.5 (CAr), 154.7 (CAr), 139.7 (CAr), 137.7 (HCAr), 
130.2 (CAr), 128.8 (HCAr), 128.7 (HCAr), 126.9 (HCAr), 118.6 (HCAr), 52.0 (CHNH2), 32.3 
(CH2CHNH2), 29.0 (ArCH2), 20.6 (CH2CH2CH2) ppm. b.p.: 150–155 °C (0.3 mbar). 
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8.6.3 Enzymatic Kinetic Resolution of Primary Amines 
 
 
 
General Procedure J: Ethyl acetate (>4 eq.) was added to a mixture of pyridyl amine 
(1.0 eq.) and CAL-B (40-50 mg/mmol) in diisopropyl ether (0.35 M). The reaction mixture 
was stirred for a given time at 60 °C. After cooling down to RT, the reaction mixture was 
filtered over a Celite® pad and washed with DCM (3×50 mL). The solvents were removed 
under reduced pressure. The products were separated by flash chromatography. The formed 
(R)-amide was recrystallized in order to obtain enaniomeric pure material. 
The unreacted (S)-amine was directly converted to the tartat salt: A boiling solution of L-
tartaric acid (>1.3 eq.) in ethanol (0.7 M) was added to a boiling solution of (S)-amine 
(1.0 eq.) in ethanol (0.7 M). The solution was allowed to cool down to RT; while the tartaric 
salt precipitate. After stirring for 1 h at rt the product was separated by filtration and washed 
with ethanol (2×0.5 mL).  
 
 
(R)-N-(6,7-Dihydro-5H-cyclopenta[1]pyridin-7-yl) acetamide ((R)-137a) 
 
The title compound (R)-137a was obtained following the general procedure J 
using ethyl acetate (3.0 mL, 2.69 g, 30.5 mmol, 52 eq.), amine 136a (79.0 mg, 
589 µmol, 1.0 eq.), CAL-B (39 mg), after stirring 3.5 h at 60 °C and 
separation by chromatography (SiO2, 1.5 cm × 11 cm, DCM / MeOH 9:1) as pale yellow solid 
(59 mg, 334 µmol, 57%, 79% ee).  
 
C10H12N2O (176.22 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 8.34 (s, 1H, HAr), 7.53 (d, J = 7.5 Hz, 1H, HAr), 7.18–7.03 
(m, 1H, HAr), 6.50 (br s, 1H, NH), 5.21 (q, J = 8.0 Hz, 1H, CH), β.98‒β.75 (m, γH, CH2), 2.04 
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(s, 3H, CH3), 1.85‒1.7γ (m, 1H, CH2) ppm. 13C{1H}-NMR (101 MHz, CDCl3): δ = 170.8 
(C=O), 162.5 (CAr), 148.1 (HCAr), 137.0 (CAr), 133.1 (HCAr), 121.8 (HCAr), 55.4 (CH), 33.7 
(CH2), 28.0 (CH2), 23.4 (CH3) ppm. HPLC (chiral, Daicel Chiracel AD-H, (2.6 mm × 250 
mm), heptane / i-PrOH 90:10, 0.5 mL/min, 25 °C: tR = 19.3 min (R), 33.8 min (S).  
 
 
(S)-2-Phenyl-6,7-dihydro-5H-cyclopenta[1]pyridin-7-amine (S)-136a 
 
The title compound (S)-136a was obtained from the enzymatic kinetic 
resolution after flash chromatography (SiO2, 1.5 cm × 11 cm, DCM / MeOH 
9:2) as brown oil (37 mg, 0.276 µmol, 47%, >99% ee).  
 
TLC: (SiO2, DCM/MeOH 9:2): Rf = 0.33. HPLC (chiral, Daicel Chiracel AD-H, (2.6 mm × 
250 mm), heptane / i-PrOH 95:5 + 0.1% n-BuNH2, 0.8 mL/min, 40 °C: tR = 13.7 min (S), 19.8 
min (R) or Daicel Chiracel OD-H, (2.6 mm × 250 mm), heptane / i-PrOH 95:5 + 0.1% 
n-BuNH2, 0.8 mL/min, 40 °C: tR = 14.8 min (S), 17.4 min (R). [α]D20: −γ9.8 (c = 0.35, 
CHCl3).  
 
 
(R)-N-(2-Phenyl-6,7-dihydro-5H-cyclopenta[1]pyridin-7-yl) acetamide ((R)-137b) 
 
The title compound (R)-137b was obtained following the general 
procedure J using ethyl acetate (6.0 mL, 5.41 g, 61.4 mmol, 42 eq.), 
amine 136b (310 mg, 1.47 mmol, 1.0 eq.), CAL-B (80 mg) after 
stirring for 3.5 h at 60 °C. Isolation by flash chromatography (SiO2, 
1.5 cm × 10 cm, ethyl acetate) and recrystallization from boiling ethyl acetate (2.5 mL) gave a 
with solid (186 mg, 0.737 mmol, 50%, 85% ee).  
 
C16H16N2O (252.31 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 7.96–7.89 (m, 2H, HAr), 7.62–7.51 (m, 2H, HAr), 7.50–7.34 
(m, 3H, HAr), 6.68 (br s, 1H, NH), 5.βγ‒5.14 (m, 1H, CH), β.95‒β.80 (m, γH, CH2), 2.10 (s, 
3H, CH3), 1.87‒1.7β (m, 1H, CH2) ppm. 13C{1H}-NMR (101 MHz, CDCl3): δ = 170.8 (C=O), 
162.5 (CAr), 156.5 (CAr), 139.4 (CAr), 135.5 (CAr), 133.6 (HCAr), 129.0 (HCAr), 128.9 (HCAr), 
127.1 (HCAr), 120.0 (HCAr), 55.7 (CH), 33.8 (CH2), 27.8 (CH2), 23.5 (CH3) ppm. HPLC 
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(chiral, Daicel Chiracel AD-H, (2.6 mm × 250 mm), heptane / i-PrOH 90:10, 0.5 mL/min, 
25 °C: tR = 19.3 min (R), 33.8 min (S). [α]D20: −86.2 (c = 0.70, CHCl3). 
 
 
(S)-2-Phenyl-6,7-dihydro-5H-cyclopenta[1]pyridin-7-amine ((S)-136b) 
 
The title compound (S)-136b was obtained after enzymatic kinetic 
resolution and separation by flash chromatography (SiO2, 1.5 cm × 10 
cm, DCM / MeOH 9:1) as brown oil (141 mg, 671 µmol, 46%, >99% 
ee).  
 
HPLC (chiral, Daicel Chiracel AD-H, (2.6 mm × 250 mm), heptane / i-PrOH 95:5 + 0.1% 
n-BuNH2, 0.8 mL/min, 40 °C: tR = 13.7 min (S), 19.8 min (R) or Daicel Chiracel OD-H, (2.6 
mm × 250 mm), heptane / i-PrOH 95:5 + 0.1% n-BuNH2, 0.8 mL/min, 40 °C: tR = 14.8 min 
(S), 17.4 min (R). [α]D20: +56 (c = 0.82, CHCl3). 
 
 
(R)-N-(5,6,7,8-Tetrahydroquinolin-8-yl)acetamide ((R)-137c) 
 
The title compound (R)-137c was obtained following the general procedure J 
using ethyl acetate (2.0 mL, 1.80 g, 20.5 mmol, 4.1 eq.), amine 136c (740 mg, 
4.99 mmol, 1.0 eq.), CAL-B (230 mg) and diisopropyl ether (15 mL). The 
reaction mixture was stirred at 60 °C for 6 hours. Isolation by flash 
chromatography (SiO2, 3 cm × 15 cm, DCM/MeOH 9:1  9:3) gave the amide (459 mg, 
2.41 mmol, 48%, 96% ee), which was recrystallized from boiling ethyl acetate (9.0 mL) to 
give enantiopure material (344 mg, 1.81 mmol, 36%, >99% ee). The analytical data match the 
reported values.[124] 
 
C11H14N2O (190.24 g/mol):  
1
H-NMR (400 MHz, CDCl3): δ = 8.38 (d, J = 4.6 Hz, 1H, HAr), 7.41 (d, J = 7.7 Hz, 1H, HAr), 
7.11 (dd, J = 7.6, 4.8 Hz, 1H, HAr), 6.79 (br s, 1H, NH) 4.91 (m, 1H, CH), 2.80 (t, J = 6.6 Hz, 
2H, CH2), β.60‒β.54 (m, 1H, CH2), 2.06 (s, 3H, CH3) 1.94‒1.84 (m, βH, CH2), 1.7β‒1.55 (m, 
1H, CH2) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 170.6 (C=O), 155.5 (CAr), 147.0 
(HCAr), 137.3 (HCAr), 133.2 (CAr), 122.6 (HCAr), 51.3 (CH), 29.6 (CH2), 28.4 (CH2), 23.9 
(CH3), 20.1 (CH2) ppm. MS (EI, 70 eV, 100 °C) m/z (%): 190 (13, [M
+]), 147 (100). EA: 
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calc. (%) C 69.26; H 7.36; N 14.54; found C 69.36, H 7.36, N 14.73. TLC: (SiO2, 
DCM/MeOH 9:1): Rf  = 0.33. HPLC (chiral, Daicel Chiracel AD-H, (2.6 mm × 250 mm), 
heptane / i-PrOH 90:10, 1.0 mL/min, 40 °C: tR = 9.3 min (R), 15.1 min (S). [α]D20: −105 (c = 
1.10, CHCl3), lit: −90 (c = 0.52, CHCl3), for 98% ee).[124] 
 
 
(S)-5,6,7,8-Tetrahydro-8-quinolinamine (2R,3R)-2,3-dihydroxybutanedioate (1:1) 
((SRR)-140a) 
 
The amine (S)-136c was obtained from the enzymatic kinetic 
resolution after the flash chromatography as a slightly yellow oil 
(323 mg, 2.18 mmol, 44%, ee 85%). It was directly converted to 
the title compound (S,R,R)-140a using L-tartaric acid (436 mg, 2.90 mmol, 1.3 eq.) and 
ethanol (8.0 mL) and recrystallized from boiling methanol (5.0 mL) to give a colorless solid 
(476 mg, 1.60 mmol, 32%, >99% ee determinined as the free amine).  
 
C13H18N2O6 (298.29 g/mol): 
1
H-NMR (400 MHz, (CD3)2SO): δ = 8.45 (dd, J = 4.7, 1.5 Hz, 1H, HAr) 7.61 (dd, J = 7.7, 
1.4 Hz, 1H, HAr), 7.32 (dd, J = 7.7, 4.7 Hz, 1H, HAr), 4.γ5‒4.γ1 (m, 1H, CH), 4.10 (br s, 6H, 
NH, OH), 3.82 (s, 2H, CHOH) 2.78 (t, J = 5.8 Hz, 2H, CH2), β.β7‒β.19 (m, 1H, CH2), 1.96‒
1.88 (m, 1H, CH2), 1.8β‒1.69 (m, βH, CH2) ppm. 13C{1H}-NMR (101 MHz, 
(CD3)2SO): δ = 174.4 (C=O), 152.3 (CAr), 146.8 (HCAr), 137.6 (HCAr), 132.8 (CAr), 123.4 
(HCAr), 71.4 (CHOH), 50.1 (CHNH2), 27.5 (CH2), 27.4 (CH2), 19.4 (CH2) ppm. MS (FAB 
NBA) m/z (%): 149 (100, [M+H]+), 132 (25). EA: calc. (%) C 52.35; H, 6.08; N, 9.39; found 
C 52.17, H 6.12, N 9.41. m.p.: 165‒166 °C (dec.). [α]D20: +43.9 (c = 0.35, H2O). 
 
 
(S)-5,6,7,8-Tetrahydroquinolin-8-amine ((S)-136c) 
 
A solution of tartaric salt (S,R,R)-140a (414 mg, 1.39 mmol) in NaOH 3 M aq. 
solution (10 mL) was extracted with DCM (5×15 mL). After drying over 
MgSO4, filtration and removing of the solvent under reduced pressure, the title 
compound (S)-136c (190 mg, 1.28 mmol, 92%) was obtained as a colorless oil.  
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GC (Brechbühler ȕ-cyclodextrin DetTButSil (SE54) 25 m × 0.25 mm × 0.25 mm), 120 °C, 15 
min, 10 °C/min, 180 °C, 5 min, 100 kPa): tR = 11.8 min (S), 13.7 min (R) or HPLC (chiral, 
Daicel Chiracel OD-H, (2.6 mm × 250 mm), heptane / i-PrOH 95:5 + 0.1% n-BuNH2, 
0.8 mL/min, 40 °C: tR = 9.6 min (S), 10.7 min (R).  
 
 
(R)-N-(2-phenyl-5,6,7,8-tetrahydroquinolin-8-yl)acetamide ((R)-137d) 
 
The title compound (R)-137d was obtained following the general 
procedure J using ethyl acetate (0.90 mL, 812 g, 9.21, 4.0 eq.), amine 
136d (516 mg, 2.30 mmol, 1.0 eq.), CAL-B (106 mg), diisopropyl ether 
(6 mL), after stirring for 6 h at 60 °C. Isolation by flash chromatography 
(SiO2, 3 cm × cm 15 cm, ethylacetate) gave the crude amide (327 mg, 1.23 mmol, 53%, 98% 
ee), which was recrystallized from boiling ethyl acetate (1.5 mL) to give enantiopure material 
(R)-137d (190 mg, 0.713 mmol, 30%, >99% ee) as a colorless solid.  
 
C17H18N2O (266.34 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 8.05‒7.97 (m, βH, HAr), 7.59 (d, J = 8.0 Hz, 1H, HAr), 
7.51‒7.44 (m, γH, HAr), 7.4γ‒7.γ8 (m, 1H, HAr), 6.76 (br s, 1H, NH), 4.88 (dt, J = 10.1, 
5.1 Hz, 1H, CH), 2.84 (t, J = 6.6 Hz, 2H, CH2), β.76 ‒β.59 (m, 1H, CH2CH), 2.12 (s, 3H, 
CH3), 1.98‒1.87 (m, βH, CH2C), 1.70‒1.57 (m, 1H, CH2), ppm. 13C{1H}-NMR (101 MHz, 
CDCl3): δ = 170.8 (C=O), 155.2 (CAr), 154.4 (CAr), 139.2 (CAr), 138.1 (HCAr), 131.5 (CAr), 
129.1 (HCAr), 129.0 (HCAr), 126.8 (HCAr), 119.2 (HCAr), 51.7 (CH), 29.6 (CH2), 28.1 (CH2), 
24.0 (CH3), 20.3 (CH2) ppm. MS (EI, 70 eV, 200 °C) m/z (%): 266 (37, [M
+]), 223 (100), 207 
(24), 195 (8). EA: calc. (%) C 76.66; H 6.81; N 10.52; found C 76.37, H 6.96, N 10.49. TLC: 
(SiO2, ethyl acetate 9:1): Rf  = 0.33 m.p.: 1γ5‒1γ6 °C. HPLC (chiral, Daicel Chiracel AD-H, 
(2.6 mm × 250 mm), heptane / i-PrOH 80:20, 0.5 mL/min, 25 °C: tR = 10.8 min (R), 14.5 min 
(S). [α]D20: −69.0 (c = 0.37, CHCl3). 
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(S)-2-Phenyl-5,6,7,8-tetrahydro-8-quinolinamine (2R,3R)-2,3-dihydroxybutanedioate 
(1:1) ((SRR)-140b) 
 
The amine (S)-137d was obtained from the enzymatic 
kinetic resolution after the flash chromatography as a 
slightly yellow oil (320 mg, 1.43 mmol, 62%, 94% ee). It 
was directly converted to the title compound (S,R,R)-140b using L-tartaric acid (236 mg, 
1.57 mmol, 1.1 eq.) and ethanol (4.0 mL) and recrystallized from boiling methanol (6.0 mL) 
to give a colorless solid (215 mg, 0.575 mmol, 25%, >99% ee).  
 
C19H22N2O6 (374.39 g/mol): 
1
H-NMR (400 MHz, (CD3)2SO): δ = 8.β6‒8.ββ (m, βH, HAr), 7.92 (d, J = 8.1 Hz, 1H, HAr), 
7.71 (d, J = 8.1 Hz, 1H, HAr), 7.5‒7.40 (m, γH, HAr), 4.43 (dd, J = 9.0, 6.1 Hz 1H, CHNH2), 
3.84 (s, 2H, CHOH), 3.74 (br s, 6H), β.86‒β.76 (m, βH, CH2), β.γ6‒β.β6 (m, 1H, CH2), 1.99 
(td, J = 10.3, 4.7 Hz 1H, CH2), 1.90‒1.7γ (m, βH, CH2) ppm. 13C{1H}-NMR (101 MHz, 
(CD3)2SO): δ = 174.3 (C=O), 153.4 (CAr), 152.0 (CAr), 138.7 (HCAr), 137.9 (CAr), 131.4 (CAr), 
129.2 (HCAr), 128.7 (HCAr), 126.7 (HCAr), 119.5 (HCAr), 71.3 (CHOH), 50.3 (CHNH), 27.6 
(CH2), 27.2 (CH2), 19.6 (CH2) ppm. MS (FAB NBA) m/z (%): 225 (100, [M
+]), 208 (26). 
IR: ṽ = 3364 (w), 2925 (m), 2858 (m), 1746 (m), 1584 (m), 1569 (s), 1426 (s), 1374 (m), 
1352 (w), 1215 (w), 1116 (w), 928 (w), 880 (m), 849 (m), 821 (w), 784 (s) cm-1. EA: calc. 
(%) C 60.95; H, 5.92; N, 7.48; found C 59.42, H 6.17, N 7.41. m.p.: 178‒179 °C (dec.). 
[α]D20: +70.4 (c = 0.35, H2O). 
 
 
(S)-2-phenyl-5,6,7,8-tetrahydroquinolin-8-amine ((S)-137d) 
 
A solution of tartaric salt (S,R,R)-140b (152 mg, 406 µmol) in aqueous 
NaOH 3 M aq.solution (10 mL) was extracted with DCM (5×10 mL). 
After drying over MgSO4, filtration and removing of the solvent under 
reduced pressure, the title compound (S)-137d was obtained as a colorless 
oil (91 mg, 406 µmol, quant.). 
 
HPLC (chiral, Daicel Chiracel OD-H, (2.6 mm × 250 mm), heptane / i-PrOH 95:5 + 0.1% 
n-BuNH2, 0.8 mL/min, 40 °C: tR = 11.1 min (S), 13.1 min (R).  
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8.6.4 Hydrolysis of Amides 
 
 
 
A solution of amide in HCl 2 M aq. Solution was stirred for 2 h. After cooling down to RT, 
the reaction mixture was made basic by adding NaOH 50% aq. solution (1 mL). Extraction 
with DCM (5×10 mL) gave the free amine, which was purified by Kugelrohr distillation 
(>90% yield). 
 
 
8.6.5 Preparation of Ligands and Complexes 
 
 
 
Formation of the Aminophosphine Derived N,P Ligands, General Procedure K: 
Diethylaminophosphine (1.0 eq.) was added to a solution of pyridyl amine (1.0 eq.) in toluene 
(0.2-0.3 M). The reaction mixture was stirred at (120-130 °C) under a slightly stream of argon 
for 12-18 hours. Reaction progress was checked by 31P-NMR analasys. After complete 
reaction, the solvent was removed in vacuo and the crude ligand was converted to the irdium 
complex using general procedure G for the formation of iridium complexes without additional 
purification.  
Diethylaminophosphines: were prepared according to the procedure described by S. 
Kaiser.[57a]   
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(S)-(+)-[η4-1,5-Cyclooctadiene-N-(diphenylphosphino)-(2-phenyl-6,7-dihydro-5H-
[1]pyrindin)-7-amine-iridium(I)]-tetrakis-(3,5-bis-(trifluoromethyl)-phenyl)-borate 
((S)-142a) 
 
The intermediate ligand (S)-141a was obtained following general 
procedure K using diethylaminodiphenyl-phosphine (65 uL, 67.8 mg, 
263 µmol), amine (S)-136b (50 mg, 238 µmol, 1.0 eq.) and toluene 
(1.0 mL) as a colorless solid (94 mg, 238 µmol, 91%).  
The title compound (S)-142a was obtained following general procedure G for the formation 
of iridium complexes using (S)-141a (94 mg, 238 µmol, 91%), [Ir(COD)Cl]2 (87.8 mg, 
131 μmol, 0.55 eq.), DCM (5.0 mL), NaBArF (253 mg, 285 μmol, 1.2 eq.), after purification 
by flash chromatography (SiO2, 1.5 cm × 20 cm) as a red-brown foam (286 mg, 184 μmol, 
70% over two steps). 
 
31
P{
1
H}-NMR of Ph2PNEt2 (162 MHz, CD2Cl2): δ = 61.4 (s) ppm. 
31
P{
1
H}-NMR of the ligand (S)-141a (162 MHz, CD2Cl2): δ = 33.9 (s) ppm. 
 
C66H47BF24IrNOP (1558.05 g/mol): 
1
H-NMR (500 MHz, CD2Cl2): δ = 7.87 (d, J = 7.9 Hz, 1H, HAr), 7.74 (s, 8H, BArF-H), 7.69‒
7.63 (m, 3H, HAr), 7.6β‒7.45 (m, 17H, BArF-H, HAr), 5.54‒5.41 (m, 1H, CH), 4.41‒4.γ1 (m, 
1H, CH COD), 4.27 (dd, J = 3.6 Hz, 1H, CH COD), γ.β4‒γ.04 (m, γH, CH2, CH COD), γ.04‒
2.96 (m, 1H, CH2), β.9γ‒β.79 (m, 1H, CH COD), 2.63 (s, 1H, NH), β.β8‒β.1β (m, 4H, CH2 
1H, CH2 COD 3H), 2.02 (dd, J = 15.1, 7.8 Hz, 1H, CH2 COD), 1.87 (m, 1H, CH2 COD), 
1.γ4‒1.19 (m, βH, CH2 COD), 1.19‒1.10 (m, 1H, CH2 COD) ppm. 13C{1H}-NMR (126 MHz, 
CD2Cl2): δ = 165.0 (s, CAr), 165.0 (d, J = 4 Hz, CAr), 162.3 (q, JBC = 50 Hz, CAr BArF), 160.7 
(s, CAr), 139.5 (s, CAr), 137.8 (s, CAr), 137.2 (s, HCAr), 135.9 (s, CAr), 135.4 (s, HCAr BArF), 
132.1 (s, HCAr), 132.0 (s, HCAr), 131.9 (s, HCAr), 131.4 (s, HCAr), 131.3 (s, HCAr), 131.2 (s, 
HCAr), 129.9 (s, HCAr), 129.8 (d, J = 11 Hz, HCAr), 129.5 (qq, JFC = 31 Hz, JBC = 3 Hz, CAr 
BArF), 129.4 (d, J = 11 Hz, HCAr), 127.8 (s, HCAr), 126.7 (s, HCAr), 125.2 (q, JFC = 273 Hz, 
CF3 BArF), 118.1 (septett, JFC = 4 Hz, HCAr BArF), 96.5 (d, J = 10 Hz, CH COD), 88.1 (d, J = 
16 Hz, CH COD), 68.1 (s, CH COD), 64.1 (s, CH COD), 63.2 (d, J = 8 Hz, CH), 37.0 (s, CH2 
COD), 34.5 (s, CH2 COD), 31.8 (d, J = 11 Hz, CH2), 28.8 (s, CH2 COD), 28.7 (s, CH2), 25.3 
(s, CH2 COD) ppm. 
31
P{
1
H}-NMR (202 MHz, CD2Cl2): δ = 49.7 (s) ppm. MS (FAB NBA) 
m/z (%): 695 ([Ir(L)(COD)]+, 100), 585 (18), 507 (22). EA: calc. (%) C 50.88, H, 3.04, 
N, 180; found C 50.77, H 3.13, N 2.06. m.p.: 91‒9β °C. [α]D20: +31.2 (c = 1.00, CHCl3).  
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(S)-(+)-[η4-1,5-Cyclooctadiene-N-(di-ortho-tolylphosphino)-(2-phenyl-6,7-dihydro-5H-
[1]pyrindin)-7-amine-iridium(I)]-tetrakis-(3,5-bis-(trifluoromethyl)-phenyl)-borate 
((S)-142b) 
 
The intermediate ligand (S)-141b was obtained following general 
procedure K using diethylamino-di-ortho-tolylphosphine (73.0 mg, 
256 µmol, 1.1 eq.), amine (S)-136b (50 mg, 238 µmol, 1.0 eq.) and 
toluene (1.0 mL) as a colorless solid (77.6 mg, 184 µmol, 77%).  
The title compound (S)-142b was obtained following general procedure G for the formation 
of iridium complexes using ligand (S)-141b (77.6 mg, 184 µmol, 1.0 eq.). [Ir(COD)Cl]2 (85.9 
mg, 128 μmol, 0.55 eq.), DCM (5.0 mL), NaBArF (247 mg, 279 μmol, 1.2 eq.), after 
purification by flash chromatography (SiO2, 1.5 cm × 20 cm) as a red-brown foam (254 mg, 
160 μmol, 67% over two steps). 
 
31
P{
1
H}-NMR of (o-Tol)2PNEt2 (162 MHz, CD2Cl2): δ = 49.7 (s) ppm. 
31
P{
1
H}-NMR of the ligand (162 MHz, CD2Cl2): δ = 18.4 (s) ppm. 
 
C68H50BF24IrNOP (1587.11 g/mol):  
1
H-NMR (500 MHz, CD2Cl2): δ = 8.γ0‒7.79 (m, βH, HAr), 7.75 (s, 8H, BArF-H), 7.71‒7.64 
(m, 2H, HAr), 7.6γ‒7.50 (m, 8H, BArF-H, HAr), 7.48‒7.γ0 (m, 5H, HAr), 7.17‒7.09 (m, 1H, 
HAr), 6.77 (br s, 1H, HAr), 5.49‒5.γ5 (m, 1H, CH COD), 4.66‒4.β9 (m, 1H, CH COD), 4.33 
(br s, 1H, CH), γ.40‒γ.16 (m, 1H, CH2), γ.16‒γ.06 (m, 1H, CH2), γ.04‒β.88 (m, 5H, CH 
COD, CH2 1H, CH3), 2.41 (br s, 3H, CH3), β.γ5‒β.β1 (m, βH, CH COD, CH2 COD 1H), 
β.15‒1.8β (m, 5H, CH2 1H, CH2 COD 4H), 1.4β‒1.0β (m, γH, CH2 COD) ppm. 
13
C{
1
H}-NMR (126 MHz, CD2Cl2): δ = 164.8 (d, J = 1 Hz, CAr), 162.3 (q, JBC = 50 Hz, CAr 
BArF), 161.1 (s, CAr), 139.7 (s, CAr), 138.0 (s, CAr), 137.0 (s, HCAr), 135.4 (s, HCAr BArF), 
133.3 (d, J = 15 Hz, CAr), 133.0 (s, HCAr), 132.6 (d, J = 5 Hz, HCAr), 132.3 (s, HCAr), 131.7 
(s, HCAr), 129.8 (s, HCAr), 129.5 (qq, JFC = 31 Hz, JBC = 3 Hz, CAr BArF), 128.4 (s, CAr), 
128.1 (s, CAr), 127.1 (s, HCAr), 126.9 (d, J = 10 Hz, HCAr), 125.2 (q, JFC = 273 Hz, CF3 BArF), 
118.1 (septett, JFC = 4 Hz, HCAr BArF), 100.4 (s, CH COD), 94.0 (s, CH), 68.0 (d, J = 16 Hz, 
CH COD), 67.8 (s, CH COD), 61.9 (s, CH COD), 36.8 (s, CH2 COD), 34.7 (s, CH2 COD), 
32.2 (d, J = 10 Hz, CH2), 28.7 (s, CH2 COD), 28.4 (s, CH2), 24.9 (s, CH2 COD), 23.7 (br s, 
CH3), 23.3 (s, CH3) ppm.
31
P{
1
H}-NMR (202 MHz, CD2Cl2): δ = 59.8 (br s) ppm. MS (FAB 
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NBA) m/z (%): 723 ([Ir(L)(COD)]+, 100), 611 (79). EA: calc. (%) C 51.49, H, 3.24, N, 1.77; 
found C 50.70, H 3.06, N 0.78. m.p.: 85‒86 °C. [α]D20: +9.3 (c = 1.06, CHCl3).  
 
 
(S)-(+)-[η4-1,5-Cyclooctadiene-N-(diphenylphosphino)-5,6,7,8-tetrahydrochinolin-8-
amine-iridium(I)]-tetrakis-[3,5-bis(trifluormethyl)phenyl]borate ((S)-142c) 
 
The intermediate ligand (S)-141c was obtained following general 
procedure K using diethylaminodiphenyl-phosphine (90 uL, 93.9 mg, 
365 µmol, 1.1 eq.), amine (S)-136c (50 mg, 337 µmol, 1.0 eq.) and 
toluene (1.0 mL) as a colorless solid (77.6 mg, 234 µmol, 69%). The title 
compound (S)-142c was obtained following general procedure G using 
ligand (S)-141c (77.6 mg, 234 µmol, 1.0 eq.), [Ir(COD)Cl]2 (86.5 mg, 129 μmol, 0.55 eq), 
DCM (5.0 mL), NaBArF (251 mg, 283 μmol, 1.2 eq.), after purification by flash 
chromatography (SiO2, 1.5 cm × 15 cm) and recrystallization from diethyl ether (1 mL) and 
n-pentane (25 mL) as a red-brown solid (260 mg, 174 μmol, 48% over two steps). 
 
31
P{
1
H}-NMR of Ph2PNEt2 (162 MHz, CD2Cl2): δ = 61.4 (s) ppm. 
31
P{
1
H}-NMR of the ligand (162 MHz, CD2Cl2): δ = 29.1 (s) ppm. 
 
C61H45BF24IrN2P (1495.99 g/mol): 
1
H-NMR (500 MHz, CD2Cl2): δ = 8.44 (d, J = 5.4 Hz, 1H, HAr), 7.75 (s, 8H, BArF-H), 7.59‒
7.50 (m, 7H, BArF-H, HAr), 7.49‒7.42 (m, 3H, HAr), 7.41 (d, J = 7.4 Hz, 1H, HAr), 7.γ8‒7.γ1 
(m, 4H, HAr), 7.β9‒7.ββ (m, 1H, HAr), 5.γβ‒5.β5 (m, 1H, CH), 4.98‒4.91 (m, 1H, CH COD), 
4.58 (p, J = 7.2 Hz, 1H, CH COD), γ.98‒γ.87 (m, 1H, CH COD), β.99‒β.9β (m, 1H, CH 
COD), β.84‒β.7β (m, βH, CH2), β.71‒β.58 (s, βH, CH2 COD), β.5γ‒β.γβ (m, 5H, NH, CH2 
2H, CH2 COD 2H), 2.24 (dt, J = 15.0, 8.8 Hz, 1H, CH2 COD), 1.98‒1.90 (dt, J = 14.3, 8.3 
Hz, 2H, CH2 1H, CH2 COD 1H), 1.86‒1.78 (m, 1H, CH2 COD), 1.77‒1.66 (m, 1H, CH2), 
1.54‒1.4γ (m, 1H, CH2 COD) ppm. 13C{1H}-NMR (126 MHz, CD2Cl2): δ = 162.3 (q, JBC = 
50 Hz, CAr BArF), 158.6 (s, CAr), 149.0 (s, HCAr), 141.2 (s, HCAr), 136.4 (s, CAr), 136.1 (s, 
CAr), 135.4 (s, HCAr BArF), 133.5 (s, HCAr), 133.4 (s, HCAr), 132.6 (d, J = 2 Hz, HCAr), 132.1 
(d, J = 2 Hz, HCAr), 131.8 (s, HCAr), 131.6 (s, HCAr), 130.1 (s, CAr), 129.7 (s, HCAr), 129.6 (s, 
HCAr), 129.5 (qq, JFC = 31 Hz, JBC = 3 Hz, CAr BArF), 129.2 (s, HCAr), 129.1 (s, HCAr), 125.9 
(s, HCAr), 125.2 (q, JFC = 273 Hz, CF3 BArF), 118.1 (septett, JFC = 4 Hz, HCAr BArF), 96.5 (d, 
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J = 10 Hz, CH COD), 88.1 (d, J = 16 Hz, CH COD), 68.1 (s, CH COD), 64.1 (s, CH COD), 
63.2 (d, J = 8 Hz, CH), 37.0 (s, CH2 COD), 34.5 (s, CH2 COD), 31.8 (d, J = 11 Hz, CH2), 
28.8 (s, CH2 COD), 28.7 (s, CH2), 25.3 (s, CH2 COD), 18.5 (s, CH2) ppm. 
31
P{
1
H}-NMR 
(162 MHz, CD2Cl2): δ = 51.1 ppm. MS: (FAB NBA) m/z (%): 633 ([Ir(L)(COD)]+, 100), 445 
(21). IR: ṽ = 2951 (w), 2887 (w), 1609 (w), 1453 (w), 1436 (w), 1353 (s), 1271 (s), 1160 (s), 
1119 (s), 996 (w), 885 (m), 838 (m), 790 (w), 724 (w), 713 (m), 698 (w), 679 (m), 669 (m), 
620 (w) cm-1. EA: calc. (%) C 48.98, H, 3.03, N, 1.87; found C 48.98, H 3.14, N 2.03. [α]D20: 
+46.2 (c = 1.09, CHCl3). m.p.: 159‒161 °C.  
 
 
(R)-(−)-[η4-1,5-Cyclooctadiene-N-(di-ortho-tolylphosphino)-5,6,7,8-tetrahydrochinolin-8-
amine-iridium(I)]-tetrakis-[3,5-bis(trifluormethyl)phenyl]borate ((R)-142d) 
 
The intermediate ligand (R)-141d was obtained following a 
modifaction of general procedure C using amine (R)-136c (21 mg, 
142 µmol, 1.0 eq.), DMAP (20.8 mg, 170 µmol, 1.2 eq.), chloro-di-
ortho-tolyl-phosphine (42.3 mg, 170 µmol, 1.2 eq.), and DCM (0.5 
mL) after purification by filtration over aluminum oxide (d×h, 2 cm × 3 cm, cyclohexane / 
TBME 1:1, degassed) as a colorless solid (33.0 mg, 91.6 µmol, 65%). The title compound 
(R)-142d was obtained following general procedure G using (R)-141d (33.0 mg, 91.6 µmol, 
1.0 eq.), [Ir(COD)Cl]2 (30.9 mg, 46.0 μmol, 0.5 eq.), DCM (2.0 mL), NaBArF (98.0 mg, 
111 μmol, 1.2 eq.), after purification by flash chromatography (SiO2, 1 cm × 12 cm) and 
recrystallization from diethyl ether (1 mL) and n-pentane (25 mL) as a red-brown solid 
(45.0 mg, 29.5 μmol, 21% over two steps). 
 
31
P{
1
H}-NMR of (o-Tol)2PCl (162 MHz, CD2Cl2): δ = 75.3 (s) ppm. 
31
P{
1
H}-NMR of the ligand (162 MHz, CD2Cl2): δ = 13.5 (s) ppm. 
 
C63H49BF24IrN2P (1524.04 g/mol): 
1
H-NMR (500 MHz, CD2Cl2): δ = 8.64–8.43 (m, 1H, HAr), 8.24 (br s, 1H, HAr), 7.73 (s, 8H, 
BArF-H), 7.56 (m, 4H, BArF-H), 7.52 (d, J = 7.8 Hz, 1H HAr), 7.42–7.30 (m, 3H, HAr), 7.β8‒
7.08 (m, 4H, HAr), 6.68 (br s, 1H, HAr), 5.β0‒5.10 (m, 1H, CH COD), 5.10‒4.88 (m, 1H, CH), 
4.46‒4.β6 (m, 1H, CH COD), γ.88‒γ.76 (m, 1H, CH COD), β.94‒β.44 (m, 9H, CH COD 1H, 
CH2 2H, CH2 COD 2H, CH3 3H, NH), β.44‒β.γ0 (m, γH, CH3), β.β7‒β.1β (m, βH, CH2 
COD), β.09‒1.87 (m, 5H, CH2 3H, CH2 COD βH), 1.86‒1.71 (m, 1H, CH2 COD), 1.7β‒1.59 
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(m, 1H, CH2), 1.58‒1.40 (m, 1H, CH2 COD) ppm. 13C{1H}-NMR (126 MHz, CD2Cl2): δ = 
162.3 (q, JBC = 50 Hz, CAr BArF), 158.7 (s, CAr), 149.3 (s, HCAr), 141.2 (s, HCAr), 136.3 (s, 
CAr), 135.4 (s, HCAr BArF), 132.9 (d, J = 6.8 Hz, HCAr), 132.3 (d, J = 1 Hz, HCAr), 129.5 (qq, 
JFC = 31 Hz, JBC = 3 Hz, CAr BArF), 126.7 (d, J = 11 Hz, HCAr), 126.5 (d, J = 7.9 Hz, CAr), 
125.7 (s, HCAr), 125.2 (q, JFC = 273 Hz, CF3 BArF), 118.1 (septett, JFC = 4 Hz, HCAr BArF), 
95.8 (s, CH COD), 92.7 (s, CH COD), 66.7 (s, CH COD), 66.2 (s, CH COD), 57.2 (s, CH), 
37.4 (s, CH2 COD), 34.4 (d, J = 6 Hz, CH2 COD), 30.7 (d, J = 11 Hz, CH2), 29.3 (s, CH3), 
28.8 (s, CH2 COD), 28.8 (s, CH2), 22.5 (s, CH3), 25.3 (s, CH2 COD), 18.7 (s, CH2) ppm. 
31
P{
1
H}-NMR (162 MHz, CD2Cl2): δ = 54.7 ppm. MS: (FAB NBA) m/z (%): 661 
([Ir(L)(COD)]+, 100), 549 (27), 443 (11), 371 (12). EA: calc. (%) C 49.65, H, 3.24, N, 1.84; 
found C 48.85, H 3.06, N 1.58. 
 
 
(R)-(+)-[η4-1,5-Cyclooctadiene-N-(dicyclohexylphosphino)-5,6,7,8-tetrahydrochinolin-8-
amine-iridium(I)]-tetrakis-[3,5-bis(trifluormethyl)phenyl]borate ((R)-142e) 
 
The intermediate ligand was obtained following general procedure H 
using amine (R)-136c (43.6 mg, 294 µmol, 1.0 eq.), chloro-
dicyclohexylphosphine (70.0 µL, 73.8 mg, 317 µmol, 1.1 eq.), NaH 
(17.7 mg, 736 µmol, 2.5 eq.), THF (1 mL), DMF (0.1 mL) and filtration 
over aluminum oxide (d×h, 2 cm × 3 cm, cyclohexane / TBME 9:1, degassed) as a colorless 
solid (23.4 mg, 67.9 µmol, 23%). The title compound (R)-142e was obtained following 
general procedure G using (R)-136c (23.4 mg, 67.9 µmol, 23%), [Ir(COD)Cl]2 (22.8 mg, 
34.0 μmol, 0.5 eq.), DCM (1.0 mL), NaBArF (70.9 mg, 80.0 μmol, 1.2 eq.), after purification 
by flash chromatography (SiO2, 1.5 cm × 15 cm) and recrystallization from diethyl ether (1 
mL) and n-pentane (25 mL) as a red-brown solid (49.0 mg, 32.5 μmol, 11% over two steps). 
 
31
P{
1
H}-NMR of Cy2PCl (162 MHz, CD2Cl2): δ = 126.1 (s) ppm. 
31
P{
1
H}-NMR of the ligand (162 MHz, CD2Cl2): δ = 45.8 (s) ppm. 
 
C61H57BF24IrN2P (1508.08 g/mol): 
1
H-NMR (500 MHz, CD2Cl2): δ = 8.50 (d, J = 5.4 Hz, 1H, HAr), 7.73 (s, 8H, BArF-H), 7.63 
(d, J = 7.7 Hz, 1H, HAr), 7.56 (s 4H, BArF-H), 7.34–7.26 (m, 1H, HAr), 4.95–4.85 (m, 1H, CH 
COD), 4.62–4.52 (m, 1H, CH), 4.50–4.40 (m, 1H, CH COD), 4.09 (p, J = 7.1 Hz, 1H, CH 
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COD), 3.57–3.48 (m, 1H, CH COD), 2.90–2.81 (m, 1H, CH2), 2.79–2.66 (m, 2H, CH2 1H, 
CH2 COD 1H ), 2.66–2.54 (m, 1H, CH2 COD), 2.44–2.33 (m, 1H, CH2), 2.32–2.19 (m, 2H, 
CHP, CH2 COD 1H), 2.19–1.97 (m, 5H, CHP, CH2 COD 2H, CH2 Cy 3H), 1.94–1.85 (m, 2H, 
CH2), 1.84–1.75 (m, 2H, CH2 COD 1H, NH), 1.75–1.62 (m, 5H, CH2 Cy 3H, CH2 COD 1H, 
CH2 1H), 1.62–1.45 (m, 4H, CH2 COD 1H, CH2 Cy 3H), 1.43–1.08 (m, 8H, CH2 Cy), 1.05 – 
0.93 (m, 1H, CH2 Cy), 0.74–0.60 (m, 2H, CH2 Cy) ppm.13C{1H}-NMR (126 MHz, CD2Cl2): 
δ = 162.3 (q, JBC = 50 Hz, CAr BArF), 159.1 (s, CAr), 150.0 (s, HCAr), 141.2 (s, HCAr), 135.7 
(s, CAr), 135.4 (s, HCAr BArF), 129.4 (qq, JFC = 31 Hz, JBC = 3 Hz, CAr BArF), 125.3 (s, HCAr), 
125.2 (q, JFC = 272 Hz, CF3 BArF), 118.0 (septett, JFC = 4 Hz, HCAr BArF), 94.3 (d, J = 14 Hz, 
CH COD), 94.2 (d, J = 10 Hz, CH COD), 66.4 (s, CH COD), 62.9 (s, CH COD), 58.3 (d, J = 
7 Hz, CH), 38.8 (d, J = 32 Hz, CHP), 38.3 (d, J = 3 Hz, CH2 COD), 34.2 (d, J = 34 Hz, CHP), 
34.1 (s, CH2), 30.7 (d, J = 9 Hz, CH2 COD), 29.4 (s, CH2), 29.3 (d, J = 5.5 Hz, CH2 Cy), 29.0 
(s, CH2 Cy), 28.8 (s, CH2 COD), 28.5 (s, CH2 Cy), 27.2 (d, J = 9 Hz, CH2 Cy), 27.0 (d, J = 6 
Hz, CH2 Cy), 26.91 (s, CH2 Cy), 26.89 (d, J = 20 Hz, CH2 Cy), 26.8 (s, CH2 Cy), 26.4 (s, CH2 
Cy), 26.0 (d, J = 7 Hz, CH2 Cy), 25.8 (s, CH2 COD), 18.7 (s, CH2) ppm. 
31
P{
1
H}-NMR 
(162 MHz, CD2Cl2): δ = 61.5 ppm. MS: (FAB NBA) m/z (%): 645 ([M]+, 100), 533 (13), 443 
(11), 371 (12). EA: calc. (%) C 48.58, H, 3.81, N, 1.86; found C 48.01, H 3.66, N 1.59. 
[α]D20: +56 (c = 1.01, CHCl3). m.p.: 10β‒10γ °C. 
 
 
(S)-(+)-[η4-1,5-Cyclooctadiene-N-(diphenylphosphino)-2-phenyl-5,6,7,8-
tetrahydrochinolin-8-amine-iridium(I)]-tetrakis-[3,5-bis(trifluormethyl)phenyl]borate 
((S)-142f) 
 
The intermediate ligand (S)-141f was obtained following general 
procedure K using diethylaminodiphenyl-phosphine (40 uL, 41.7 mg, 
162 µmol, 1.1 eq.), amine (S)-137d (33.0 mg, 141 µmol, 1.0 eq.) and 
toluene (1.0 mL) as a colorless solid (49.0 mg, 120 µmol, 85%).  
The title compound (S)-142f was obtained following general procedure 
G using ligand (S)-141f (49.0 mg, 120 µmol, 1.0 eq.), [Ir(COD)Cl]2 (40.3 mg, 60.0 μmol, 0.5 
eq.), DCM (3.0 mL), NaBArF (127 mg, 143 μmol, 1.2 eq.), after purification by flash 
chromatography (SiO2, 3 cm × 15 cm) and recrystallization from diethyl ether (1 mL) and n-
pentane (25 mL) as a red-brown foam (94.0 mg, 59.8 μmol, 50% over two steps). 
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31
P{
1
H}-NMR of Ph2PNEt2 (162 MHz, CD2Cl2): δ = 61.4 (s) ppm. 
31
P{
1
H}-NMR of the ligand (162 MHz, CD2Cl2): δ = 30.6 (s) ppm. 
 
C67H49BF24IrN2P (1572.08 g/mol): 
1
H-NMR (500 MHz, CD2Cl2): δ = 7.74 (s, 8H, BArF-H), 7.68 (t, J = 7.3 Hz, 1H, HAr), 7.6γ‒
7.54 (m, 9H, BArF-H, HAr), 7.54‒7.46 (m, 8H, HAr), 7.44‒7.41 (m, 1H, HAr), 7.γ9‒7.γγ (m, 
2H, HAr), 5.52 (p, J = 6.5 Hz, 1H, CH), 4.45‒4.γ8 (m, 1H, CH COD), 4.γ5‒4.β8 (m, 1H, CH 
COD), 3.15 (p, J = 7.1 Hz, 1H, CH COD), 3.00 (dt, J = 16.7, 5.8 Hz, 1H, CH2), 2.91 (dt, J = 
17.0, 6.0 Hz, 1H, CH2), β.74‒β.6β (m, 2H, CH COD, CH2 COD 1H), β.γ4‒β.18 (m, βH, CH2 
1H, CH2 COD 1H), β.08‒1.8β (m, 5H, NH, CH2 2H, CH2 COD βH), 1.81‒1.70 (m, 1H, CH2 
COD 1H), 1.γ5‒1.19 (m, βH, CH2 COD), 1.19‒1.10 (m, 1H, CH2), 1.10‒1.00 (m, 1H, CH2 
COD) ppm. 13C{1H}-NMR (126 MHz, CD2Cl2): δ = 162.3 (q, JBC = 50 Hz, CAr BArF), 160.5 
(s, CAr), 159.2 (s, CAr), 141.4 (s, HCAr), 139.6 (s, CAr), 135.8 (s, CAr), 135.4 (s, HCAr BArF), 
132.3 (d, J = 58 Hz, CAr), 132.0 (s, HCAr), 131.94 (d, J = 3 Hz, HCAr), 131.88 (d, J = 2 Hz, 
HCAr), 130.92 (s, HCAr), 130.85 (s, HCAr), 130.77 (s, HCAr), 130.67 (s, HCAr), 130.4 (s, 
HCAr), 129.9 (s, HCAr), 129.8 (s, HCAr), 129.7 (s, HCAr), 129.6 (s, HCAr), 129.5 (qq, JFC = 31 
Hz, JBC = 3 Hz, CAr BArF), 128.4 (s, CAr), 126.1 (s, HCAr), 125.8 (s, HCAr), 125.2 (q, JFC = 
273 Hz, CF3 BArF), 118.1 (septett, JFC = 4 Hz, HCAr BArF), 96.3 (d, J = 8 Hz, CH COD), 82.4 
(d, J = 17 Hz, CH COD), 69.7 (s, CH COD), 65.9 (s, CH COD), 57.2 (d, J = 9 Hz, CH), 36.4 
(d, J = 4 Hz, CH2 COD), 35.4 (s, CH2), 32.0 (d, J = 11 Hz, CH2 COD), 29.7 (s, CH2), 28.8 (s, 
CH2 COD), 24.4 (s, CH2 COD), 20.2 (s, CH2) ppm. 
31
P{
1
H}-NMR (162 MHz, CD2Cl2): δ = 
40.8 ppm. MS: (FAB NBA) m/z (%): 709 ([Ir(L)(COD)]+, 100), 599 (23), 521 (15). IR: 
ṽ = 2951 (w), 2887 (w), 1609 (w), 1453 (w), 1434 (w), 1437 (w), 1353 (s), 1274 (s), 1158 
(m), 1118 (s), 1000 (w), 933 (w), 885 (m), 839 (m), 761 (w), 744 (w), 713 (m), 697 (w), 680 
(s), 669 (m), 636 (w), 621 (w) cm-1. [α]D20: +36.3 (c = 1.02, CHCl3). m.p.: 76‒77 °C. 
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(S)-(+)-[η4-1,5-Cyclooctadiene-N-(di-ortho-tolylphosphino)-2-phenyl-5,6,7,8-
tetrahydrochinolin-8-amine-iridium(I)]-tetrakis-[3,5-bis(trifluormethyl)phenyl]borate 
((S)-142g) 
 
The intermediate ligand (S)-141g was obtained following general 
procedure K using diethylamino-di-ortho-tolylphosphine (63 mg, 221 
µmol, 1.0 eq.), amine (S)-137d (49. 0 mg, 218 µmol, 1.0 eq.) and 
toluene (1.0 mL) as a colorless solid (83.0 mg, 190 µmol, 87%). 
The title compound (S)-142g was obtained following general procedure G using ligand (S)-
141g (83.0 mg, 190 µmol, 1.0 eq.), [Ir(COD)Cl]2 (63.8 mg, 95.0 μmol, 0.5 eq.), DCM 
(3.0 mL), NaBArF (186 mg, 210 μmol, 1.2 eq.), after purification by flash chromatography 
(SiO2, 3 cm × 14 cm) and recrystallization from diethyl ether (1 mL) and n-pentane (25 mL) 
as a red-brown foam (162 mg, 101 μmol, 46% over two steps). 
 
31
P{
1
H}-NMR of (o-Tol)2PNEt2 (162 MHz, CD2Cl2): δ = 49.7 (s) ppm. 
31
P{
1
H}-NMR of the ligand (162 MHz, CD2Cl2): δ = 19.3 (s) ppm. 
 
C69H53BF24IrN2P (1600.14 g/mol): 
1
H-NMR (500 MHz, CD2Cl2): δ = 7.75 (s, 8H, BArF-H), 7.70 (d, J = 8.0 Hz, 1H, HAr), 7.66 
(t, J = 7.5 Hz, 1H, HAr), 7.57 (s, 4H, BArF-H), 7.5β‒7.40 (m, 6H, HAr), 7.γ9‒7.β9 (m, 4H, 
HAr), 7.β6‒7.15 (m, βH, HAr), 7.04‒6.96 (m, 1H, HAr), 5.γ0‒5.βγ (m, 1H, CH), 4.58 (t, J = 6.4 
Hz, 1H, CH COD), 4.4γ‒4.γ4 (m, 1H, CH COD), 3.36 (br s, 1H, CH COD), 3.08 (s, 3H, 
CH3), 3.01 (dt, J = 16.9, 5.5 Hz, 1H, CH2), 2.89 (dt, J = 17.0, 6.1 Hz, 1H, CH2), β.68‒β.54 (m, 
2H, CH COD, CH2 COD 1H), 2.47 (s, 3H, CH3), β.44‒β.γβ (m, βH, CH2 1H, CH2 COD 1H), 
β.β1‒β.07 (m, βH, CH2), β.06‒1.9γ (m, βH, CH2 COD), 1.72 (ddd, J = 25.9, 15.1, 8.0 Hz, 2H, 
CH2 COD), 1.60‒1.48 (m, 1H, CH2 COD 1H), 1.γ5‒1.ββ (m, βH, CH2 COD), 1.16‒0.99 (m, 
2H, CH2, CH2 COD) ppm. 
13
C{
1
H}-NMR (126 MHz, CD2Cl2): δ = 162.3 (q, JBC = 50 Hz, CAr 
BArF), 160.7 (s, CAr), 158.5 (s, CAr), 142.6 (d, J = 11 Hz, CAr), 141.2 (s, HCAr), 140.6 (d, J = 
12 Hz, CAr), 139.7 (s, CAr), 135.4 (s, HCAr BArF), 135.1 (s, CAr), 134.7 (s, CAr), 134.6 (s, CAr), 
133.1 (d, J = 9 Hz, HCAr), 132.8 (d, J = 10 Hz, HCAr), 132.7 (d, J = 8 Hz, HCAr), 132.3 (d, J = 
2 Hz, HCAr), 133.1 (s, HCAr), 131.7 (s, HCAr), 130.2 (s, HCAr), 129.5 (qq, JFC = 31 Hz, JBC = 3 
Hz, CAr BArF), 127.3 (d, J = 10 Hz, HCAr), 126.9 (d, J = 10 Hz, HCAr), 126.7 (s, HCAr), 125.2 
(q, JFC = 273 Hz, CF3 BArF), 118.1 (septett, JFC = 4 Hz, HCAr BArF), 89.8 (br s, CH COD), 
77.7 (br s, CH COD), 72.3 (br s, CH COD), 67.8 (s, CH COD), 55.8 (d, J = 8 Hz, CH), 36.2 
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(d, J = 4 Hz, CH2 COD), 35.2 (s, CH2), 32.0 (d, J = 10 Hz, CH2 COD), 29.7 (s, CH2), 29.2 (s, 
CH2 COD), 24.2 (d, J = 3 Hz, CH2 COD), 24.0 (d, J = 7 Hz, CH3), 22.7 (d, J = 7 Hz, CH3), 
20.1 (s, CH2) ppm. 
31
P{
1
H}-NMR (162 MHz, CD2Cl2): δ = 43.4 (br s) ppm. MS: (FAB NBA) 
m/z (%): 737 ([Ir(L)(COD)]+, 100), 625 (50), 533 (11). IR: ṽ = 2952 (w), 2882 (w), 1609 (w), 
1464 (w), 1433 (w), 1352 (s), 1271 (s), 1159 (m), 1117 (s), 1096 (s), 999 (w), 929 (w), 885 
(m), 838 (m), 806 (w), 758 (m), 744 (w), 713 (m), 698 (w), 681 (m), 669 (m), 622 (w) cm-1. 
EA: calc. (%) C 51.79, H, 3.34, N, 1.75; found C 51.71, H 3.46, N 1.93. [α]D20: +15.9 
(c = 1.06, CHCl3). m.p.: 140‒141 °C. 
 
 
8.7 Iridium-Catalyzed Enantioselective Hydrogenation of Alkenylboronic 
Esters 
8.7.1 Substrate Synthesis 
Substrates 146g (Aldrich 659193), 149d (Alfa-Aesar L19651) and 146h (Alfa-Aesar L19576) 
are commercially available and were used as received.  
 
8.7.2 Terminal Vinylboronates via Vinylbromides 
 
 
 
General Procedure L: Alkyne (10 mmol) was added drop wise to a 1 M solution of boron 
tribromide (5.0 mmol) at ‒78 °C. The resulting solution was allowed to warm to room 
temperature over 3 h. Glacial acetic acid ( mL) was added to the mixture and stirred for 1 h. 
This mixture was quenched with water (10 mL), extracted with pentane (3×20 mL). 
Combined organic layers were washed with sat. NaHCO3 solution (4×15 mL) until the pH of 
the water phase stays basic, than with water (15 mL) and brine (15 mL). After drying over 
MgSO4, the solvent was removed under reduced pressure. The crude product was diluted with 
pentane (1 mL) and purified over a plug of silica gel (SiO2, 3 cm × 4 cm), followed by elution 
with n-pentane (300 mL). The solvent was removed under reduced pressure (>300 mbar, 
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40 °C) to obtain the intermediate vinyl bromide which was subsequently dissolved in THF 
(0.6 M) and cooled to −78 °C. t-BuLi 1.6 M solution in pentane (2 eq.) was added drop wise, 
and the resulting mixture (dark brown solution) was stirred for 45 minutes at ‒78 °C. A 
solution of 2-Isopropoxy-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (1.5 eq.) in THF (1.5 M) 
was added drop wise and the mixture was allowed to warm to rt over 2.5 h (1 h stirred without 
cooling). 1 M aq. HCl (10 mL) was added under ice bath control and the mixture was stirred 
for 30 min. Extraction with DCM (3×50 mL), followed by drying over MgSO4, filtration and 
concentration in vacuo provided the crude product. Purification was performed by flash 
chromatography, Kugelrohr distillation or using both methods if necessary.  
 
 
2-(Oct-1-en-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (146a): 
 
Following the general procedure L using 1-octyne (1.3 mL, 970 mg, 
8.80 mmol, 1 eq.), 1 M solution of boron tribromide (4.5 mL, 4.5 mmol, 
0.5 eq.) and glacial acetic acid (2 mL), vinyl bromide (913 mg, 
4.78 mmol, 54%) was isolated, which was subsequently converted to the 
vinylboronate 146a using 1.6 M solution of t-BuLi in pentane (6 mL, 9.6 mmol, 2 eq.) and 
2-isopropoxy-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (1.56 mL, 1.43 g, 7.66 mmol, 1.6 eq.). 
After purification by flash chromatography (1.5 cm × 20 cm, n-pentane / TBME 1:0  50:1  20:1) the title compound 146a (660 mg, 2.77 mmol, 31% over two steps) was obtained as a 
colorless liquid. The analytical data are in agreement with reported values.[141]  
 
C14H27BO2 (238.17 g/mol):  
1
H-NMR (400 MHz, CDCl3): δ = 5.74 (d, J = 3.4 Hz, 1H, C=CH2), 5.38 (br s, 1H, C=CH2), 
2.13 (t, J = 7.5 Hz, 2H, CH2C=C), 1.46‒1.γ5 (m, βH, CH2), 1.γβ‒1.16 (m, 18H, 6×CH2, 
CH3-pin), 0.87 (t, J = 6.8 Hz, 3H CH3CH2) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): 
δ = 128.9 (C=CH2), 83.5 (CCH3-pin), 35.6 (CH2), 32.0 (CH2), 29.4 (CH2), 29.2 (CH2), 25.0 
(CH3-pin), 22.9 (CH2), 14.3 (CH3) ppm. GC (Restek Rtx
®-1701 (30 m × 0.25 mm × 0.25 µm), 
60 kPa He, 100 °C, 2 min, 10 °C/min, 250 °C, 5 min): tR = 13.2 min. TLC (SiO2, n-pentane / 
TBME 20:1): Rf = 0.50 (visualization with KMnO4).
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2-(Hex-1-en-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (146b) 
 
Following the general procedure L using 1-hexyne (2.1 mL, 1.49 g, 
18.1 mmol, 1 eq.), 1 M solution of boron tribromide (9.0 mL, 9.0 mmol, 
0.49 eq.) and glacial acetic acid (2 mL), vinyl bromide (2.60 g, 15.9 mmol, 
88%) was isolated, which was subsequently converted to the vinylboronates 
146b using 1.6 M solution of t-BuLi in pentane (20 mL, 32.0 mmol, 2.0 eq.) and 
2-isopropoxy-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (5.0 mL, 4.56 g, 24.5 mmol, 1.5 eq.). 
After purification by flash chromatography (3.5 cm × 13 cm, n-pentane / Et2O 20:1) and 
distillation over a short Vigreux (3 cm, 65−68 °C / 12 mbar) the title compound 146b (1.09 g, 
5.17 mmol, 29% over two steps) was obtained as a colorless liquid. 
 
C12H23BO2 (210.12 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 5.75 (d, J = 3.3 Hz, 1H, C=CH2), 5.58 (br s, 1H, C=CH2), 
2.14 (t, J = 7.4 Hz, 2H, CH2C), 1.47‒1.γ4 (m, βH, CH2), 1.γγ‒1.β4 (m, 14H, CH2, CH3-pin), 
0.89 (t, J = 7.2 Hz, 3H CH3) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 128.8 (C=CH2), 
83.4 (CCH3-pin), 35.2 (CH2), 31.5 (CH2), 24.9 (CH3-pin), 22.5 (CH2), 14.2 (CH3) ppm. MS 
(EI) m/z (%): 210 ([M]+, 58), 194 (43), 167 (26), 152 (100), 139 (5), 125 (15), 110 (32), 101 
(18), 95 (17), 82 (43), 69 (42), 59 (23), 41 (47). EA: calc. (%) for C12H23BO2 C 68.50, 
H 11.03; found C 68.45, H 11.13. IR: ṽ = 2974 (m), 2959 (m), 2956 (w), 2926 (s), 2361 (w), 
1740 (w), 1616 (w), 1427 (m), 1369 (s), 1346 (m), 1308 (s), 1144 (s), 968 (w), 939 (w), 862 
(w), 677 (m) cm-1. GC (Restek Rtx®-1701 (30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 
2 min, 10 °C/min, 250 °C, 5 min): tR = 9.3 min. TLC (SiO2, n-pentane / TBME 20:1): 
Rf = 0.55 (visualization with KMnO4). 
 
 
2-(4-Phenylbut-1-en-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (146e) 
 
Following the general procedure L using 4-phenyl-1-butyne (1.2 mL, 
1.11 g, 8.54 mmol, 1 eq.), 1 M solution of boron tribromide (5.0 mL, 
5.0 mmol, 0.58 eq.) and glacial acetic acid (1 mL), vinyl bromide (981 mg, 
4.65 mmol, 54%) was isolated, which was subsequently converted to the 
vinylboronate 146e using 1.6 M solution of t-BuLi in pentane (6.0 mL, 9.60 mmol, 2.06 eq.) 
and 2-isopropoxy-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (1.70 mL, 1.55 g, 8.31 mmol, 
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1.5 eq.). After purification by Kugelrohr distillation (1β5−1γ0 °C / 0.β mbar) the title 
compound 146e (799 mg, 3.03 mmol, 36% over two steps) was obtained as a colorless oil. 
 
 
C16H23BO2 (258.16 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 7.33–7.26 (m, 2H, HAr), 7.23–7.11 (m, 3H, HAr), 5.80 (d, 
J = 3.3 Hz, 1H, C=CH2), 5.62 (br s, 1H, C=CH2), 2.76 (dd, J = 9.3, 6.7 Hz, 2H, Ar-CH2), 
2.51–2.36 (m, 2H, CH2C), 1.27 (s, 12H, CH3-pin) ppm. 13C{1H}-NMR (101 MHz, CDCl3): 
δ = 142.6 (CAr), 129.6 (C=CH2), 128.7 (HCAr), 128.3 (HCAr), 125.7 (HCAr), 83.5 (CCH3-pin), 
37.4 (CH2), 35.8 (CH2), 24.9 (CH3-pin) ppm. MS (EI) m/z (%): 258 ([M]
+, 7), 243 (5), 201 
(7), 158 (33), 130 (75), 117 (12), 105 (9), 101 (24), 91 (100), 84 (47), 77 (6), 69 (11), 65(17), 
57 (12), 43 (32). HRMS: calc. (%) 258.1786; found 258.1788. IR: ṽ = 2977 (m), 2927 (m), 
2858 (w), 1615 (w), 1604 (w), 1496 (w), 1452 (m), 1439 (m), 1425 (m), 1408 (w), 1367 (s), 
1344 (m), 1307 (s), 1271 (w), 1213 (m), 1195 (m), 1165 (m), 1140 (s), 1110 (w), 1074 (w), 
969 (m), 941 (m), 836 (w), 749 (w), 699 (s), 672 (w) cm-1. GC (Restek Rtx®-1701 
(30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 5 min): 
tR = 20.1 min.  
 
 
2-(3-Phenylprop-1-en-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (146f)  
 
Following the general procedure L using 3-phenyl-1-propyne (0.6 mL, 560 g, 
4.82 mmol, 1 eq.), 1 M solution of boron tribromide (2.9 mL, 2.90 mmol, 
0.6 eq.) and glacial acetic acid (1 mL) the intermediate vinyl bromide 
(450 mg, 2.28 mmol, 47%) was isolated, which was subsequently converted 
to the vinylboronate 146f using 1.6 M solution of t-BuLi in pentane (3.0 mL, 9.60 mmol, 
2.1 eq.) and 2-isopropoxy-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (0.70 mL, 1.55 g, 
8.31 mmol, 1.5 eq.). After purification by flash chromatography (1.5 cm × 18 cm, 
cyclohexane / TMBE 1:0100:150:120:1) and by Kugelrohr distillation (100-110 °C / 
0.2 mbar) the title compound 146f (162 mg, 0.664 mmol, 14% over two steps) was obtained 
as a colorless oil. The analytical data are in agreement with reported values.[141]  
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C15H21BO2 (244.14 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 7.31–7.23 (m, 2H, HAr), 7.22–7.12 (m, 3H, HAr), 5.83 (d, 
J = 3.2 Hz, 1H, C=CH2), 5.52 (br s, 1H, C=CH2), 3.48 (s, 2H, Ar-CH2), 1.21 (s, 12H, pin-
CH3) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 140.8 (CAr), 130.0 (C=CH2), 129.3 (HCAr), 
128.2 (HCAr), 125.8 (HCAr), 83.6 (CCH3-pin), 41.5 (Ar-CH2), 24.8 (CH3-pin) ppm. GC 
(Restek Rtx®-1701 (30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 2 min, 10 °C/min, 
250 °C, 5 min): tR = 14.9 min. TLC (SiO2, cyclohexane / TBME 20:1): Rf = 0.35.  
 
 
2-(1-Cyclohexylvinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (146h)  
 
Following the general procedure L using cyclohexylacetylene (1.31 mL, 1.08 g, 
10.0 mmol, 1 eq.), 1 M solution of boron tribromide (5.0 mL, 5.0 mmol, 0.5 eq.) 
and glacial acetic acid (1 mL), the intermediate vinyl bromide (1.10 g, 
5.82 mmol, 58%) was isolated, which was subsequently converted to the 
vinylboronate 146h using 1.6 M solution of t-BuLi in pentane (7.5 mL, 
12 mmol, 2.1 eq.) and 2-isopropoxy-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (3.1 mL, 2.83 g, 
15.2 mmol, 1.5 eq.). After purification by Kugelrohr distillation (75−80 °C / 0.2 mbar) the 
title compound 146h (560 mg, 2.37 mmol, 24% over two steps) was obtained as a colorless 
oil. The analytical data are in agreement with reported values.[141]  
 
C14H25BO2 (236.19 g/mol):  
1
H-NMR (400 MHz, CDCl3): δ = 5.70 (d, J = 3.0 Hz, 1H, C=CH2), 5.58 (br s, 1H, C=CH2), 
β.β0‒β.0γ (m, 1H, CHC), 1.8β‒1.6γ (m, 5H, CH2), 1.γ6‒1.β4 (m, 14H, CH2, pin-CH3), 1.β1‒
1.08 (m, 3H, CH2) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 126.0 (C=CH2), 83.3 (CCH3-
pin), 42.9 (CH), 32.6 (CH2), 26.9 (CH2), 26.5 (CH2), 24.8 (CH3-pin) ppm. GC (Restek Rtx
®-
1701 (30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 2 min, 10 °C/min, 250 °C, 5 min): 
tR = 13.2 min. 
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8.7.3 Terminal Vinylboronates via Vinyliodides 
 
 
 
Preparation of the vinyliodides: To a solution of sodium iodide (1.2 eq.) in acetonitrile 
(0.25 M) was added TMSCl (1.2 eq.) at 0 °C, followed 15 min later by H2O (0.6 eq.) and 
alkyne (1.0 eq.). The reaction mixture was slowly allowed to reach rt and stirring was 
continued for 2 h. The reaction mixture was diluted with ether (50 mL) and washed with ½-
sat. NaHCO3 solution (50 mL, pH 8), water (25 mL) and with aq. Na2S2O3 5% solution (25 
mL) to obtain a clear solution. The organic phase was dried over MgSO4, filtrated and the 
solvent was removed under reduced pressure (40 °C / 500 mbar).  
Important Note: The TBS protecting group was not stable under these reaction conditions 
and thus had to be introduced after the reaction.  
Miyaura-Borylation: Free alcohols were protected using TBSCl (1.1 eq.) and DMAP (1.1 
eq.) in DCM (0.1 M). A mixture of PdCl2(PPh3)2 (3 mol-%), Ph3P (6 mol-%), 
bis(pinacolato)dibron (1.1 eq.), and potassium phenoxide (1.5 eq.) was treated with vinyl 
iodine (1.0 eq.) and toluene (0.6 M). The red brown reaction mixture was stirred for 5 hours at 
50 °C. After cooling down to rt the reaction mixture was extracted with water (10 mL). The 
aquous phase was washed with DCM (5 mL) and combined organic layers were washed with 
brine (10 mL). Drying over MgSO4 and concentration in vacuo gave a red crude oil. 
Purification by Kugelrohr distillation or by flash chromatography (SiO2) gave the desired 
vinylboronate. 
 
 
2-(6-Chlorohex-1-en-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1c)  
 
Following the general procedure L (1st part) using 6-chloro-1-hexyne 
(1.1 mL, 972 mg, 8.33 mmol, 1 eq.), 1 M solution of boron tribromide 
(5.0 mL, 5.0 mmol, 0.55 eq.) and glacial acetic acid (1 mL), the 
intermediate vinyl bromide (1.43 g, 5.47 mmol, 80%) was isolated. A 
partial amount (395 mg, 2.00 mmol, 1.0 eq.) was subsequently converted to the vinylboronate 
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146c following the procedure for Miyaura Borylation) using PdCl2(PPh3)2 (43.0 mg, 
61.3 µmol, 3 mol-%), Ph3P (32.5 mg, 123 µmol 6 mol-%), bis(pinacolato)dibron (559 mg, 
2.20 mmol, 1.1 eq.) and 1 M potassium phenoxide suspension in toluene (3 mL, 3.00 mmol, 
1.5 eq.). After purification by Kugelrohr distillation and by flash chromatography (SiO2, 
3 cm × 18 cm, cyclohexane / ethyl acetate 50:1) the title compound 146c (160 mg, 654 µmol, 
32% for the second step) was obtained as a colorless liquid. 
 
C12H22BClO2 (244.57 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 5.79 (d, J = 3.4 Hz, 1H, C=CH2), 5. (d, J = 1.3 Hz, 1H, 
C=CH2), 3.54 (t, J = 6.8 Hz, 2H, ClCH2), β.βγ‒β.11 (m, βH, CH2), 1.86‒1.70 (m, βH, CH2), 
1.6β‒1.49 (m, βH, CH2), 1.26 (s, 12H, CH3-pin) ppm. 13C{1H}-NMR (101 MHz, CDCl3): 
δ = 129.6 (C=CH2), 83.5 (CCH3-pin), 45.3 (ClCH2), 34.6 (CH2C), 32.3 (CH2), 26.5 (CH2), 
24.9 (CH3-pin) ppm. MS (EI) m/z (%): 244 ([M]
+, 1), 229 (13), 187 (14), 167 (15), 153 (33), 
123 (12), 111 (15), 101 (10), 95 (10), 84 (44), 67 (39), 59 (33), 44 (47), 41 (100). EA: calc. 
(%) for C12H22BClO2 C 58.93, H 9.07; found C 58.86, H 9.03. IR: ṽ = 2978 (m), 2961 (w), 
2933 (m), 1864 (w), 1615 (w), 1443 (w), 1427 (m), 1368 (s), 1309 (s), 1273 (w), 1261 (w), 
1214 (w), 1143 (s), 1110 (w), 968 (w), 942 (w), 860 (m) cm-1. GC (Restek Rtx®-1701 
(30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 2 min, 10 °C/min, 250 °C, 5 min): 
tR = 13.7 min. TLC (SiO2, cyclohexane / ethyl acetate 50:1): Rf = 0.11 (visualization with 
KMnO4). 
 
 
tert-Butyldimethyl((2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)allyl)oxy)silane (146d) 
 
The vinyl iodine was obtained using sodium iodide (3.04 g, 20.3 mmol, 
1.2 eq.), TMSCl (2.6 mL, 2.23 g, 20.5 mmol, 1.1 eq.), water (183 µL, 
183 mg 10.2 mmol, 0.6 eq.) and propargyl alcohol (1.0 mL, 949 mg, 
16.9 mmol, 1 eq.) as purple luquide (1.75 g, 9.51 mmol, 56%). A partial 
amount (500 mg, 2.72 mmol, 1.0 eq.) was protected using TBSCl (451 mg, 2.99 mmol, 
1.1 eq.), DMAP (365 mg, 2.99 mmol, 1.1 eq.) and DCM (20 mL). The isolated TBS-protected 
alcohol (650 mg, 2.18 mmol, 80%) was applied for the Miyaura Borylation using 
PdCl2(PPh3)2 (48.4 mg, 69.0 µmol, 3 mol-%), Ph3P (36.6 mg, 138 µmol, 6 mol-%), 
bis(pinacolato)dibron (601 mg, 2.37 mmol, 1.1 eq.) and potassium phenoxide (427 mg, 
3.23 mmol, 1.5 eq.) in toluene (6.0 mL). After work-up and purification by flash 
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chromatography (2 cm × 13 cm, n-pentane / Et2O 20:1) the title compound 146d (370 mg, 
1.24 mmol, 58%) was obtained as a colorless liquid. The analytical data are in agreement with 
reported values.[154]  
 
C15H31BO3Si (298.30 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 5.96 (br s, 1H, C=CH2), 5.92–5.81 (m, 1H, C=CH2), 4.28 (t, 
J = 2.0 Hz, 2H, OCH2C), 1.26 (s, 12H, CH3-pin), 0.92 (s, 9H, CCH3), 0.06 (s, 6H, CH3) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 127.3 (C=CH2), 83.5 (CCH3-pin), 64.7 (OCH2), 26.1 
(C(CH3)3), 18.6 (C(CH3)3), −5.β (SiCH3) ppm. MS (EI) m/z (%): 283 ([M-CH3]+, 3), 241 (79), 
167 (11), 157 (34), 141 (26), 125 (30), 119 (41), 99 (28), 83 (100), 75 (18), 55 (16). IR: 
ṽ = 2956 (m), 2929 (s), 2897 (w), 2886 (w), 2856 (m), 1597 (w), 1494 (w), 1471 (m), 1448 
(m), 1441 (m), 1303 (w), 1258 (s), 1086 (s), 1036 (s), 1005 (w), 858 (w), 835 (s), 797 (s), 679 
(w), 631 (w) cm-1. GC (Restek Rtx®-1701 (30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 
2 min, 7 °C/min, 250 °C, 10 min): tR = 18.0 min. TLC (SiO2, n-pentane / Et2O 20:1): 
Rf = 0.36 (visualization with KMnO4). 
 
 
2-(3,3-Dimethylbut-1-en-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (146i) 
 
The intermediate vinyl iodide was obtained using 3,3-dimethyl-1-butyne (1.2 mL, 
792 mg, 9.64 mmol, 1.0 eq.) sodium iodide (3.66 g, 11.6 mmol, 1.2 eq.), TMSCl 
(1.5 mL, 1.28 g, 11.8 1.23 eq.) and water (110 µL, 110 mg, 6.11 mmol, 0.63 eq.) 
in acetonitrile (10 mL) after purification by flash chromatography (SiO2, 
n-pentane, 3 cm × 15 cm) as a purple liquid (1.63 mg, 7.76 mmol, 81%). A partial amount of 
the vinyl iodide (420 mg, 2.00 mmol, 1.0 eq.) was applied in the Miyaura Borylation using 
PdCl2(PPh3)2 (45.0 mg, 64.1 µmol, 3.2 mol-%), Ph3P (34 mg, 128 µmol, 6.4 mol-%), 
bis(pinacolato)dibron (559 mg, 2.20 mmol, 1.1 eq.) and potassium phenoxide (197 mg, 
3.00 mmol, 1.5 eq.) in toluene (12 mL). After work-up and purification by flash 
chromatography (3 cm × 8 cm, n-pentane / Et2O 100:1) the title compound 146i (153 mg, 
728 µmol, 36%) was obtained as a colorless liquid. The analytical data are in agreement with 
reported values.[154] 
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C12H23BO2 (210.18 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 5.66 (d, J = 2.7 Hz, 1H, C=CH2), 5.56 (br s, 1H, C=CH2), 
1.27 (s, 12H, pin-CH3), 1.09 (s, 9H, CH3) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 124.2 
(CH2), 83.2 (CCH3-pin), 35.5 (CCH3), 29.6 (CH3), 24.9 (CH3-pin) ppm. GC-MS (Restek 
Rtx®-5MS, 100 °C, 2 min, 10 °C/min, 270 °C, 10 min): 13.9 min. MS (EI) m/z (%): 210 (M+, 
16), 195 (18), 153 (78), 137 (10), 109 (56), 101 (80), 95 (52), 84 (100), 69 (67), 67 (28), 59 
(11), 57 (18), 55 (29), 43 (32), 41 (47). HRMS: calc. (%) 210.1786; found 210.1786. IR: 
ṽ = 2978 (m), 2954 (m), 2930 (w), 2870 (w), 1603 (w), 1481 (w), 1468 (w), 1410 (w), 1354 
(s), 1300 (s), 1246 (m), 1146 (s), 1124 (s), 968 (m), 943 (w), 883 (w), 862 (m), 835 (w), 741 
(w), 702 (m), 699 (w) cm-1. 
 
 
8.7.4 Preparation of 1,2-Bis-Boronates  
 
 
General Procedure M: To a solution of bis(pinacolato)diboron (1.0 eq.) and 
tetrakis(triphenylphosphine)platinum (0) (3 mol%) in dimethylformamide (0.2 M) the 
corresponding alkyne (1.1 eq.) was added. The obtained bright yellow solution was stirred at 
80 °C for 20 hours. After cooling down to RT; the reaction mixture was diluted with TBME 
(100 mL) and extracted with ½-sat. NaCl solution (5×150 mL). The organic layer was dried 
over MgSO4, filtered and the solvent was removed under reduced pressure. Purification was 
performed by flash chromatography, Kugelrohr distillation or using both methods if 
necessary. 
 
(E)-2,2‘-(1-Cyclohexylethene-1,2-diyl)bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolane) (149a)  
 
Following the general procedure M using bis(pinacolato)diboron 
(883 mg, 3.48 mmol, 1.0 eq.), tetrakis(triphenylphosphine)platinum (0) 
(130 mg, 104 μmol, 3 mol-%), and cyclohexylacetylene (0.5 mL, 
414 mg, 3.83 mmol, 1 eq.) in DMF (20 mL), after purification by 
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Kugelrohr distillation (β00−β10 °C / 0.4 mbar) and flash chromatography (SiO2, 
4 cm × 10 cm, cyclohexane/TBME 20:1) the title compound 149a (1.02 g, 2.82 mmol, 83%) 
was obtained as a colorless solid. The analytical data are in agreement with reported 
values.[155] 
 
C20H36B2O4 (362.12 g/mol):  
1
H-NMR (400 MHz, CDCl3): δ = 5.79 (s, 1H, C=CH), 2.09 (t, J = 11.1 Hz, 1H, CH), 1.78‒
1.69 (m, 4H, CH2), 1.64 (t, J = 12.4 Hz, 1H, CH2), 1.33 (s, 12H, pin-CH3), 1.25 (s, 12H, pin-
CH3), 1.γ0‒1.07 (m, 5H, CH2) ppm. 13C{1H}-NMR (101 MHz, CDCl3): δ = 83.8 (CCH3-pin), 
83.4 (CCH3-pin), 47.8 (CH), 32.4 (CH2), 26.8 (CH2), 26.4 (CH2), 25.2 (CH3-pin), 25.0 (CH3-
pin) ppm. GC (Restek Rtx®-1701 (30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 2 min, 
7 °C/min, 250 °C, 10 min): tR = 27.7 min. TLC (SiO2, cyclohexane/TBME 20:1): Rf = 0.12 
(visualization with KMnO4). m.p.: 6γ−64 °C.  
 
 
(E)-2,2‘-(Oct-1-ene-1,2-diyl)bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolane) (149b)  
 
Following the general procedure M using bis(pinacolato)diboron 
(1.25 g, 4.92 mmol, 1.0 eq.) tetrakis(triphenylphosphine)-
platinum (0) (184 mg, 148 μmol, 3 mol-%), and 1-octyne 
(0.8 mL, 597 mg, 5.42 mmol, 1.1 eq.) in DMF (30 mL) and after 
purification by Kugelrohr distillation (β00−β10 °C / 0.4 mbar) and flash chromatography 
(SiO2, 4 cm × 12 cm, cyclohexane/TBME 20:1) the title compound 149b (1.32 g, 3.62 mmol, 
74%) was obtained as a colorless liquid. The analytical data are in agreement with reported 
values.[155] 
 
C20H38B2O4 (364.14 g/mol):  
1
H-NMR (500 MHz, CDCl3): δ = 5.83 (s, 1H, C=CH), 2.21 (t, J = 7.7 Hz, 2H, CH2), 1.47‒
1.36 (m, 2H, CH2), 1.31 (s, 12H, pin-CH3), 1.26 (s, 12H, pin-CH3), 1.β9‒1.10 (m, 6H, CH2), 
0.86 (t, J = 6.8 Hz, 3H, CH3) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 83.7 (CCH3-pin), 
83.4 (CCH3-pin), 40.0 (CH2), 31.9 (CH2), 29.2 (CH2), 28.7 (CH2), 25.04 (CH3-pin), 25.01 
(CH3-pin), 22.7 (CH2), 14.2 (CH3) ppm. GC (Restek Rtx
®-1701 (30 m × 0.25 mm × 0.25 µm), 
60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 10 min): tR = 25.5 min. TLC (SiO2, 
cyclohexane/TBME 20:1): Rf = 0.15 (visualization with KMnO4). m.p.: 100−101 °C. 
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(E)-2,2‘-(3,3-Dimethylbutane-1,2-diyl)bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolane) 
(149c) 
 
Following the general procedure M using bis(pinacolato)diboron (1.30 g, 
5.11 mmol, 1.0 eq.) tetrakis(triphenylphosphine)-platinum (0) (191 mg, 
153 μmol, 3 mol-%), and 3,3-dimethyl-1-butyne (0.7 mL, 462 mg, 
5.62 mmol, 1.1 eq.) in DMF (30 mL) and after purification by Kugelrohr 
distillation (180−190 °C / 0.2 mbar) the title compound 149c (1.43 g, 4.25 mmol, 83%) was 
obtained as a white solid. 
 
C18H34B2O4 (336.08 g/mol):  
1
H-NMR (500 MHz, CDCl3): δ = 5.83 (s, 1H, C=CH), 1.35 (s, 12H, pin-CH3), 1.25 (s, 12H, 
pin-CH3), 1.08 (s, 9H, CH3) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 83.9 (CCH3-pin), 
83.4 (CCH3-pin), 37.8 (C(CH3)3), 29.9 (C(CH3)3), 25.5 (CH3-pin), 25.0 (CH3-pin) ppm. GC 
(Restek Rtx®-1701 (30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 2 min, 7 °C/min, 
250 °C, 10 min): tR = 21.7 min. MS (EI) m/z (%): 321 ([M-CH3]
+, 1), 278 (10), 236 (8), 221 
(5), 195 (72), 166 (37), 154 (19), 139 (10), 123 (6), 109 (12), 96 (21), 83 (100), 69 (22), 55 
(19), 41 (15). EA: calc. (%) for C18H34B2O4 C 64.33, H 10.20; found C 64.18, H 9.94. IR: 
ṽ = 2976 (m), 2964 (w), 1606 (m), 1380 (m), 1371 (m), 1336 (s), 1305 (s), 1269 (w), 1244 
(w), 1221 (m), 1212 (w), 1166 (w), 1138 (s), 1110 (w), 983 (w), 969 (m), 900 (w), 874 (w), 
858 (m), 851 (m), 835 (w), 825 (w) cm-1. m.p.: 101−10β °C.  
 
 
8.7.5 Suzuki-Miyaura Coupling  
 
 
 
General Procedure N: To a mixture of aryl bromide (1.1 eq.), PdCl2(dppf)-DCM complex 
(2 mol%), bis boronate 149a-d (1.0 eq.) and K3PO4 (3.0 eq.) were added THF (0.15 M) and 
degassed water (10.0 eq.). The obtained brown suspension was stirred at 80 °C for 16 hours. 
After cooling down to RT; the reaction mixture was diluted with water (5 mL) and extracted 
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with TBME (3×5 mL). Combined organic layers were dried over MgSO4, filtered and the 
solvent was removed under reduced pressure. Purification was performed by flash 
chromatography, Kugelrohr distillation or even using both methods if necessary. 
 
 
(E)-2-(1-Cyclohexyl-2-(p-tolyl)vinyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (149e) 
 
Following the general procedure N using 4-bromotoluene (88 mg, 
513 μmol, 1.1 eq.), PdCl2(dppf)-DCM complex (7.62 mg, 9.33 μmol, 
2 mol%), 149a (169 mg, 467 μmol, 1.0 eq.), K3PO4 (306 mg, 
1.40 mmol, 3.0 eq.), THF (2.80 mL) and H2O (85 μL, 85 mg, 
4.72 mmol, 10 eq.), after purification by flash chromatography (SiO2, 1.5 cm × 20 cm, 
cyclohexane/TBME 1:0  500:1  250:1  100:1  50:1) the title compound 149e (92 mg, 
282 μmol, 60%) was obtained as a white solid.  
 
C21H31BO2 (326.28 g/mol):  
1
H-NMR (400 MHz, CDCl3): δ = 7.21 (d, J = 8.0 Hz, 2H, HAr), 7.05 (d, J = 7.9 Hz, 2H, HAr), 
6.80 (s, 1H, C=CH), 2.31 (s, 3H, CH3), β.β6‒β.10 (m, 1H, CH), 1.87‒1.74 (m, 4H, C6H11), 
1.7γ‒1.61 (m, 1H, C6H11), 1.γ0‒1.β4 (m, 4H, C6H11), 1.27 (s, 12H, pin-CH3), 1.ββ‒1.07 (m, 
1H, C6H11) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 136.8 (C=CH), 136.7 (CAr), 136.5 
(CAr), 128.7 (HCAr), 128.1 (HCAr), 83.6 (CCH3-pin), 46.6 (CH), 33.3 (CH2), 26.9 (CH2), 26.4 
(CH2), 25.1 (CH3-pin), 21.3 (CH3) ppm. MS (EI) m/z (%): 326 ([M]
+, 74), 311 (7), 283 (6), 
269 (13), 244 (29), 231 (18), 226 (24), 211 (8), 198 (100), 187 (5), 183 (32), 169 (16), 158 
(35), 155 (27), 143 (41), 131 (25), 128 (35), 117 (22), 115 (21), 105 (35), 101 (35), 95 (6), 91 
(18), 84 (52), 79 (14), 77 (11), 69 (18), 59 (15), 57 (17), 55 (46), 43 (45), 41 (68). HRMS: 
calc. (%) 326.2412; found 326.2409. IR: ṽ = 2990 (w), 2978 (w), 2918 (s), 2847 (m), 1615 
(w), 1569 (w), 1510 (m), 1227 (w), 1420 (w), 1392 (m), 1339 (w), 1301 (s), 1291 (s), 1253 
(s), 1207 (w), 1167 (w), 1134 (s), 1104 (m), 981 (w), 960 (m), 945 (w), 906 (w), 883 (m), 854 
(s), 827 (m), 804 (m), 761 (w), 724 (m), 710 (w), 670 (w), 620 (w) cm-1. GC (Restek Rtx®-
1701 (30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 10 min): 
tR = 29.1 min. TLC (SiO2, cyclohexane/TBME 20:1): Rf = 0.24. m.p.: 54−55 °C. 
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(E)-2-(1-(p-Tolyl))oct-1-en-2-yl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (149f) 
 
Following the general procedure N using 4-bromotoluene 
(150 µL, 209 mg, 1.22 mmol, 1.1 eq.), PdCl2(dppf)-DCM 
complex (14.4 mg, 22 μmol, 2 mol%), 149b (404 mg, 
1.11 mmol, 1.0 eq.), K3PO4 (721 mg, 3.30 mmol, 3.0 eq.), THF 
(7 mL) and H2O (200 μL, 200 mg, 11.1 mmol, 10 eq.), after purification by flash 
chromatography (SiO2, 3 cm × 15 cm, cyclohexane/TBME 1:0  20:1) and Kugelrohr 
distillation (150‒160 °C / 0.15 mbar) the title compound 149f (230 mg, 701 μmol, 62%) was 
obtained as a colorless oil.  
 
C21H33BO2 (328.30 g/mol):  
1
H-NMR (400 MHz, CDCl3): δ = 7.24 (d, J = 8.0 Hz, 2H, HAr), 7.06 (d, J = 7.9 Hz, 2H, HAr), 
6.84 (s, 1H, C=CH), 2.32 (s, 3H, Ar-CH3), β.γ1‒β.β6 (m, βH, C6H10), 1.5γ‒1.4γ (m, 2H, 
C6H10), 1.40‒1.β6 (m, 6H, C6H10), 1.26 (s, 12H, pin-CH3), 0.89 (t, J = 6.8 Hz, 3H, CH3) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 139.8 (C=CH), 136.6 (CAr), 136.3 (CAr), 128.7 
(HCAr), 128.1 (HCAr), 83.5 (CCH3-pin), 38.4 (CH2), 31.9 (CH2), 29.9 (CH2), 29.2 (CH2), 24.9 
(CH3-pin), 22.8 (CH2), 21.3 (Ar-CH3), 14.3 (CH3) ppm. MS (EI) m/z (%): 328 ([M]
+, 99), 271 
(14), 244 (42), 228 (38), 213 (44), 200 (51), 171 43), 157 (80), 143 (61), 139 (12), 131 (47), 
129 (67), 118 (68), 115 (30), 105 (44), 101 (100), 91 (22), 83 (78), 55 (61), 43 (80), 41 (79). 
HRMS: calc. (%) 328.2574; found 328.2572. IR: ṽ = 2977 (m), 2955 (m), 2924 (s), 2853 (m), 
1615 (w), 1510 (w), 1463 (w), 1391 (m), 1370 (w), 1339 (w), 1302 (s), 1253 (s), 1212 (w), 
1164 (w), 1143 (s), 1111 (w), 964 (w), 863 (w), 803 (w), 713 (w) cm-1. GC (Restek Rtx®-
1701 (30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 10 min): 
tR = 26.9 min. TLC (SiO2, cyclohexane/TBME 20:1): Rf = 0.24. 
 
 
(E)-2-(3,3-Dimethyl-1-(p-tolyl)but-1-en-2-yl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
(149g) 
 
Following the general procedure N using 4-bromotoluene (112 mg, 
655 μmol, 1.1 eq.), PdCl2(dppf)-DCM complex (10.0 mg, 12.2 μmol, 
2 mol%), 149c (200 mg, 595 μmol, 1.0 eq.), K3PO4 (721 mg, 3.30 mmol, 
3.0 eq.), THF (4 mL) and H2O (110 μL, 110 mg, 6.11 mmol, 10 eq.), after 
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purification by flash chromatography (SiO2, 3 cm × 12 cm, cyclohexane/TBME 1:0  100:1) 
and Kugelrohr distillation (150‒160 °C / 0.15 mbar) the title compound 149g (118 mg, 
393 μmol, 66%) was obtained as a colorless oil.  
 
C19H29BO2 (300.24 g/mol):  
1
H-NMR (400 MHz, CDCl3): δ = 7.22 (d, J = 8.0 Hz, 2H, HAr), 7.06 (d, J = 7.9 Hz, 2H, HAr), 
6.84 (s, 1H, C=CH), 2.31 (s, 3H, Ar-CH3), 1.24 (s, 12H, pin-CH3), 1.19 (s, 9H, CH3) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 137.1 (CAr), 136.3 (CAr), 133.9 (C=CH), 128.7 
(HCAr), 128.1 (HCAr), 83.6 (CCH3-pin), 36.2 (CCH3), 30.4 (CCH3), 25.3 (CH3-pin), 21.3 (Ar-
CH3) ppm. MS (EI) m/z (%): 300 ([M]
+, 67), 285 (31), 200 (41), 185 (100), 172 (56), 169 
(11), 157 (78), 143 (35), 131 (20), 128 (28), 119 (15), 115 (21), 105 (13), 101 (47), 91 (17), 
83 (54), 77 (9), 69 (13), 67 (13), 59 (12), 55 (41), 43 (50), 41 (79). EA: calc. (%) for 
C19H29BO2 C 76.01, H 9.74; found C 76.22, H 9.71. IR: ṽ = 2961 (m), 2951 (w), 2903 (w), 
2366 (w), 1516 (w), 1511 (m), 1479 (w), 1462 (w), 1412 (w), 1384 (s), 1336 (w), 1298 (s), 
1251 (s), 1210 (w), 1142 (s), 1110 (w), 1037 (w), 1006 (w), 960 (w), 860 (m), 832 (w), 808 
(w), 686 (w) cm-1. GC (Restek Rtx®-1701 (30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 
2 min, 7 °C/min, 250 °C, 10 min): tR = 22.2 min. TLC (SiO2, cyclohexane/TBME 20:1): 
Rf = 0.23.  
 
 
(E)-2-(1-Cyclohexyl-2-phenylvinyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (4i) 
 
Following the general procedure N using bromobeneze (70 μL, 104 mg, 
664 μmol, 1.1 eq.), PdCl2(dppf)-DCM complex (9.9 mg, 12.1 μmol, 
2 mol%), 149a (219 mg, 604 μmol, 1.0 eq.), K3PO4 (397 mg, 1.81 mmol, 
3.0 eq.), THF (4.0 mL) and H2O (109 μL, 109 mg, 6.05 mmol, 10 eq.), 
after purification by flash chromatography (SiO2, 3 cm × 12 cm, cyclohexane/TBME 1:0  
500:1  250:1  100:1) the title compound 149i (137 mg, 439 μmol, 73%) was obtained as a 
white solid. 
 
C20H29BO2 (312.25 g/mol):  
1
H-NMR (400 MHz, CDCl3): δ = 7.32 (d, J = 7.5 Hz, 2H, HAr), 7.28–7.22 (m, 2H, HAr), 7.21–
7.14 (m, 1H, HAr), 6.85 (s, 1H, C=CH), β.β6‒β.14 (m, 1H, C6H11), 1.88‒1.74 (m, 4H, C6H11), 
1.70 (d, J = 12.5 Hz, 1H, C6H11), 1.γ9‒1.β5 (m, 4H, C6H11), 1.26 (s, 12H, pin-CH3), 1.βγ‒
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1.09 (m, 1H, C6H11) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 139.5 (CAr), 136.7 (C=CH), 
128.0 (HCAr), 127.8 (HCAr), 126.7 (HCAr), 83.5 (CCH3-pin), 46.5 (CH), 33.1 (CH2), 26.7 
(CH2), 26.2 (CH2), 24.9 (CH3-pin) ppm. MS (EI) m/z (%): 312 ([M]
+, 43), 297 (3), 255 (13), 
230 (16), 212 (19), 199 (4), 184 (100), 169 (13), 155 (26), 144 (51), 129 (48), 117 (31), 115 
(31), 105 (23), 101 (37), 95 (11), 91 (35), 84 (81), 79 (14), 77 (18), 69 (25), 67 (21), 59 (14), 
57 (16), 55 (46), 43 (48), 41 (76). EA: calc. (%) for C20H29BO2 C 76.93; H 9.36; found C 
76.72; H 9.19;. IR: ṽ = 2981 (m), 2925 (s), 2848 (s), 1617 (w), 1598 (w), 1574 (w), 1486 (w), 
1427 (m), 1410 (m), 1370 (m), 1344 (w), 1305 (s), 1293 (s), 1256 (s), 1207 (m), 1166 (w), 
1135 (s), 1113 (s), 1028 (w), 962 (m), 936 (w), 914 (w), 882 (m), 863 (m), 852 (s), 823 (w), 
783 (m) 749 (s), 731 (s), 690 (s), 668 (m), 635 (m) cm-1. GC (Restek Rtx®-1701 
(30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 10 min): 
tR = 27.2 min. TLC (SiO2, cyclohexane/TBME 20:1): Rf = 0.22. m.p.: 5γ−54 °C.  
 
 
(E)-2-(1-Cyclohexyl-2-(4-methoxyphenyl)vinyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
(149j) 
 
Following the general procedure N using 4-bromoanisole (80 μL, 
119 mg, 637 μmol, 1.1 eq.), PdCl2(dppf)-DCM complex (10.2 mg, 
12.5 μmol, 2 mol%), 149a (210 mg, 579 μmol, 1.0 eq.), K3PO4 
(380 mg, 1.74 mmol, 3.0 eq.), THF (4.0 mL) and H2O (104 μL, 104 
mg, 5.79 mmol, 10 eq.), after purification by flash chromatography (SiO2, 1.5 cm × 27 cm, 
cyclohexane / TBME 100:1  50:1) the title compound 149j (126 mg, 368 μmol, 64%) was 
obtained as a white solid.  
 
C21H31BO3 (342.28 g/mol):  
1
H-NMR (500 MHz, CDCl3): δ = 7.28–7.23 (m, 2H, HAr), 6.81–6.76 (m, 3H, HAr, C=CH), 
3.79 (s, 3H, OCH3), β.β4‒β.09 (m, 1H, C6H11), 1.8γ‒1.74 (m, 4H, C6H11), 1.72–1.65 (m, 1H, 
C6H11), 1.γ6‒1.β8 (m, 4H, C6H11), 1.27 (s, 12H, pin-CH3), 1.β1‒1.1γ (m, 1H, C6H11) ppm. 
13
C{
1
H}-NMR (126 MHz, CDCl3): δ = 158.8 (CAr), 136.5 (C=CH), 132.4 (CAr), 129.4 
(HCAr), 113.4 (HCAr), 83.6 (CCH3-pin), 55.4 (CH3), 46.6 (CH), 33.3 (CH2), 26.9 (CH2), 26.4 
(CH2), 25.1 (CH3-pin) ppm. MS (EI) m/z (%): 342 ([M]
+, 98), 327 (57), 299 (6), 285 (9), 270 
(8), 260 (39), 247 (21), 242 (18), 234 (8), 227 (8), 214 (51), 199 (19), 184 (19), 171 (22), 159 
(37), 155 (14), 147 (21), 144 (31), 134 (23), 128 (26), 121 (79), 115 (36), 108 (11), 101 (42), 
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91 (19), 83 (100), 77 (19), 69 (18), 59 (20), 57 (21), 55 (63), 43 (57), 41 (85). HRMS: calc. 
(%) 342.2361; found 342.2367. IR: ṽ = 2976 (w), 2921 (m), 2849 (m), 1607 (m), 1572 (w), 
1508 (s), 1443 (w), 1391 (w), 1368 (w), 1338 (w), 1309 (m), 1290 (s), 1258 (m), 1241 (s), 
1215 (m), 1176 (m), 1147 (w), 1136 (s), 1121 (w), 1106 (m), 1205 (s), 983 (w), 960 (w), 906 
(w), 881 (m), 861 (m), 832 (s), 808 (m), 758 (w), 731 (w), 716 (m), 672 (w), 653 (w) cm-1. 
GC (Restek Rtx®-1701 (30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 2 min, 7 °C/min, 
250 °C, 20 min): tR = 34.7 min. TLC (SiO2, cyclohexane/TBME 20:1): Rf = 0.22. m.p.: 
66−67 °C.  
 
 
(E)-2-(1-Cyclohexyl-2-(4-(trifluoromethyl)phenyl)vinyl-4,4,5,5-tetramethyl-1,3,2-
dioxaborolane (149k) 
 
Following the general procedure N using 4-bromo-trifluorotoluene 
(90 μL, 144 mg, 640 μmol, 1.1 eq.), PdCl2(dppf)-DCM complex 
(10.2 mg, 12.5 μmol, 2 mol%), 149a (211 mg, 582 μmol, 1.0 eq.), 
K3PO4 (382 mg, 1.75 mmol, 3.0 eq.), THF (4.0 mL) and H2O 
(105 μL, 105 mg, 5.81 mmol, 10 eq.), after purification by flash chromatography (SiO2, 2 cm 
× 13 cm, cyclohexane/TBME 100:1  50:1) the title compound 149k (142 mg, 374 μmol, 
64%) was obtained as a white solid. 
 
C21H28BF3O2 (380.25 g/mol):  
1
H-NMR (400 MHz, CDCl3): δ = 7.50 (d, J = 8.2 Hz, 2H, HAr), 7.41 (d, J = 8.5 Hz, 2H, HAr), 
6.84 (s, 1H, C=CH), β.β6‒β.14 (m, 1H, C6H11), 1.88‒1.75 (m, 4H, C6H11), 1.74–1.64 (m, 1H, 
C6H11), 1.γ8‒1.β8 (m, 4H, C6H11), 1.25 (s, 12H, pin-CH3), 1.19‒1.1β (m, 1H, C6H11) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 143.2 (CAr), 135.5 (C=CH), 128.8 (q, JCF = 32.3 Hz, 
CAr), 128.4 (HCAr), 124.9 (q, JCF = 3.8 Hz, HCArCCF3), 124.5 (q, JCF = 272 Hz, CF3), 83.9 
(CCH3-pin), 46.6 (CH), 33.0 (CH2), 27.8 (CH2), 26.3 (CH2), 25.0 (CH3-pin) ppm. 
19
F{
1
H}-NMR (376 MHz, CDCl3): −6β.γ (s) ppm. MS (EI) m/z (%): 380 ([M]+, 30), 365 (5), 
361 (8), 323 (19), 298 (12), 279 (12), 252 (47), 212 (26), 197 (9), 183 (17), 177 (9), 265 (8), 
159 (9), 143 (5), 128 (6), 101 (40), 95 (18), 84 (100), 69 (20), 67 (18), 59 (12), 57 (13), 55 
(31), 43 (35), 41 (50). HRMS: calc. (%) 380.2129; found 380.2137. IR: ṽ = 2981 (w), 2925 
(m), 2851 (w), 1612 (m), 1573 (w), 1447 (w), 1423 (w), 1391 (m), 1370 (w), 1320 (s), 1302 
(s), 1250 (s), 1210 (w), 1161 (s), 1138 (m), 1107 (s), 1064 (s), 1014 (m), 987 (w), 960 (m), 
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906 (w), 888 (w), 867 (w), 853 (m), 832 (s), 819 (m), 790 (w), 763 (w), 718 (w), 679 (m), 658 
(m) cm-1. GC (Restek Rtx®-1701 (30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 2 min, 
7 °C/min, 250 °C, 10 min): tR = 25.9 min. TLC (SiO2, cyclohexane/TBME 20:1): Rf = 0.22. 
m.p.: 6γ−64 °C. 
 
 
(E)-2-(1-Cyclohexyl-2-(3-fluorophenyl)vinyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
(149l) 
 
Following the general procedure N using 1-bromo-3-fluorobenzene 
(80 μL, 125 mg, 716 μmol, 1.1 eq.), PdCl2(dppf)-DCM complex 
(11.5 mg, 14.0 μmol, 2 mol%), 149a (236 mg, 651 μmol, 1.0 eq.), 
K3PO4 (428 mg, 1.95 mmol, 3.0 eq.), THF (5.0 mL) and H2O (120 μL, 
120 mg, 6.66 mmol, 10 eq.), after purification by flash chromatography (SiO2, 2 cm × 15 cm, 
cyclohexane/ethyl acetate 50:1) the title compound 149l (161 mg, 488 μmol, 75%) was 
obtained as a white solid.  
 
C20H28BFO2 (330.24 g/mol):  
1
H-NMR (400 MHz, CDCl3): δ = 7.βγ‒7.14 (m, 1H, HAr), 7.10‒7.0β (m, βH, HAr), 6.87 (ddd, 
J = 8.5, 2.5, 1.2 Hz, 1H, HAr), 6.79 (s, 1H, C=CH), β.β6‒β.1γ (m, 1H, C6H11), 1.88‒1.7γ (m, 
4H, C6H11), 1.69 (dd, J = 12.6, 1.3 Hz, 1H, C6H11), 1.γ7‒1.β8 (m, 4H, C6H11), 1.26 (s, 12H, 
pin-CH3), 1.β1‒1.08 (m, 1H, C6H11) ppm. 13C{1H}-NMR (101 MHz, CDCl3): δ = 162.8 (d, 
JCF = 245 Hz, FCAr), 142.0 (d, JCF = 7.6 Hz, CAr-m-F), 135.6 (d, JCF = 2.3 Hz, C=CH), 129.4 (d, 
JCF = 8.5 Hz, HCAr-m-F), 124.0 (d, JCF = 1.7 Hz, HCAr-p-F), 114.7 (d, JCF = 21.4 Hz, HCAr-o-F), 
113.6 (d, JCF = 21.2 Hz, HCAr-o-F), 83.9 (CCH3-pin), 46.6 (CH), 33.1 (CH2), 26.8 (CH2), 26.4 
(CH2), 25.0 (CH3-pin) ppm. 
19
F{
1
H}-NMR (376 MHz, CDCl3): −114.6 (s) ppm. MS (EI) m/z 
(%): 330 ([M]+, 47), 273 (15), 248 (12), 230 (19), 205 (10), 202 (80), 187 (7), 174 (8), 162 
(36), 147 (28), 141 (10), 135 (15), 128 (10), 123 (9), 115 (10), 109 (17), 101 (49), 95 (20), 84 
(100), 81 (10), 69 (21), 55 (22), 43 (16), 41 (24). EA: calc. (%) for C20H28BFO2 C 72.74; H 
8.55; found C 72.64, H 8.57. IR: ṽ = 2979 (m), 2927 (s), 2849 (m), 1609 (w), 1580 (m), 1482 
(w), 1445 (m), 1416 (w), 1390 (m), 1369 (w), 1338 (w), 1301 (s), 1291 (s), 1256 (m), 1240 
(m), 1209 (w), 1165 (w), 1133 (s), 1115 (s), 986 (m), 960 (m), 901 (w), 882 (w), 863 (w), 848 
(m), 830 (w), 800 (w), 776 (s), 752 (w), 728 (w), 688 (s), 667 (w) cm-1. GC (Restek Rtx®-
1701, 100 °C, 2 min, 7 °C/min, 270 °C, 10 min): 27.0 min. TLC (SiO2, cyclohexane/ethyl 
acetate 50:1): Rf = 0.11. m.p.: γγ−γ4 °C. 
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(E)-2-(1-Cyclohexyl-3-phenylprop-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
(149m) 
 
This compound was obtained according to the procedure published by 
Shimizu and coworkers:[156] To a mixture of Pd(PPh3)4 (28.9 mg, 
25.0 μmol, 5 mol%), Cs2CO3 (977 mg, 3.00 mmol, 6.0 eq.), and 149a 
(217 mg, 600 μmol) 1.3 eq.) were added subsequently benzyl bromide 
(60 μL, 85.8 mg, 502 μmol, 1.0 eq.), THF (10 mL) and water (450 μL, 
450 mg, 25.0 mmol, 50 eq.). The obtained suspension was stirred at 60 °C for 3 h. After 
cooling down to rt the reaction mixture was treated with water (10 mL) and extracted with 
ethyl acetate (3×10 mL). The combined organic layers were dried over MgSO4, filtered and 
the solvent was removed under reduced pressure. After purification by flash chromatography 
(SiO2, 2 cm × 16 cm, cyclohexane/TBME 100:1  50:1) the title compound 149m (127 mg, 
389 μmol, 78%) was obtained as a white solid. 
 
C21H31BO2 (326.28 g/mol):  
1
H-NMR (400 MHz, CDCl3): δ = 7.γ1‒7.β4 (m, βH, HAr), 7.β4‒7.1γ (m, γH, HAr), 6.03 (t, 
J = 7.5 Hz, 1H, C=CH), 3.61 (d, J = 7.6 Hz, 2H, Ar-CH2), 2.07 (t, J = 11.2 Hz, 1H, C6H11), 
1.76‒1.58 (m, 4H, C6H11), 1.30 (s, 12H, pin-CH3), 1.β8‒1.05 (m, 6H, C6H11) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 141.8 (CAr), 139.6 (C=CH), 128.8 (HCAr), 128.4 
(HCAr), 125.8 (HCAr), 83.2 (CCH3-pin), 44.6 (CH), 38.0 (Ar-CH2), 33.3 (CH2), 27.0 (CH2), 
26.5 (CH2), 25.0 (CH3-pin) ppm. MS (EI) m/z (%): 326 ([M]
+, 23), 241 (32), 235 (13), 230 
(5), 226 (17), 199 (6), 197 (9), 191 (5), 165 (8), 155 (5), 144 (89), 135 (44), 129 (16), 121 (5), 
117 (20), 107 (23), 101 (100), 91 (33), 85 (2), 83 (54), 81 (11), 79 (12), 69 (10), 67 (17), 57 
(15), 55 (31), 43 (12), 41 (19). EA: calc. (%) for C21H31BO2 C 77.30, H 9.58; found C 77.21, 
H 9.44. IR: ṽ = 2977 (m), 2919 (s), 2851 (m), 1628 (m), 1601 (w), 1494 (w), 1449 (w), 1421 
(w), 1402 (s), 1368 (m), 1356 (m), 1345 (w), 1313 (m), 1298 (w), 1285 (m), 1251 (s), 1210 
(m), 1163 (w), 1136 (s), 1068 (w), 1030 (w), 983 (m), 962 (m), 932 (m), 890 (w), 873 (m), 
849 (m), 832 (m), 746 (s), 732 (w), 715 (m), 699 (s), 681 (m), 661 (w), 620 (w) cm-1. GC 
(Restek Rtx®-1701 (30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 2 min, 7 °C/min, 
250 °C, 10 min): tR = 28.7 min. TLC (SiO2, cyclohexane/ethyl acetate 50:1): Rf = 0.30. m.p.: 
48−49 °C. 
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(E)-2-(1-Cyclohexylbut-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (149n) 
 
This compound was obtained according to the procedure published by 
Shimizu and coworkers:[157] To a mixture of Pd(OAc)2 (6.2 mg, 27.9 μmol, 
5 mol%), [t-Bu2MePH]BF4 (13.8 mg, 55.8 μmol, 10 mol%), NaOH 
(67.0 mg, 1.67 mmol, 3.0 eq.), and 149a (202 mg, 558 μmol, 1.0 eq.) were 
added ethyl bromide (50 μL, 73.0 mg, 670 μmol, 1.2 eq.) and dry dioxane 
(1.5 mL). The obtained suspension was stirred at 60 °C for 20 h. After cooling down to rt the 
reaction mixture was diluted with ethyl acetate (5 mL), filtered over a plug of silica gel (2 cm 
× 2 cm) and washed with ethyl acetate (3×5 mL). Combined filtrates were concentrated in 
vacuo. After purification by flash chromatography (SiO2, 2 cm × 20 cm, cyclohexane/ethyl 
acetate 500:1) the title compound 149n (28 mg, 106 μmol, 19%) was obtained as a colorless 
oil. 
 
C16H29BO2 (264.21 g/mol):  
1
H-NMR (400 MHz, CDCl3): δ = 5.87 (t, J = 7.4 Hz, 1H, C=CH), 2.22 (pent., J = 7.5 Hz, 2H, 
CH2CH3), 1.98 (dq, J = 11.6, 4.0, 3.2 Hz, 1H, C6H11), 1.77‒1.55 (m, 5H, C6H11), 1.28 (s, 12H, 
pin-CH3), 1.γγ‒1.06 (m, 5H, C6H11), 0.95 (p, J = 7.5 Hz, 3H, CH2CH3) ppm. 13C{1H}-NMR 
(101 MHz, CDCl3): δ = 142.9 (C=CH), 83.0 (CCH3-pin), 44.6 (CH), 33.4 (CH2), 27.0 (CH2), 
26.5 (CH2), 25.0 (CH3-pin), 24.9 (CH2CH3), 14.9 (CH2CH3) ppm. MS (EI) m/z (%): 264 
([M]+, 15), 207 (23), 179 (12), 164 (17), 149 (5), 136 (100), 121 (9), 107 (21), 101 (50), 95 
(14), 84 (81), 81 (18), 79 (12), 69 (15), 67 (20), 57 (10), 55 (22), 43 (12), 41 (18). HRMS: 
calc. (%) 264.2256; found 264.2256. IR: ṽ = 2975 (m), 2923 (s), 2852 (s), 2360 (w), 1702 
(w), 1626 (w), 1473 (w), 1448 (m), 1405 (w), 1370 (m), 1325 (m), 1298 (m), 1285 (s), 1251 
(s), 1214 (w), 1143 (s), 1105 (m), 1023 (w), 983 (w), 864 (w), 803 (w), 714 (m), 676 (w) 
cm-1. GC (Restek Rtx®-1701 (30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 2 min, 
7 °C/min, 250 °C, 10 min): tR = 17.7 min. TLC (SiO2, cyclohexane/ethyl acetate 500:1): 
Rf = 0.10 (visualization with KMnO4). 
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(Z)-4,4,5,5-Tetramethyl-2-(2-phenylbut-1-en-1-yl)-1,3,2-dioxaborolane (149o):  
 
To a solution of zirconocene dichloride (351 mg, 1.20 mmol, 1.2 eq.) in THF 
(6.0 mL) n-BuLi (1.6 M, 1.5 mL, 2.40 mmol, 2.4 mmol, 2.4 eq.) was added 
drop wise at −78 °C. The reaction mixture was stirred for 1 h at −78 °C. 
Ethylene gas was passed into the reaction mixture using a Teflon® cannula 
during 5 min, than a ballon filled with ethylene gas was placed on the reaction flask for 1 h. 
The cooling bath was removed and the reaction mixture was stirred for additional 1 h. 
2-Phenyl-1-ethynylboronic acid pinacol ester (228 mg, 1.00 mmol, 1.0 eq.) was added and the 
reaction mixture was stirred for 1 h at RT. The reaction mixture was quenched by adding HCl 
1M solution (5 mL) and extracted with diethyl ether (3×10 mL). The combined organic layers 
were dried over MgSO4, filtered and concentrated under reduced pressure. Purification by 
Kugelrohr distillation (115‒120 °C/ 0.4 mbar) gave the title compound 149o (96 mg, 372 
μmol, 37%) as a colorless oil. The analytical data are in agreement with reported values.[148] 
 
C16H23BO2 (258.16 g/mol):  
1
H-NMR (400 MHz, CDCl3): δ = 7.γ0‒7.ββ (m, 5H, HAr), 5.44 (d, J = 1.3 Hz, 1H, C=CH), 
2.48 (qd, J = 7.2, 1.3 Hz, 2H, CH2CH3), 1.12 (s, 12H, pin-CH3), 1.04 (t, J = 7.4 Hz, 3H, 
CH2CH3) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 163.8 (C=CH), 143.2 (CAr), 128.0 
(HCAr), 127.7 (HCAr), 127.3 (HCAr), 83.1 (CCH3-pin), 33.5 (CH2CH3), 24.7 (CH3-pin), 12.7 
(CH2CH3) ppm. GC (Restek Rtx
®-1701 (30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 
2 min, 7 °C/min, 250 °C, 10 min): tR = 18.7 min.  
 
 
8.7.6 Hydrogenation at Low Pressure and Low Temperature, General Procedure O 
A 2 mL-glass vial was charged with a stirring bar, iridium catalyst (0.5 mol-%) and substrate 
(50-100 µmol). The mixture was dissolved in DCM (0.2 M) and placed in an autoclave. The 
equipment was pressurized with nitrogen (1 bar) and cooled down to −β0 °C for 1 hour. The 
autoclave was then five times pressurized up to 10 bar with hydrogen and the pressure 
released. The reaction was performed under 2 bar H2 atmosphere during 4 hours at −β0 °C. 
After releasing the hydrogen pressure the reaction mixture was allowed to reach rt and the 
solvent was removed under reduced pressure. The crude product was taken up in n-heptane 
(1 mL) and purified over a plug of silica gel (SiO2, 0.5 cm × 1 cm n-heptane/TBME 10:1) to 
obtain analytically pure hydrogenation product.  
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General Procedure P for the Oxidation of the Analytical Samples: 
In a 2 mL-glass vial hydrogenation product (50-100 µmol) was dissolved in THF/water 1:1 
(0.2 M) and oxidized using potassium perborate monohydrate (1.5 eq.). After stirring for 1 h at 
RT, the reaction mixture was extracted with DCM (3×1 mL). The combined organic layers 
were dried over MgSO4 and filtrated. To the filtrate trifluoroacetic anhydride TFAA 
(5-10 eq.) was added and the mixture was stirred for 30 min at RT. The volatiles were 
removed by purging with nitrogen (carefully, some samples are volatile). The residue was 
dissolved in n-heptane (1 mL) and analyzed by GC. 
 
 
 
 
Assignment of the Absolute Configuration:  
The absolute configuration of 147a was assigned by comparison of the chiral GC spectra 
obtained after oxidation and trifluoroacetylation with an authentic GC spectra of 
trifluoroacetylated (S)-octan-2-ol obtained via enzymatic kinetic resolution of racemic 
secondary alcohols.[95] All other products were assigned in analogy with this.  
 
 
8.7.7 Analytical Data for the Hydrogenation Products Derived from Terminal 
Alkenylboronic Esters 
For known compounds only [α]D20, 1H, 13C-NMR and conditions for ee determination (tr of 
main enantiomer highlighted in bold in all cases) are listed. 
 
(R)-2-(Octan-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (147a)
[141]
  
 
C14H29BO2 (240.19 g/mol):  
1
H-NMR (400 MHz, CDCl3): δ = 1.49–1.40 (m, 1H, CH), 1.39–1.12 (br 
m, 9H, CH2), 1.23 (s, 12H, CH3-pin), 1.09–0.92 (m, 4H, CH3, CH2), 0.87 
(t, J = 6.8 Hz, 3H, CH3) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): 
δ = 82.9 (CCH3-pin), 33.4 (CH2), 32.0 (CH2), 29.7 (CH2), 29.1 (CH2), 24.89 (CH3-pin), 24.86 
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(CH3-pin), 22.8 (CH2), 15.7 (CHCH3), 14.3 (CH3) ppm. GC (Restek Rtx
®-1701 
(30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 2 min, 10 °C/min, 270 °C, 5 min): 
tR = 13.1 min. [α]D20: −1.5 (c = 1.00, CH2Cl2). GC (chiral, (30 m × 0.25 mm × 0.12 µm), 60 
kPa H2, 50 °C, 1 °C/min, 65 °C, 10 °C/min, 160 °C, 10 min): 96% ee, tR = 13.0 min (R), 
14.3 min (S) as oxidation / trifluoroacetylation product.  
 
 
(R)-2-(Hexan-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (147b)  
 
C12H25BO2 (212.14 g/mol):  
1
H-NMR (400 MHz, CD2Cl2): δ = 1.45–1.35 (m, 1H, CH), 1.34–1.22 (m, 6H, 
CH2), 1.20 (s, 12H, CH3-pin), 1.00–0.78 (m, 6H, CH3) ppm. 13C{1H}-NMR 
(101 MHz, CD2Cl2): δ = 83.2 (CCH3-pin), 33.5 (CH2), 31.7 (CH2), 25.10 
(CH3-pin), 25.07 (CH3-pin), 23.5 (CH2), 15.9 (CHCH3), 14.6 (CH3) ppm. GC (Restek Rtx
®-
1701 (30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 2 min, 10 °C/min, 270 °C, 5 min): 
tR = 9.0 min. MS (EI) m/z (%): 212 ([M]
+, 0.9), 197 (33), 170 (6), 154 (5), 141 (5), 129 (23), 
126 (34), 112 (34), 101 (14), 85 (67), 71 (64), 55 (42), 43 (100). HRMS: calc. (%) for [M-
CH3] 197.1708; found 197.1700. IR: ṽ = 2976 (m), 2956 (s), 2924 (s), 2871 (m), 2855 (m), 
2361 (w), 2324 (w), 1463 (m), 1407 (w), 1381 (s), 1373 (s), 1313 (s), 1275 (m), 1249 (w), 
1229 (w), 1144 (s), 1111 (w), 967 (w), 859 (w), 786 (w), 670 (w), 631 (w) cm-1. [α]D20: −4.4 
(c = 0.55, CHCl3). GC (chiral, Chiraldex G-TA, Ȗ–cyclodextrin TFA (30 m × 0.25 mm × 
0.12 µm), 60 kPa H2, 40 °C, 10 min, 10 °C/min, 160 °C, 10 min): 95% ee, tR = 8.0 min (R), 
11.7 min (S) as oxidation / trifluoroacetylation product.  
 
 
(R)-2-(6-Chlorohexan-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (147c)  
 
C12H24BClO2 (246.58 g/mol):  
1
H-NMR (400 MHz, CD2Cl2): δ = 3.54 (t, J = 6.8 Hz, 2H, ClCH2), 1.75 
(dt, J = 13.7, 6.8 Hz, 2H, ClCH2CH2), 1.50‒1.γ7 (m, γH, CH2, CH), 
1.γβ‒1.β4 (m, βH, CH2), 1.21 (s, 12H, CH3-pin), 0.95‒0.77 (m, γH, CH3) 
ppm. 13C{1H}-NMR (101 MHz, CD2Cl2): δ = 83.4 (CCH3-pin), 45.9 (ClCH2), 33.5 (CH2), 
33.0 (CH2), 26.7 (CH2), 25.12 (CH3-pin), 25.08 (CH3-pin), 15.8 (CHCH3) ppm. MS (EI) m/z 
(%): 246 ([M]+, 0.6), 233 (10), 231 (32), 162 (15), 160 (39), 146 (18), 131 (11), 118 (15), 105 
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(16), 101 (13), 83 (66), 69 (47), 55 (72), 43 (100). EA: calc. (%) for C12H24BClO2 C 58.45, H 
9.81; found C 58.70, H 9.98. IR: ṽ = 2977 (s), 2930 (s), 2868 (m), 2361 (w), 2330 (w), 1463 
(m), 1379 (s), 1314 (s), 1256 (w), 1217 (m), 1145 (s), 1110 (w), 967 (w), 858 (w), 688 (w), 
649 (w) cm-1. GC (Restek Rtx®-1701 (30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 
2 min, 7 °C/min, 250 °C, 10 min): tR = 16.0 min. [α]D20: −5.β (c = 1.20, CH2Cl2). GC (chiral, 
Chiraldex G-TA, Ȗ–cyclodextrin TFA (30 m × 0.25 mm × 0.12 µm), 60 kPa H2, 40 °C, 
40 min, 10 °C/min, 160 °C, 10 min): 94% ee, tR = 31.8 min (R), 34.3 min (S) as oxidation / 
trifluoroacetylation product.  
 
 
(R)-tert-Butyldimethyl((2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propoxy)silane 
(147d)  
 
C15H33BO3Si (300.32 g/mol):  
1
H-NMR (400 MHz, CDCl3): δ = 3.67 (dd, J = 9.5, 6.1 Hz, 1H, OCH2), 
3.60 (dd, J = 9.4, 7.4 Hz, 1H, OCH2), 1.28–1.25 (m, 1H, CH), 1.23 (s, 12H, 
CH3-pin), 0.97 (d, J = 7.4 Hz, 3H, CHCH3), 0.88 (s, 9H, C CH3), 0.06 (s, 
6H, SiCH3) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 83.1 (CCH3-pin), 66.3 (OCH2), 26.1 
(CCH3), 24.94 (CH3-pin), 24.92 (CH3-pin), 12.3 (CHCH3), –5.2 (s, SiCH3) ppm. MS (EI) m/z 
(%): 285 ([M-CH3]
+, 2), 243 (54), 185 (10), 143 (23), 119 (29), 101 (35), 83 (100), 75 (18), 
55 (10). HRMS: calc. (%) for [M-CH3] 285.2052; found 285.2055. IR: ṽ = 2959 (m), 2928 
(m), 2360 (w), 2328 (w), 1469 (w), 1460 (w), 1375 (w), 1318 (w), 1259 (s), 1217 (m), 1145 
(w), 1090 (s), 1024 (s), 803 (m), 757 (s), 667 (w) cm-1. GC (Restek Rtx®-1701 
(30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 10 min): tR = 
15.3 min. GC (chiral, Macherey-Nagel Hydrodex-ß-3P (25 m × 0.25 mm × 0.25 µm), 60 kPa 
H2, 90 °C, 90 min, 10 °C/min, 180 °C, 10 min): 88% ee, tR = 74.1 min (S), 78.7 min (R). 
[α]D20: −0.6 (c = 0.70, CHCl3). 
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(R)-2-(4-Phenylbutan-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (147e)  
 
C16H25BO2 (260.18 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 7.29–7.23 (m, 2H, HAr), 7.22–7.11 (m, 
3H, HAr), 2.61 (t, J = 8.1 Hz, 2H, Ar-CH2), 1.80–1.66 (m, 1H, CH2), 1.62–
1.49 (m, 1H, CH2), 1.31–1.19 (m, 13H, CH, CH3-pin), 1.06–0.94 (m, 3H, 
CH3) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 143.7 (CAr), 128.8 
(HCAr), 128.5 (HCAr), 125.8 (HCAr), 83.2 (CCH3-pin), 35.5 (CH2), 35.4 (CH2), 25.95 
(CH3-pin), 25.90 (CH3-pin), 15.6 (CH3) ppm. MS (EI) m/z (%): 260 ([M]
+, 12), 245 (5), 187 
(7), 160 (5), 145 (5), 132 (100), 117 (14), 105 (11), 101 (30), 99 (22), 91 (45), 85 (69), 69 
(15), 57 (18), 55 (13), 43 (12), 41 (11). HRMS: calc. (%) 260.1943; found 260.1948. IR: 
ṽ = 3025 (w), 2976 (m), 2925 (m), 2870 (w), 2854 (w), 1603 (w), 1496 (w), 1457 (m), 1382 
(m), 1368 (s), 1314 (s), 1273 (w), 1213 (w), 1165 (m), 1143 (s), 1111 (w), 1010 (w), 967 (w), 
861 (m), 847 (w), 746 (w), 699 (s), 670 (w) cm-1. GC (Restek Rtx®-1701 
(30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 10 min): tR = 
20.0 min. [α]D20: −8.7 (c = 1.20, CH2Cl2). GC (chiral, Chiraldex G-TA, Ȗ–cyclodextrin TFA 
(30 m × 0.25 mm × 0.12 µm), 60 kPa H2, 75 °C, 0 min, 1 °C/min, 100 °C, 0 min, 10 °C/min, 
160 °C, 10 min): 94% ee, tR = 22.0 min (R), 22.7 min (S) as oxidation / trifluoroacetylation 
product.  
 
 
(R)-2-(1-Phenylpropan-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (147f)
[141]
  
 
C15H23BO2 (246.15 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 7.28–7.18 (m, 4H, HAr), 7.17–7.11 (m, 1H, 
HAr), 2.81 (dd, J = 13.6, 7.5 Hz, 1H, Ar-CH2), 2.54 (dd, J = 13.6, 8.4 Hz, 1H, 
Ar-CH2), 1.42–1.31 (m, 1H, CH), 1.19 (s, 6H, CH3-pin), 1.18 (s, 6H, 
CH3-pin), 0.97 (d, J = 7.4 Hz, 3H, CH3) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 142.5 
(CAr), 129.0 (HCAr), 128.1 (HCAr), 125.7 (HCAr), 83.1 (CCH3-pin), 39.1 (Ar-CH2), 24.86 (s, 
CH3-pin), 24.84 (s, CH3-pin), 15.3 (CH3) ppm. MS (EI) m/z (%): 246 ([M]
+, 5), 231 (8), 189 
(16), 145 (29), 131 (15), 118 (34), 105 (21), 91 (67), 84 (100), 69 (11), 65 (11), 59 (11), 55 
(14), 43 (30). GC (Restek Rtx®-1701 (30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 
2 min, 7 °C/min, 250 °C, 10 min): tR = 17.9 min. HPLC (chiral, Daicel Chiracel OD-H, 
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0.46 cm×25 cm, n-heptane, 0.5 mL/min, 25 °C): 94% ee, tR = 22.8 min (R), 26.2 min (S). 
[α]D20: −β.1 (c = 0.71, CHCl3). 
 
 
(R)-2-(1-Phenylethyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (147g)
[158]
  
 
C14H21BO2 (232.13 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 7.21–7.12 (m, 4H, HAr), 7.10–6.99 (m, 1H, 
HAr), 2.36 (q, J = 7.5 Hz, 1H, Ar-CH), 1.26 (d, J = 7.5 Hz, 3H, CH3), 1.14 (s, 
6H, CH3-pin), 1.12 (s, 6H, CH3-pin) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): 
δ = 145.1 (CAr), 128.4 (HCAr), 127.9 (HCAr), 125.2 (HCAr), 83.4 (CCH3-pin), 24.76 (s, 
CH3-pin), 24.72 (s, CH3-pin), 17.2 (CH3) ppm. GC (Restek Rtx
®-1701 
(30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 10 min): 
tR = 16.1 min. HPLC (chiral, Daicel Chiracel OJ-H, 4.6 mm × 250 mm, n-heptane / 
i-propanol 99:1, 0.5 mL/min, 20 °C): 4% ee, tR = 9.4 min (R), 11.0 min (S). 
 
 
(R)-2-(1-Cyclohexylethyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (147h)
[141]
  
 
C14H27BO2 (238.17 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 1.77–1.56 (m, 5H, CHB, CH, CH2), 1.37–
0.83 (m, 10H, CH2, CH3), 1.23 (m, 12H, CH3-pin) ppm. 
13
C{
1
H}-NMR 
(101 MHz, CDCl3): δ = 82.9 (CCH3-pin), 40.6 (CH), 32.9 (CH2), 32.0 (CH2), 
26.92 (CH2), 26.86 (2×CH2), 24.97 (CH3-pin), 24.88 (CH3-pin), 12.7 (CH3) ppm. GC (Restek 
Rtx®-1701 (30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 2 min, 10 °C/min, 250 °C, 
5 min): tR = 13.1 min. [α]D20: −0.γ (c = 0.70, CHCl3). GC (chiral, Brechbühler SE54 ß-
cyclodextrin DEtTButSil, (25 m × 0.25 mm × 0.25 μm) 100 kPa H2, 50 °C, 0 min, 1 °C/min, 
70 °C, 10 °C/min, 160 °C, 10 min): 33% ee, tR = 15.3 min (S), 16.0 min (R) as oxidation / 
trifluoroacetylation product.  
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8.7.8 General Procedure R for Hydrogenation at Elevated Pressure 
A 2 mL-glass vial was charged with a stirring bar, iridium catalyst (1.0 mol%) and substrate 
(25-200 µmol). The mixture was dissolved in DCM (0.2 M) and placed in an autoclave. The 
autoclave was then three times pressurized up to 50 bar with hydrogen and the pressure 
released. The reaction was performed under 50 bar H2 atmosphere for a given time at RT. 
After releasing the hydrogen pressure the solvent was removed under reduced pressure or 
under a stream of nitrogen. The crude product was taken up in n-heptane (1 mL) and purified 
over a plug of silica (SiO2, 0.5 cm × 1 cm, n-heptane/TBME 10:1) to obtain the 
hydrogenation product suitable for analysis. 
 
 
8.7.9 Analytical Data for the Hydrogenation Products Derived from Trisubstituted 
Boronic Esters 
 
(+)-2,2‘-(1-Cyclohexylethane-1,2-diyl)bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolane) 
(150a)
[159]
  
 
C20H38B2O4 (364.14 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 1.68‒1.5γ (m, 5H, C6H11,), 1.γ7‒1.β7 
(m, 1H, CH), 1.23 (s, 12H, pin-CH3), 1.22 (s, 12H, pin-CH3), 1.18‒0.96 
(m, 6H, C6H11), 0.86 (dd, J = 15.7, 11.1 Hz, 1H, CH2B), 0.76 (dd, 
J = 15.7, 5.0 Hz, 1H, CH2B) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 82.90 (CCH3-pin), 
82.87 (CCH3-pin), 41.6 (CH), 32.3 (CH2), 32.1 (CH2), 27.03 (CH2), 27.00 (CH2), 26.88 
(CH2), 25.10 (CH3-pin), 25.09 (CH3-pin), 24.9 (CH3-pin), 24.8 (CH3-pin) ppm. GC (Restek 
Rtx®-1701 (30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 
5 min): tR = 25.9 min. [α]D20: +3.0 (c = 0.90, CHCl3). GC (chiral, Varian CP-Chiralsil-dex 
CB (25 m × 0.25 mm × 0.25 μm), 60 kPa H2, 120 °C, 0 min, 0.1 °C/min, 142 °C, 0 min, 
10 °C/min, 160 °C, 10 min): 95% ee , tR = 204 min (+), 206 min (−) or Chiraldex G-TA Ȗ–
cyclodextrin TFA (30 m × 0.25 mm × 0.12 µm), 60 kPa H2, 100 °C, 10 min, 10 °C/min, 
160 °C, 10 min): tR = 9.8 min (+), 10.4 (−) as oxidation / trifluoroacetylation product.  
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(+)-2,2‘-(Octane-1,2-diyl)bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolane) (150b) 
  
C20H40B2O4 (366.15 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 1.51‒1.γ6 (m, 1H, CH), 1.γ5‒
1.04 (m, 10H, C6H13), 1.23 (s, 12H, pin-CH3), 1.22 (s, 12H, 
pin-CH3), 0.9γ‒0.8γ (m, 4H, CH3, CH2B), 0.76 (dd, J = 15.8, 
5.9 Hz, 1H, CH2B) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 82.94 (CCH3-pin), 82.87 
(CCH3-pin), 34.0 (CH2), 32.0 (CH2), 29.7 (CH2), 29.0 (CH2), 25.06 (CH3-pin), 24.99 
(CH3-pin), 24.92 (CH3-pin), 24.89 (CH3-pin), 22.8 (CH2), 14.3 (CH3) ppm. MS (EI) m/z (%): 
351 ([M-CH3]
+, 2), 307 (7), 225 (33), 183 (9), 127 (9), 113 (14), 101 (6), 84 (100), 69 (18), 55 
(13), 41 (9). EA: calc. (%) for C20H40B2O4 C 65.61, H 11.01; found C 65.41; H, 10.78. IR: 
ṽ = 2977 (m), 2959 (w), 2923 (s), 2853 (w), 1466 (w), 1368 (m), 1334 (s), 1311 (s), 1267 (w), 
1214 (w), 1163 (w), 1140 (s), 968 (m), 885 (w), 845 (w), 671 (w), 631 (w) cm-1. GC (Restek 
Rtx®-1701 (30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 
10 min): tR = 24.2 min. [α]D20: +0.9 (c = 0.93, CHCl3). GC (chiral, Chiraldex Ȗ–cyclodextrin 
TFA G-TA (30 m × 0.25 mm × 0.12 µm), 60 kPa H2, 100 °C, 10 min, 10 °C/min, 160 °C, 
10 min): tR = 8.3 min (+), 8.8 (−) as oxidation / trifluoroacetylation product.  
 
 
(+)-2,2‘-(3,3-Dimethlybutane-1,2-diyl)bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolane) (150c)  
 
C18H36B2O4 (338.10 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 1.25 (s, 12H, pin-CH3), 1.22 (s, 6H, 
pin-CH3), 1.21 (s, 6H, pin-CH3), 0.96 (dd, J = 11.8, 4.5 Hz, 1H, CHB), 
0.91 (s, 9H, CH3), 0.86‒0.74 (m, βH, CH2B) ppm. 13C{1H}-NMR 
(101 MHz, CDCl3): δ = 83.0 (CCH3-pin), 82.8 (CCH3-pin), 32.5 (C(CH3)3), 29.2 (C(CH3)3), 
25.35 (CH3-pin), 25.24 (CH3-pin), 24.99 (CH3-pin), 24.76 (CH3-pin) ppm. MS (EI) m/z (%): 
323 ([M-CH3]
+, 4), 280 (11), 223 (15), 197 (75), 182 (78), 167 (16), 140 (16), 127 (6), 101 
(10), 97 (8), 83 (100), 69 (29), 57 (19), 55 (27), 43 (13), 41 (20). EA: calc. (%) for 
C18H36B2O4 C 63.94, H 10.73; found C 63.94; H 10.60. IR: ṽ = 2976 (m), 2932 (w), 2886 
(w), 1609 (w), 1267 (w), 1389 (m), 1368 (s), 1353 (s), 1305 (s), 1274 (w), 1237 (m), 1214 
(w), 1191 (w), 1163 (m), 1139 (s), 1110 (m), 1095 (w), 1051 (w), 1007 (w), 967 (s), 919 (w), 
879 (m), 846 (m), 835 (w), 815 (w), 769 (w), 691 (w), 673 (m) cm-1. GC (Restek Rtx®-1701 
(30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 10 min): 
tR = 20.5 min. [α]D20: +0.5 (c = 0.77, CHCl3). GC (chiral, Brechbühler SE54 ß-cyclodextrin 
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DEtTButSil (25 m × 0.25 mm × 0.25 μm), 100 kPa H2, 50 °C, 0 min, 1 °C/min, 60 °C, 0 min, 
10 °C/min, 180 °C, 10 min): 86% ee, tR = 5.3 min (‒), 7.0 min (+) as oxidation / 
trifluoroacetylation product.  
 
 
(+)-2,2‘-(1-Phenylethane-1,2-diyl)bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolane) (150d)[159]  
 
C20H32B2O4 (358.09 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 7.22 (d, J = 4.4 Hz, 4H, HAr), 7.09 (h, 
J = 4.1 Hz, 1H, HAr), 2.52 (dd, J = 11.0, 5.7 Hz, 1H, Ar-CH), 1.38 (dd, 
J = 16.0, 11.0 Hz, 1H, CH2), 1.20 (s, 12H, pin-CH3), 1.19 (s, 6H, 
pin-CH3), 1.17 (s, 6H, pin-CH3), 1.11 (dd, J = 16.0, 5.7 Hz, 1H, CH2) ppm. 
13
C{
1
H}-NMR 
(101 MHz, CDCl3): δ = 145.5 (CAr), 128.3 (HCAr), 128.0 (HCAr), 125.0 (HCAr), 83.3 
(CCH3-pin), 83.2 (CCH3-pin), 25.1 (CH3-pin), 24.84 (CH3-pin), 24.81 (CH3-pin), 24.6 
(CH3-pin) ppm. GC (Restek Rtx
®-1701 (30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 
2 min, 7 °C/min, 250 °C, 10 min): tR = 26.9 min. HPLC (chiral, Daicel Chiracel OD-H, 
0.46 cm × 25 cm, n-heptane, 0.5 mL/min, 20 °C): 98% ee, tR = 26.4 min (–), 32.4 min (+). 
[α]D20: +31.0 (c = 0.80, CHCl3). 
 
 
(–)-2-(1-Cyclohexyl-2-(p-tolyl)ethyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (150e)  
 
C21H33BO2 (328.30 g/mol): 
1
H-NMR (500 MHz, CDCl3): δ = 7.11‒7.08 (m, βH, HAr), 7.03 (d, 
J = 7.9 Hz, 2H, HAr), 2.74 (dd, J = 13.5, 6.2 Hz, 1H, Ar-CH2), 2.61 (dd, 
J = 13.5, 10.7 Hz, 1H, Ar-CH2), 2.29 (s, 3H, Ar-CH3), 1.85‒1.66 (m, 
4H, C6H11,), 1.64 (dddd, J = 12.4, 5.0, 3.1, 1.6 Hz, 1H, CH), 1.47–1.35 
(m, 1H, C6H11), 1.32–1.10 (m, 4H, C6H11), 1.13 (s, 6H, pin-CH3), 1.08 (s, 6H, pin-CH3), 
1.09‒0.9γ (m, βH, C6H11) ppm. 13C{1H}-NMR (126 MHz, CDCl3): δ = 139.7 (CAr), 134.9 
(CAr), 128.9 (HCAr), 128.8 (HCAr), 83.0 (CCH3-pin), 40.0 (CH), 34.7 (CH2), 33.3 (CH2), 32.4 
(CH2), 26.92 (CH2), 26.91 (CH2), 26.87 (CH2), 24.99 (CH3-pin), 24.96 (CH3-pin), 21.1 (CH3) 
ppm. MS (EI) m/z (%): 328 ([M]+, 12), 271 (2), 223 (3), 200 (100), 179 (2), 167 (8), 165 (10), 
145 (7), 143 (5), 131 (7), 118 (22), 105 (72), 101 (34), 91 (12), 84 (60), 79 (12), 69 (10), 57 
(16), 55 (37), 41 (34). HRMS: calc. (%) 328.2569 found 328.2571. IR: ṽ = 3382 (br m), 3026 
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(w), 2977 (m), 2928 (w), 2862 (w), 2362 (w), 2335 (w), 1600 (w), 1497 (m), 1449 (m), 1236 
(m), 1364 (s), 1326 (s), 1248 (w), 1213 (w), 1142 (s), 1105 (w), 1071 (w), 1028 (w), 971 (m), 
910 (w), 852 (m), 789 (w), 734 (m), 700 (s), 671 (w) cm-1. GC (Restek Rtx®-1701 
(30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 10 min): 
tR = 28.2 min. HPLC (chiral, Daicel Chiracel OD-H, 4.6 mm × 250 mm, n-heptane, 
0.5 mL/min, 20 °C): 97% ee, tR = 11.0 min (−), 1γ.9 min (+). [α]D20: –8.8 (c = 0.76, CHCl3). 
 
 
(+)-2-(1-(p-Tolyl)octan-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (150f)  
 
C21H35BO2 (330.31 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 7.09 (d, J = 8.1 Hz, 2H, HAr), 
7.04 (d, J = 7.9 Hz, 2H, HAr), 2.68 (dd, J = 13.6, 8.3 Hz, 1H, Ar-
CH2), 2.60 (dd, J = 15.7, 7.2 Hz, 1H, Ar-CH2), 2.29 (s, 3H, Ar-
CH3), 1.4β‒1.β0 (m, 11H, C5H10, CH), 1.17 (s, 6H, pin-CH3), 1.14 (s, 6H, pin-CH3), 0.87 (t, 
J = 6.9 Hz, 3H, CH3) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 139.4 (CAr), 135.0 (CAr), 
128.9 (HCAr), 128.8 (HCAr), 83.0 (CCH3-pin), 37.0 (CH2), 32.0 (CH2), 31.2 (CH2), 29.7 
(CH2), 29.3 (CH2), 24.92 (CH3-pin), 24.87 (CH3-pin), 22.8 (CH2), 14.2 (CH3) ppm. MS (EI) 
m/z (%): 330 ([M]+, 12), 315 (3), 273 (4), 229 (3), 202 (100), 159 (7), 145 (7), 131 (21), 118 
(22), 105 (94), 101 (17), 91 (11), 84 (78), 79 (9), 69 (12), 57 (12), 55 (23), 43 (31), 41 (32). 
EA: calc. (%) for C 76.36, H 10.68; found C 76.08; H, 10.55. IR: ṽ = 2974 (m), 2951 (s), 
2866 (m), 2362 (w), 2328 (w), 1514 (s), 1473 (w), 1370 (s), 1319 (s), 1239 (m), 1213 (w), 
1142 (s), 1104 (w), 975 (w), 864 (w), 839 (w), 805 (w), 667 (w) cm-1. GC (Restek Rtx®-1701 
(30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 10 min): 
tR = 25.9 min. HPLC (chiral, Daicel Chiracel OD-H, 4.6 mm × 250 mm, n-heptane, 
1.0 mL/min, 20 °C): 95% ee, tR = 6.1 min (−), 9.2 min (+). [α]D20: +3.3 (c = 0.81, CHCl3). 
 
 
(‒)-2-(3,3-Dimethyl-1-(p-tolyl)butan-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (150g)  
 
C19H31BO2 (302.26 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 7.10 (d, J = 8.0 Hz, 2H, HAr), 7.06 (d, 
J = 7.9 Hz, 2H, HAr), 2.78 (dd, J = 13.1, 4.2 Hz, 1H, Ar-CH2), 2.56 (t, 
J = 12.9 Hz, 1H, Ar-CH2), 2.27 (s, 3H, Ar-CH3), 1.β9‒1.ββ (m, 1H, CH), 
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1.04 (d, J = 33.8 Hz, 12H, pin-CH3), 1.02 (s, 9H, CH3) ppm. 
13
C{
1
H}-NMR (101 MHz, 
CDCl3): δ = 137.1 (CAr), 134.9 (CAr), 129.1 (HCAr), 128.8 (HCAr), 82.9 (CCH3-pin), 32.7 
(CCH3), 32.3 (ArCH2), 29.8 (CCH3), 25.2 (CH3-pin), 24.7 (CH3-pin), 21.3 (Ar-CH3) ppm. 
MS (EI) m/z (%): 302 ([M]+, 14), 287 (3), 245 (9), 231 (2), 201 (3), 189 (12), 174 (100), 159 
(22), 145 (16), 131 (7), 128 (4), 118 (9), 105 (80), 101 (21), 97 (9), 84 (95), 77 (8), 69 (13), 
57 (40), 55 (21), 43 (30), 41 (40). EA: calc. (%) for C19H31BO2 302.2417; found submitted. 
IR: ṽ = 2974 (m), 2951 (s), 2886 (m), 2361 (w), 2329 (w), 1514 (m), 1473 (w), 1370 (s), 1319 
(s), 1239 (m), 1213 (w), 1142 (s), 1104 (w), 975 (w), 864 (w), 839 (w), 805 (m), 776 (w), 667 
(w), 631 (w) cm-1. GC (Restek Rtx®-1701 (30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 
2 min, 7 °C/min, 250 °C, 5 min): tR = 21.8 min. HPLC (chiral, Daicel Chiracel OD-H, 4.6 
mm × 250 mm, n-heptane, 1.0 mL/min, 20 °C): 96% ee, tR = 4.3 min (+), 4.7 min (−). [α]D20: 
‒ β6.8 (c = 0.80, CHCl3). 
 
 
(−)-2-(1,2-Diphenylethyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (150h)[160]  
 
C20H25BO2 (308.22 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 7.41–7.10 (m, 10H, HAr), 3.17 (dd, 
J = 13.5, 9.8 Hz, 1H, Ar-CH2), 2.98 (dd, J = 13.6, 7.0 Hz, 1H, Ar-CH2), 
2.70 (dd, J = 9.8, 6.9 Hz, 1H, Ar-CH), 1.13 (s, 6H, pin-CH3), 1.12 (s, 6H, 
pin-CH3) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 142.7 (CAr), 141.9 
(CAr), 129.0 (HCAr), 128.5 (HCAr), 128.4 (HCAr), 128.2 (HCAr), 125.9 (HCAr), 125.5 (HCAr), 
83.5 (CCH3-pin), 39.0 (CH2), 24.7 (s, CH3-pin), 24.6 (s, CH3-pin) ppm. GC (Restek Rtx
®-
1701 (30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 10 min): 
tR = 27.2 min. HPLC (chiral, Daicel Chiracel OJ-H, 4.6 mm × 250 mm, n-heptane / 
i-propanol 99:1, 0.5 mL/min, 20 °C): 96% ee, tR = 10.6 min (−), 15.0 min (+). [α]D20: −4β.β 
(c = 0.78, CHCl3). 
 
 
(−)-2-(1-Cyclohexyl-2-phenylethyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane) (150i)  
 
C20H31BO2 (314.27 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 7.25–7.18 (m, 4H, HAr), 7.16–7.08 (m, 
1H HAr), 2.80 (dd, J = 13.4, 6.1 Hz, 1H, Ar-CH2), 2.63 (dd, J = 13.4, 
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11.0 Hz, 1H, Ar-CH2), 1.88‒1.60 (m, 5H, C6H11), 1.48‒1.γ7 (m, 1H, CH), 1.γ4‒1.04 (m, 6H, 
C6H11), 1.11 (s, 6H, pin-CH3), 1.06 (s, 6H, pin-CH3) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): 
δ = 142.9 (CAr), 129.1 (HCAr), 128.1 (HCAr), 125.6 (HCAr), 83.0 (CCH3-pin), 40.1 (CH), 35.1 
(CH2), 33.3 (CH2), 32.5 (CH2), 26.92 (CH2), 26.90 (CH2), 26.87 (CH2), 25.0 (CH3-pin), 24.9 
(CH3-pin) ppm. MS (EI) m/z (%): 314 ([M]
+, 4), 299 (5), 257 (7), 223 (13), 186 (100), 179 
(3), 167 (12), 145 (4), 131 (9), 129 (6), 123 (5), 117 (6), 109 (3), 104 (16), 101 (44), 95 (9), 
91 (45), 84 (63), 81 (6), 69 (8), 67 (7), 65 (6), 57 (12), 55 (29), 43 (17), 41 (26). EA: calc. (%) 
for C20H31BO2 C 76.44, H 9.94; found C 76.23, H 9.83. IR: ṽ = 2977 (m), 2920 (s), 2850 (m), 
1602 (w), 1495 (w), 1447 (m), 1205 (w), 1379 (s), 1360 (m), 1315 (m), 1239 (m), 1213 (w), 
1143 (s), 1107 (w), 1030 (w), 975 (w), 961 (w), 863 (w), 699 (m) cm-1. GC (Restek Rtx®-
1701 (30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 20 min): 
tR = 26.7 min. HPLC (chiral, Daicel Chiracel IC, 4.6 mm × 250 mm, n-heptane, 
0.75 mL/min, 20 °C): 99% ee, tR = 10.0 min (+), 10.5 min (−). [α]D20: −8.1 (c = 0.78, CHCl3). 
 
 
(−)-2-(1-Cyclohexyl-2-(4-methoxyphenyl)ethyl)--4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
(150j)  
 
C21H33BO3 (344.39 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 7.15–7.09 (m, 2H, HAr), 6.80–
6.75 (m, 2H HAr), 3.76 (s, 3H, OCH3), 2.73 (dd, J = 13.5, 6.1 Hz, 
1H, Ar-CH2), 2.58 (dd, J = 13.5, 10.9 Hz, 1H, Ar-CH2), 1.85‒1.59 
(m, 5H, C6H11), 1.49‒1.γ6 (m, 1H, CH), 1.β9‒0.99 (m, 6H, C6H11), 1.12 (s, 6H, pin-CH3), 
1.07 (s, 6H, pin-CH3) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 157.7 (CAr), 135.0 (CAr), 
130.0 (HCAr), 113.6 (HCAr), 83.0 (CCH3-pin), 55.4 (CH3), 40.0 (CH), 34.2 (CH2), 33.3 (CH2), 
32.4 (CH2), 26.93 (CH2), 26.92 (CH2), 26.88 (CH2), 25.01 (CH3-pin), 24.97 (CH3-pin) ppm. 
MS (EI) m/z (%): 344 ([M]+, 12), 215 (17), 121 (100), 84 (6), 77 (5), 55 (11), 43 (7), 41 (12). 
EA: calc. (%) for C21H33BO3 C 73.26; H 9.66; found C 73.32; H 9.56. IR: ṽ = 2974 (m), 2920 
(s), 2849 (m), 1717 (w), 1609 (w), 1582 (w), 1510 (s), 1463 (w), 1447 (m), 1379 (m), 1259 
(w), 1240 (s), 1215 (m), 1176 (m), 1165 (m), 1142 (s), 1101 (w), 1034 (m), 976 (w), 961 (w), 
889 (w), 864 (w), 839 (m), 807 (w), 720 (w) cm-1. GC (Restek Rtx®-1701 
(30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 20 min): 
tR = 33.2 min. HPLC (chiral, Daicel Chiracel OD-H, 4.6 mm × 250 mm, n-heptane, 
0.5 mL/min, 20 °C): 97% ee, tR = 23.0 min (+), 26.4 min (−). [α]D20: −1β.0 (c = 0.85, CHCl3). 
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(−)-2-(1-Cyclohexyl-2-(4-(trifluoromethyl)phenyl)ethyl)-4,4,5,5-tetramethyl-1,3,2-
dioxaborolane (150k)  
 
C21H30BF3O2 (382.27 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 7.48 (d, J = 8.1 Hz, 2H, HAr), 7.31 
(d, J = 8.0 Hz, 2H, HAr), 2.82 (dd, J = 13.5, 6.0 Hz, 1H, Ar-CH2), 
2.70 (dd, J = 13.4, 11.0 Hz, 1H, Ar-CH2), 1.85‒1.61 (m, 5H, C6H11), 
1.48‒1.γ6 (m, 1H, CH), 1.γ5‒0.98 (m, 6H, C6H11), 1.11 (s, 6H, pin-CH3), 1.06 (s, 6H, 
pin-CH3) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 147.3 (CAr), 129.4 (HCAr), 125.0 (q, 
JCF = 3.7 Hz, HCAr), 83.2 (CCH3-pin), 40.1 (CH), 35.0 (CH2), 33.2 (CH2), 32.4 (CH2), 26.9 
(CH2), 26.8 (CH2), 24.9 (s, CH3-pin) ppm. 
19
F{
1
H}-NMR (382 MHz, CDCl3): −6β.γ (s) ppm. 
MS (EI) m/z (%): 382 ([M]+, 0.5), 367 ([M-CH3]
+,9), 363 (7), 325 (29), 299 (4), 282 (3), 263 
(8), 254 (5), 243 (5), 234 (14), 223 (7), 213 (7), 199 (5), 179 (6), 167 (14), 159 (31), 153 (6), 
140 (11), 128 (15), 123 (7), 109 (8), 101 (44), 95 (10), 91 (4), 84 (100), 81 (7), 69 (11), 59 
(12), 57 (16), 55 (41), 43 (25), 41 (34). EA: calc. (%) for C21H30BF3O2 C 65.98, H 7.91; 
found C 65.78; H 7.92. IR: ṽ = 2979 (w), 2923 (s), 2852 (m), 2361 (w), 2338 (w), 1617 (w), 
1450 (w), 1415 (w), 1376 (m), 1323 (s), 1267 (w), 1240 (w), 1163 (m), 1142 (s), 1123 (s), 
1068 (m), 1018 (w), 976 (w), 961 (w), 844 (w), 815 (w), 634 (w) cm-1. GC (Restek Rtx®-1701 
(30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 10 min): 
tR = 25.7 min. [α]D20: −8.γ (c = 0.93, CHCl3). HPLC (chiral, Daicel Chiracel AD-H, 4.6 mm 
× 250 mm, n-heptane / i-propanol 99:1, 0.5 mL/min, 20 °C): 98% ee, tR = 19.8 min (+), 
32.2 min (−) as oxidation product.  
 
 
(−)-2-(1-Cyclohexyl-2-(3-fluorophenyl)ethyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
(150l)  
 
C20H30BFO2 (332.26 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 7.17 (td, J = 7.9, 6.2 Hz, 1H, HAr), 
6.97 (d, J = 7.7 Hz, 1H, HAr), 6.94‒6.88 (m, 1H, HAr), 6.81 (td, J = 8.3, 
2.0 Hz, 1H, HAr), 2.77 (dd, J = 13.5, 6.0 Hz, 1H, Ar-CH2), 2.64 (dd, 
J = 13.4, 11.0 Hz, 1H, Ar-CH2), 1.84‒1.60 (m, 5H, C6H11), 1.42 (dddd, 
J = 14.7, 11.5, 6.4, 3.2 Hz, 1H, CH), 1.γγ‒1.00 (m, 6H, C6H11), 1.12 (s, 6H, pin-CH3), 1.08 (s, 
6H, pin-CH3) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 162.9 (d, JCF = 245 Hz, FCAr), 
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145.7 (d, JCF = 7.2 Hz, CAr-m-F), 129.5 (d, JCF = 8.3 Hz, HCAr-m-F), 124.7 (d, JCF = 2.7 Hz, 
HCAr-p-F), 115.9 (d, JCF = 20.7 Hz, HCAr-o-F), 112.4 (d, JCF = 21.1 Hz, HCAr-o-F), 83.2 (CCH3-
pin), 40.1 (CH), 35.0 (d, JCF = 1.1 Hz, Ar-CH2), 33.2 (CH2), 32.4 (CH2), 26.90 (CH2), 26.85 
(CH2), 24.99 (s, CH3-pin), 24.95 (s, CH3-pin) ppm. 
19
F{
1
H}-NMR (382 MHz, CDCl3): 
−114.6 (s) ppm. MS (EI) m/z (%): 332 ([M]+, 3), 317 (10), 275 (39), 179 (12), 167 (18), 149 
(7), 141 (6), 137 (5), 135 (5), 128 (14), 123 (16), 110 (72), 101 (79), 95 (15), 84 (100), 69 
(13), 57 (19), 55 (32), 43 (13), 41 (19). EA: calc. (%) for C20H30BFO2 C 72.30, H 9.10; found 
C 72.11, H 9.08. IR: ṽ = 2978 (m), 2922 (s), 2851 (m), 2360 (w), 2335 (w), 1615 (w), 1588 
(m), 1487 (m), 1447 (m), 1404 (w), 1376 (s), 1360 (m), 1315 (m), 1285 (w), 1268 (w), 1239 
(m), 1215 (m), 1165 (w), 1142 (s), 1106 (w), 1070 (w), 977 (w), 960 (w), 945 (w), 887 (w), 
858 (m), 779 (w), 756 (s), 688 (m) cm-1. GC (Restek Rtx®-1701 (30 m × 0.25 mm × 
0.25 µm), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 10 min): tR = 26.6 min. HPLC 
(chiral, Daicel Chiracel OD-H, 4.6 mm × 250 mm, n-heptane / i-propanol 95:5, 0.5 mL/min, 
20 °C): 98% ee, tR = 10.4 min (+), 12.2 min (−) as oxidation product. [α]D20: −6.5 (c = 0.79, 
CHCl3). 
 
 
(−)-2-(1-Cyclohexyl-3-phenylpropyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (150m)  
 
C21H33BO2 (328.30 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 7.30–7.23 (m, 2H, HAr), 7.21–7.12 
(m, 3H, HAr), 2.63 (ddd, J = 13.5, 10.8, 5.3 Hz, 1H, Ar-CH2), 2.60 
(ddd, J = 13.5, 10.5, 6.3 Hz, 1H, Ar-CH2), 1.81‒1.59 (m, 7H, C6H11), 
1.46–1.37 (m, 1H, CH2), 1.γγ‒1.00 (m, 6H, C6H11), 1.28 (s, 12H, 
pin-CH3) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 143.4 (CAr), 128.5 (HCAr), 128.3 
(HCAr), 125.7 (HCAr), 83.0 (CCH3-pin), 39.8 (CH), 36.2 (CH2), 33.0 (CH2), 32.6 (CH2), 31.2 
(CH2), 26.95 (CH2), 26.93 (CH2), 26.90 (CH2), 25.3 (CH3-pin), 25.0 (CH3-pin) ppm. MS (EI) 
m/z (%): 328 ([M]+, 8), 237 (4), 200 (100), 153 (4), 145 (6), 140 (6), 137 (8), 131 (6), 129 (7), 
117 (23), 109 (29), 104 (56), 101 (46), 95 (9), 91 (39), 85 (98), 81 (9), 79 (5), 69 (14), 67 
(13), 57 (8), 55 (30), 43 (12), 41 (16). EA: calc. (%) for C21H33BO2 C 76.83, H 10.13; found 
C 76.67, H 10.21. IR: ṽ = 2976 (w), 2922 (s), 2850 (m), 1495 (w), 1448 (m), 1386 (m), 1370 
(w), 1355 (m), 1310 (s), 1268 (w), 1273 (w), 1223 (s), 1213 (m), 1167 (w), 1139 (s), 1105 
(w), 1029 (w), 967 (m), 960 (m), 906 (w), 888 (w), 864 (s), 843 (m), 770 (m), 732 (s), 724 (s), 
697 (s), 671 (m) cm-1. GC (Restek Rtx®-1701 (30 m × 0.25 mm × 0.25 µm), 60 kPa He, 
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100 °C, 2 min, 7 °C/min, 250 °C, 10 min): tR = 29.2 min. HPLC (chiral, Daicel Chiracel OD-
H, 4.6 mm × 250 mm, n-heptane, 0.2 mL/min, 20 °C): 96% ee, tR = 29.6 min (−), γβ.γ min 
(+). [α]D20: −1.1 (c = 0.80, CHCl3). 
 
 
(+)-2-(1-Cyclohexylbutyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (150n)  
 
C16H31BO2 (266.23 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 1.8γ‒1.5β (m, 5H, C6H11), 1.48‒1.08 (m, 
8H, C6H11, C3H7), 1.25 (s, 12H, pin-CH3), 1.08‒0.9β (m, 2H, C4H8), 0.91–
0.80 (m, 4H, C4H8) ppm.
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 82.9 
(CCH3-pin), 39.9 (CH), 33.1 (CH2), 32.7 (CH2), 31.3 (CH2), 29.7 (CH2), 26.99 (CH2), 26.96 
(CH2), 25.1 (CH3-pin), 25.0 (CH3-pin), 23.0 (CH2), 14.7 (CH3) ppm. MS (EI) m/z (%): 266 
([M]+, 2), 251 (13), 209 (11), 181 (5), 165 (8), 155 (7), 138 (24), 129 (65), 123 (8), 110 (8), 
101 (43), 97 (36), 84 (100), 69 (19), 67 (16), 57 (9), 55 (36), 43 (17), 41 (20). HRMS: calc. 
(%) 266.2412; found 266.2412. IR: ṽ = 2967 (m), 2921 (s), 2952 (s), 2359 (w), 2332 (w), 
1454 (w), 1377 (s), 1312 (m), 1243 (w), 1146 (s), 968 (w), 891 (w), 860 (w), 627 (w) cm-1. 
GC (Restek Rtx®-1701 (30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 2 min, 7 °C/min, 
250 °C, 10 min): tR = 18.0 min. [α]D20: +0.5, (c = 0.60, CHCl3). GC (chiral, Brechbühler 
SE54 ß-cyclodextrin DEtTButSil (25 m × 0.25 mm × 0.25 μm), 100 kPa H2, 80 °C, 0 min, 
0.25 °C/min, 100 °C, 10 °C/min, 180 °C, 10 min): 97% ee, tR = 107 min (−), 110 min (+).  
 
 
(R)-Methyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)octanoate (150p) 
[64]
 
 
C15H29BO4 (284.20 g/mol): 
1
H-NMR (400 MHz, CDCl3): δ = 3.64 (m, 3H, OCH3), 2.48‒2.33 
(m, 2H, CH2CO), 1.49‒1.38 (m, 1H, CH), 1.36‒1.26 (m, 8H, CH2), 
1.24 (s, 6H, pin-CH3), 1.23 (s, 6H, pin-CH3), 0.86 (t, J = 6.8 Hz, 3H, 
CH3) ppm. GC (Restek Rtx
®-1701 (30 m × 0.25 mm × 0.25 µm), 60 kPa He, 100 °C, 2 min, 
10 °C/min, 250 °C, 10 min): tR = 16.3 min, 17.2 min (146p). GC (chiral, Varian CP-Sil 88 
(25 m × 0.25 mm × 0.25 μm), 60 kPa H2, 110 °C, 80 min, 10 °C/min, 160 °C, 5 min):, 90% 
ee, tR = 75.2 min (R), 77.5 min (S).  
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8.8 P-Alkyl SimplePHIM Derived Ir-Complexes and Modification of 
SimplePHOX Derived Ir- Complexes for Asymmetric Hydrogenation 
8.8.1 Formation of Ligand Precursorsors  
(S,Z)-iso-Propyl 2-chloro-2-((1-chloro-3-methylbutan-2-yl)imino)acetate ((S)-169a)  
 
DMF (12 μL, 11.3 mg, 155 μmol, 0.025 eq.) was added to a solution of 
(S)-isopropyl 2-((1-hydroxy-3-methylbutan-2-yl)amino)-2-oxoacetate 
(1.33 g, 6.12 mmol, 1.0 eq.) in thionyl chloride (3.6 mL, 5.90 g, 
49.6 mmol, 8.1 eq.). The reaction mixture was stirred at 85 °C for 6 hours. After removing the 
excess of thionyl chlorid in vacuo, the crude product was purified by Kugelrohr distillation 
(140‒150 °C, 0.3mbar) to obtain the title compound (S)-169a as a colorless oil (1.17 g, 4.60 
mmol, 75%). The analytical data match the reported values.[147a] 
 
C10H17ClNO2 (254.15 g/mol):  
1
H-NMR (400 MHz, CDCl3): δ = 5.17 (p, J = 6.3 Hz, 1H, OCH), 3.94 (ddd, J = 8.3, 6.1, 
4.0 Hz, 1H, CH2Cl), 3.81–3.59 (m, 2H CCHN, CH2Cl), 2.07 (dq, J = 13.8, 6.8 Hz, 1H, 
CH(CH3)2), 1.37 (dd, J = 6.3, 0.8 Hz, 6H, OCH(CH3)2), 0.95 (dd, J = 10.4, 6.8 Hz, 6H, 
(CH(CH3)2) ppm. MS (EI) m/z (%): 218 ([M-Cl]
+, 3), 211 (13), 176 (35), 168 (32), 134 (22), 
105 (26), 91 (11), 69 (99), 54 (10), 43 (100). b.p.: 140‒150 °C (0.3 mbar), lit. 100 °C 
(0.15 mbar).[147a]  
 
 
(S,Z)-iso-Propyl 2-chloro-2-((1-chloro-3,3-dimethylbutan-2-yl)imino)acetate ((S)-169b) 
 
DMF (8 μL, 7.58 mg, 104 μmol, 0.025 eq.) was added to a solution of 
(S)-isopropyl 2-((1-hydroxy-3,3-dimethylbutan-2-yl)amino)-2-oxo-
acetate (960 mg, 4.15 mmol, 1.0 eq.) in thionyl chloride (2.4 mL, 3.95 g, 
33.2 mmol, 8.0 eq.). The reaction mixture was stirred at 85 °C for 16 
hours. After removing the excess of thionyl chlorid in vacuo, the crude product was purified 
by Kugelrohr distillation (100‒105 °C, 0.15 mbar) to obtain the title compound (S)-169b as a 
slightly yellow oil (1.03 g, 3.84 mmol, 93%). The analytical data match the reported 
values.[147a] 
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C11H19ClNO2 (268.18 g/mol):  
1
H-NMR (400 MHz, CDCl3): δ = 5.27–5.09 (m, 1H, OCH), 3.88 (ddd, J = 19.1, 10.5, 2.1 Hz, 
2H, CH2Cl), 3.73–3.59 (m, 1H CCHN), 1.37 (dd, J = 6.2, 3.1 Hz, 6H, CH(CH3)2), 0.97 (s, 9H, 
(CH3)3C) ppm. GC (Me2Si, 100 °C, 2 min, 10 °C/min, 270 °C, 10 min): 9.92 min. MS (EI) 
m/z (%): 267 ([M]+, 0.3), 225 (10), 169 (78), 134 (87), 88 (12), 83 (36), 69 (14), 57 (84), 43 
(100). b.p.: 100‒105 °C (0.15 mbar), lit. 100 °C (0.15 mbar).[147a]  
 
 
(S)-iso-Propyl 4-(iso-propyl)-1-phenyl-4,5-dihydro-1H-imidazole-2-carboxylate 
((S)-170a)  
 
A solution of aniline (0.6 mL, 0.613 g, 6.58 mmol, 1.4 eq.) in toluene 
(3.0 mL) was added to solution of (S)-169a (1.17 g, 4.62 mmol, 1.0 eq.) 
and triethylamine (4.2 mL, 3.04 g, 30.0 mmol, 6.5 eq.) in toluene 
(12 mL). The clear reaction mixture was stirred at 120 °C for 15 hours. 
After cooling down to rt the reaction mixture was extracted with 1M aq. KOH solution (2×10 
mL) and combined aqueous layers were washed with toluene (2×20 mL). After drying over 
MgSO4, the solvent was removed under reduced pressure. The crude product was purified by 
Kugelrohr distillation (140‒145 °C / 0.γ mbar) to obtain the title compound (S)-170a as a 
slightly yellow oil (833 mg, 3.04 mmol, 66%). The analytical data match the reported 
values.[147a] 
 
C16H22N2O2 (274.36 g/mol):  
1
H-NMR (400 MHz, CDCl3): δ = 7.30–7.21 (m, 2H, HAr), 7.07 (t, J = 7.4 Hz, 1H, HAr), 6.93 
(d, J = 7.6 Hz, 2H, HAr), 5.08 (hept, J = 6.3 Hz, 1H, OCH), 4.03 (ddd, J = 10.5, 9.2, 6.4 Hz, 
1H, CH2N), 3.90 (dd, J = 10.6, 9.2 Hz, 1H, CH2N), 3.57 (t, J = 9.1 Hz, 1H, CHN), 1.96–1.83 
(m, 1H, CH(CH3)2), 1.15 (dd, J = 12.9, 6.3 Hz, 6H, OCH(CH3)2), 1.02 (d, J = 6.7 Hz, 3H, 
CH3), 0.91 (d, J = 6.8 Hz, 3H, CH3) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 161.0 
(C=O), 154.3 (C=N), 141.5 (CAr), 129.2 (HCAr), 124.5 (HCAr), 121.1 (HCAr), 71.7 (NCH), 
70.5 (OCH), 55.0 (CH2), 33.0 (CH(CH3)2), 21.5 (OCH(CH3)2), 21.4 (OCH(CH3)2), 19.2 
(CH3), 18.2 (CH3) ppm. MS (EI) m/z (%): 274 ([M]
+, 15), 231 (68), 189 (46), 171 (100), 145 
(13), 118 (14), 77 (17), 43 (13). b.p.: 140‒145 °C (0.2 mbar). 
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(S)-iso-Propyl 4-(tert-butyl)-1-phenyl-4,5-dihydro-1H-imidazole-2-carboxylate ((S)-170b) 
  
A solution of aniline (0.45 mL, 0.46 g, 4.93 mmol, 1.3 eq.) in toluene 
(2.0 mL) was added to solution of (S)-169b (1.03 g, 3.84 mmol, 1.0 eq.) 
and triethylamine (3.5 mL, 2.53 g, 25.0 mmol, 6.5 eq.) in toluene 
(10 mL). The clear reaction mixture was stirred at 110 °C for 14 hours. 
After cooling down to rt the reaction mixture was extracted with KOH 1 M aq. solution (2×6 
mL) and combined aqueous layers were washed with toluene (2×20 mL). After drying over 
MgSO4, the solvent was removed under reduced pressure. The crude product was purified by 
Kugelrohr distillation (140‒145 °C / 0.2 mbar) to obtain the title compound (S)-170b as a 
slightly yellow oil (345 mg, 1.20 mmol, 31%). The analytical data match the reported 
values.[147a] 
 
C17H24N2O2 (288.38 g/mol):  
1
H-NMR (400 MHz, CDCl3): δ = 7.32–7.26 (m, 2H, HAr), 7.12–7.06 (m, 1H, HAr), 6.99–6.94 
(m, 2H, HAr), 5.10 (hept, J = 6.3 Hz, 1H, OCH), 4.01 (dd, J = 11.0, 9.0 Hz, 1H, CH2N), 3.89 
(dd, J = 11.0, 9.3 Hz, 1H, CH2N), 3.66 (t, J = 9.2 Hz, 1H, CCHN), 1.16 (dd, J = 18.7, 6.3 Hz, 
6H, CH(CH3)2), 0.97 (s, 9H, (CH3)3C) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 161.2 
(C=O), 154.3 (C=N), 141.6 (CAr), 129.2 (HCAr), 124.4 (HCAr), 121.0 (HCAr), 75.2 (NCH), 
70.4 (OCH), 53.5 (CH2), 34.3 (C(CH3)3), 26.1 (C(CH3)3), 21.5 (OCH(CH3)2), 21.4 
(OCH(CH3)2) ppm. MS (EI) m/z (%): 267 ([M]
+, 0.3), 225 (10), 169 (78), 134 (87), 88 (12), 
83 (36), 69 (14), 57 (84), 43 (100). b.p.: 1γ0‒1γ5 °C (0.2 mbar). 
 
 
(S)-2-4-(iso-Propyl)-1-phenyl-4,5-dihydro-1H-imidazol-2-yl)propan-2-ol ((S)-171b)  
 
A methylmagnesium bromide 3 M solution in diethyl ether (1.0 mL, 
3.00 mmol, 2.8 eq.) was slowly added to a solution of (S)-171a (295 mg, 
1.08 mmol, 1.0 eq.) in diethyl ether (12 mL) at −78 °C. The reaction mixture 
was slowly allowed to reach rt and stirred for additional 15 hours. NH4Cl-aq. 
sat. solution (10 mL) was added under ice bath control. After warming to RT; the layers were 
separated and the aqueous phase was washed with TBME (2×10 mL). The combined organic 
layers were dried over MgSO4, filtered and the solvent was removed under reduced pressure 
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to obtain the title compound (S)-171b without further purification (257 mg, 1.04 mmol, 97%). 
The analytical data match the reported values.[147a] 
 
C15H22N2O (246.35 g/mol):  
1
H-NMR (400 MHz, CDCl3): δ = 7.41–7.35 (m, 2H, HAr), 7.34–7.27 (m, 1H, HAr), 7.28–7.20 
(m, 2H, HAr), 4.88 (br s, 1H, OH), 3.95–3.79 (m, 2H, CH2N), 3.59 (t, J = 8.0 Hz, 1H, CH), 
1.89–1.70 (m, 1H, CH(CH3)2), 1.20 (s, 3H, CH3), 1.15 (s, 3H, CH3), 1.02 (d, J = 6.7 Hz, 3H, 
CHCH3), 0.91 (d, J = 6.8 Hz, 3H, CHCH3) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): 
δ = 170.4 (C=N), 142.9 (CAr), 129.5 (HCAr), 129.2 (HCAr), 127.8 (HCAr), 69.5 (COH), 68.5 
(NCH), 61.4 (CH2N), 33.4 (CH(CH3)2), 29.3 (C(CH3)2), 28.9 (C(CH3)2), 18.8 (CH3), 18.2 
(CH3) ppm.  
 
 
(S)-2-4-(tert-Butyl)-1-phenyl-4,5-dihydro-1H-imidazol-2-yl)propan-2-ol (171a) 
 
A methylmagnesium bromide 3 M solution in diethyl ether (1.3 mL, 
3.90 mmol, 3.40 eq.) was slowly added to a solution of (S)-171b (335 mg, 
1.16 mmol, 1.0 eq.) in diethyl ether (13 mL) at −78 °C. The reaction mixture 
was slowly allowed to reach rt and stirred for additional 15 hours. NH4Cl-aq. 
sat. solution (10 mL) was added under ice bath control. After warming to rt, the layers were 
separated and the aqueous phase was washed with TBME (2×10 mL). The combined organic 
layers were dried over MgSO4, filtered and the solvent was removed under reduced pressure 
to obtain the title compound (S)-171a without further purification (303 mg, 1.16 mmol, 
quant.). The analytical data match the reported values.[147a] 
 
C16H24N2O (260.37 g/mol):  
1
H-NMR (400 MHz, CDCl3): δ = 7.41–7.35 (m, 2H, HAr), 7.33–7.28 (m, 1H, HAr), 7.25–7.21 
(m, 2H, HAr), 5.08 (br s, 1H, OH), 3.88 (dd, J = 10.6, 8.7 Hz, 1H, CH2N), 3.78 (dd, J = 8.6, 
7.8 Hz, 1H, CH2N), 3.68 (dd, J = 10.6, 8.7 Hz, 1H, CCHN), 1.20 (s, 3H, CH3), 1.15 (s, 3H, 
CH3), 0.95 (s, 9H, (CH3)3C) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 170.3 (C=N), 142.8 
(CAr), 129.5 (HCAr), 129.3 (HCAr), 127.9 (HCAr), 71.5 (NCH), 69.4 (COH), 60.1 (CH2N), 34.4 
(C(CH3)3), 29.5 (C(CH3)2), 28.7 (C(CH3)2), 25.9 (C(CH3)3), 22.3 (CH3) ppm. MS (FAB 
NBA) m/z (%): 261 ([M+H]+, 100), 203 (20), 145 (7), 106 (6).  
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(S)-2-4-(Benzyl)-4,5-dihydrooxazol-2-yl)propan-2-ol ((S)-173d)  
 
A mixture of 2-hydroxyisobutyric acid (2.60 g, 25.0 mmol, 1.0 eq.) and (S)-
phenylalaninol (3.97 g, 26.3 mmol, 1.05 eq.) in mesytelene (50 mL) was 
stirred using a Dean-Stark at 170 °C for 16 h. After cooling down to RT, the 
reaction mixture was washed with NH4Cl aq. sat. solution (100 mL) and brine 
(100 mL). After drying over MgSO4, and filtration, the solvent was removed under reduce 
pressure. Purification by flash chromatography (SiO2, 3 cm × 15 cm, ethyl acetate / 
cyclohexane 1:1) gave the title compound (S)-173d as a colorless oil (1.53 g, 6.98 mmol, 
28%).  
 
C13H17NO2 (219.28 g/mol):  
1
H-NMR (400 MHz, CDCl3): δ = 7.33–7.27 (m, 2H, HAr), 7.25–7.17 (m, 3H, HAr), 4.48–4.36 
(m, 1H, NCH), 4.30 (dd, J = 9.3, 8.5 Hz, 1H, CH2O), 4.10 (dd, J = 8.4, 7.9 Hz, 1H, CH2O), 
3.28 (br s, 1H, OH), 3.06 (dd, J = 13.8, 5.1 Hz, 2H, CH2), 2.71 (dd, J = 13.8, 7.9 Hz, 2H, 
CH2), 1.42 (s, 3H, CH3), 1.39 (s, 3H, CH3) ppm. 
13
C{
1
H}-NMR (101 MHz, CDCl3): δ = 173.0 
(C=N), 137.6 (CAr), 129.6 (HCAr), 128.7 (HCAr), 126.7 (HCAr), 72.4 (NCH), 69.0 (COH), 66.8 
(CH2O), 41.6 (CH2), 28.0 (CH3), 27.8 (CH3) ppm. MS (FAB NBA) m/z (%): 220 ([M-H]
+, 
100), 191 (11). EA: calc. (%) C 71.21; H 7.81; N 6.39; found C 70.32, H 8.20, N 6.74. [α]D20: 
−β0.8 (c = 1.00, CHCl3). TLC (SiO2, cyclohexane / ethyl acetate 1:1): Rf = 0.23. 
 
 
  
Experimental Part 
271 
8.8.2 Formation of the P-Aryl Ligands and Their Complexes  
 
 
General Procedure Q (Formation of P-Aryl Ligands): A 1.6 M solution of n-BuLi (1.3 eq.) 
and TMEDA (1.3 eq.) were added to a solution of the tertiary alcohol (1.0 eq.) in n-pentane 
(0.1 M) at −78 °C. After removing the cooling bath, the reaction mixture was stirred for 1 h at 
rt. Afterwards arylchlorophosphine (1.3 eq.) was added at 0 °C. The reaction mixture was 
stirred at rt, while the reaction progress was analyzed by 31P-NMR. After reaching full 
conversion the solvent was removed in vacuo. The obtained crude product was purified by 
flash chromatography under inert conditions (degassed solvents). The obtained N,P ligand 
was converted to the corresponding iridium complex following general procedure G.  
 
 
(S)-(−)-[η4-1,5-Cyclooctadiene-{2-(4-tert-butyl)-4,5-dihydro-oxazole-2-yl)-2-
bis(3,5(trifluoromethyl)phenyl)phosphinite-propane}-iridium(I)]-tetrakis-(3,5-bis-
(trifluoromethyl)-phenyl)-borate ((S)-26d)  
 
The intermediate ligand (S)-174d was obtained following 
general procedure Q for using (S)-2-(4-(tert-butyl)-4,5-
dihydrooxazol-2-yl)propan-2-ol (79.4 mg, 428 μmol, 1.0 eq.), 
n-pentane (5 mL), TMEDA (85 μL, 65.5 mg, 563 μmol, 1.3 
eq.), n-BuLi (0.35 mL, 560 μmol, 1.3 eq.), and bis(3,5-di(trifluoromethyl)phenyl)-
chlorophosphine (276 mg, 560 μmol, 1.3 eq.). After stirring for 16 hours at rt and purification 
by flash chromatography (SiO2, 1.5 cm × 15 cm, n-pentane / TBME 20:1) the N,P ligand (S)-
174d was obtained as a colorless oil (107 mg, 167 μmol, 39%). Subsequent complexation 
following general procedure G using [Ir(COD)Cl]2 (56.0 mg, 83.4 μmol, 0.5 eq.), DCM 
(5.0 mL) and NaBArF (177 mg, 200 μmol, 1.2 eq.) gave the title compound (S)-26d after 
purification by flash chromatography (SiO2, 1.5 cm × 18 cm) and recrystallization from 
dethyl ether (1.0 mL) and n-pentane (25 mL) as an orange solid (202 mg, 112 μmol, 26% over 
two steps). 
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31
P{
1
H}-NMR of Ph2PCl (162 MHz, CD2Cl2): δ = 79.1 (s) ppm. 
31
P{
1
H}-NMR of the ligand (162 MHz, CD2Cl2): δ = 83.3 (p, JFP = 6.0 Hz) ppm. 
 
C66H48BF36IrNO2P (1805.04 g/mol):  
1
H-NMR (400 MHz, CD2Cl2): δ = 8.30 (d, J = 11.5 Hz, 2H, HAr), 8.15 (d, J = 43.1 Hz, 2H, 
HAr), 7.76 ((s, 8H, BArF-H), 7.64 (d, J = 11.1 Hz, 2H, HAr), 7.59 (s, 4H, BArF-H), 5.59–5.51 
(m, 1H, CH COD), 5.35–5.26 (m, 1H, CH COD), 4.71 (dd, J = 10.2, 3.7 Hz, 1H, CH2), 4.48 
(t, J = 9.9 Hz, 1H, CH), 3.90 (dd, J = 9.5, 3.7 Hz, 1H, CH2), 3.85–3.74 (m, 1H, CH COD), 
2.78 (dd, J = 15.9, 7.9 Hz, 1H, CH2 COD), 2.72–2.50 (m, 3H, CH COD, CH2 COD), 2.43 (s, 
3H, CH3), 2.40–2.31 (m, 1H, CH2 COD), 2.28–2.15 (m, 1H, CH2 COD), 2.10–1.89 (m, 2H, 
CH2 COD), 1.85 (d, J = 1.4 Hz, 3H, CH3), 1.78–1.64 (m, 1H, CH2 COD), 0.66 (s, 9H, 
(CH3)3C) ppm. 
31
P{
1
H}-NMR (162 MHz, CD2Cl2): δ = 96.6 (s) ppm. 19F{1H}-NMR 
(377 MHz, CD2Cl2): −6γ.β (s, CF3 BArF), −64.0 (d, JFP = 32.5 Hz, CF3) ppm. MS: (FAB 
NBA) m/z (%): 942 ([Ir(L)(COD)]+, 100), 466 (10), 168 (66). m.p.: 160‒161 °C. [α]D20: –24.3 
(c = 1.03, CHCl3). 
 
 
(S)-(+)-[η4-1,5-Cyclooctadiene-{2-(4-phenyl)-4,5-dihydro-oxazole-2-yl)-2-
diphenylphosphinite-propane}-iridium(I)]-tetrakis-(3,5-bis-(trifluoromethyl)-phenyl)-
borate ((S)-26h)  
 
The intermediate ligand (S)-174h was obtained following general 
procedure Q using (S)-2-(4-phenyl-4,5-dihydrooxazol-2-yl)propan-2-
ol (87.9 mg, 428 μmol, 1.0 eq.), n-pentane (5 mL), TMEDA (84 μL, 
64.7 mg, 557 μmol, 1.3 eq.), n-BuLi (0.35 mL, 560 μmol, 1.3 eq.), and 
diphenylchlorophosphine (100 μL, 123 mg, 557 μmol, 1.3 eq.). After stirring for 5 hours at rt 
and purification by flash chromatography (SiO2, 1.5 cm × 15 cm, n-pentane / TBME 10:1) the 
N,P ligand (S)-174h (14 mg, 35.9 μmol, 8%) was obtained as a colorless oil. Subsequent 
complexation following general procedure G using [Ir(COD)Cl]2 (13.2 mg, 19.7 μmol, 0.5 
eq.), DCM (1.0 mL) and NaBArF (38.2 mg, 43.1 μmol, 1.2 eq.) gave the title compound (S)-
26h after purification by flash chromatography (SiO2, 1.5 cm × 12 cm) as an orange-red solid 
(25 mg, 16.1 μmol, 4% over two steps). 
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31
P{
1
H}-NMR of Ph2PCl (162 MHz, CD2Cl2): δ = 79.1 (s) ppm. 
31
P{
1
H}-NMR of the ligand (162 MHz, CD2Cl2): δ = 95.5 (s) ppm. 
 
C64H48BF24IrNO2P (1805.04 g/mol):  
1
H-NMR (400 MHz, CD2Cl2): δ = 7.75 (s, 8H, BArF-H), 7.66 (dd, J = 14.4, 5.3 Hz, 3H, HAr), 
7.57 (s, 4H, BArF-H), 7.54–7.40 (m, 5H, HAr), 7.39–7.32 (m, 1H, HAr), 7.28–7.12 (m, 4H, 
HAr), 6.76 (d, J = 7.9 Hz, 2H, HAr), 5.23 (dd, J = 10.4, 6.9 Hz, 1H, CH2), 5.15–5.03 (m, 1H, 
CH COD), 4.89 (t, J = 10.0 Hz, 1H, CH), 4.44 (dd, J = 9.5, 6.8 Hz, 1H, CH2), 3.47–3.33 (m, 
1H, CH COD), 2.90–2.70 (m, 1H, CH COD), 2.51–2.31 (m, 6H, CH COD, CH3, CH2 COD), 
2.29–2.16 (m, 2H, CH2 COD), 2.08–1.99 (m, 1H, CH2 COD), 1.97–1.84 (m, 4H, CH3, CH2 
COD), 1.81–1.72 (m, 1H, CH2 COD), 1.68–1.61 (m, 1H, CH2 COD) ppm. 31P{1H}-NMR 
(162 MHz, CD2Cl2): δ = 101.8 (s) ppm. MS: (FAB NBA) m/z (%): 690 ([Ir(L)(COD)]+, 100), 
620 (24), 580 (10), 602 (11), 484 (15), 168 (66). EA: calc. (%) C 49.50, H 3.12, N 0.90; 
found C 48.87, H 3.13, N 1.17. m.p.: 87‒88 °C. [α]D20: +5.0 (c = 0.90, CHCl3). 
 
 
(S)-(−)-[η4-1,5-Cyclooctadiene-{2-(4-benzyl)-4,5-dihydro-oxazole-2-yl)-2-
diphenylphosphinite-propane}-iridium(I)]-tetrakis-(3,5-bis-(trifluoromethyl)-phenyl)-
borate (26i)  
 
The intermediate ligand (S)-174i was obtained following the general 
procedure H using alcohol (S)-173d (61.1 mg, 279 μmol, 1.0 eq.), KH 
(22.3 mg, 557 μmol, 2.0 eq.), diphenylchlorophosphine (50 µL, 61.5 
mg, 279 μmol, 1.0 eq.), and THF (0.5 mL). After stirring for 40 hours 
at rt and flash chromatography (SiO2, 1.5 cm × 13 cm, n-pentane / TBME 20:1) the N,P 
ligand (S)-174i (102 mg, 253 μmol, 91%) was obtained as a colorless oil. Subsequent 
complexation following general procedure G using [Ir(COD)Cl]2 (93.4 mg, 139 μmol, 0.5 
eq.), DCM (5.0 mL) and NaBArF (269 mg, 304 μmol, 1.2 eq.) gave the title compound (S)-26i 
after purification by flash chromatography (SiO2, 3 cm × 11 cm) as an orange foam (43 mg, 
27.4 μmol, 10% over two steps). 
 
31
P{
1
H}-NMR of Ph2PCl (162 MHz, CD2Cl2): δ = 79.1 (s) ppm. 
31
P{
1
H}-NMR of the ligand (162 MHz, CD2Cl2): δ = 94.8 (s) ppm. 
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C65H50BF24IrNO2P (1567.06 g/mol):  
1
H-NMR (400 MHz, CD2Cl2): δ = 7.97–7.86 (m, 2H, HAr), 7.74 (s, 8H, BArF-H), 7.69–7.57 
(m, 3H, HAr), 7.56 (s, 4H, BArF-H), 7.55–7.43 (m, 3H, HAr), 7.32–7.18 (m, 5H, HAr), 6.95 (dd, 
J = 6.4, 2.9 Hz, 2H, HAr), 5.38–5.32 (m, 1H, CH COD), 5.19 (p, J = 7.4 Hz, 1H, CH COD), 
4.47–4.33 (m, 3H, CH2, CH), 3.70–3.61 (m, 1H, CH COD), 3.27–3.18 (m, 1H, CH2), 2.92 – 
2.79 (m, 1H, CH COD), 2.65–2.32 (m, 4H, CH2 1H, CH2 COD 3H), 2.29 (s, 4H, CH2 COD 
1H, CH3), 2.18–2.00 (m, 2H, CH2 COD), 1.99–1.85 (m, 1H, CH2 COD), 1.78–1.62 (m, 4H, 
CH2 COD 1H, CH3) ppm. 
13
C{
1
H}-NMR (101 MHz, CD2Cl2): δ = 176.0 (d, J = 7.2, C=N), 
162.3 (q, JBC = 50 Hz, CAr BArF), 135.4 (s, HCAr BArF), 134.8 (s, CAr), 134.5 (s, CAr), 133.7 
(s, HCAr), 133.6 (d, J = 3 Hz, HCAr), 133.5 (s, HCAr), 132.7 (d, J = 2 Hz, HCAr), 131.2 (s, 
HCAr), 131.0 (s, HCAr), 130.4 (s, CAr), 130.0 (s, HCAr), 129.9 (s, HCAr), 129.8 (s, HCAr), 129.5 
(qq, JFC = 31 Hz, JBC = 3 Hz, CAr BArF), 129.4 (s, HCAr), 129.42 (s, HCAr), 129.35 (s, HCAr), 
129.31 (s, HCAr), 128.5 (s, HCAr), 125.2 (q, JFC = 273 Hz, CF3 BArF), 118.1 (septett, JFC = 4 
Hz, HCAr BArF), 98.9 (d, J = 12 Hz, CH COD), 97.9 (d, J = 12 Hz, CH COD), 79.9 (d, J = 4 
Hz, C(CH3)2), 74.8 (s, CH2), 67.0 (s, CH), 66.0 (s, CH COD), 62.8 (s, CH COD), 42.9 (s, 
CH2), 36.0 (d, J = 4 Hz, CH2 COD), 33.3 (d, J = 3 Hz, CH2 COD), 32.4 (d, J = 2.0 Hz, 
C(CH3)2), 30.0 (d, J = 2 Hz, C(CH3)2), 27.3 (s, CH2 COD), 26.0 (d, J = 6 Hz, CH2 COD) ppm. 
31
P{
1
H}-NMR (162 MHz, CD2Cl2): δ = 102.0 (s) ppm. MS: (FAB NBA) m/z (%): 704 
([Ir(L)(COD)]+, 100), 596 (12), 500 (19), 393 (14). m.p.: 89‒90 °C. [α]D20: –16.1 (c = 0.97, 
CHCl3). 
 
 
(S)-(−)-[η4-1,5-Cyclooctadiene-{2-(4-tert-butyl)-4,5-dihydro-1H-imidazol-2-yl)-2-di-
ortho-tolylphosphinite-propane}-iridium(I)]-tetrakis-(3,5-bis-(trifluoromethyl)-phenyl)-
borate ((S)-162g)  
 
The intermediate ligand was obtained following general procedure 
Q using alcohol (S)-171b (96.1 mg, 369 μmol, 1.0 eq.), n-pentane (5 
mL), TMEDA (73 μL, 56.2 mg, 484 μmol, 1.3 eq.), n-BuLi (0.30 
mL, 480 μmol, 1.3 eq.) and di-ortho-tolylchlorophosphine (119 mg, 
480 μmol, 1.3 eq.). After stirring for 16 hours at rt and purification by flash chromatography 
(SiO2, 1.5 cm × 12 cm, n-pentane / diethylether / triethylamine 8:1:1) the N,P ligand (21 mg, 
44.4 μmol, 12%) was obtained as a colorless oil. Subsequent complexation following general 
procedure G using [Ir(COD)Cl]2 (14.9 mg, 22.2 μmol, 0.5 eq.), DCM (1.0 mL) and NaBArF 
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(47.2 mg, 53.3 μmol, 1.2 eq.) gave the title compound (S)-162g after purification by flash 
chromatography (SiO2, 1.5 cm × 12 cm) as an orange foam (65 mg, 39.7 μmol, 11% over two 
steps). 
 
31
P{
1
H}-NMR of (o-Tol) 2PCl (162 MHz, CD2Cl2): δ = 75.3 (s) ppm. 
31
P{
1
H}-NMR of the ligand (162 MHz, CD2Cl2): δ = 75.2 (s) ppm. 
 
C70H61BF24IrN2OP (1636.21 g/mol):  
1
H-NMR (500 MHz, CD2Cl2): δ = 8.36 (br s, 1H, HAr), 7.75 (s, 8H, BArF-H), 7.57 (s, 4H, 
BArF-H), 7.52–7.03 (m, 12H, HAr), 5.46–5.38 (m, 1H, CH COD), 5.04–4.90 (m, 1H, CH 
COD), 3.96–3.87 (m, 2H, CH2), 3.85–3.73 (m, 2H, CH, CH COD, 2.73–2.54 (m, 2H, CH2 
COD 1H, CH COD 1H), 2.54–2.32 (m, 7H, CH2 COD, CH COD, C(CH3)2),2.19–1.89 (m, 7H, 
CH2 COD 1H, 2×Ar-CH3), 1.81–1.65 (m, 1H, CH2 COD), 1.62–1.48 (m, 1H, CH2 COD), 1.25 
(s, 3H, C(CH3)2), 0.92 (s, 9H, (CH3)3C) ppm.
13
C{
1
H}-NMR (126 MHz, CD2Cl2): δ = 169.4 
(d, JCP = 4 Hz, C=N), 162.4 (q, JBC =50 Hz, CAr BArF), 140.6 (s, CAr), 135.4 (s, HCAr BArF), 
133.2 (d, JPC = 3 Hz, HCAr), 132.9 (d, JCP = 4 Hz, HCAr), 132.8 (d, JPC = 6 Hz, HCAr), 132.2 
(d, JPC = 2 Hz, HCAr),131.2 (s, HCAr),130.5 (s, HCAr), 129.5 (qq, JFC = 31 Hz, JBC = 3 Hz, CAr 
BArF), 126.9 (d, J = 11 Hz, HCAr), 126.1 (d, J = 13 Hz, CAr), 125.2 (q, JCF = 272 Hz, CF3 
BArF), 118.1 (septet, JCF = 4 Hz, HCAr BArF), 98.4 (br s, CH COD), 95.5 (d, JPC = 13 Hz, CH 
COD), 82.2 (d, JPC = 5 Hz, C(CH3)2), 72.1 (s, CH), 63.6 (s, CH COD), 59.7 (s, CH2), 37.6 (br 
s, C(CH3)3, 35.0 (s, CH COD), 34.5 (s, CH2 COD), 33.4 (s, C(CH3)2), 29.6 (d, J = 6 Hz, CH2 
COD), 29.3 (s, C(CH3)2), 26.2 C(CH3)3, 25.6 (s, 2×CH2 COD), 23.3 (s, CH3), 21.8 (br s, CH3) 
ppm. 31P{1H}-NMR (162 MHz, CD2Cl2): δ = 105.2 (br s) ppm. [α]D20: –16.1 (c = 0.97, CHCl3). 
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8.8.3 Formation of the P-Alkyl Ligands and Their Complexes 
(S)-(+)-[η4-1,5-Cyclooctadiene-{2-(4-tert-butyl)-4,5-dihydro-1H-imidazol-2-yl)-2-
dicyclohexyl-phosphinite-propane}-iridium(I)]-tetrakis-(3,5-bis-(trifluoromethyl)-
phenyl)-borate ((S)-162h)  
 
The intermediate ligand was obtained following general procedure H 
using alcohol (S)-171a (59.0 mg, 226 μmol, 1.0 eq.), chloro-
dicyclohexylphosphine (50 µL, 52.7 mg, 226 μmol, 1.0 eq.), KH (15.5 
mg, 386 μmol, 1.7 eq.), and THF (0.5 mL), after stirring for 12 hours 
at rt and filtration over a plug of er a plug of Celite® using a Schlenk fritt (d × h, 2 cm × 1 cm). 
The N,P ligand was subsequently converted to the Ir-complex following general procedure G 
using [Ir(COD)Cl]2 (76.0 mg, 113 μmol, 0.5 eq.), DCM (5.0 mL) and NaBArF (221 mg, 249 
μmol, 1.1 eq.) to obtain the title compound (S)-162h after purification by flash 
chromatography (SiO2, 1.5 cm × 15 cm) as an orange-yellow foam (90 mg, 55.5 μmol, 25% 
over two steps).  
 
31
P{
1
H}-NMR of Cy2PCl (162 MHz, CD2Cl2): δ = 126.1 (s) ppm. 
31
P{
1
H}-NMR of the ligand (162 MHz, CD2Cl2): δ = 129.8 (s) ppm. 
 
C68H69BF24IrN2OP (1636.21 g/mol):  
1
H-NMR (500 MHz, CD2Cl2): δ = 7.76 (s, 8H, BArF-H), 7.59 (s, 4H, BArF-H), 7.52–7.43 (m, 
3H, HAr), 7.21 (br s, 2H, HAr), 5.19–5.12 (m, 1H, CH COD), 4.84 (p, J = 7.7 Hz, 1H, CH 
COD), 4.12–4.05 (m, 1H, CH COD), 4.02 (dd, J = 11.4, 3.2 Hz, 1H, CH2), 3.86 (t, J = 11.2 
Hz, 1H, NCH), 3.71 (dd, J = 11.0, 3.3 Hz, 1H, CH2N), 3.54–3.46 (m, 1H, CH COD), 2.58 (dd, 
J = 15.3, 7.8 Hz, 1H, CH2 COD), 2.53–2.37 (m, 3H, CH2 COD, CH2 Cy 2H), 2.37–2.28 (m, 
1H, CH2 COD), 2.28–2.14 (m, 5H, C(CH3)2 3H, CHP 1H, CH2 COD 1H), 2.14–2.05 (m, 2H, 
CHP, CH2 COD), 2.03–1.97 (m, 1H, CH2 COD), 1.96–1.79 (m, 5H, CH2 Cy), 1.77–1.69 (m, 
2H, CH2 Cy), 1.65–1.47 (m, 5H, CH2 COD 2H, CH2 Cy), 1.46–1.31 (m, 2H, CH2 Cy), 1.31–
1.18 (m, 6H, CH2 Cy), 1.12 (s, 9H, (CH3)3C), 1.06 (d, J = 1.5 Hz, 3H, C(CH3)2) ppm. 
13
C{
1
H}-NMR (126 MHz, CD2Cl2): δ = 171.8 (s, C=N),162.4 (q, JBC = 50 Hz, CAr BArF), 
140.6 (s, CAr), 135.4 (s, HCAr BArF), 131.2 (s, HCAr), 130.5 (s, HCAr), 129.5 (qq, JFC = 31 Hz, 
JBC = 3 Hz, CAr BArF), 125.2 (q, JCF = 272 Hz, CF3 BArF), 118.1 (septet, JCF = 4 Hz, HCAr 
BArF), 96.2 (d, JPC = 11 Hz CH COD), 95.7 (d, JPC = 12 Hz, CH COD), 80.0 (d, JPC = 5Hz, 
C(CH3)2), 70.8 (s, CH), 59.7 (s, CH2), 57.8 (s, CH COD), 57.4 (s, CH COD), 47.2 (d, J = 33 
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Hz, CHP), 43.4 (d, J = 28 Hz, CHP), 37.9 (d, J = 3 Hz, CH2 COD), 35.3 (s, C(CH3)3, 33.5 (d, 
J = 6 Hz, CH2 COD), 32.7 (s, C(CH3)2), 29.8 (s, CH2 COD), 29.3 (d, J = 6 Hz, CH2 Cy), 29.1 
(d, J = 3 Hz, CH2 Cy), 28.7 (d, J = 4 Hz, CH2 Cy), 28.3 (d, J = 4 Hz, CH2 Cy), 28.2 (s, 
C(CH3)2), 28.0 (d, J = 9 Hz, CH2 Cy), 27.9 (d, J = 5 Hz, CH2 Cy), 27.7 (d, J = 10 Hz, CH2 
Cy), 27.5 (d, J = 13 Hz, CH2 Cy), 26.8 (s, CH2 Cy), 26.6 (s, CH2 Cy), 25.8 C(CH3)3, 25.1 (s, 
CH2 COD) ppm. 
31
P{
1
H}-NMR (162 MHz, CD2Cl2): δ = 109.2 (s) ppm. [α]D20: +6.7 (c = 0.53, 
CHCl3). 
 
 
(S)-(+)-[η4-1,5-Cyclooctadiene-{2-(4-tert-butyl)-4,5-dihydro-1H-imidazol-2-yl)-2-di-tert-
butyl-phosphinite-propane}-iridium(I)]-tetrakis-(3,5-bis-(trifluoromethyl)-phenyl)-
borate ((S)-162i)  
 
The intermediate ligand was obtained following general procedure 
H using alcohol (S)-171a (34.0 mg, 131 μmol, 1.0 eq.), di-tert-
butyl-chlorophosphine (25 µL, 23.8 mg, 131 μmol, 1.0 eq.), KH 
(9.0 mg, 224 μmol, 1.7 eq.), and THF (0.5 mL), after stirring for 13 
hours at rt and filtration over a plug of er a plug of Celite® using a 
Schlenk fritt (d × h, 2 cm × 1 cm). The N,P ligand was subsequently converted to the Ir-
complex following general procedure G using [Ir(COD)Cl]2 (43.9 mg, 65.3 μmol, 0.5 eq.), 
DCM (3.0 mL) and NaBArF (127 mg, 144 μmol, 1.1 eq.) and purification by flash 
chromatography (SiO2, 1.5 cm × 15 cm) to provide the title compound (S)-162i as a orange-
yellow foam (112 mg, 71.4 μmol, 55% over two steps).  
 
31
P{
1
H}-NMR of (t-Bu)2PCl (162 MHz, CD2Cl2): δ = 146.4 (s) ppm. 
31
P{
1
H}-NMR of the ligand (162 MHz, CD2Cl2): δ = 144.2 (s) ppm. 
 
C64H65BF24IrN2OP (1568.18 g/mol):  
1
H-NMR (500 MHz, CD2Cl2): δ = 7.76 (s, 8H, BArF-H), 7.58 (s, 4H, BArF-H), 7.51–7.42 (m, 
3H, HAr), 7.21 (br d, J = 5.7 Hz, 2H, HAr), 5.37–5.32 (m, 1H, CH COD), 4.74 (p, J = 7.8 Hz, 
1H, CH COD), 4.44–4.37 (m, 1H, CH COD), 3.97 (t, J = 11.2 Hz, 1H, NCH), 3.91 (dd, J = 
11.0, 3.3 Hz, 1H, CH2), 3.86 (dd, J = 11.1, 3.0 Hz, 1H, CH2N), 3.73–3.65 (m, 1H, CH COD), 
2.53 (dd, J = 15.6, 7.7 Hz, 1H, CH2 COD), 2.49–2.38 (m, 2H, CH2 COD), 2.30 (dd, J = 15.5, 
8.0 Hz, 1H, CH2 COD), 2.19–2.08 (m, CH2 COD 1H), 1.96–1.87 (m, 4H, C(CH3)2, CH2 COD 
1H), 1.63–1.52 (m, 2H, CH2 COD), 1.42–1.31 (br m, 18H, (CH3)3C)2P), 1.19 (s, (CH3)3C), 
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1.15 (s, 3H, C(CH3)2) ppm. 
13
C{
1
H}-NMR (126 MHz, CD2Cl2): δ = 170.6 (d, JPC = 2 Hz, 
C=N), 162.4 (q, JBC = 50 Hz, CAr BArF), 140.5 (s, CAr), 135.4 (s, HCAr BArF), 131.1 (s, HCAr), 
130.5 (s, HCAr), 129.5 (qq, JFC = 31 Hz, JBC = 3 Hz, CAr BArF), 125.2 (q, JCF = 272 Hz, CF3 
BArF), 118.1 (septet, JCF = 4 Hz, HCAr BArF), 95.3 (d, JPC = 10 Hz CH COD), 92.7 (d, JPC = 
14 Hz, CH COD), 80.0 (d, JPC = 8Hz, C(CH3)2), 69.8 (s, NCH), 61.7 (s, CH2N), 61.7 (s, CH 
COD), 57.3 (s, CH COD), 43.1 (d, J = 26 Hz, (CH3)3C)2P), 39.9 (d, J = 24 Hz, (CH3)3C)2P), 
38.2 (d, J = 4 Hz, CH2 COD), 35.5 (s, C(CH3)3, 34.9 (d, J = 2 Hz, CH2 COD), 33.7 (s, 
C(CH3)2), 30.6 (d, J = 5 Hz, (CH3)3C)2P), 28.5 (s, C(CH3)2), 27.3 (s, CH2 COD), 26.4 (br s, 
(CH3)3C)2P), 23.8 (s, CH2 COD) ppm. 
31
P{
1
H}-NMR (162 MHz, CD2Cl2): δ = 138.7 (s) ppm. 
[α]D20: +60.8 (c = 0.56, CHCl3). 
 
 
(S)-(−)-[η4-1,5-Cyclooctadiene-{2-(4-iso-propyl)-4,5-dihydro-1H-imidazol-2-yl)-2-
dicyclohexyl-phosphinite-propane}-iridium(I)]-tetrakis-(3,5-bis-(trifluoromethyl)-
phenyl)-borate ((S)-162j)  
 
The intermediate ligand was obtained following general procedure H 
using alcohol (S)-171b (67 mg, 272 μmol, 1.0 eq.), chlorodicyclo-
hexylphosphine (60 µL, 63.2 mg, 272 μmol, 1.0 eq.), KH (22.0 mg, 
548 μmol, 2.0 eq.), and THF (0.5 mL), after stirring for 12 hours at rt 
and filtration over a plug of er a plug of Celite® using a Schlenk (d × h, 2 cm × 1 cm). The N,P 
ligand was subsequently converted to the Ir-complex following general procedure G using 
[Ir(COD)Cl]2 (62.0 mg, 92.3 μmol, 0.5 eq.), DCM (5.0 mL) and NaBArF (178 mg, 201 μmol, 
1.1 eq.) and after purification by flash chromatography (SiO2, 1 cm × 10 cm) to give the title 
compound (S)-162j as an orange-yellow foam (70.0 mg, 43.6 μmol, 24%). This compound 
contains the corresponding cyclometalled complex 175a (ca. 20%; 1H-NMR of the Ir-H: 
−16.40 (d, J = 18.4 Hz)).  
 
31
P{
1
H}-NMR of Cy2PCl (162 MHz, CD2Cl2): δ = 126.1 (s) ppm. 
31
P{
1
H}-NMR of the ligand (162 MHz, CD2Cl2): δ = 122.3 (s) ppm. 
31
P{
1
H}-NMR of the Ir(III)-complex 175a (162 MHz, CD2Cl2): δ = 145.8 (s) ppm. 
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C67H67BF24IrN2OP (1606.25 g/mol):  
1
H-NMR (400 MHz, CDCl3): δ = 7.72 (s, 8H, BArF-H), 7.53 (s, 4H, BArF-H), 7.45–7.37 (m, 
3H, HAr), 7.21–7.06 (m, 2H, HAr), 5.15–5.07 (m, 1H, CH COD), 4.77 (dd, J = 12.2, 6.6 Hz, 
1H, CH COD), 4.20–4.05 (m, 1H, CH COD), 4.02–3.91 (m, 1H), 3.91–3.72 (m, 3H), 3.50–
3.42 (m, 1H), 2.60–2.37 (m, 4H), 2.20–1.95 (m, 1H), 1.93–1.79 (m, 6H), 1.78–1.78 (m, 2H, 
CH2), 1.68–1.55 (m, 4H), 1.51–1.15 (m, 16H), 1.03 (s, 3H), 0.99 (dd, J = 12.5, 6.8 Hz, 6H) 
ppm. 31P{1H}-NMR (162 MHz, CD2Cl2): δ = 112.9 (s) ppm. MS: (FAB NBA) m/z (%): 743 
([Ir(L)(COD)]+, 100), 691 (21), 529 (28), 229 (73. EA: calc. (%) C 50.10; H 4.20; N 1.74; 
found C 48.83, H 4.31, N 1.87. m.p.: 65‒66 °C. [α]D20: −γ.0 (c = 0.56, CHCl3). 
 
 
(S)-(−)-[η4-1,5-Cyclooctadiene-{2-(4-iso-propyl)-4,5-dihydro-1H-imidazol-2-yl)-2-di-tert-
butyl-phosphinite-propane}-iridium(I)]-tetrakis-(3,5-bis-(trifluoromethyl)-phenyl)-
borate ((S)-162k)  
 
The intermediate ligand was obtained following general procedure 
H using alcohol (S)-171b (65.0 mg, 263 μmol, 1.0 eq), di-tert-
butyl-chlorophosphine (50 µL, 47.5 mg, 263 μmol, 1.0 eq.), KH 
(22.0 mg, 548 μmol, 2.1 eq.), and THF (0.5 mL), after stirring for 
15 hours at rt and filtration over a plug of er a plug of Celite® using 
a Schlenk fritt. (d × h, 2 cm × 1 cm). The intermediate N,P was subsequently converted to the 
Ir-complex following general procedure G using [Ir(COD)Cl]2 (65.0 mg, 96.8 μmol, 0.5 eq.), 
DCM (5.0 mL) and NaBArF (221 mg, 249 μmol, 1.1 eq.) and purification by flash 
chromatography (SiO2, 2 cm × 13 cm) to give the title compound (S)-162k as an orange-
yellow foam (254 mg, 163 μmol, 62%). This compound consist predominatly in the 
corresponding cyclometalled form (175b).  
 
31
P{
1
H}-NMR of (t-Bu)2PCl (162 MHz, CD2Cl2): δ = 146.4 (s) ppm. 
31
P{
1
H}-NMR of the ligand (162 MHz, CD2Cl2): δ = 143.8 (s) ppm. 
 
C63H63BF24IrN2OP (1554.15 g/mol):  
1
H-NMR (400 MHz, CDCl3): δ = 7.76 (s, 8H, BArF-H), 7.56 (s, 4H, BArF-H), 7.48–7.36 (m, 
3H, HAr), 7.22–7.04 (m, 2H, HAr), 4.97 (t, J = 6.8 Hz, 1H, 1H), 4.81–4.73 (m, 1H), 4.73–4.66 
(m, 1H), 4.21–4.13 (m, 1H), 4.13–4.06 (m, 1H), 4.02–3.98 (m, 1H), 3.97–3.90 (m, 1H), 3.31–
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3.25 (m, 1H), 3.16–3.07 (m, 1H), 2.65–2.45 (m, 1H), 2.40–2.24 (m, 3H), 2.20–2.00 (m, 1H), 
1.81–1.63 (m, 2H), 1.37 (d, J = 14.7 Hz, 9H), 1.30 (dd, J = 13.9, 7.2 Hz, 6H), 1.24 (d, J = 
14.7 Hz, 9H), 1.15 (s, 3H), 1.01 (d, J = 6.9 Hz, 3H) ppm. 31P{1H}-NMR (162 MHz, CD2Cl2): 
δ = 133.2 (s) ppm.MS: (FAB NBA) m/z (%): 691 ([Ir(L)(COD)]+, 100), 529 (29), 465 (14), 
229 (81). EA: calc. (%) C 48.69; H 4.09; N 1.80; found C 47.37, H 4.96, N 1.92. m.p.: 119‒
120 °C (dec.). [α]D20: −8.7 (c = 0.59, CHCl3). 
 
 
(S)-(−)-[η4-1,5-Cyclooctadiene-{2-(4-iso-propyl)-4,5-dihydro-1H-imidazol-2-yl)-2-di-tert-
butyl-phosphinite-propane}-hydrido-iridium(III)]-tetrakis-(3,5-bis-(trifluoromethyl)-
phenyl)-borate ((S)-175b)  
 
The cyclometallated complex was obtained by slowly bubbling (1 
bubble / second) hydrogen gas in to a solution of (S)-162k in THF 
(1 mL) at −γ0 °C during 1β h. The complex (S)-175b is not stable at 
rt and it was directly analyzed by NMR at −30 °C  
 
C63H63BF24IrN2OP (1554.15 g/mol):  
1
H{
31
P}--NMR (500 MHz, THF-d8, 248 K): δ = 7.83 (s, 8H, BArF-H), 7.62 (s, 4H, BArF-H), 
7.56–7.35 (m, 5H, HAr), 5.12–5.03 (m, 1H, CH COD), 4.90–4.80 (m, 2H, CH COD), 4.41 (d, J 
= 10.6 Hz, 1H, NCH), 4.27–4.20 (m, 1H, CH2N), 4.15 (q, J = 7.5 Hz, 1H, CH COD), 4.02 (t, J 
= 11.0 Hz, 1H, CH2N), 3.32 (dd, J = 15.5, 8.0 Hz, 1H, CH2 COD), 3.26–3.16 (m, CH2 COD), 
2.80–2.67 (m, 1H, CH2 COD), 2.67–2.55 (m, 1H, CH2 COD), 2.47–2.32 (m, 3H, CH2 COD 
2H, CH(CH3)2)), 1.97–1.78 (m, 2H, CH2 COD ), 1.54 (m, 3H, CCH3), 1.43 (s, 9H, C(CH3)3), 
1.31 (s, 9H, C(CH3)3), 1.07 (d, J = 6.6 Hz, 6H, CH(CH3)2), 0.99 (d, J = 11.1 Hz, 2H, Ir-CH2), 
−16.β (s, 1H, Ir-H) ppm. 31P{1H}-NMR (202 MHz, THF-d8, 248 K): δ = 146.03 (d, J = 4.9 
Hz) ppm. 
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8.9 Asymmetric Hydrogenations of Model Olefins 
8.9.1 Hydrogenation at Elevated Pressure 
A 2 mL-glass vial was charged with a stirring bar, iridium catalyst (1.0 mol%) and substrate 
(25-200 µmol). The mixture was dissolved in DCM (0.2 M) and placed in an autoclave. The 
autoclave was then three times pressurized up to 50 bar with hydrogen and the pressure 
released. The reaction was performed under 50 bar H2 atmosphere for a given time at RT. 
After releasing the hydrogen pressure the solvent was removed under reduced pressure or 
under a stream of nitrogen. Heptane (1 mL) was added to the crude product, which was 
purified over a plug of silica gel (SiO2, 0.5 cm × 1 cm, n-heptane / TBME 10:1) to obtain the 
hydrogenation product suitable for analysis. 
 
 
8.9.2 Hydrogenation at Ambient Pressure 
A 2 mL-glass vial was charged with a stirring bar, iridium catalyst (1.0 mol%) and substrate 
(25-200 µmol). The mixture was dissolved in DCM (0.2 M) and placed in a glas flask, which 
was closed with a rubber septum. A H2-filled ballon equipped with a needle was put on the 
septum and the flask was flushed with hydrogen for 5 min. The reaction was performed under 
H2-filled ballon for a given time at RT. Afterwards the solvent was removed under reduced 
pressure or under a stream of nitrogen. Th crude product was taken up in n-heptane (1 mL) 
and purified over a plug of silica gel (SiO2, 0.5 cm × 1 cm, n-heptane / TBME 10:1) to obtain 
the hydrogenation product suitable for analysis. 
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8.9.3 Analytical Data for the Model Olefins 
(E)-Prop-1-ene-1,2-diyldibenzene (7) 
GC (Restek Rtx-1701 (30 m × 0.β5 mm × 0.β5 μm), 60 kPa He, 100 
°C, 2 min, 7 °C/min, 250 °C, 10 min): tR = 18.3 min (7), 21.4 min (8). 
HPLC (chiral, Daicel Chiracel OJ, 0.46 cm × 25 cm, n-heptane / 
i-PrOH = 99:1, 0.5 mL/min, 25 °C): tR = 15.6 min ((R)-8), 23.8 min 
((S)-8). 
 
(E)-2-(4-Methoxyphenyl)-2-butene (90) 
GC (Chiraldex Ȗ-cyclodextrin TFA G-TA, (30 m × 0.25 mm × 0.12 
μm), 60 kPa H2, (60 °C, 30 min, 5 °C/min, 100 °C, 20 °C/min, 160 °C, 
10 min): tR = 38.4 min ((S)-89), 38.6 min ((R)- 89), 41.2 min (90). 
 
(Z)-2-(4-Methoxyphenyl)-2-butene (91) 
GC (Chiraldex Ȗ-cyclodextrin TFA G-TA (30 m × 0.25 mm × 0.12 
μm), 60 kPa H2, 60 °C, 30 min, 5 °C/min, 100 °C, 20 °C/min, 160 °C, 
10 min): tR = 38.4 min ((S)-89), 38.6 min ((R)- 89), 39.3 min (91). 
 
2-(4-Methoxyphenyl)-1-butene (88) 
GC (Chiraldex Ȗ-cyclodextrin TFA G-TA (30 m × 0.25 mm × 0.12 
μm), 60 kPa H2, 60 °C, 30 min, 5 °C/min, 100 °C, 20 °C/min, 160 °C, 
10 min): tR = 38.4 min ((S)-89), 38.6 min ((R)- 89), 40.3 min (88). 
 
7-Methoxy-1,2-dihydro-naphthalene (72) 
GC (Restek Rtx-1701 (γ0 m × 0.β5 mm × 0.β5 μm), 60 kPa He, 100 
°C, 2 min, 7 °C/min, 250 °C, 10 min): tR = 15.0 min (72), 17.6 min 
(73), 19.8 min (115). HPLC (chiral, Daicel Chiracel OD-H, 0.46 cm × 
25 cm, n-heptane, 0.75 mL/min, 25 °C): tR = 20.4 min ((R)-73), 27.0 
min ((S)-73). 
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(E)-2-Methyl-3-phenylprop-2-en-1-ol (24) 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 μm), 60 kPa He, 100 
°C, 2 min, 7 °C/min, 250 °C, 10 min): tR = 14.6 min (25), 16.5 min 
(24). HPLC (chiral, Daicel Chiracel OD-H, 0.46 cm × 25 cm, 
n-heptane / i-PrOH = 95.5, 0.5 mL/min, 40 °C): tR = 15.3 min ((R)-
25), 17.5 min ((S)-25). 
 
(E)-Ethyl 3-phenylbut-2-enoate (98) 
GC (Chiraldex Ȗ-cyclodextrin TFA G-TA (30 m × 0.25 mm × 0.12 
μm), 60 kPa H2, 85 °C, 50 min, 10 °C/min, 160 °C, 5 min): tR = 42.9 
min ((R)-99), 44.9 min ((S)-99), 57.0 min (98). 
 
(E)-N-(1-phenylethylidene)aniline (13) 
GC (Macherey-Nagel Optima 5-Amin (30 m × 0.25 mm × 0.5 μm), 
60 kPa He, 150 °C, 7 °C/min, 250 °C, 10 min): tR = 12.6 min (14), 
12.9 min (13), 4.9 min (48), 5.4 (116). HPLC (chiral, Daicel Chiracel 
OD-H, 0.46 cm × 25 cm, n-heptane / i-PrOH = 99.1, 0.5 mL/min, 25 
°C): tR = 24.6 min ((S)-14), 33.0 min ((R)-14). 
 
N-(1-phenylvinyl)acetamide (92) 
GC (Macherey-Nagel Optima 5-Amin (30 m × 0.25 mm × 0.5 μm), 
60 kPa He, 150 °C, 15 min, 10 °C/min, 250 °C, 15 min): tR = 19.2 min 
(H2-92), 19.8 min (92). GC (Macherey-Nagel Hydroxyȕ γP (30 m × 
0.25 mm × 0.25 μm), 60 kPa H2, (150 °C, 20 min, 10 °C/min, 180 °C, 
10 min)): tR = 14.6 min ((−)-H2-92), 15.2 min ((+)-H2-92). 
 
Dimethyl 2-methylenesuccinate (93) 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 μm), 60 kPa He, 100 
°C, 2 min, 7 °C/min, 250 °C, 10 min): tR = 8.9 min (H2-93), 9.8 min 
(93). GC (Chiraldex Ȗ-cyclodextrin TFA G-TA (30 m × 0.25 mm × 
0.12 μm), 60 kPa H2, 85 °C, 50 min, 10 °C/min, 160 °C, 5 min): tR = 
19.2 min ((S)-H2-93), 20.2 min ((R)-H2-99). 
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9.1 Crystallographic Data 
 (S)-36a (S)-36b 
molecular formula C66H46BF24IrNOP C68H50BF24IrNOP 
molecular weight [g mol-1] 1559.06 1587.11 
shape plate plate 
color red red 
temperature [K] 123 123 
crystal system triclinic triclinic 
space group P −1 P 1 
crystal size [mm3] 0.06 · 0.14 · 0.21 0.05 · 0.12 · 0.18 
α [Å] 14.0804(5) 13.0655(3) 
ȕ [Å] 15.0274(5) 13.5579(3) 
Ȗ [Å] 16.3297(6) 18.9456(5) 
α [°] 95.216(2) 89.6510(10) 
ȕ [°] 106.248(2) 73.6170(10) 
Ȗ [°] 103.438(2) 89.2350(10) 
V [Å3] 3181.1 3219.48 
Z 4 2 
F(000) 1540 1572 
θ-range for data collection [°] 1.704–27.960 1.625–34.971 
ρcalc. [g cm-3] 1.628 1.637 
absorption coeff. µ [mm-1] 2.238 2.213 
measured reflections 60034 177675 
independent reflections 15146 (merging r = 0.027) 55681 (merging r = 0.030) 
used refelctions[a] 13416 46871 
parameters refined 991 1937 
R[c] 0.0292 0.0289 
Rw
[d] 0.0397 0.0372 
goodness of fit 1.2551 1.1422 
[a] Observation criterion: I>2σ(I); [c] R = Σ||F0| - |FC|| / Σ |F0|; [d] Rw = {Σ[w(F0 - FC)2] / Σ [w(F0)2]}1/2. 
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 (S)-36e rac.-81 
molecular formula C69H52BF24IrNOP C62H45BF24IrNOP 
molecular weight [g mol-1] 1601.13 1510.00 
shape plate  
color orange  
temperature [K] 123 293 
crystal system orthorhombic monoclinic 
space group P 21 21 21 P 1 21/c 1  
crystal size [mm3] 0.06 · 0.24 · 0.34  
α [Å] 12.9995(3) 12.7350(6) 
ȕ [Å] 13.2409(3) 22.6817(11) 
Ȗ [Å] 37.3728(10) 21.3144(10) 
α [°] 90 90 
ȕ [°] 90 102.276(2) 
Ȗ [°] 90 90 
V [Å3] 6432.8(3) 6015.9(5 
Z 4 4 
F(000) 3176 2980 
θ-range for data collection [°] 1.632–36.328 2.045–34.167 
ρcalc. [g cm-3] 1.653 1.667 
absorption coeff. µ [mm-1] 2.216 2.363 
measured reflections 156484 117359 
independent reflections[a] 30871 (merging r = 0.030) 24169 (merging r = 0.042) 
used refelctions β867γ (I>β.0σ(I)) 1γ9γ6 (I>γ.0σ(I)) 
parameters refined 911 964 
R[c] 0.0332 0.0676 
Rw
[d] 0.0275 0.1368 
goodness of fit 1.1068 1.0037 
[a] Observation criterion: I>2σ(I); [c] R = Σ||F0| - |FC|| / Σ |F0|; [d] Rw = {Σ[w(F0 - FC)2] / Σ [w(F0)2]}1/2. 
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 rac.-87b (S)-142c 
molecular formula C65H54BF24IrNOPSi C61H45BF24IrN2P 
molecular weight [g mol-1] 1583.19 1496.00 
shape plate block 
color red red 
temperature [K] 223 123 
crystal system monoclinic monoclinic 
space group P 21/c C 2/c 
crystal size [mm3] 0.06 · 0.17 · 0.31 0.12 · 0.21 · 0.39 
α [Å] 12.7903(4) 18.5427(4) 
ȕ [Å] 26.6398(8) 17.9275(4) 
Ȗ [Å] 19.6578(6) 36.1256(8) 
α [°] 90 90 
ȕ [°] 97.2480(10) 94.1250(10) 
Ȗ [°] 90 90 
V [Å3] 6644.5(4) 11977.9(5) 
Z 4 9 
F(000) 3144 5904 
θ-range for data collection [°] 2.089–33.772 1.582–37.833 
ρcalc. [g cm-3] 1.583 1.659 
absorption coeff. µ [mm-1] 2.161 2.372 
measured reflections 229385 194372 
independent reflections[a] 24168 (merging r = 0.030) 32197 (merging r = 0.028) 
used refelctions 1γγβ4 (I>γ.0σ(I)) β1977 (I>β.0σ(I)) 
parameters refined 1081 892 
R[c] 0.0508 0.0455 
Rw
[d] 0.0838 0.0643 
goodness of fit 1.0244 1.0954 
[a] Observation criterion: I>2σ(I); [c] R = Σ||F0| - |FC|| / Σ |F0|; [d] Rw = {Σ[w(F0 - FC)2] / Σ [w(F0)2]}1/2. 
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 (S)-142c (S)-162k 
molecular formula C66H47BF24IrN2P C63H62BF24IrN2OP  
molecular weight [g mol-1] 1558.07 1553.16 
shape block block 
color orange orange 
temperature [K] 123 123 
crystal system monoclinic monoclinic 
space group P 21 P 21 
crystal size [mm3] 0.04 · 0.09 · 0.23 0.040 · 0.110 · 0.180 
α [Å] 13.0936(4) 18.2207(4) 
ȕ [Å] 35.2531(10) 17.5477(5) 
Ȗ [Å] 13.4599(4) 20.3871(5) 
α [°] 90 90 
ȕ [°] 90.7950(10) 97.4150(10) 
Ȗ [°] 90 90 
V [Å3] 6212.4(3) 6463.9(3 
Z 4 4 
F(000) 3080 3100 
θ-range for data collection [°] 1.938–29.995 1.606-32.576 
ρcalc. [g cm-3] 1.666 1.596 
absorption coeff. µ [mm-1] 2.291 2.202 
measured reflections 55185 89879 
independent reflections[a] 32967 (merging r = 0.019) 44797 (merging r = 0.048) 
used refelctions β8450 (I>β.0σ(I)) β8065 (I>β.0σ(I)) 
parameters refined 1712 1898 
R[c] 0.0228 0.0450 
Rw
[d] 0.0269 0.0549 
goodness of fit 1.1195 0.0549 
[a] Observation criterion: I>2σ(I); [c] R = Σ||F0| - |FC|| / Σ |F0|; [d] Rw = {Σ[w(F0 - FC)2] / Σ [w(F0)2]}1/2. 
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9.2 List of Abbraviations 
Å Ångström 
Ac acetyl 
AcOAC acetic anhydride 
AcOH acetic acid 
Alk alkyl 
anth anthracenyl 
aq. aqueous 
Ar aryl 
BArF tetrakis[3,5-bis(trifluoro-methyl)phenyl]borate 
BINAP 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl 
Bn benzyl 
br broad 
Bu butyl 
c concentration 
CAL-B Candida Antartica Lipase B 
calc. calculated 
cat. catalytic or catalyst 
COD cycloocta-1,5-diene 
conv. conversion 
COSY correlation spectroscopy 
Cy cyclohexyl 
D sodim D line 
d  day(s) or doublet (NMR) 
δ chemical shift 
DCE  1,2-dichloroethane 
DCM dichloromethane 
dec. decomposition 
DIPAMP 1,2-bis((R)-(2-methoxyphenyl)(phenyl)phosphino)ethane 
DIPEA N,N-diisopropylethylamine 
DMAP N,N-4-(dimethylamino)pyridine 
DMF dimethylformamide 
DMSO dimethyl sulfoxide 
dppf 1,1’-bis(diphenyl-phosphino)ferrocene 
E opposite 
EA elemental analysis 
ee enantiomeric excess 
EI  electron-impact ionization 
eq.  equivalent(s) 
ESI  electrospray ionization 
Et  ethyl 
EtOH ethanol 
FAB  fast atom bomardement 
GC gas chromatography 
h hour(s) 
HPLC high performance liquid chromatography 
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Hz  Hertz 
i-Pr 2-propyl 
Im imidazoline 
i-PrOH or IPA 2-propanol 
J  coupling constant 
M molar [mol / L] 
m  multiplet (NMR) or medium (IR) 
m.p. melting point 
m/z  mass-to-charge ratio 
MALDI  matrix assisted laser desorption ionization 
MCPBA  3-chloroperoxybenzoic acid 
Me  methyl 
MeOH methanol 
min  minute(s) 
mL  milliliter 
MS  mass spectrometry or mole-sieves 
n.d.  not determined 
n.o. not observed 
NBA 3-nitrobenzyl aclohol 
n-BuLi 1-butyl lithium 
NfF nonafluorobutanesulfonyl fluoride 
NMR  nuclear magnetic resonance 
NOESY nuclear Overhauser enhancement spectroscopy 
n-Pr  1-propyl 
o ortho 
o-Tol ortho-tolyl 
p para 
Ph phenyl 
PHIM phosphino-imidazoline 
PHOX phosphino-oxazoline 
ppm parts per million 
q quartet 
quint quintet 
rac. racemic 
RF retention factor 
rt room temperature 
s singlet (NMR) or strong (IR) 
SAMP (S)-(–)-1-amino-2-methoxy-methylpyrrolidine 
sat. saturated 
sec second(s) 
T  temperature 
t  triplet (NMR) or time 
t or tert. tertiary 
TBAF tetrabutylammonium fluoride 
TBME tert-butyl methyl ether 
TBS tert-butyldimethylsilyl 
t-Bu  tert-butyl 
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t-BuLi t-butyl lithium  
TEA triethylamine 
tert  tertiary 
Tf  trifluoromethanesulfonyl 
TFAA trifluoroacetic anhydride 
THF  tetrahydrofurane 
TIPS triisopropylsilyl 
TLC thin layer chromatography 
TMS trimethylsilyl  
Tol  tolyl 
tR retention time 
Ts  tosyl 
w weak (IR) 
Z  together  
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The aim of this thesis was the development of new N,P ligands for iridium-catalyzed 
asymmetric hydrogenations and evaluation of alkenyl boronic esters as substrates for this 
transformation. Initially, a concise synthetic route towards bicyclic pyridine-phosphinite 
ligand complexes was implemented. The characteristic features of the new synthesis are a 
regioselective C−H functionalization, which allows fast preparation of pyridyl alcohols and 
the operationally simple synthesis of phosphinite ligand complexes (scheme 11.1). 
 
Scheme 11.1: Fast preparation of pyridyl alcohols and formation of pyridine-phosphinite ligand 
complexes. 
 
The middle section is mainly dedicated to structural modifications of the N,P ligand scaffold, 
in order to tune the activity and the selectivity. First the development of pyridine derived N,P 
ligands containing a quaternary stereogenic center is described. While a phosphinite based 
N,P ligand was found to undergo an irreversible cyclometallation reaction to produce stable, 
but catalytically inactive Ir(III)-complexes, five novel pyridine-phosphine derived Ir(I)-
complexes were synthesized and applied in the asymmetric hydrogenation of olefins. A 
remarkably high selectivity towards the reduction of terminal versus trisubstituted C=C bonds 
was found. These are the first examples of Ir-complexes being able to chemoselectively 
reduce a terminal C=C bond in the presence of a trisubstitued C=C bond even at elevated 
pressure. However, for several variably substituted terminal olefins only moderate 
enatioselectivities were obtained (up to 78% ee; scheme 11.2). 
 
Scheme 11.2: New Ir-complexes derived from N,P ligands bearing quaternary stereogenic center for 
the selective hydrogenation of terminal olefins. 
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Furthermore, pyridine-phosphinite ligands lacking the fused bicyclic motif were investigated 
during this work. Six new iridium complexes, with different electronic and steric properties 
were obtained and applied in the iridium-catalyzed asymmetric hydrogenation. They provided 
high enantioselectivities (86-96% ee) in the hydrogenation of several unfunctionalized olefins 
(scheme 11.3). 
 
Scheme 11.3: Application of new Ir-complexes lacking the rigid bicyclic motif in the hydrogenation of 
unfunctionalized olefins. 
 
Amino-phosphine derived N,P ligands were investigated as well. The corresponding iridium 
complexes were successfully applied in the asymmetric hydrogenation of unfunctionalized 
and partially functionalized olefins, furnishing excellent enantioselectivities (up to 98% ee; 
scheme 11.4). 
 
Scheme 11.4: Application of new Ir-complexes lacking the rigid bicyclic motif in the hydrogenation of 
unfunctionalized olefins. 
 
Chiral alkyl boronic esters are useful building blocks in organic chemistry, since the C−B 
bond can be readily converted into C−O, C−N and C−C bonds in a stereospecific manner. In 
this work two different iridium complexes are reported, which provide efficient access to this 
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valuable class of compounds. While an Ir-complex derived from an phosphine-imidazoline 
ligand was identified as a highly efficient catalyst for the enantioselective hydrogenation of 
terminal vinyl boronic esters, trisubstituted boronates were reduced with high activity and 
excellent enantioselectivity employing a pyridine-phosphinite derived Ir-complex (scheme 
11.5). 
 
Scheme 11.5: Ir-catalyzed symmetric hydrogenation of alkenyl boronic esters. 
 
Finally the synthesis of the phosphinitoimidazoline ligand complexes, which were identified 
as the best catalysts for the hydrogenation of terminal vinyl boronic esters, is described. 
Besides boron-based substrates, these complexes showed also high activity and 
enantioselecitvity in the asymmetric hydrogenation of unfunctionalized olefins and imines 
(scheme 11.6). In this context an unusual cyclometallation was observed for Ir-complexes 
with an isopropyl residue on the imidazoline scaffold. The cyclometallation arises from the 
insertion of the metal into one of the geminal methyl groups and was found to be reversible 
and temperature dependent. 
 
 
Scheme 11.6: Ir-catalyzed symmetric hydrogenation C=C and C=N bonds using phosphine-
imidazoline derived Ir-compelxes. 
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